Church & Dwight

CHURCH & DWIGHT CO., INC.

CHURCH & DWIGHT CO., INC.
A N N U A L   R E P O R T

annual 
report

IN MILLIONS, EXCEPT PER SHARE DATA

(cid:25)(cid:11)(cid:36)(cid:2)(cid:34)(cid:3)(cid:21)(cid:11)(cid:34) (cid:2)

(cid:14)(cid:33)(cid:27)(cid:34)(cid:34)(cid:2)(cid:30)(cid:33)(cid:27)(cid:13)(cid:17)(cid:36)(cid:2)(cid:24)(cid:3)(cid:33)(cid:14)(cid:17)(cid:25)(cid:2)

(cid:17)(cid:25)(cid:7)(cid:27)(cid:24)(cid:11)(cid:2)(cid:13)(cid:33)(cid:27)(cid:24)(cid:2)(cid:27)(cid:30)(cid:11)(cid:33)(cid:3)(cid:36)(cid:17)(cid:27)(cid:25)(cid:34)(cid:2)

(cid:27)(cid:30)(cid:11)(cid:33)(cid:3)(cid:36)(cid:17)(cid:25)(cid:14)(cid:2)(cid:30)(cid:33)(cid:27)(cid:13)(cid:17)(cid:36)(cid:2)(cid:24)(cid:3)(cid:33)(cid:14)(cid:17)(cid:25)(cid:2)

(cid:25)(cid:11)(cid:36)(cid:2)(cid:17)(cid:25)(cid:7)(cid:27)(cid:24)(cid:11)(cid:2)

(cid:25)(cid:11)(cid:36)(cid:2)(cid:17)(cid:25)(cid:7)(cid:27)(cid:24)(cid:11)(cid:2)(cid:30)(cid:11)(cid:33)(cid:2)(cid:34)(cid:15)(cid:3)(cid:33)(cid:11)(cid:2)(cid:1156)(cid:2)(cid:9)(cid:17)(cid:21)(cid:38)(cid:36)(cid:11)(cid:9)(cid:2)

(cid:9)(cid:17)(cid:40)(cid:17)(cid:9)(cid:11)(cid:25)(cid:9)(cid:34)(cid:2)(cid:30)(cid:11)(cid:33)(cid:2)(cid:34)(cid:15)(cid:3)(cid:33)(cid:11)(cid:2)

(cid:43)(cid:11)(cid:3)(cid:33)(cid:1155)(cid:11)(cid:25)(cid:9)(cid:2)(cid:34)(cid:36)(cid:27)(cid:7)(cid:20)(cid:2)(cid:30)(cid:33)(cid:17)(cid:7)(cid:11)(cid:2)

2023

2022

reported

adjusted*

reported

adjusted*

(cid:2)(cid:362)(cid:2)(cid:2)(cid:404)(cid:311)(cid:1142)(cid:1141)(cid:1142)(cid:2)(cid:2) (cid:2)

(cid:362)(cid:2) (cid:404)(cid:311)(cid:1142)(cid:1141)(cid:1142)(cid:2)(cid:2) (cid:2)

(cid:362)(cid:2) (cid:404)(cid:311)(cid:402)(cid:405)(cid:1141)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:362)(cid:2) (cid:404)(cid:311)(cid:402)(cid:405)(cid:1141)(cid:2)

(cid:2)

(cid:403)(cid:403)(cid:314)(cid:400)(cid:2)(cid:1143)(cid:2)

(cid:2)

(cid:403)(cid:403)(cid:314)(cid:400)(cid:2)(cid:1143)(cid:2)

(cid:2)

(cid:403)(cid:400)(cid:314)(cid:406)(cid:2)(cid:1143)(cid:2)

(cid:2)

(cid:403)(cid:400)(cid:314)(cid:406)(cid:2)(cid:1143)

(cid:2)(cid:2)(cid:362)(cid:2)(cid:400)(cid:311)(cid:399)(cid:404)(cid:405)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:362)(cid:2) (cid:400)(cid:311)(cid:399)(cid:1142)(cid:405)(cid:2)(cid:2) (cid:2)

(cid:362)(cid:2) (cid:404)(cid:406)(cid:1142)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:362)(cid:2) (cid:400)(cid:311)(cid:399)(cid:400)(cid:404)(cid:2)(cid:2)

(cid:2)

(cid:400)(cid:1142)(cid:314)(cid:399)(cid:2)(cid:1143)(cid:2)

(cid:2)

(cid:400)(cid:1142)(cid:314)(cid:404)(cid:2)(cid:1143)(cid:2)

(cid:2)

(cid:400)(cid:400)(cid:314)(cid:400)(cid:2)(cid:1143)(cid:2)

(cid:2)

(cid:400)(cid:1142)(cid:314)(cid:406)(cid:2)(cid:1143)

(cid:2)(cid:2)(cid:362)(cid:2) (cid:405)(cid:404)(cid:1141)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:362)(cid:2) (cid:405)(cid:1142)(cid:404)(cid:2)(cid:2) (cid:2)

(cid:362)(cid:2) (cid:403)(cid:400)(cid:403)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:2)(cid:362)(cid:2) (cid:402)(cid:314)(cid:399)(cid:404)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:362)(cid:2) (cid:402)(cid:314)(cid:400)(cid:405)(cid:2)(cid:2) (cid:2)

(cid:362)(cid:2) (cid:400)(cid:314)(cid:1141)(cid:1142)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:2)(cid:362)(cid:2) (cid:400)(cid:314)(cid:399)(cid:406)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:362)(cid:2) (cid:400)(cid:314)(cid:399)(cid:406)(cid:2)(cid:2) (cid:2)

(cid:362)(cid:2) (cid:400)(cid:314)(cid:399)(cid:404)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:2)(cid:362)(cid:2)(cid:406)(cid:403)(cid:314)(cid:404)(cid:1141)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:362)(cid:2) (cid:406)(cid:403)(cid:314)(cid:404)(cid:1141)(cid:2)(cid:2) (cid:2)

(cid:362)(cid:2) (cid:1142)(cid:399)(cid:314)(cid:1141)(cid:400)(cid:2)(cid:2) (cid:2)

(cid:2)(cid:362)(cid:2) (cid:405)(cid:402)(cid:400)(cid:2)(cid:2)

(cid:2)(cid:362)(cid:2) (cid:401)(cid:314)(cid:406)(cid:405)(cid:2)(cid:2)

(cid:2)(cid:362)(cid:2) (cid:400)(cid:314)(cid:399)(cid:404)(cid:2)(cid:2)

(cid:2)(cid:362)(cid:2) (cid:1142)(cid:399)(cid:314)(cid:1141)(cid:400)(cid:2)(cid:2)

(cid:27)(cid:109)(cid:2)(cid:19)(cid:45)(cid:109)(cid:134)(cid:45)(cid:117)(cid:139)(cid:2)(cid:402)(cid:400)(cid:311)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:311)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:55)(cid:59)(cid:49)(cid:1140)(cid:45)(cid:117)(cid:59)(cid:55)(cid:2)(cid:45)(cid:2)(cid:403)(cid:314)(cid:399)(cid:1143)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:98)(cid:124)(cid:118)(cid:2)
(cid:116)(cid:134)(cid:45)(cid:117)(cid:124)(cid:59)(cid:117)(cid:1140)(cid:139)(cid:2)(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:362)(cid:399)(cid:314)(cid:401)(cid:405)(cid:401)(cid:404)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:362)(cid:399)(cid:314)(cid:401)(cid:1142)(cid:402)(cid:405)(cid:404)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:314)

2023 Key Financial Results 

– Worldwide net sales increased 9.2%. 

– Organic sales increased 5.3%.   

(cid:331)(cid:2)(cid:14)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:114)(cid:117)(cid:111)(cid:67)(cid:124)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:401)(cid:401)(cid:399)(cid:2)(cid:48)(cid:45)(cid:118)(cid:98)(cid:118)(cid:2)(cid:114)(cid:111)(cid:98)(cid:109)(cid:124)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:403)(cid:403)(cid:314)(cid:400)(cid:1143)(cid:314)(cid:2)

(cid:331)(cid:2)(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:114)(cid:117)(cid:111)(cid:67)(cid:124)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:55)(cid:59)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:400)(cid:1142)(cid:314)(cid:404)(cid:1143)(cid:314)(cid:2)

(cid:331)(cid:2)(cid:25)(cid:59)(cid:124)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:362)(cid:400)(cid:2)(cid:48)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:314)(cid:2)
– Adjusted earnings per shared increased 6.7%. 

(cid:2)

(cid:2)

(cid:2)

(cid:2)

(cid:2)

(cid:2)

(cid:2)

(cid:2)

(cid:2)

NET SALES

(in millions of dollars)  

2021

2022

2023

  $5,190 

  $5,376 

  $5,868 

ADJUSTED EARNINGS PER SHARE (1)

(in dollars)  

2021

2022

2023

  $3.02(2)

  $2.97(3)

  $3.17(4)

(cid:13)(cid:111)(cid:117)(cid:2)(cid:45)(cid:55)(cid:55)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:118)(cid:59)(cid:59)(cid:2)(cid:24)(cid:45)(cid:109)(cid:45)(cid:93)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:317)(cid:118)(cid:2)(cid:9)(cid:98)(cid:118)(cid:49)(cid:134)(cid:118)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:3)(cid:109)(cid:45)(cid:1140)(cid:139)(cid:118)(cid:98)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:13)(cid:98)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:7)(cid:111)(cid:109)(cid:55)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:33)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:124)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:27)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:3)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:33)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:111)(cid:109)(cid:2) 
(cid:13)(cid:111)(cid:117)(cid:108)(cid:2)(cid:400)(cid:399)(cid:330)(cid:20)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:2)(cid:59)(cid:109)(cid:55)(cid:59)(cid:55)(cid:2)(cid:9)(cid:59)(cid:49)(cid:59)(cid:108)(cid:48)(cid:59)(cid:117)(cid:2)(cid:402)(cid:400)(cid:311)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:314) 

(cid:342)(cid:2)(cid:2)(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:118)(cid:2)(cid:109)(cid:111)(cid:109)(cid:330)(cid:14)(cid:3)(cid:3)(cid:30)(cid:2)(cid:67)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:118)(cid:311)(cid:2)(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:49)(cid:111)(cid:108)(cid:59)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:311)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:114)(cid:117)(cid:111)(cid:67)(cid:124)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:311)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:109)(cid:59)(cid:124)(cid:2)(cid:98)(cid:109)(cid:49)(cid:111)(cid:108)(cid:59)(cid:311)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:11)(cid:30)(cid:34)(cid:311)(cid:2)

(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:311)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:55)(cid:98)(cid:64)(cid:59)(cid:117)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:59)(cid:55)(cid:2)(cid:117)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:124)(cid:118)(cid:2)(cid:134)(cid:118)(cid:98)(cid:109)(cid:93)(cid:2)(cid:14)(cid:59)(cid:109)(cid:59)(cid:117)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:3)(cid:49)(cid:49)(cid:59)(cid:114)(cid:124)(cid:59)(cid:55)(cid:2)(cid:3)(cid:49)(cid:49)(cid:111)(cid:134)(cid:109)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:30)(cid:117)(cid:98)(cid:109)(cid:49)(cid:98)(cid:114)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:336)(cid:14)(cid:3)(cid:3)(cid:30)(cid:337)(cid:314) 

(cid:336)(cid:400)(cid:337)(cid:2)(cid:2)(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:11)(cid:30)(cid:34)(cid:311)(cid:2)(cid:109)(cid:45)(cid:108)(cid:59)(cid:1140)(cid:139)(cid:311)(cid:2)(cid:59)(cid:45)(cid:117)(cid:109)(cid:98)(cid:109)(cid:93)(cid:118)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:49)(cid:45)(cid:1140)(cid:49)(cid:134)(cid:1140)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:45)(cid:49)(cid:49)(cid:111)(cid:117)(cid:55)(cid:45)(cid:109)(cid:49)(cid:59)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:14)(cid:3)(cid:3)(cid:30)(cid:311)(cid:2)(cid:45)(cid:118)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:2)(cid:118)(cid:98)(cid:93)(cid:109)(cid:98)(cid:67)(cid:49)(cid:45)(cid:109)(cid:124)(cid:2)(cid:111)(cid:109)(cid:59)(cid:330)(cid:2462)(cid:108)(cid:59)(cid:2)(cid:98)(cid:124)(cid:59)(cid:108)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:109)(cid:111)(cid:124)(cid:2)(cid:2)
(cid:98)(cid:109)(cid:55)(cid:98)(cid:49)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:55)(cid:2)(cid:114)(cid:59)(cid:117)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:109)(cid:49)(cid:59)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:48)(cid:59)(cid:1140)(cid:98)(cid:59)(cid:136)(cid:59)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:108)(cid:59)(cid:124)(cid:117)(cid:98)(cid:49)(cid:2)(cid:114)(cid:117)(cid:111)(cid:136)(cid:98)(cid:55)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:111)(cid:117)(cid:118)(cid:2)(cid:45)(cid:2)(cid:134)(cid:118)(cid:59)(cid:61)(cid:134)(cid:1140)(cid:2)(cid:114)(cid:59)(cid:117)(cid:118)(cid:114)(cid:59)(cid:49)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:134)(cid:109)(cid:55)(cid:59)(cid:117)(cid:1140)(cid:139)(cid:98)(cid:109)(cid:93)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:124)(cid:117)(cid:59)(cid:109)(cid:55)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:117)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:124)(cid:118)(cid:2)(cid:2)
(cid:2)
(cid:45)(cid:109)(cid:55)(cid:2)(cid:114)(cid:117)(cid:111)(cid:136)(cid:98)(cid:55)(cid:59)(cid:118)(cid:2)(cid:134)(cid:118)(cid:59)(cid:61)(cid:134)(cid:1140)(cid:2)(cid:118)(cid:134)(cid:114)(cid:114)(cid:1140)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:117)(cid:59)(cid:93)(cid:45)(cid:117)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:2)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:2)(cid:59)(cid:45)(cid:117)(cid:109)(cid:98)(cid:109)(cid:93)(cid:118)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:314)(cid:2) 
(cid:2)

(cid:336)(cid:401)(cid:337)(cid:2)(cid:2)(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:401)(cid:399)(cid:401)(cid:400)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:118)(cid:2)(cid:362)(cid:399)(cid:314)(cid:402)(cid:399)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:114)(cid:111)(cid:118)(cid:98)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:98)(cid:108)(cid:114)(cid:45)(cid:49)(cid:124)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:13)(cid:21)(cid:3)(cid:41)(cid:21)(cid:11)(cid:34)(cid:34)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:59)(cid:45)(cid:117)(cid:109)(cid:330)(cid:111)(cid:134)(cid:124)(cid:2)(cid:59)(cid:118)(cid:2462)(cid:108)(cid:45)(cid:124)(cid:59)(cid:314) 

(cid:336)(cid:402)(cid:337)(cid:2)(cid:2)(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:401)(cid:399)(cid:401)(cid:401)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:118)(cid:2)(cid:362)(cid:400)(cid:314)(cid:401)(cid:1141)(cid:2)(cid:98)(cid:108)(cid:114)(cid:45)(cid:49)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:13)(cid:21)(cid:3)(cid:41)(cid:21)(cid:11)(cid:34)(cid:34)(cid:2)(cid:98)(cid:109)(cid:124)(cid:45)(cid:109)(cid:93)(cid:98)(cid:48)(cid:1140)(cid:59)(cid:2)(cid:45)(cid:118)(cid:118)(cid:59)(cid:124)(cid:2)(cid:98)(cid:108)(cid:114)(cid:45)(cid:98)(cid:117)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:362)(cid:399)(cid:314)(cid:399)(cid:402)(cid:2)(cid:98)(cid:108)(cid:114)(cid:45)(cid:49)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:49)(cid:95)(cid:45)(cid:117)(cid:93)(cid:59)(cid:118)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:98)(cid:118)(cid:118)(cid:134)(cid:59)(cid:55)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:2)
(cid:2) (cid:15)(cid:59)(cid:117)(cid:111)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:98)(cid:118)(cid:2)(cid:124)(cid:117)(cid:59)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:45)(cid:118)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:59)(cid:109)(cid:118)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:109)(cid:118)(cid:59)(cid:314) 

(cid:336)(cid:403)(cid:337)(cid:2)(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:118)(cid:2)(cid:362)(cid:399)(cid:314)(cid:400)(cid:401)(cid:2)(cid:98)(cid:108)(cid:114)(cid:45)(cid:49)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:49)(cid:95)(cid:45)(cid:117)(cid:93)(cid:59)(cid:118)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:98)(cid:118)(cid:118)(cid:134)(cid:59)(cid:55)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:15)(cid:59)(cid:117)(cid:111)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:98)(cid:118)(cid:2)(cid:124)(cid:117)(cid:59)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:45)(cid:118)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:59)(cid:109)(cid:118)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:109)(cid:118)(cid:59)(cid:314)

 
 
 
 
 
 
 
 
 
 
 
 
(cid:7)(cid:111)(cid:117)(cid:114)(cid:111)(cid:117)(cid:45)(cid:124)(cid:59)(cid:2)(cid:17)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)

Church & Dwight Co., Inc., founded in 1846, is the  

(cid:40)(cid:17)(cid:36)(cid:3)(cid:13)(cid:38)(cid:34)(cid:17)(cid:27)(cid:25)(cid:311)(cid:2)(cid:6)(cid:3)(cid:36)(cid:17)(cid:34)(cid:36)(cid:11)(cid:311)(cid:2)(cid:41)(cid:3)(cid:36)(cid:11)(cid:33)(cid:30)(cid:17)(cid:20)(cid:311)(cid:2)(cid:36)(cid:15)(cid:11)(cid:33)(cid:3)(cid:6)(cid:33)(cid:11)(cid:3)(cid:36)(cid:15)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)

leading U.S. producer of sodium bicarbonate, popularly 

(cid:15)(cid:11)(cid:33)(cid:27)(cid:314)(cid:2)(cid:3)(cid:48)(cid:111)(cid:134)(cid:124)(cid:2)(cid:403)(cid:404)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:55)(cid:111)(cid:108)(cid:59)(cid:118)(cid:2462)(cid:49)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)

known as baking soda, a natural product that cleans,  

(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:118)(cid:111)(cid:1140)(cid:55)(cid:2)(cid:134)(cid:109)(cid:55)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:3)(cid:33)(cid:24)(cid:2)(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:2)(cid:109)(cid:45)(cid:108)(cid:59)(cid:2)

(cid:55)(cid:59)(cid:111)(cid:55)(cid:111)(cid:117)(cid:98)(cid:140)(cid:59)(cid:118)(cid:311)(cid:2)(cid:1140)(cid:59)(cid:45)(cid:136)(cid:59)(cid:109)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:48)(cid:134)(cid:64)(cid:59)(cid:117)(cid:118)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:3)(cid:33)(cid:24)(cid:2) 

(cid:45)(cid:109)(cid:55)(cid:2)(cid:55)(cid:59)(cid:117)(cid:98)(cid:136)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:124)(cid:117)(cid:45)(cid:55)(cid:59)(cid:108)(cid:45)(cid:117)(cid:104)(cid:118)(cid:311)(cid:2)(cid:118)(cid:134)(cid:49)(cid:95)(cid:2)(cid:45)(cid:118)(cid:2)(cid:3)(cid:33)(cid:24)(cid:2)(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:2)(cid:1140)(cid:98)(cid:116)(cid:134)(cid:98)(cid:55)(cid:2)

(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:118)(cid:2)(cid:111)(cid:109)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:317)(cid:118)(cid:2)(cid:108)(cid:111)(cid:118)(cid:124)(cid:2)(cid:124)(cid:117)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2) 

(cid:45)(cid:109)(cid:55)(cid:2)(cid:114)(cid:111)(cid:137)(cid:55)(cid:59)(cid:117)(cid:2)(cid:1140)(cid:45)(cid:134)(cid:109)(cid:55)(cid:117)(cid:139)(cid:2)(cid:55)(cid:59)(cid:124)(cid:59)(cid:117)(cid:93)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2)(cid:3)(cid:33)(cid:24)(cid:2)(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:2)(cid:49)(cid:45)(cid:124)(cid:2)(cid:1140)(cid:98)(cid:130)(cid:59)(cid:117)(cid:311)(cid:2)

trademarks for a broad range of consumer and specialty 

(cid:3)(cid:33)(cid:24)(cid:2)(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:2)(cid:55)(cid:59)(cid:109)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:49)(cid:45)(cid:117)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:3)(cid:33)(cid:24)(cid:2)(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:2)(cid:48)(cid:45)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)

products developed from the base of sodium bicarbonate 

(cid:118)(cid:111)(cid:55)(cid:45)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:117)(cid:59)(cid:108)(cid:45)(cid:98)(cid:109)(cid:98)(cid:109)(cid:93)(cid:2)(cid:1141)(cid:2)(cid:114)(cid:111)(cid:137)(cid:59)(cid:117)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:48)(cid:59)(cid:59)(cid:109)(cid:2)(cid:45)(cid:55)(cid:55)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2) 

and related technologies.

(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:114)(cid:111)(cid:117)(cid:127)(cid:111)(cid:1140)(cid:98)(cid:111)(cid:2)(cid:118)(cid:98)(cid:109)(cid:49)(cid:59)(cid:2)(cid:401)(cid:399)(cid:399)(cid:400)(cid:2)(cid:124)(cid:95)(cid:117)(cid:111)(cid:134)(cid:93)(cid:95)(cid:2)(cid:45)(cid:2)(cid:118)(cid:59)(cid:117)(cid:98)(cid:59)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)

(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:317)(cid:118)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:98)(cid:118)(cid:2) 

(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:314)

(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:140)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:124)(cid:111)(cid:2)(cid:124)(cid:137)(cid:111)(cid:2)(cid:118)(cid:59)(cid:93)(cid:108)(cid:59)(cid:109)(cid:124)(cid:118)(cid:313)(cid:2)(cid:7)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:9)(cid:111)(cid:108)(cid:59)(cid:118)(cid:2462)(cid:49)(cid:311)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)

(cid:36)(cid:95)(cid:59)(cid:2)(cid:49)(cid:111)(cid:108)(cid:48)(cid:98)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:49)(cid:111)(cid:117)(cid:59)(cid:2)(cid:3)(cid:33)(cid:24)(cid:2)(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:2) 

encompasses both household and personal care products, 

and the other 6 power brands make Church & Dwight one 

(cid:45)(cid:109)(cid:55)(cid:2)(cid:7)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:311)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:114)(cid:117)(cid:98)(cid:108)(cid:45)(cid:117)(cid:98)(cid:1140)(cid:139)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:98)(cid:118)(cid:124)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)

of the leading consumer packaged goods companies in the 

(cid:114)(cid:59)(cid:117)(cid:118)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:49)(cid:45)(cid:117)(cid:59)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:118)(cid:59)(cid:136)(cid:59)(cid:109)(cid:2)(cid:104)(cid:59)(cid:139)(cid:2)(cid:318)(cid:114)(cid:111)(cid:137)(cid:59)(cid:117)(cid:2)

(cid:38)(cid:109)(cid:98)(cid:124)(cid:59)(cid:55)(cid:2)(cid:34)(cid:124)(cid:45)(cid:124)(cid:59)(cid:118)(cid:314)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:317)(cid:118)(cid:2)(cid:124)(cid:95)(cid:98)(cid:117)(cid:55)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:118)(cid:59)(cid:93)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2) 

(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:319)(cid:2)(cid:117)(cid:59)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:45)(cid:114)(cid:114)(cid:117)(cid:111)(cid:138)(cid:98)(cid:108)(cid:45)(cid:124)(cid:59)(cid:1140)(cid:139)(cid:2)(cid:405)(cid:399)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:98)(cid:124)(cid:118)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:118)(cid:314)(cid:2)

(cid:98)(cid:118)(cid:2)(cid:34)(cid:114)(cid:59)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:124)(cid:139)(cid:2)(cid:30)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:314)(cid:2)(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:98)(cid:118)(cid:2)(cid:45)(cid:2)(cid:1140)(cid:59)(cid:45)(cid:55)(cid:59)(cid:117)(cid:2)(cid:98)(cid:109)(cid:2)(cid:118)(cid:114)(cid:59)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:124)(cid:139)(cid:2) 

(cid:36)(cid:95)(cid:59)(cid:118)(cid:59)(cid:2)(cid:318)(cid:114)(cid:111)(cid:137)(cid:59)(cid:117)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:319)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:3)(cid:33)(cid:24)(cid:2)(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:311)(cid:2)(cid:27)(cid:42)(cid:17)(cid:7)(cid:21)(cid:11)(cid:3)(cid:25)(cid:311)(cid:2)

(cid:98)(cid:109)(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:49)(cid:95)(cid:59)(cid:108)(cid:98)(cid:49)(cid:45)(cid:1140)(cid:118)(cid:311)(cid:2)(cid:45)(cid:109)(cid:98)(cid:108)(cid:45)(cid:1140)(cid:2)(cid:109)(cid:134)(cid:124)(cid:117)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:118)(cid:114)(cid:59)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:124)(cid:139)(cid:2)(cid:49)(cid:1140)(cid:59)(cid:45)(cid:109)(cid:59)(cid:117)(cid:118)(cid:314)

Growth Driven by 7 Power Brands

VITAFUSION  
#2 Branded 
Gummy Vitamin

OXICLEAN 
#1 Stain Fighter

WATERPIK 
#1 Power  
Water Flosser

ARM & HAMMER 

(cid:24)(cid:111)(cid:117)(cid:59)(cid:2)(cid:45)(cid:98)(cid:118)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:93)(cid:117)(cid:111)(cid:49)(cid:59)(cid:117)(cid:139)(cid:2)(cid:118)(cid:124)(cid:111)(cid:117)(cid:59)(cid:2)(cid:124)(cid:95)(cid:45)(cid:109)(cid:2)(cid:45)(cid:109)(cid:139)(cid:2)(cid:111)(cid:124)(cid:95)(cid:59)(cid:117)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:312)(cid:2)
(cid:3)(cid:351)(cid:15)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:1142)(cid:1141)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:38)(cid:314)(cid:34)(cid:314)(cid:2)(cid:95)(cid:111)(cid:134)(cid:118)(cid:59)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:118)

BATISTE   
#1 Dry Shampoo

THERABREATH 
(cid:370)(cid:400)(cid:2)(cid:3)(cid:1140)(cid:49)(cid:111)(cid:95)(cid:111)(cid:1140)(cid:330)(cid:13)(cid:117)(cid:59)(cid:59)(cid:2) 
(cid:24)(cid:111)(cid:134)(cid:124)(cid:95)(cid:137)(cid:45)(cid:118)(cid:95)

HERO 

(cid:370)(cid:400)(cid:2)(cid:3)(cid:49)(cid:109)(cid:59)(cid:2)(cid:30)(cid:45)(cid:124)(cid:49)(cid:95)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)
(cid:3)(cid:49)(cid:109)(cid:59)(cid:2)(cid:36)(cid:117)(cid:59)(cid:45)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)

(cid:6)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:2)(cid:17)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:33)(cid:59)(cid:118)(cid:111)(cid:134)(cid:117)(cid:49)(cid:59)(cid:118)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)(cid:2)(cid:332)(cid:2)(cid:336)(cid:17)(cid:33)(cid:17)(cid:337)(cid:2)(cid:36)(cid:111)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:38)(cid:34)(cid:2)(cid:332)(cid:2)(cid:24)(cid:38)(cid:21)(cid:27)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:55)(cid:2)(cid:59)(cid:109)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:400)(cid:401)(cid:326)(cid:401)(cid:403)(cid:326)(cid:401)(cid:402)(cid:314)

  A N N U A L   R E P O R T   202 3   |  1

 
 
MATTHEW T. FARRELL

RICHARD A. DIERKER 

PATRICK D. DE MAYNADIER, ESQ. 

Chairman, President
(cid:45)(cid:109)(cid:55)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:13)(cid:98)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)
(cid:15)(cid:59)(cid:45)(cid:55)(cid:2)(cid:111)(cid:61)(cid:2)(cid:6)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:27)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)

(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)
General Counsel and Secretary

Dear Fellow Stockholder,
I am pleased to report that we delivered a year of strong 
revenue and earnings growth:

(cid:332)(cid:2)(cid:33)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:59)(cid:55)(cid:2)(cid:109)(cid:59)(cid:124)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:137)(cid:59)(cid:117)(cid:59)(cid:2)(cid:362)(cid:404)(cid:311)(cid:1142)(cid:1141)(cid:1142)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:311)(cid:2)(cid:45)(cid:2)(cid:406)(cid:314)(cid:401)(cid:1143)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:314)

(cid:332)(cid:2)(cid:2)(cid:27)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:404)(cid:314)(cid:402)(cid:1143)(cid:2)(cid:55)(cid:117)(cid:98)(cid:136)(cid:59)(cid:109)(cid:2)(cid:48)(cid:139)(cid:2)(cid:404)(cid:314)(cid:405)(cid:1143)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:98)(cid:109)(cid:2) 
(cid:111)(cid:134)(cid:117)(cid:2)(cid:7)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:9)(cid:111)(cid:108)(cid:59)(cid:118)(cid:2462)(cid:49)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:311)(cid:2)(cid:1142)(cid:314)(cid:404)(cid:1143)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:98)(cid:109)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2) 
(cid:7)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:2)(cid:405)(cid:314)(cid:406)(cid:1143)(cid:2)(cid:55)(cid:59)(cid:49)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2) 
our Specialty Products business.

(cid:332)(cid:2)(cid:2)(cid:14)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:401)(cid:401)(cid:399)(cid:2)(cid:48)(cid:45)(cid:118)(cid:98)(cid:118)(cid:2)(cid:114)(cid:111)(cid:98)(cid:109)(cid:124)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:403)(cid:403)(cid:314)(cid:400)(cid:1143)(cid:2)(cid:45)(cid:118)(cid:2) 

(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:2462)(cid:136)(cid:98)(cid:124)(cid:139)(cid:311)(cid:2)(cid:114)(cid:117)(cid:98)(cid:49)(cid:98)(cid:109)(cid:93)(cid:311)(cid:2)(cid:136)(cid:111)(cid:1140)(cid:134)(cid:108)(cid:59)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:118)(cid:124)(cid:117)(cid:111)(cid:109)(cid:93)(cid:2)(cid:49)(cid:111)(cid:109)(cid:124)(cid:117)(cid:98)(cid:48)(cid:134)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)
(cid:95)(cid:98)(cid:93)(cid:95)(cid:59)(cid:117)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:108)(cid:111)(cid:117)(cid:59)(cid:2)(cid:124)(cid:95)(cid:45)(cid:109)(cid:2)(cid:111)(cid:64)(cid:118)(cid:59)(cid:124)(cid:2)(cid:98)(cid:109)(cid:89)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:314)

(cid:332)(cid:2)(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:362)(cid:402)(cid:314)(cid:400)(cid:405)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:311)(cid:2)(cid:45)(cid:2)(cid:1141)(cid:314)(cid:405)(cid:1143)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:314)

(cid:332)(cid:2)(cid:2)(cid:41)(cid:59)(cid:2)(cid:93)(cid:59)(cid:109)(cid:59)(cid:117)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:362)(cid:400)(cid:2)(cid:48)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:2)(cid:111)(cid:61)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)

(cid:45)(cid:49)(cid:2462)(cid:136)(cid:98)(cid:2462)(cid:59)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:362)(cid:401)(cid:401)(cid:403)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:2)(cid:98)(cid:109)(cid:2)(cid:49)(cid:45)(cid:114)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:109)(cid:55)(cid:98)(cid:124)(cid:134)(cid:117)(cid:59)(cid:118)(cid:2)
(cid:117)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:98)(cid:109)(cid:2)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)(cid:111)(cid:61)(cid:2)(cid:362)(cid:1142)(cid:399)(cid:405)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2) 
(cid:137)(cid:59)(cid:2)(cid:117)(cid:59)(cid:124)(cid:134)(cid:117)(cid:109)(cid:59)(cid:55)(cid:2)(cid:362)(cid:404)(cid:1141)(cid:405)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:2)(cid:111)(cid:61)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:124)(cid:111)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:118)(cid:2)(cid:124)(cid:95)(cid:117)(cid:111)(cid:134)(cid:93)(cid:95)(cid:2)
(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:118)(cid:2)(cid:336)(cid:362)(cid:401)(cid:1141)(cid:405)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:337)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:48)(cid:134)(cid:139)(cid:48)(cid:45)(cid:49)(cid:104)(cid:118)(cid:2)(cid:336)(cid:362)(cid:402)(cid:399)(cid:399)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:337)(cid:314)(cid:2)

Evergreen Model
(cid:27)(cid:134)(cid:117)(cid:2)(cid:1140)(cid:111)(cid:109)(cid:93)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:114)(cid:1140)(cid:45)(cid:109)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:55)(cid:59)(cid:1140)(cid:98)(cid:136)(cid:59)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:118)(cid:134)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:117)(cid:2)(cid:117)(cid:59)(cid:124)(cid:134)(cid:117)(cid:109)(cid:118)(cid:2)(cid:98)(cid:118)(cid:2)(cid:48)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2) 
(cid:111)(cid:109)(cid:2)(cid:137)(cid:95)(cid:45)(cid:124)(cid:2)(cid:137)(cid:59)(cid:2)(cid:49)(cid:45)(cid:1140)(cid:1140)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:318)(cid:11)(cid:136)(cid:59)(cid:117)(cid:93)(cid:117)(cid:59)(cid:59)(cid:109)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:108)(cid:111)(cid:55)(cid:59)(cid:1140)(cid:319)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)
(cid:59)(cid:136)(cid:111)(cid:1140)(cid:136)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:1140)(cid:111)(cid:109)(cid:93)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:11)(cid:136)(cid:59)(cid:117)(cid:93)(cid:117)(cid:59)(cid:59)(cid:109)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:108)(cid:111)(cid:55)(cid:59)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:314)(cid:2)
(cid:36)(cid:95)(cid:59)(cid:2)(cid:1140)(cid:45)(cid:118)(cid:124)(cid:2)(cid:117)(cid:59)(cid:136)(cid:98)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:400)(cid:1142)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:109)(cid:59)(cid:137)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:11)(cid:136)(cid:59)(cid:117)(cid:93)(cid:117)(cid:59)(cid:59)(cid:109)(cid:2)
(cid:108)(cid:111)(cid:55)(cid:59)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:89)(cid:59)(cid:49)(cid:124)(cid:118)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:111)(cid:61)(cid:2)(cid:61)(cid:45)(cid:118)(cid:124)(cid:59)(cid:117)(cid:2)(cid:124)(cid:111)(cid:114)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:311)(cid:2)
(cid:93)(cid:117)(cid:59)(cid:45)(cid:124)(cid:59)(cid:117)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:59)(cid:138)(cid:114)(cid:45)(cid:109)(cid:118)(cid:98)(cid:111)(cid:109)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:2)(cid:95)(cid:98)(cid:93)(cid:95)(cid:59)(cid:117)(cid:2)(cid:49)(cid:45)(cid:55)(cid:59)(cid:109)(cid:49)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)
(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2)(cid:118)(cid:114)(cid:59)(cid:49)(cid:98)(cid:67)(cid:49)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:98)(cid:109)(cid:2)(cid:59)(cid:49)(cid:111)(cid:108)(cid:108)(cid:59)(cid:117)(cid:49)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:314)(cid:2)(cid:2) 
(cid:36)(cid:95)(cid:59)(cid:2)(cid:117)(cid:59)(cid:136)(cid:98)(cid:118)(cid:59)(cid:55)(cid:2)(cid:59)(cid:136)(cid:59)(cid:117)(cid:93)(cid:117)(cid:59)(cid:59)(cid:109)(cid:2)(cid:108)(cid:111)(cid:55)(cid:59)(cid:1140)(cid:2)(cid:49)(cid:45)(cid:1140)(cid:1140)(cid:118)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:403)(cid:1143)(cid:2)(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:109)(cid:59)(cid:124)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)

2  |  CHURCH & DWIGHT CO., INC.

(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:336)(cid:114)(cid:117)(cid:59)(cid:136)(cid:98)(cid:111)(cid:134)(cid:118)(cid:1140)(cid:139)(cid:2)(cid:402)(cid:1143)(cid:337)(cid:311)(cid:2)(cid:401)(cid:404)(cid:2)(cid:124)(cid:111)(cid:2)(cid:404)(cid:399)(cid:2)(cid:48)(cid:45)(cid:118)(cid:98)(cid:118)(cid:2)(cid:114)(cid:111)(cid:98)(cid:109)(cid:124)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:93)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)
(cid:59)(cid:138)(cid:114)(cid:45)(cid:109)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:336)(cid:114)(cid:117)(cid:59)(cid:136)(cid:98)(cid:111)(cid:134)(cid:118)(cid:1140)(cid:139)(cid:2)(cid:401)(cid:404)(cid:2)(cid:48)(cid:114)(cid:118)(cid:337)(cid:311)(cid:2)(cid:108)(cid:45)(cid:117)(cid:104)(cid:59)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:45)(cid:118)(cid:2)(cid:45)(cid:2)(cid:114)(cid:59)(cid:117)(cid:49)(cid:59)(cid:109)(cid:124)(cid:45)(cid:93)(cid:59)(cid:2) 
(cid:111)(cid:61)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:49)(cid:111)(cid:109)(cid:2462)(cid:109)(cid:134)(cid:59)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:45)(cid:114)(cid:114)(cid:117)(cid:111)(cid:138)(cid:98)(cid:108)(cid:45)(cid:124)(cid:59)(cid:2)(cid:400)(cid:400)(cid:1143)(cid:2)(cid:336)(cid:109)(cid:111)(cid:2)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:337)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)
(cid:34)(cid:14)(cid:351)(cid:3)(cid:2)(cid:1140)(cid:59)(cid:136)(cid:59)(cid:117)(cid:45)(cid:93)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:399)(cid:330)(cid:401)(cid:404)(cid:2)(cid:48)(cid:114)(cid:118)(cid:2)(cid:336)(cid:114)(cid:117)(cid:59)(cid:136)(cid:98)(cid:111)(cid:134)(cid:118)(cid:1140)(cid:139)(cid:2)(cid:401)(cid:404)(cid:2)(cid:48)(cid:114)(cid:118)(cid:337)(cid:2)(cid:117)(cid:59)(cid:89)(cid:59)(cid:49)(cid:2462)(cid:109)(cid:93)(cid:2)
investments which will help sustain accelerated growth for 

(cid:139)(cid:59)(cid:45)(cid:117)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:49)(cid:111)(cid:108)(cid:59)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:108)(cid:45)(cid:98)(cid:109)(cid:124)(cid:45)(cid:98)(cid:109)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:1142)(cid:1143)(cid:2)(cid:98)(cid:109)(cid:55)(cid:134)(cid:118)(cid:124)(cid:117)(cid:139)(cid:2)(cid:1140)(cid:59)(cid:45)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)
(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:124)(cid:45)(cid:117)(cid:93)(cid:59)(cid:124)(cid:314)(cid:2)(cid:3)(cid:49)(cid:95)(cid:98)(cid:59)(cid:136)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:11)(cid:136)(cid:59)(cid:117)(cid:93)(cid:117)(cid:59)(cid:59)(cid:109)(cid:2)
(cid:108)(cid:111)(cid:55)(cid:59)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:89)(cid:134)(cid:59)(cid:109)(cid:49)(cid:59)(cid:118)(cid:2)(cid:48)(cid:111)(cid:124)(cid:95)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:95)(cid:111)(cid:117)(cid:124)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:1140)(cid:111)(cid:109)(cid:93)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:55)(cid:59)(cid:49)(cid:98)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)
(cid:108)(cid:45)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:114)(cid:117)(cid:111)(cid:108)(cid:111)(cid:124)(cid:59)(cid:118)(cid:2)(cid:67)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:1140)(cid:98)(cid:124)(cid:59)(cid:117)(cid:45)(cid:49)(cid:139)(cid:2)(cid:98)(cid:109)(cid:118)(cid:98)(cid:55)(cid:59)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:314)(cid:2) 
(cid:17)(cid:124)(cid:2)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:2)(cid:98)(cid:108)(cid:114)(cid:111)(cid:117)(cid:124)(cid:45)(cid:109)(cid:124)(cid:2)(cid:114)(cid:45)(cid:117)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:134)(cid:49)(cid:49)(cid:59)(cid:118)(cid:118)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:2)(cid:27)(cid:134)(cid:124)(cid:1140)(cid:111)(cid:111)(cid:104)(cid:2) 
(cid:49)(cid:45)(cid:1140)(cid:1140)(cid:118)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:403)(cid:330)(cid:404)(cid:1143)(cid:2)(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:405)(cid:330)(cid:406)(cid:1143)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)
(cid:336)(cid:108)(cid:98)(cid:55)(cid:330)(cid:114)(cid:111)(cid:98)(cid:109)(cid:124)(cid:2)(cid:362)(cid:402)(cid:314)(cid:403)(cid:401)(cid:337)(cid:314)(cid:2)

Total Shareholder Return (TSR)
(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:45)(cid:49)(cid:95)(cid:98)(cid:59)(cid:136)(cid:59)(cid:55)(cid:2)(cid:45)(cid:2)(cid:36)(cid:34)(cid:33)(cid:2)(cid:111)(cid:61)(cid:2)(cid:400)(cid:1142)(cid:314)(cid:405)(cid:1143)(cid:314)(cid:2)(cid:36)(cid:111)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:34)(cid:95)(cid:45)(cid:117)(cid:59)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:2) 
(cid:33)(cid:59)(cid:124)(cid:134)(cid:117)(cid:109)(cid:2)(cid:117)(cid:59)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:49)(cid:111)(cid:108)(cid:48)(cid:98)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:111)(cid:61)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:114)(cid:117)(cid:98)(cid:49)(cid:59)(cid:2) 
(cid:45)(cid:114)(cid:114)(cid:117)(cid:59)(cid:49)(cid:98)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:108)(cid:45)(cid:109)(cid:45)(cid:93)(cid:59)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)
(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:59)(cid:117)(cid:59)(cid:109)(cid:109)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:93)(cid:111)(cid:45)(cid:1140)(cid:2)(cid:111)(cid:61)(cid:2)(cid:55)(cid:59)(cid:1140)(cid:98)(cid:136)(cid:59)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:118)(cid:124)(cid:117)(cid:111)(cid:109)(cid:93)(cid:2)(cid:36)(cid:34)(cid:33)(cid:2)(cid:124)(cid:111)(cid:2)(cid:139)(cid:111)(cid:134)(cid:311)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)
(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:118)(cid:314)(cid:2)(cid:27)(cid:136)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:45)(cid:118)(cid:124)(cid:2)(cid:55)(cid:59)(cid:49)(cid:45)(cid:55)(cid:59)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:55)(cid:59)(cid:1140)(cid:98)(cid:136)(cid:59)(cid:117)(cid:59)(cid:55)(cid:2)(cid:45)(cid:109)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)
(cid:36)(cid:34)(cid:33)(cid:2)(cid:111)(cid:61)(cid:2)(cid:45)(cid:114)(cid:114)(cid:117)(cid:111)(cid:138)(cid:98)(cid:108)(cid:45)(cid:124)(cid:59)(cid:1140)(cid:139)(cid:2)(cid:400)(cid:401)(cid:314)(cid:1141)(cid:1143)(cid:311)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:48)(cid:59)(cid:130)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:45)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:406)(cid:314)(cid:406)(cid:1143)(cid:2)
(cid:36)(cid:34)(cid:33)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:34)(cid:351)(cid:30)(cid:2)(cid:404)(cid:399)(cid:399)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:98)(cid:109)(cid:55)(cid:59)(cid:138)(cid:2)(cid:55)(cid:134)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:118)(cid:45)(cid:108)(cid:59)(cid:2)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:55)(cid:314)(cid:2)

Key Drivers of TSR
(cid:41)(cid:59)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:98)(cid:118)(cid:124)(cid:59)(cid:109)(cid:124)(cid:1140)(cid:139)(cid:2)(cid:55)(cid:59)(cid:1140)(cid:98)(cid:136)(cid:59)(cid:117)(cid:2)(cid:118)(cid:124)(cid:117)(cid:111)(cid:109)(cid:93)(cid:2)(cid:36)(cid:34)(cid:33)(cid:2)(cid:55)(cid:134)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:55)(cid:59)(cid:136)(cid:111)(cid:2462)(cid:111)(cid:109)(cid:2) 
(cid:124)(cid:111)(cid:2)(cid:59)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:111)(cid:109)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:55)(cid:111)(cid:2)(cid:137)(cid:95)(cid:45)(cid:124)(cid:2)(cid:137)(cid:59)(cid:2)(cid:118)(cid:45)(cid:139)(cid:2)(cid:137)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:93)(cid:111)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:55)(cid:111)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2) 
following are the key drivers of our success:

(cid:336)(cid:400)(cid:337)(cid:2)(cid:3)(cid:2)(cid:9)(cid:98)(cid:136)(cid:59)(cid:117)(cid:118)(cid:98)(cid:67)(cid:59)(cid:55)(cid:2)(cid:30)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:2)(cid:30)(cid:111)(cid:117)(cid:127)(cid:111)(cid:1140)(cid:98)(cid:111)(cid:2)

(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:317)(cid:118)(cid:2)(cid:55)(cid:98)(cid:136)(cid:59)(cid:117)(cid:118)(cid:59)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:2)(cid:114)(cid:111)(cid:117)(cid:127)(cid:111)(cid:1140)(cid:98)(cid:111)(cid:311)(cid:2)
(cid:49)(cid:111)(cid:109)(cid:118)(cid:98)(cid:118)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:111)(cid:61)(cid:2)(cid:48)(cid:111)(cid:124)(cid:95)(cid:2)(cid:114)(cid:117)(cid:59)(cid:108)(cid:98)(cid:134)(cid:108)(cid:2)(cid:336)(cid:1141)(cid:402)(cid:1143)(cid:337)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:136)(cid:45)(cid:1140)(cid:134)(cid:59)(cid:2)(cid:336)(cid:402)(cid:405)(cid:1143)(cid:337)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:311)(cid:2)
enables us to succeed in various economic environments.  
(cid:41)(cid:59)(cid:2)(cid:48)(cid:59)(cid:1140)(cid:98)(cid:59)(cid:136)(cid:59)(cid:2)(cid:109)(cid:111)(cid:2)(cid:111)(cid:124)(cid:95)(cid:59)(cid:117)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:114)(cid:45)(cid:49)(cid:104)(cid:45)(cid:93)(cid:59)(cid:55)(cid:2)(cid:93)(cid:111)(cid:111)(cid:55)(cid:118)(cid:2)(cid:336)(cid:7)(cid:30)(cid:14)(cid:337)(cid:2) 
(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:118)(cid:134)(cid:49)(cid:95)(cid:2)(cid:45)(cid:2)(cid:137)(cid:59)(cid:1140)(cid:1140)(cid:330)(cid:48)(cid:45)(cid:1140)(cid:45)(cid:109)(cid:49)(cid:59)(cid:55)(cid:2)(cid:114)(cid:111)(cid:117)(cid:127)(cid:111)(cid:1140)(cid:98)(cid:111)(cid:2)(cid:111)(cid:61)(cid:2)(cid:48)(cid:111)(cid:124)(cid:95)(cid:2)(cid:114)(cid:117)(cid:59)(cid:108)(cid:98)(cid:134)(cid:108)(cid:2)
and value brands.

(cid:336)(cid:401)(cid:337)(cid:2)(cid:13)(cid:111)(cid:49)(cid:134)(cid:118)(cid:2)(cid:111)(cid:109)(cid:2)(cid:30)(cid:111)(cid:137)(cid:59)(cid:117)(cid:2)(cid:6)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)

In past years, we have highlighted and discussed 14  
(cid:114)(cid:111)(cid:137)(cid:59)(cid:117)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:98)(cid:109)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:114)(cid:111)(cid:117)(cid:127)(cid:111)(cid:1140)(cid:98)(cid:111)(cid:314)(cid:2)(cid:6)(cid:59)(cid:93)(cid:98)(cid:109)(cid:109)(cid:98)(cid:109)(cid:93)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:2) 
(cid:137)(cid:59)(cid:2)(cid:137)(cid:98)(cid:1140)(cid:1140)(cid:2)(cid:61)(cid:111)(cid:49)(cid:134)(cid:118)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:49)(cid:111)(cid:108)(cid:108)(cid:134)(cid:109)(cid:98)(cid:49)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:111)(cid:109)(cid:2)(cid:118)(cid:59)(cid:136)(cid:59)(cid:109)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:137)(cid:59)(cid:2)
(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:124)(cid:111)(cid:2)(cid:48)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:104)(cid:59)(cid:139)(cid:2)(cid:55)(cid:117)(cid:98)(cid:136)(cid:59)(cid:117)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:61)(cid:134)(cid:124)(cid:134)(cid:117)(cid:59)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:118)(cid:59)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:311)(cid:2)
(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:124)(cid:111)(cid:55)(cid:45)(cid:139)(cid:2)(cid:117)(cid:59)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:124)(cid:2)(cid:405)(cid:399)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:114)(cid:117)(cid:111)(cid:67)(cid:124)(cid:118)(cid:311)(cid:2)(cid:114)(cid:117)(cid:98)(cid:108)(cid:45)(cid:117)(cid:98)(cid:1140)(cid:139)(cid:2)
(cid:49)(cid:111)(cid:108)(cid:114)(cid:59)(cid:124)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:1140)(cid:45)(cid:117)(cid:93)(cid:59)(cid:117)(cid:2)(cid:49)(cid:45)(cid:124)(cid:59)(cid:93)(cid:111)(cid:117)(cid:98)(cid:59)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:111)(cid:124)(cid:59)(cid:109)(cid:2462)(cid:45)(cid:1140)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2) 
(cid:93)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)(cid:59)(cid:138)(cid:114)(cid:45)(cid:109)(cid:118)(cid:98)(cid:111)(cid:109)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:118)(cid:59)(cid:136)(cid:59)(cid:109)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:3)(cid:33)(cid:24)(cid:2)(cid:351)(cid:2)(cid:15)(cid:3)(cid:24)(cid:24)(cid:11)(cid:33)(cid:356)(cid:311)(cid:2)
(cid:27)(cid:42)(cid:17)(cid:7)(cid:21)(cid:11)(cid:3)(cid:25)(cid:356)(cid:311)(cid:2)(cid:6)(cid:3)(cid:36)(cid:17)(cid:34)(cid:36)(cid:11)(cid:356)(cid:311)(cid:2)(cid:40)(cid:17)(cid:36)(cid:3)(cid:13)(cid:38)(cid:34)(cid:17)(cid:27)(cid:25)(cid:356)(cid:311)(cid:2)(cid:41)(cid:3)(cid:36)(cid:11)(cid:33)(cid:30)(cid:17)(cid:20)(cid:356)(cid:311)(cid:2)
(cid:36)(cid:15)(cid:11)(cid:33)(cid:3)(cid:6)(cid:33)(cid:11)(cid:3)(cid:36)(cid:15)(cid:356)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:356)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:405)(cid:2)(cid:30)(cid:111)(cid:137)(cid:59)(cid:117)(cid:2)(cid:6)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)
(cid:318)(cid:6)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:2)(cid:7)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:118)(cid:2)(cid:21)(cid:111)(cid:136)(cid:59)(cid:319)(cid:2)(cid:45)(cid:109)(cid:55)(cid:311)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:59)(cid:116)(cid:134)(cid:59)(cid:109)(cid:124)(cid:1140)(cid:139)(cid:311)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:108)(cid:45)(cid:117)(cid:104)(cid:59)(cid:124)(cid:2) 
leaders in most categories. We connect with consumers 
(cid:124)(cid:95)(cid:117)(cid:111)(cid:134)(cid:93)(cid:95)(cid:2)(cid:98)(cid:109)(cid:109)(cid:111)(cid:136)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:109)(cid:59)(cid:137)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:311)(cid:2)(cid:49)(cid:117)(cid:59)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:108)(cid:45)(cid:117)(cid:104)(cid:59)(cid:2462)(cid:109)(cid:93)(cid:2) 
(cid:49)(cid:45)(cid:108)(cid:114)(cid:45)(cid:98)(cid:93)(cid:109)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:118)(cid:134)(cid:118)(cid:124)(cid:45)(cid:98)(cid:109)(cid:59)(cid:55)(cid:2)(cid:108)(cid:45)(cid:117)(cid:104)(cid:59)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:118)(cid:114)(cid:59)(cid:109)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:117)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:2462)(cid:109)(cid:93)(cid:2) 
in high market shares for our brands.

(cid:336)(cid:402)(cid:337)(cid:2)(cid:15)(cid:98)(cid:93)(cid:95)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:14)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)

(cid:27)(cid:134)(cid:117)(cid:2)(cid:11)(cid:136)(cid:59)(cid:117)(cid:93)(cid:117)(cid:59)(cid:59)(cid:109)(cid:2)(cid:108)(cid:111)(cid:55)(cid:59)(cid:1140)(cid:2)(cid:49)(cid:45)(cid:1140)(cid:1140)(cid:118)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:7)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)
(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:118)(cid:2)(cid:1142)(cid:1143)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:314)(cid:2)(cid:36)(cid:111)(cid:55)(cid:45)(cid:139)(cid:311)(cid:2)(cid:400)(cid:405)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2) 
(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:111)(cid:134)(cid:124)(cid:118)(cid:98)(cid:55)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:38)(cid:314)(cid:34)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:61)(cid:134)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)
(cid:118)(cid:134)(cid:48)(cid:118)(cid:98)(cid:55)(cid:98)(cid:45)(cid:117)(cid:98)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:118)(cid:98)(cid:138)(cid:2)(cid:49)(cid:111)(cid:134)(cid:109)(cid:124)(cid:117)(cid:98)(cid:59)(cid:118)(cid:2)(cid:336)(cid:38)(cid:314)(cid:20)(cid:314)(cid:311)(cid:2)(cid:13)(cid:117)(cid:45)(cid:109)(cid:49)(cid:59)(cid:311)(cid:2)(cid:14)(cid:59)(cid:117)(cid:108)(cid:45)(cid:109)(cid:139)(cid:311)(cid:2)(cid:7)(cid:45)(cid:109)(cid:45)(cid:55)(cid:45)(cid:311)(cid:2)
(cid:24)(cid:59)(cid:138)(cid:98)(cid:49)(cid:111)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:3)(cid:134)(cid:118)(cid:124)(cid:117)(cid:45)(cid:1140)(cid:98)(cid:45)(cid:337)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:59)(cid:138)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:400)(cid:402)(cid:399)(cid:2)
(cid:49)(cid:111)(cid:134)(cid:109)(cid:124)(cid:117)(cid:98)(cid:59)(cid:118)(cid:2)(cid:124)(cid:95)(cid:117)(cid:111)(cid:134)(cid:93)(cid:95)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:14)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)(cid:24)(cid:45)(cid:117)(cid:104)(cid:59)(cid:124)(cid:118)(cid:2)(cid:14)(cid:117)(cid:111)(cid:134)(cid:114)(cid:2)(cid:336)(cid:318)(cid:14)(cid:24)(cid:14)(cid:319)(cid:337)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)
(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:98)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:114)(cid:111)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2) 
(cid:111)(cid:61)(cid:2)(cid:1142)(cid:314)(cid:404)(cid:1143)(cid:311)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:98)(cid:118)(cid:2)(cid:45)(cid:48)(cid:111)(cid:136)(cid:59)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:1142)(cid:1143)(cid:2)(cid:11)(cid:136)(cid:59)(cid:117)(cid:93)(cid:117)(cid:59)(cid:59)(cid:109)(cid:2)(cid:108)(cid:111)(cid:55)(cid:59)(cid:1140)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)
(cid:111)(cid:134)(cid:117)(cid:2)(cid:98)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:118)(cid:134)(cid:48)(cid:118)(cid:98)(cid:55)(cid:98)(cid:45)(cid:117)(cid:98)(cid:59)(cid:118)(cid:2)(cid:124)(cid:111)(cid:93)(cid:59)(cid:124)(cid:95)(cid:59)(cid:117)(cid:2)(cid:93)(cid:117)(cid:59)(cid:137)(cid:2)(cid:405)(cid:314)(cid:403)(cid:1143)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2) 
(cid:45)(cid:49)(cid:49)(cid:111)(cid:134)(cid:109)(cid:124)(cid:59)(cid:55)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:1141)(cid:402)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:98)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:314)(cid:2)(cid:14)(cid:24)(cid:14)(cid:2) 
(cid:93)(cid:117)(cid:59)(cid:137)(cid:2)(cid:400)(cid:402)(cid:314)(cid:1141)(cid:1143)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:49)(cid:111)(cid:109)(cid:2462)(cid:109)(cid:134)(cid:59)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:48)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:1140)(cid:45)(cid:117)(cid:93)(cid:59)(cid:118)(cid:124)(cid:2)(cid:98)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)
(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:311)(cid:2)(cid:117)(cid:59)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:402)(cid:405)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:98)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:118)(cid:314)(cid:2) 
(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:137)(cid:98)(cid:1140)(cid:1140)(cid:2)(cid:49)(cid:111)(cid:109)(cid:2462)(cid:109)(cid:134)(cid:59)(cid:2)(cid:108)(cid:45)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:98)(cid:109)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:48)(cid:45)(cid:49)(cid:104)(cid:330)
(cid:111)(cid:76)(cid:49)(cid:59)(cid:2)(cid:98)(cid:109)(cid:61)(cid:117)(cid:45)(cid:118)(cid:124)(cid:117)(cid:134)(cid:49)(cid:124)(cid:134)(cid:117)(cid:59)(cid:311)(cid:2)(cid:59)(cid:118)(cid:114)(cid:59)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:117)(cid:59)(cid:93)(cid:134)(cid:1140)(cid:45)(cid:124)(cid:111)(cid:117)(cid:139)(cid:311)(cid:2)(cid:109)(cid:59)(cid:137)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:2) 
(cid:55)(cid:59)(cid:136)(cid:59)(cid:1140)(cid:111)(cid:114)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:118)(cid:139)(cid:118)(cid:124)(cid:59)(cid:108)(cid:118)(cid:311)(cid:2)(cid:124)(cid:111)(cid:2)(cid:118)(cid:134)(cid:114)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2) 
(cid:1140)(cid:111)(cid:109)(cid:93)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:137)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:14)(cid:24)(cid:14)(cid:314)(cid:2)

(cid:336)(cid:403)(cid:337)(cid:2)(cid:3)(cid:109)(cid:98)(cid:108)(cid:45)(cid:1140)(cid:2)(cid:25)(cid:134)(cid:124)(cid:117)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:14)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:27)(cid:114)(cid:114)(cid:111)(cid:117)(cid:124)(cid:134)(cid:109)(cid:98)(cid:124)(cid:139)(cid:2)

(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:34)(cid:114)(cid:59)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:124)(cid:139)(cid:2)(cid:30)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:2)(cid:55)(cid:98)(cid:136)(cid:98)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:336)(cid:318)(cid:34)(cid:30)(cid:9)(cid:319)(cid:337)(cid:2)(cid:124)(cid:111)(cid:2) 
(cid:93)(cid:117)(cid:111)(cid:137)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:118)(cid:2)(cid:404)(cid:1143)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)(cid:34)(cid:30)(cid:9)(cid:2)(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:118)(cid:2) 
(cid:55)(cid:59)(cid:49)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:55)(cid:2)(cid:405)(cid:314)(cid:406)(cid:1143)(cid:2)(cid:1140)(cid:45)(cid:117)(cid:93)(cid:59)(cid:1140)(cid:139)(cid:2)(cid:55)(cid:134)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:55)(cid:59)(cid:49)(cid:1140)(cid:98)(cid:109)(cid:98)(cid:109)(cid:93)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:24)(cid:11)(cid:14)(cid:3)(cid:21)(cid:3)(cid:7)(cid:2)
(cid:55)(cid:45)(cid:98)(cid:117)(cid:139)(cid:2)(cid:118)(cid:134)(cid:114)(cid:114)(cid:1140)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:98)(cid:109)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:3)(cid:109)(cid:98)(cid:108)(cid:45)(cid:1140)(cid:2)(cid:25)(cid:134)(cid:124)(cid:117)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:314)(cid:2) 

(cid:11)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:24)(cid:11)(cid:14)(cid:3)(cid:21)(cid:3)(cid:7)(cid:311)(cid:2)(cid:34)(cid:30)(cid:9)(cid:2)(cid:93)(cid:117)(cid:59)(cid:137)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:2)(cid:401)(cid:314)(cid:404)(cid:1143)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:314)(cid:2) 
(cid:41)(cid:59)(cid:2)(cid:137)(cid:98)(cid:1140)(cid:1140)(cid:2)(cid:48)(cid:59)(cid:2)(cid:59)(cid:138)(cid:98)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:114)(cid:45)(cid:117)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:3)(cid:109)(cid:98)(cid:108)(cid:45)(cid:1140)(cid:2)(cid:25)(cid:134)(cid:124)(cid:117)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)
(cid:55)(cid:134)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:32)(cid:400)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:1140)(cid:111)(cid:109)(cid:93)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:98)(cid:118)(cid:2)(cid:55)(cid:117)(cid:98)(cid:136)(cid:59)(cid:109)(cid:2)
(cid:48)(cid:139)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:45)(cid:109)(cid:98)(cid:108)(cid:45)(cid:1140)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:61)(cid:111)(cid:111)(cid:55)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:117)(cid:59)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)
(cid:45)(cid:48)(cid:111)(cid:134)(cid:124)(cid:2)(cid:124)(cid:137)(cid:111)(cid:330)(cid:124)(cid:95)(cid:98)(cid:117)(cid:55)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:34)(cid:30)(cid:9)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:45)(cid:91)(cid:59)(cid:117)(cid:2)(cid:59)(cid:138)(cid:98)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:24)(cid:11)(cid:14)(cid:3)(cid:21)(cid:3)(cid:7)(cid:2)
(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:336)(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:117)(cid:59)(cid:108)(cid:45)(cid:98)(cid:109)(cid:55)(cid:59)(cid:117)(cid:2)(cid:1140)(cid:45)(cid:117)(cid:93)(cid:59)(cid:1140)(cid:139)(cid:2)(cid:48)(cid:134)(cid:1140)(cid:104)(cid:2)(cid:118)(cid:111)(cid:55)(cid:98)(cid:134)(cid:108)(cid:2)(cid:48)(cid:98)(cid:49)(cid:45)(cid:117)(cid:48)(cid:111)(cid:109)(cid:45)(cid:124)(cid:59)(cid:337)(cid:314)(cid:2)
(cid:36)(cid:95)(cid:59)(cid:2)(cid:93)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)(cid:114)(cid:111)(cid:114)(cid:134)(cid:1140)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:98)(cid:118)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:98)(cid:118)(cid:59)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:1142)(cid:2)(cid:48)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:2)(cid:124)(cid:111)(cid:55)(cid:45)(cid:139)(cid:2)
(cid:124)(cid:111)(cid:2)(cid:406)(cid:314)(cid:405)(cid:2)(cid:48)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:404)(cid:399)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:55)(cid:59)(cid:108)(cid:45)(cid:109)(cid:55)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:114)(cid:117)(cid:111)(cid:124)(cid:59)(cid:98)(cid:109)(cid:2)(cid:137)(cid:98)(cid:1140)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:2)
(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:114)(cid:111)(cid:114)(cid:134)(cid:1140)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:314)(cid:2)(cid:3)(cid:124)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:118)(cid:45)(cid:108)(cid:59)(cid:2)(cid:2462)(cid:108)(cid:59)(cid:311)(cid:2)(cid:124)(cid:95)(cid:59)(cid:117)(cid:59)(cid:2)(cid:98)(cid:118)(cid:2)(cid:45)(cid:2)(cid:124)(cid:117)(cid:59)(cid:109)(cid:55)(cid:2)
(cid:45)(cid:137)(cid:45)(cid:139)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:134)(cid:118)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:45)(cid:109)(cid:2462)(cid:48)(cid:98)(cid:111)(cid:2462)(cid:49)(cid:118)(cid:311)(cid:2)(cid:95)(cid:111)(cid:117)(cid:108)(cid:111)(cid:109)(cid:59)(cid:118)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:49)(cid:95)(cid:59)(cid:108)(cid:98)(cid:49)(cid:45)(cid:1140)(cid:118)(cid:2)
(cid:98)(cid:109)(cid:2)(cid:45)(cid:109)(cid:98)(cid:108)(cid:45)(cid:1140)(cid:2)(cid:109)(cid:134)(cid:124)(cid:117)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:114)(cid:111)(cid:117)(cid:127)(cid:111)(cid:1140)(cid:98)(cid:111)(cid:2)(cid:111)(cid:61)(cid:2)(cid:109)(cid:45)(cid:124)(cid:134)(cid:117)(cid:45)(cid:1140)(cid:2)(cid:118)(cid:134)(cid:114)(cid:114)(cid:1140)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:118)(cid:311)(cid:2)
(cid:114)(cid:117)(cid:59)(cid:48)(cid:98)(cid:111)(cid:2462)(cid:49)(cid:118)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:49)(cid:134)(cid:118)(cid:124)(cid:111)(cid:108)(cid:2)(cid:114)(cid:117)(cid:111)(cid:48)(cid:98)(cid:111)(cid:2462)(cid:49)(cid:118)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:55)(cid:45)(cid:98)(cid:117)(cid:139)(cid:2)(cid:49)(cid:111)(cid:137)(cid:118)(cid:311)(cid:2)(cid:114)(cid:111)(cid:134)(cid:1140)(cid:124)(cid:117)(cid:139)(cid:311)(cid:2)
(cid:49)(cid:45)(cid:130)(cid:1140)(cid:59)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:118)(cid:137)(cid:98)(cid:109)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:137)(cid:59)(cid:1140)(cid:1140)(cid:330)(cid:114)(cid:111)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:59)(cid:55)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:93)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:314)(cid:2)
(cid:7)(cid:111)(cid:109)(cid:118)(cid:98)(cid:55)(cid:59)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:111)(cid:114)(cid:134)(cid:1140)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:124)(cid:45)(cid:98)(cid:1140)(cid:137)(cid:98)(cid:109)(cid:55)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:118)(cid:124)(cid:117)(cid:59)(cid:109)(cid:93)(cid:124)(cid:95)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)
(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:118)(cid:124)(cid:117)(cid:111)(cid:109)(cid:93)(cid:2)(cid:49)(cid:111)(cid:109)(cid:67)(cid:55)(cid:59)(cid:109)(cid:49)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:1140)(cid:111)(cid:109)(cid:93)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:314)

(5) Winning Online

(cid:27)(cid:134)(cid:117)(cid:2)(cid:1140)(cid:111)(cid:109)(cid:93)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:118)(cid:134)(cid:49)(cid:49)(cid:59)(cid:118)(cid:118)(cid:2)(cid:117)(cid:59)(cid:116)(cid:134)(cid:98)(cid:117)(cid:59)(cid:118)(cid:2)(cid:134)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:48)(cid:59)(cid:2)(cid:318)(cid:55)(cid:98)(cid:93)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:118)(cid:45)(cid:136)(cid:136)(cid:139)(cid:314)(cid:319)(cid:2) 
(cid:41)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:114)(cid:117)(cid:59)(cid:114)(cid:45)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:134)(cid:117)(cid:118)(cid:59)(cid:1140)(cid:136)(cid:59)(cid:118)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:45)(cid:2)(cid:137)(cid:111)(cid:117)(cid:1140)(cid:55)(cid:2)(cid:137)(cid:95)(cid:59)(cid:117)(cid:59)(cid:2)(cid:403)(cid:399)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2) 
(cid:109)(cid:59)(cid:124)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:111)(cid:117)(cid:55)(cid:59)(cid:117)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:400)(cid:404)(cid:311)(cid:2)(cid:111)(cid:109)(cid:1140)(cid:139)(cid:2)(cid:400)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)
(cid:137)(cid:59)(cid:117)(cid:59)(cid:2)(cid:111)(cid:109)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)(cid:45)(cid:114)(cid:114)(cid:117)(cid:111)(cid:138)(cid:98)(cid:108)(cid:45)(cid:124)(cid:59)(cid:1140)(cid:139)(cid:2)(cid:401)(cid:399)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:93)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2) 
(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:137)(cid:59)(cid:117)(cid:59)(cid:2)(cid:111)(cid:109)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:314)(cid:2)(cid:9)(cid:98)(cid:93)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:45)(cid:55)(cid:136)(cid:59)(cid:117)(cid:2462)(cid:118)(cid:98)(cid:109)(cid:93)(cid:2)(cid:98)(cid:109)(cid:89)(cid:134)(cid:59)(cid:109)(cid:49)(cid:59)(cid:118)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)
(cid:114)(cid:134)(cid:117)(cid:49)(cid:95)(cid:45)(cid:118)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:45)(cid:1140)(cid:1140)(cid:2)(cid:49)(cid:1140)(cid:45)(cid:118)(cid:118)(cid:59)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:117)(cid:45)(cid:55)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:109)(cid:111)(cid:137)(cid:2)(cid:45)(cid:49)(cid:49)(cid:111)(cid:134)(cid:109)(cid:124)(cid:118)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:1142)(cid:399)(cid:1143)(cid:2)
(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:118)(cid:114)(cid:59)(cid:109)(cid:55)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:111)(cid:109)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:2)(cid:49)(cid:95)(cid:45)(cid:109)(cid:109)(cid:59)(cid:1140)(cid:2)(cid:49)(cid:111)(cid:109)(cid:2462)(cid:109)(cid:134)(cid:59)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:48)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)
fastest growing class of trade in our company, both in the U.S. 

(cid:45)(cid:109)(cid:55)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:108)(cid:45)(cid:117)(cid:104)(cid:59)(cid:124)(cid:118)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:114)(cid:117)(cid:111)(cid:93)(cid:117)(cid:59)(cid:118)(cid:118)(cid:2)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:2)(cid:98)(cid:1140)(cid:1140)(cid:134)(cid:118)(cid:124)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)
of the digital skills we have developed and the adaptability  
of our Company to be ready for the future. 

(cid:336)(cid:1141)(cid:337)(cid:2)(cid:13)(cid:111)(cid:49)(cid:134)(cid:118)(cid:2)(cid:111)(cid:109)(cid:2)(cid:14)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:24)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)

(cid:14)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:59)(cid:138)(cid:114)(cid:45)(cid:109)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:61)(cid:134)(cid:59)(cid:1140)(cid:118)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:48)(cid:59)(cid:49)(cid:45)(cid:134)(cid:118)(cid:59)(cid:2) 
(cid:98)(cid:124)(cid:2)(cid:59)(cid:109)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:134)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:108)(cid:45)(cid:117)(cid:104)(cid:59)(cid:2462)(cid:109)(cid:93)(cid:311)(cid:2)(cid:33)(cid:351)(cid:9)(cid:311)(cid:2) 
(cid:45)(cid:109)(cid:55)(cid:2)(cid:124)(cid:59)(cid:49)(cid:95)(cid:109)(cid:111)(cid:1140)(cid:111)(cid:93)(cid:139)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:93)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:401)(cid:401)(cid:399)(cid:2)
(cid:48)(cid:45)(cid:118)(cid:98)(cid:118)(cid:2)(cid:114)(cid:111)(cid:98)(cid:109)(cid:124)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:403)(cid:403)(cid:314)(cid:400)(cid:1143)(cid:2)(cid:45)(cid:118)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:2462)(cid:136)(cid:98)(cid:124)(cid:139)(cid:311)(cid:2)(cid:114)(cid:117)(cid:98)(cid:49)(cid:98)(cid:109)(cid:93)(cid:311)(cid:2)(cid:136)(cid:111)(cid:1140)(cid:134)(cid:108)(cid:59)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)
(cid:118)(cid:124)(cid:117)(cid:111)(cid:109)(cid:93)(cid:2)(cid:49)(cid:111)(cid:109)(cid:124)(cid:117)(cid:98)(cid:48)(cid:134)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:95)(cid:98)(cid:93)(cid:95)(cid:59)(cid:117)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:108)(cid:111)(cid:117)(cid:59)(cid:2)
(cid:124)(cid:95)(cid:45)(cid:109)(cid:2)(cid:111)(cid:64)(cid:118)(cid:59)(cid:124)(cid:2)(cid:98)(cid:109)(cid:89)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:314)(cid:2)

(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:93)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:124)(cid:111)(cid:2)(cid:59)(cid:138)(cid:114)(cid:45)(cid:109)(cid:55)(cid:2)(cid:404)(cid:399)(cid:2)(cid:124)(cid:111)(cid:2)(cid:405)(cid:404)(cid:2)(cid:48)(cid:45)(cid:118)(cid:98)(cid:118)(cid:2)
(cid:114)(cid:111)(cid:98)(cid:109)(cid:124)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:45)(cid:109)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:108)(cid:45)(cid:109)(cid:134)(cid:61)(cid:45)(cid:49)(cid:124)(cid:134)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:49)(cid:111)(cid:118)(cid:124)(cid:118)(cid:2) 
(cid:114)(cid:117)(cid:98)(cid:108)(cid:45)(cid:117)(cid:98)(cid:1140)(cid:139)(cid:2)(cid:55)(cid:134)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:49)(cid:45)(cid:114)(cid:45)(cid:49)(cid:98)(cid:124)(cid:139)(cid:330)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:118)(cid:311)(cid:2)(cid:124)(cid:95)(cid:98)(cid:117)(cid:55)(cid:2)(cid:114)(cid:45)(cid:117)(cid:124)(cid:139)(cid:2)
manufacturing cost increases, and moderate commodity 

(cid:98)(cid:109)(cid:89)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:124)(cid:111)(cid:2)(cid:108)(cid:111)(cid:117)(cid:59)(cid:2)(cid:124)(cid:95)(cid:45)(cid:109)(cid:2)(cid:111)(cid:64)(cid:118)(cid:59)(cid:124)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:49)(cid:111)(cid:118)(cid:124)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:118)(cid:2)
(cid:124)(cid:95)(cid:117)(cid:111)(cid:134)(cid:93)(cid:95)(cid:2)(cid:49)(cid:45)(cid:117)(cid:117)(cid:139)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:2)(cid:114)(cid:117)(cid:98)(cid:49)(cid:98)(cid:109)(cid:93)(cid:311)(cid:2)(cid:108)(cid:98)(cid:138)(cid:311)(cid:2)(cid:95)(cid:98)(cid:93)(cid:95)(cid:59)(cid:117)(cid:2)(cid:136)(cid:111)(cid:1140)(cid:134)(cid:108)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)
(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:2462)(cid:136)(cid:98)(cid:124)(cid:139)(cid:314)

  A N N U A L   R E P O R T   202 3   |  3

(cid:336)(cid:405)(cid:337)(cid:2)(cid:14)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:124)(cid:95)(cid:117)(cid:111)(cid:134)(cid:93)(cid:95)(cid:2)(cid:3)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)

(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:45)(cid:2)(cid:1140)(cid:111)(cid:109)(cid:93)(cid:2)(cid:95)(cid:98)(cid:118)(cid:124)(cid:111)(cid:117)(cid:139)(cid:2)(cid:111)(cid:61)(cid:2)(cid:118)(cid:134)(cid:49)(cid:49)(cid:59)(cid:118)(cid:118)(cid:61)(cid:134)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)
(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:59)(cid:118)(cid:314)(cid:2)(cid:27)(cid:136)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:45)(cid:118)(cid:124)(cid:2)(cid:401)(cid:399)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:118)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:117)(cid:59)(cid:55)(cid:2)(cid:45)(cid:1140)(cid:1140)(cid:2)(cid:111)(cid:61)(cid:2)
(cid:111)(cid:134)(cid:117)(cid:2)(cid:30)(cid:111)(cid:137)(cid:59)(cid:117)(cid:2)(cid:6)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:311)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:59)(cid:138)(cid:49)(cid:59)(cid:114)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:111)(cid:61)(cid:2)(cid:3)(cid:117)(cid:108)(cid:2)(cid:351)(cid:2)(cid:15)(cid:45)(cid:108)(cid:108)(cid:59)(cid:117)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)
(cid:114)(cid:111)(cid:118)(cid:118)(cid:59)(cid:118)(cid:118)(cid:2)(cid:45)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:59)(cid:124)(cid:59)(cid:109)(cid:49)(cid:139)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:45)(cid:117)(cid:93)(cid:59)(cid:2462)(cid:109)(cid:93)(cid:311)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:117)(cid:98)(cid:109)(cid:93)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:109)(cid:124)(cid:59)(cid:93)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)
(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:59)(cid:118)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:45)(cid:2)(cid:137)(cid:111)(cid:117)(cid:1140)(cid:55)(cid:2)(cid:137)(cid:95)(cid:59)(cid:117)(cid:59)(cid:2)(cid:118)(cid:59)(cid:136)(cid:59)(cid:109)(cid:2)(cid:111)(cid:134)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:400)(cid:399)(cid:2) 
(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:55)(cid:111)(cid:2)(cid:109)(cid:111)(cid:124)(cid:2)(cid:49)(cid:117)(cid:59)(cid:45)(cid:124)(cid:59)(cid:2)(cid:136)(cid:45)(cid:1140)(cid:134)(cid:59)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:45)(cid:2)(cid:118)(cid:134)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:117)(cid:2)(cid:124)(cid:117)(cid:45)(cid:49)(cid:104)(cid:2)
(cid:117)(cid:59)(cid:49)(cid:111)(cid:117)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:108)(cid:45)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)(cid:45)(cid:49)(cid:49)(cid:117)(cid:59)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:55)(cid:98)(cid:118)(cid:49)(cid:98)(cid:114)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:55)(cid:2) 
(cid:98)(cid:109)(cid:2)(cid:45)(cid:55)(cid:95)(cid:59)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:49)(cid:1140)(cid:59)(cid:45)(cid:117)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:93)(cid:134)(cid:98)(cid:55)(cid:59)(cid:1140)(cid:98)(cid:109)(cid:59)(cid:118)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:61)(cid:111)(cid:49)(cid:134)(cid:118)(cid:2)(cid:111)(cid:109)(cid:2)
(cid:61)(cid:45)(cid:118)(cid:124)(cid:330)(cid:108)(cid:111)(cid:136)(cid:98)(cid:109)(cid:93)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:116)(cid:134)(cid:98)(cid:49)(cid:104)(cid:1140)(cid:139)(cid:2)(cid:98)(cid:109)(cid:124)(cid:59)(cid:93)(cid:117)(cid:45)(cid:124)(cid:59)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2) 
(cid:124)(cid:111)(cid:2)(cid:1140)(cid:59)(cid:136)(cid:59)(cid:117)(cid:45)(cid:93)(cid:59)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:59)(cid:138)(cid:98)(cid:118)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:49)(cid:45)(cid:114)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:48)(cid:45)(cid:118)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:108)(cid:45)(cid:109)(cid:134)(cid:61)(cid:45)(cid:49)(cid:124)(cid:134)(cid:117)(cid:98)(cid:109)(cid:93)(cid:311)(cid:2)
(cid:1140)(cid:111)(cid:93)(cid:98)(cid:118)(cid:2462)(cid:49)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:114)(cid:134)(cid:117)(cid:49)(cid:95)(cid:45)(cid:118)(cid:98)(cid:109)(cid:93)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:111)(cid:124)(cid:95)(cid:59)(cid:117)(cid:2)(cid:48)(cid:45)(cid:49)(cid:104)(cid:330)(cid:111)(cid:76)(cid:49)(cid:59)(cid:2)(cid:61)(cid:134)(cid:109)(cid:49)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)
(cid:9)(cid:59)(cid:49)(cid:59)(cid:108)(cid:48)(cid:59)(cid:117)(cid:2)(cid:401)(cid:399)(cid:401)(cid:400)(cid:311)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:117)(cid:59)(cid:55)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:36)(cid:15)(cid:11)(cid:33)(cid:3)(cid:6)(cid:33)(cid:11)(cid:3)(cid:36)(cid:15)(cid:2)
brand which is the fastest growing mouthwash in the U.S. 

(cid:27)(cid:136)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:45)(cid:118)(cid:124)(cid:2)(cid:124)(cid:137)(cid:111)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:118)(cid:311)(cid:2)(cid:98)(cid:124)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:48)(cid:59)(cid:49)(cid:111)(cid:108)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:370)(cid:400)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:59)(cid:55)(cid:2)(cid:109)(cid:111)(cid:109)(cid:330)
(cid:45)(cid:1140)(cid:49)(cid:111)(cid:95)(cid:111)(cid:1140)(cid:2)(cid:108)(cid:111)(cid:134)(cid:124)(cid:95)(cid:137)(cid:45)(cid:118)(cid:95)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:370)(cid:402)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:124)(cid:111)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:108)(cid:111)(cid:134)(cid:124)(cid:95)(cid:137)(cid:45)(cid:118)(cid:95)(cid:2)
(cid:49)(cid:45)(cid:124)(cid:59)(cid:93)(cid:111)(cid:117)(cid:139)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:27)(cid:49)(cid:124)(cid:111)(cid:48)(cid:59)(cid:117)(cid:2)(cid:401)(cid:399)(cid:401)(cid:401)(cid:311)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:117)(cid:59)(cid:55)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:2)
(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:314)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:2)(cid:98)(cid:118)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:370)(cid:400)(cid:2)(cid:48)(cid:117)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:45)(cid:49)(cid:109)(cid:59)(cid:2)(cid:114)(cid:45)(cid:124)(cid:49)(cid:95)(cid:2)(cid:49)(cid:45)(cid:124)(cid:59)(cid:93)(cid:111)(cid:117)(cid:139)(cid:2)(cid:98)(cid:109)(cid:2)
the United States and is now the #1 brand in the broader 

(cid:45)(cid:49)(cid:109)(cid:59)(cid:2)(cid:124)(cid:117)(cid:59)(cid:45)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:49)(cid:45)(cid:124)(cid:59)(cid:93)(cid:111)(cid:117)(cid:139)(cid:314)(cid:2)(cid:36)(cid:15)(cid:11)(cid:33)(cid:3)(cid:6)(cid:33)(cid:11)(cid:3)(cid:36)(cid:15)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)
(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:55)(cid:117)(cid:98)(cid:136)(cid:59)(cid:2)(cid:48)(cid:111)(cid:124)(cid:95)(cid:2)(cid:38)(cid:314)(cid:34)(cid:314)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:98)(cid:109)(cid:2) 
the coming years. 

(8) “BEST IN CLASS” Free Cash Flow Conversion

(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)(cid:336)(cid:7)(cid:45)(cid:118)(cid:95)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:27)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:108)(cid:98)(cid:109)(cid:134)(cid:118)(cid:2)
(cid:7)(cid:45)(cid:114)(cid:59)(cid:138)(cid:337)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:362)(cid:1142)(cid:399)(cid:405)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:49)(cid:111)(cid:109)(cid:136)(cid:59)(cid:117)(cid:124)(cid:59)(cid:55)(cid:2)(cid:400)(cid:399)(cid:402)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2) 
(cid:111)(cid:134)(cid:117)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:109)(cid:59)(cid:124)(cid:2)(cid:98)(cid:109)(cid:49)(cid:111)(cid:108)(cid:59)(cid:2)(cid:98)(cid:109)(cid:124)(cid:111)(cid:2)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)(cid:336)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)
(cid:49)(cid:111)(cid:109)(cid:136)(cid:59)(cid:117)(cid:118)(cid:98)(cid:111)(cid:109)(cid:337)(cid:314)(cid:2)(cid:27)(cid:136)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:45)(cid:118)(cid:124)(cid:2)(cid:400)(cid:399)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:118)(cid:311)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2) 
(cid:49)(cid:111)(cid:109)(cid:136)(cid:59)(cid:117)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:1140)(cid:59)(cid:55)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:30)(cid:14)(cid:2)(cid:98)(cid:109)(cid:55)(cid:134)(cid:118)(cid:124)(cid:117)(cid:139)(cid:311)(cid:2)(cid:45)(cid:136)(cid:59)(cid:117)(cid:45)(cid:93)(cid:98)(cid:109)(cid:93)(cid:2)(cid:400)(cid:400)(cid:406)(cid:1143)(cid:314)(cid:2) 
(cid:27)(cid:136)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:109)(cid:59)(cid:138)(cid:124)(cid:2)(cid:124)(cid:95)(cid:117)(cid:59)(cid:59)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:118)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:45)(cid:109)(cid:2462)(cid:49)(cid:98)(cid:114)(cid:45)(cid:124)(cid:59)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:137)(cid:59)(cid:2)(cid:137)(cid:98)(cid:1140)(cid:1140)(cid:2)(cid:93)(cid:59)(cid:109)(cid:59)(cid:117)(cid:45)(cid:124)(cid:59)(cid:2)
(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:362)(cid:401)(cid:314)(cid:404)(cid:2)(cid:48)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:2)(cid:98)(cid:109)(cid:2)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:67)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)
(cid:118)(cid:124)(cid:117)(cid:59)(cid:109)(cid:93)(cid:124)(cid:95)(cid:2)(cid:124)(cid:111)(cid:2)(cid:59)(cid:109)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:2)(cid:134)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:45)(cid:93)(cid:93)(cid:117)(cid:59)(cid:118)(cid:118)(cid:98)(cid:136)(cid:59)(cid:1140)(cid:139)(cid:2)(cid:114)(cid:134)(cid:117)(cid:118)(cid:134)(cid:59)(cid:2)(cid:36)(cid:34)(cid:33)(cid:330)(cid:45)(cid:49)(cid:49)(cid:117)(cid:59)(cid:2462)(cid:136)(cid:59)(cid:2)
(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:311)(cid:2)(cid:108)(cid:45)(cid:104)(cid:59)(cid:2)(cid:49)(cid:45)(cid:114)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:49)(cid:111)(cid:109)(cid:2462)(cid:109)(cid:134)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:118)(cid:134)(cid:114)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)
(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:117)(cid:111)(cid:67)(cid:124)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:59)(cid:138)(cid:98)(cid:118)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:59)(cid:118)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:117)(cid:59)(cid:124)(cid:134)(cid:117)(cid:109)(cid:2)
(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:124)(cid:111)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:117)(cid:59)(cid:124)(cid:134)(cid:117)(cid:109)(cid:2)(cid:402)(cid:402)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2) 
net income to shareholders in the form of dividends, with a 

(cid:1140)(cid:111)(cid:109)(cid:93)(cid:330)(cid:124)(cid:59)(cid:117)(cid:108)(cid:2)(cid:124)(cid:45)(cid:117)(cid:93)(cid:59)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:402)(cid:399)(cid:1143)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:2)
(cid:48)(cid:139)(cid:2)(cid:403)(cid:1143)(cid:2)(cid:98)(cid:109)(cid:2)(cid:19)(cid:45)(cid:109)(cid:134)(cid:45)(cid:117)(cid:139)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:314)(cid:2)(cid:27)(cid:136)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:1140)(cid:45)(cid:118)(cid:124)(cid:2)(cid:67)(cid:136)(cid:59)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:118)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2) 
(cid:45)(cid:136)(cid:59)(cid:117)(cid:45)(cid:93)(cid:59)(cid:55)(cid:2)(cid:45)(cid:2)(cid:403)(cid:1143)(cid:2)(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:117)(cid:45)(cid:124)(cid:59)(cid:311)(cid:2)(cid:45)(cid:95)(cid:59)(cid:45)(cid:55)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:59)(cid:59)(cid:117)(cid:2) 
(cid:45)(cid:136)(cid:59)(cid:117)(cid:45)(cid:93)(cid:59)(cid:2)(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:117)(cid:45)(cid:124)(cid:59)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:114)(cid:45)(cid:98)(cid:55)(cid:2)(cid:45)(cid:2)(cid:116)(cid:134)(cid:45)(cid:117)(cid:124)(cid:59)(cid:117)(cid:1140)(cid:139)(cid:2) 
(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:400)(cid:401)(cid:402)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:118)(cid:314)

(9) Superior Overhead Management

(cid:24)(cid:45)(cid:98)(cid:109)(cid:124)(cid:45)(cid:98)(cid:109)(cid:98)(cid:109)(cid:93)(cid:2)(cid:2462)(cid:93)(cid:95)(cid:124)(cid:2)(cid:49)(cid:111)(cid:109)(cid:124)(cid:117)(cid:111)(cid:1140)(cid:118)(cid:2)(cid:111)(cid:109)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:59)(cid:1140)(cid:1140)(cid:98)(cid:109)(cid:93)(cid:311)(cid:2)(cid:93)(cid:59)(cid:109)(cid:59)(cid:117)(cid:45)(cid:1140)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2) 
(cid:45)(cid:55)(cid:108)(cid:98)(cid:109)(cid:98)(cid:118)(cid:124)(cid:117)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:109)(cid:118)(cid:59)(cid:2)(cid:336)(cid:318)(cid:34)(cid:14)(cid:351)(cid:3)(cid:319)(cid:337)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:48)(cid:59)(cid:59)(cid:109)(cid:2)(cid:45)(cid:2)(cid:95)(cid:45)(cid:1140)(cid:1140)(cid:108)(cid:45)(cid:117)(cid:104)(cid:2) 
(cid:111)(cid:61)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:34)(cid:14)(cid:351)(cid:3)(cid:2)(cid:98)(cid:118)(cid:2)(cid:400)(cid:403)(cid:314)(cid:405)(cid:1143)(cid:314)(cid:2)(cid:36)(cid:95)(cid:98)(cid:118)(cid:2) 
overhead rate is one of the lowest in the CPG space.  

We believe we have the highest revenue per employee  
(cid:111)(cid:61)(cid:2)(cid:45)(cid:109)(cid:139)(cid:2)(cid:108)(cid:45)(cid:102)(cid:111)(cid:117)(cid:2)(cid:7)(cid:30)(cid:14)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:336)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:362)(cid:400)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:59)(cid:108)(cid:114)(cid:1140)(cid:111)(cid:139)(cid:59)(cid:59)(cid:337)(cid:311)(cid:2) 
(cid:45)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:2462)(cid:136)(cid:98)(cid:124)(cid:139)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:98)(cid:118)(cid:2)(cid:111)(cid:91)(cid:59)(cid:109)(cid:2)(cid:111)(cid:136)(cid:59)(cid:117)(cid:1140)(cid:111)(cid:111)(cid:104)(cid:59)(cid:55)(cid:314)(cid:2) 
(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:59)(cid:117)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:49)(cid:111)(cid:108)(cid:108)(cid:98)(cid:130)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:1140)(cid:111)(cid:137)(cid:59)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2) 
costs while growing consumer loyalty to our brands and  
providing outstanding service to our retail customers.  
(cid:6)(cid:59)(cid:49)(cid:45)(cid:134)(cid:118)(cid:59)(cid:2)(cid:137)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:1140)(cid:59)(cid:45)(cid:109)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:45)(cid:2)(cid:109)(cid:98)(cid:108)(cid:48)(cid:1140)(cid:59)(cid:2)(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:140)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2) 
(cid:59)(cid:109)(cid:45)(cid:48)(cid:1140)(cid:98)(cid:109)(cid:93)(cid:2)(cid:134)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:49)(cid:111)(cid:108)(cid:108)(cid:134)(cid:109)(cid:98)(cid:49)(cid:45)(cid:124)(cid:59)(cid:2)(cid:59)(cid:45)(cid:118)(cid:98)(cid:1140)(cid:139)(cid:311)(cid:2)(cid:108)(cid:45)(cid:104)(cid:59)(cid:2)(cid:116)(cid:134)(cid:98)(cid:49)(cid:104)(cid:2)(cid:55)(cid:59)(cid:49)(cid:98)(cid:118)(cid:98)(cid:111)(cid:109)(cid:118)(cid:311)(cid:2) 
and adapt to change.

(cid:336)(cid:400)(cid:399)(cid:337)(cid:2)(cid:34)(cid:98)(cid:108)(cid:114)(cid:1140)(cid:59)(cid:2)(cid:17)(cid:109)(cid:49)(cid:59)(cid:109)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:59)(cid:109)(cid:118)(cid:45)(cid:2462)(cid:111)(cid:109)

(cid:3)(cid:124)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:59)(cid:108)(cid:48)(cid:117)(cid:45)(cid:49)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:111)(cid:137)(cid:59)(cid:117)(cid:2)(cid:111)(cid:61)(cid:2)(cid:118)(cid:98)(cid:108)(cid:114)(cid:1140)(cid:98)(cid:49)(cid:98)(cid:124)(cid:139)(cid:314)(cid:2)
(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:98)(cid:118)(cid:2)(cid:59)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:2)(cid:98)(cid:109)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:98)(cid:108)(cid:114)(cid:1140)(cid:59)(cid:2)(cid:98)(cid:109)(cid:49)(cid:59)(cid:109)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:59)(cid:109)(cid:118)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:114)(cid:1140)(cid:45)(cid:109)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)
(cid:401)(cid:399)(cid:401)(cid:402)(cid:311)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:48)(cid:111)(cid:109)(cid:134)(cid:118)(cid:59)(cid:118)(cid:2)(cid:137)(cid:59)(cid:117)(cid:59)(cid:2)(cid:2462)(cid:59)(cid:55)(cid:2)(cid:55)(cid:98)(cid:117)(cid:59)(cid:49)(cid:124)(cid:1140)(cid:139)(cid:2)(cid:124)(cid:111)(cid:2)(cid:67)(cid:136)(cid:59)(cid:2)(cid:59)(cid:116)(cid:134)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:137)(cid:59)(cid:98)(cid:93)(cid:95)(cid:124)(cid:59)(cid:55)(cid:2)
(cid:55)(cid:117)(cid:98)(cid:136)(cid:59)(cid:117)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:36)(cid:34)(cid:33)(cid:313)(cid:2)(cid:109)(cid:59)(cid:124)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:311)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:93)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2) 
(cid:114)(cid:59)(cid:117)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:109)(cid:49)(cid:59)(cid:2)(cid:336)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:55)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:114)(cid:59)(cid:59)(cid:117)(cid:118)(cid:337)(cid:311)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:311)(cid:2)
(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:118)(cid:124)(cid:117)(cid:45)(cid:124)(cid:59)(cid:93)(cid:98)(cid:49)(cid:2)(cid:98)(cid:109)(cid:98)(cid:2462)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:118)(cid:2)(cid:336)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:2)
(cid:9)(cid:98)(cid:93)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:3)(cid:49)(cid:49)(cid:59)(cid:1140)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:11)(cid:138)(cid:114)(cid:45)(cid:109)(cid:118)(cid:98)(cid:111)(cid:109)(cid:311)(cid:2)(cid:34)(cid:134)(cid:118)(cid:124)(cid:45)(cid:98)(cid:109)(cid:45)(cid:48)(cid:98)(cid:1140)(cid:98)(cid:124)(cid:139)(cid:311)(cid:2)
(cid:9)(cid:98)(cid:136)(cid:59)(cid:117)(cid:118)(cid:98)(cid:124)(cid:139)(cid:2)(cid:351)(cid:2)(cid:17)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:118)(cid:98)(cid:111)(cid:109)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:3)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:93)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:337)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:59)(cid:116)(cid:134)(cid:98)(cid:124)(cid:139)(cid:2)
(cid:49)(cid:111)(cid:108)(cid:114)(cid:59)(cid:109)(cid:118)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:98)(cid:118)(cid:124)(cid:118)(cid:2)(cid:114)(cid:117)(cid:59)(cid:55)(cid:111)(cid:108)(cid:98)(cid:109)(cid:45)(cid:109)(cid:124)(cid:1140)(cid:139)(cid:2)(cid:111)(cid:61)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:111)(cid:114)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:336)(cid:405)(cid:404)(cid:1143)(cid:337)(cid:2)
that are valuable only when the value of your investment 

(cid:117)(cid:98)(cid:118)(cid:59)(cid:118)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:117)(cid:59)(cid:108)(cid:45)(cid:98)(cid:109)(cid:98)(cid:109)(cid:93)(cid:2)(cid:401)(cid:404)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:59)(cid:116)(cid:134)(cid:98)(cid:124)(cid:139)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:59)(cid:109)(cid:118)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)
comprised of two other vehicles: performance stock units 

(cid:336)(cid:400)(cid:404)(cid:1143)(cid:337)(cid:2)(cid:2462)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:124)(cid:111)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:2)(cid:117)(cid:59)(cid:124)(cid:134)(cid:117)(cid:109)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:117)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:114)(cid:59)(cid:59)(cid:117)(cid:2)
(cid:93)(cid:117)(cid:111)(cid:134)(cid:114)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:2462)(cid:108)(cid:59)(cid:330)(cid:48)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:117)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:134)(cid:109)(cid:98)(cid:124)(cid:118)(cid:2)(cid:336)(cid:400)(cid:399)(cid:1143)(cid:337)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:118)(cid:59)(cid:109)(cid:98)(cid:111)(cid:117)(cid:2)
(cid:108)(cid:45)(cid:109)(cid:45)(cid:93)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:124)(cid:59)(cid:45)(cid:108)(cid:2)(cid:108)(cid:134)(cid:118)(cid:124)(cid:2)(cid:108)(cid:45)(cid:98)(cid:109)(cid:124)(cid:45)(cid:98)(cid:109)(cid:2)(cid:45)(cid:2)(cid:118)(cid:98)(cid:93)(cid:109)(cid:98)(cid:67)(cid:49)(cid:45)(cid:109)(cid:124)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:98)(cid:109)(cid:2)
our stock to be aligned with you, our stockholders.

Sustainability
(cid:34)(cid:134)(cid:118)(cid:124)(cid:45)(cid:98)(cid:109)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:114)(cid:117)(cid:45)(cid:49)(cid:2462)(cid:49)(cid:59)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:59)(cid:118)(cid:114)(cid:59)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:98)(cid:108)(cid:114)(cid:111)(cid:117)(cid:124)(cid:45)(cid:109)(cid:124)(cid:2) 
to our Company, our employees, our retailers, and our  
consumers. Church & Dwight has been a friend of the  
(cid:59)(cid:109)(cid:136)(cid:98)(cid:117)(cid:111)(cid:109)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:118)(cid:98)(cid:109)(cid:49)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:59)(cid:45)(cid:117)(cid:1140)(cid:139)(cid:2)(cid:401)(cid:399)(cid:124)(cid:95)(cid:2)(cid:49)(cid:59)(cid:109)(cid:124)(cid:134)(cid:117)(cid:139)(cid:314)(cid:2)(cid:17)(cid:109)(cid:2)(cid:400)(cid:406)(cid:399)(cid:405)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2) 
began using recycled paperboard in our packaging. In the 
(cid:400)(cid:406)(cid:405)(cid:399)(cid:317)(cid:118)(cid:311)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:111)(cid:109)(cid:1140)(cid:139)(cid:2)(cid:49)(cid:111)(cid:117)(cid:114)(cid:111)(cid:117)(cid:45)(cid:124)(cid:59)(cid:2)(cid:118)(cid:114)(cid:111)(cid:109)(cid:118)(cid:111)(cid:117)(cid:2) 
(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:67)(cid:117)(cid:118)(cid:124)(cid:2)(cid:11)(cid:45)(cid:117)(cid:124)(cid:95)(cid:2)(cid:9)(cid:45)(cid:139)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:67)(cid:117)(cid:118)(cid:124)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:59)(cid:108)(cid:111)(cid:136)(cid:59)(cid:2)(cid:114)(cid:95)(cid:111)(cid:118)(cid:114)(cid:95)(cid:45)(cid:124)(cid:59)(cid:118)(cid:2) 
(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:1140)(cid:45)(cid:134)(cid:109)(cid:55)(cid:117)(cid:139)(cid:2)(cid:55)(cid:59)(cid:124)(cid:59)(cid:117)(cid:93)(cid:59)(cid:109)(cid:124)(cid:314)(cid:2)(cid:34)(cid:98)(cid:109)(cid:49)(cid:59)(cid:2)(cid:401)(cid:399)(cid:400)(cid:1141)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:114)(cid:1140)(cid:45)(cid:109)(cid:124)(cid:59)(cid:55)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:118)(cid:2)
(cid:111)(cid:61)(cid:2)(cid:124)(cid:117)(cid:59)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:24)(cid:98)(cid:118)(cid:118)(cid:98)(cid:118)(cid:118)(cid:98)(cid:114)(cid:114)(cid:98)(cid:2)(cid:40)(cid:45)(cid:1140)(cid:1140)(cid:59)(cid:139)(cid:2)(cid:124)(cid:95)(cid:117)(cid:111)(cid:134)(cid:93)(cid:95)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:114)(cid:45)(cid:117)(cid:124)(cid:109)(cid:59)(cid:117)(cid:118)(cid:95)(cid:98)(cid:114)(cid:2) 
(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:3)(cid:117)(cid:48)(cid:111)(cid:117)(cid:2)(cid:9)(cid:45)(cid:139)(cid:2)(cid:13)(cid:111)(cid:134)(cid:109)(cid:55)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:314)(cid:2)(cid:36)(cid:111)(cid:55)(cid:45)(cid:139)(cid:311)(cid:2)(cid:400)(cid:399)(cid:399)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:93)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)
electricity is derived from renewable resources. We are  

(cid:49)(cid:111)(cid:108)(cid:108)(cid:98)(cid:130)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:55)(cid:111)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:114)(cid:45)(cid:117)(cid:124)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:59)(cid:109)(cid:136)(cid:98)(cid:117)(cid:111)(cid:109)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)
(cid:49)(cid:111)(cid:108)(cid:108)(cid:98)(cid:130)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:34)(cid:49)(cid:98)(cid:59)(cid:109)(cid:49)(cid:59)(cid:330)(cid:6)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:36)(cid:45)(cid:117)(cid:93)(cid:59)(cid:124)(cid:118)(cid:2)(cid:17)(cid:109)(cid:98)(cid:2462)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:336)(cid:34)(cid:6)(cid:36)(cid:98)(cid:337)(cid:314)(cid:2) 
(cid:34)(cid:6)(cid:36)(cid:98)(cid:2)(cid:98)(cid:118)(cid:2)(cid:61)(cid:111)(cid:49)(cid:134)(cid:118)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:2)(cid:117)(cid:59)(cid:55)(cid:134)(cid:49)(cid:98)(cid:109)(cid:93)(cid:2)(cid:14)(cid:117)(cid:59)(cid:59)(cid:109)(cid:95)(cid:111)(cid:134)(cid:118)(cid:59)(cid:2)(cid:14)(cid:45)(cid:118)(cid:2)(cid:11)(cid:108)(cid:98)(cid:118)(cid:118)(cid:98)(cid:111)(cid:109)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)
(cid:95)(cid:59)(cid:1140)(cid:114)(cid:2)(cid:104)(cid:59)(cid:59)(cid:114)(cid:2)(cid:93)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)(cid:49)(cid:1140)(cid:98)(cid:108)(cid:45)(cid:124)(cid:59)(cid:2)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:2)(cid:118)(cid:45)(cid:61)(cid:59)(cid:1140)(cid:139)(cid:2)(cid:48)(cid:59)(cid:1140)(cid:111)(cid:137)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:401)(cid:330)(cid:55)(cid:59)(cid:93)(cid:117)(cid:59)(cid:59)(cid:2)
(cid:124)(cid:95)(cid:117)(cid:59)(cid:118)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:311)(cid:2)(cid:45)(cid:1140)(cid:98)(cid:93)(cid:109)(cid:59)(cid:55)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:30)(cid:45)(cid:117)(cid:98)(cid:118)(cid:2)(cid:3)(cid:93)(cid:117)(cid:59)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:93)(cid:111)(cid:45)(cid:1140)(cid:118)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2) 
(cid:49)(cid:111)(cid:109)(cid:2462)(cid:109)(cid:134)(cid:59)(cid:55)(cid:2)(cid:98)(cid:108)(cid:114)(cid:117)(cid:111)(cid:136)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:117)(cid:59)(cid:93)(cid:45)(cid:117)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:34)(cid:134)(cid:118)(cid:124)(cid:45)(cid:98)(cid:109)(cid:45)(cid:48)(cid:98)(cid:1140)(cid:98)(cid:124)(cid:139)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2) 

4  |  CHURCH & DWIGHT CO., INC.

2024 Outlook* 
(cid:336)(cid:45)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:13)(cid:59)(cid:48)(cid:117)(cid:134)(cid:45)(cid:117)(cid:139)(cid:2)(cid:401)(cid:311)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:2)(cid:330)(cid:2)(cid:7)(cid:15)(cid:9)(cid:2)(cid:3)(cid:109)(cid:45)(cid:1140)(cid:139)(cid:118)(cid:124)(cid:2)(cid:9)(cid:45)(cid:139)(cid:337)

(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:59)(cid:55)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:124)(cid:111)(cid:2)(cid:48)(cid:59)(cid:2)(cid:403)(cid:330)(cid:404)(cid:1143)(cid:2)(cid:98)(cid:109)(cid:2)
(cid:401)(cid:399)(cid:401)(cid:403)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:93)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:59)(cid:138)(cid:114)(cid:45)(cid:109)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:111)(cid:61)(cid:2)(cid:404)(cid:399)(cid:2)(cid:124)(cid:111)(cid:2)(cid:405)(cid:404)(cid:2)(cid:48)(cid:45)(cid:118)(cid:98)(cid:118)(cid:2)
(cid:114)(cid:111)(cid:98)(cid:109)(cid:124)(cid:118)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:109)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:49)(cid:117)(cid:59)(cid:45)(cid:118)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:108)(cid:45)(cid:117)(cid:104)(cid:59)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:55)(cid:111)(cid:1140)(cid:1140)(cid:45)(cid:117)(cid:118)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)
(cid:45)(cid:2)(cid:89)(cid:45)(cid:124)(cid:2)(cid:124)(cid:45)(cid:117)(cid:93)(cid:59)(cid:124)(cid:2)(cid:118)(cid:114)(cid:59)(cid:109)(cid:55)(cid:2)(cid:111)(cid:61)(cid:2)(cid:400)(cid:400)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)
(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:48)(cid:59)(cid:2)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:362)(cid:400)(cid:2)(cid:48)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:114)(cid:117)(cid:98)(cid:111)(cid:117)(cid:98)(cid:2462)(cid:59)(cid:118)(cid:2)
(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:61)(cid:117)(cid:45)(cid:118)(cid:124)(cid:117)(cid:134)(cid:49)(cid:124)(cid:134)(cid:117)(cid:59)(cid:2)(cid:336)(cid:59)(cid:118)(cid:114)(cid:59)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:14)(cid:24)(cid:14)(cid:337)(cid:2)
(cid:45)(cid:109)(cid:55)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:59)(cid:49)(cid:111)(cid:108)(cid:108)(cid:59)(cid:117)(cid:49)(cid:59)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:59)(cid:2462)(cid:2462)(cid:136)(cid:59)(cid:109)(cid:59)(cid:118)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:49)(cid:124)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:49)(cid:45)(cid:114)(cid:59)(cid:138)(cid:2)
(cid:118)(cid:114)(cid:59)(cid:109)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:48)(cid:59)(cid:2)(cid:362)(cid:400)(cid:1142)(cid:399)(cid:2)(cid:108)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:111)(cid:109)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:117)(cid:59)(cid:124)(cid:134)(cid:117)(cid:109)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2) 
(cid:95)(cid:98)(cid:118)(cid:124)(cid:111)(cid:117)(cid:98)(cid:49)(cid:45)(cid:1140)(cid:2)(cid:1140)(cid:59)(cid:136)(cid:59)(cid:1140)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:401)(cid:1143)(cid:2)(cid:111)(cid:61)(cid:2)(cid:117)(cid:59)(cid:136)(cid:59)(cid:109)(cid:134)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:404)(cid:314)

(cid:41)(cid:59)(cid:2)(cid:59)(cid:138)(cid:98)(cid:124)(cid:59)(cid:55)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:118)(cid:124)(cid:117)(cid:111)(cid:109)(cid:93)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:114)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:45)(cid:49)(cid:117)(cid:111)(cid:118)(cid:118)(cid:2) 
(cid:124)(cid:95)(cid:59)(cid:2)(cid:108)(cid:45)(cid:102)(cid:111)(cid:117)(cid:98)(cid:124)(cid:139)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:49)(cid:45)(cid:124)(cid:59)(cid:93)(cid:111)(cid:117)(cid:98)(cid:59)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:49)(cid:111)(cid:109)(cid:67)(cid:55)(cid:59)(cid:109)(cid:124)(cid:2)(cid:45)(cid:48)(cid:111)(cid:134)(cid:124)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:2)
(cid:45)(cid:109)(cid:55)(cid:2)(cid:117)(cid:59)(cid:108)(cid:45)(cid:98)(cid:109)(cid:2)(cid:61)(cid:111)(cid:49)(cid:134)(cid:118)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:2)(cid:111)(cid:64)(cid:59)(cid:117)(cid:98)(cid:109)(cid:93)(cid:2)(cid:95)(cid:98)(cid:93)(cid:95)(cid:2)(cid:116)(cid:134)(cid:45)(cid:1140)(cid:98)(cid:124)(cid:139)(cid:2)(cid:114)(cid:117)(cid:111)(cid:55)(cid:134)(cid:49)(cid:124)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2) 
consumers at the right value.

I would like to thank all employees of Church & Dwight for 

(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:59)(cid:117)(cid:118)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:118)(cid:45)(cid:49)(cid:117)(cid:98)(cid:67)(cid:49)(cid:59)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:124)(cid:95)(cid:59)(cid:139)(cid:2)(cid:108)(cid:45)(cid:55)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:55)(cid:59)(cid:1140)(cid:98)(cid:136)(cid:59)(cid:117)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)
(cid:117)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:124)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:314)

MATTHEW T. FARRELL

Chairman, President
(cid:45)(cid:109)(cid:55)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

(cid:11)(cid:109)(cid:136)(cid:98)(cid:117)(cid:111)(cid:109)(cid:108)(cid:59)(cid:109)(cid:124)(cid:45)(cid:1140)(cid:311)(cid:2)(cid:34)(cid:111)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:14)(cid:111)(cid:136)(cid:59)(cid:117)(cid:109)(cid:45)(cid:109)(cid:49)(cid:59)(cid:2)(cid:336)(cid:11)(cid:34)(cid:14)(cid:337)(cid:2)(cid:98)(cid:118)(cid:2)(cid:48)(cid:59)(cid:98)(cid:109)(cid:93)(cid:2) 
(cid:117)(cid:59)(cid:49)(cid:111)(cid:93)(cid:109)(cid:98)(cid:140)(cid:59)(cid:55)(cid:2)(cid:48)(cid:139)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:111)(cid:134)(cid:124)(cid:118)(cid:98)(cid:55)(cid:59)(cid:2)(cid:137)(cid:111)(cid:117)(cid:1140)(cid:55)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:24)(cid:34)(cid:7)(cid:17)(cid:2)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:311)(cid:2)(cid:45)(cid:2)(cid:402)(cid:117)(cid:55)(cid:2) 
(cid:114)(cid:45)(cid:117)(cid:124)(cid:139)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:45)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:108)(cid:45)(cid:109)(cid:45)(cid:93)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:67)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)
(cid:117)(cid:59)(cid:1140)(cid:59)(cid:136)(cid:45)(cid:109)(cid:124)(cid:2)(cid:11)(cid:34)(cid:14)(cid:2)(cid:117)(cid:98)(cid:118)(cid:104)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:111)(cid:114)(cid:114)(cid:111)(cid:117)(cid:124)(cid:134)(cid:109)(cid:98)(cid:2462)(cid:59)(cid:118)(cid:311)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:98)(cid:108)(cid:114)(cid:117)(cid:111)(cid:136)(cid:59)(cid:55)(cid:2)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)
(cid:1140)(cid:45)(cid:118)(cid:124)(cid:2)(cid:124)(cid:95)(cid:117)(cid:59)(cid:59)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:118)(cid:311)(cid:2)(cid:49)(cid:1140)(cid:98)(cid:108)(cid:48)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:45)(cid:109)(cid:2)(cid:3)(cid:3)(cid:2)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:314)

Culture
(cid:27)(cid:134)(cid:117)(cid:2)(cid:318)(cid:118)(cid:59)(cid:49)(cid:117)(cid:59)(cid:124)(cid:2)(cid:118)(cid:45)(cid:134)(cid:49)(cid:59)(cid:319)(cid:2)(cid:98)(cid:118)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:49)(cid:134)(cid:1140)(cid:124)(cid:134)(cid:117)(cid:59)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2) 
(cid:55)(cid:59)(cid:118)(cid:49)(cid:117)(cid:98)(cid:48)(cid:59)(cid:2)(cid:111)(cid:134)(cid:117)(cid:118)(cid:59)(cid:1140)(cid:136)(cid:59)(cid:118)(cid:2)(cid:45)(cid:118)(cid:2)(cid:45)(cid:2)(cid:117)(cid:111)(cid:1140)(cid:1140)(cid:330)(cid:134)(cid:114)(cid:330)(cid:139)(cid:111)(cid:134)(cid:117)(cid:330)(cid:118)(cid:1140)(cid:59)(cid:59)(cid:136)(cid:59)(cid:118)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2) 
(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:45)(cid:2)(cid:95)(cid:98)(cid:93)(cid:95)(cid:2)(cid:45)(cid:114)(cid:2462)(cid:124)(cid:134)(cid:55)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:109)(cid:2)(cid:134)(cid:109)(cid:55)(cid:59)(cid:117)(cid:55)(cid:111)(cid:93)(cid:2)(cid:108)(cid:59)(cid:109)(cid:124)(cid:45)(cid:1140)(cid:98)(cid:124)(cid:139)(cid:314)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2) 
(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:59)(cid:117)(cid:118)(cid:2)(cid:59)(cid:138)(cid:95)(cid:98)(cid:48)(cid:98)(cid:124)(cid:2)(cid:45)(cid:109)(cid:2)(cid:45)(cid:48)(cid:118)(cid:59)(cid:109)(cid:49)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:59)(cid:93)(cid:111)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:316)(cid:137)(cid:59)(cid:45)(cid:117)(cid:2)(cid:108)(cid:45)(cid:109)(cid:139)(cid:2) 
(cid:95)(cid:45)(cid:124)(cid:118)(cid:317)(cid:2)(cid:48)(cid:59)(cid:49)(cid:45)(cid:134)(cid:118)(cid:59)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:117)(cid:59)(cid:118)(cid:114)(cid:111)(cid:109)(cid:118)(cid:98)(cid:48)(cid:98)(cid:1140)(cid:98)(cid:2462)(cid:59)(cid:118)(cid:2)(cid:111)(cid:91)(cid:59)(cid:109)(cid:2)(cid:59)(cid:138)(cid:124)(cid:59)(cid:109)(cid:55)(cid:2)(cid:48)(cid:59)(cid:139)(cid:111)(cid:109)(cid:55)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)
(cid:102)(cid:111)(cid:48)(cid:2)(cid:55)(cid:59)(cid:118)(cid:49)(cid:117)(cid:98)(cid:114)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:108)(cid:45)(cid:104)(cid:59)(cid:2)(cid:55)(cid:59)(cid:49)(cid:98)(cid:118)(cid:98)(cid:111)(cid:109)(cid:118)(cid:2)(cid:48)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:2)(cid:318)(cid:41)(cid:95)(cid:45)(cid:124)(cid:2)(cid:98)(cid:118)(cid:2) 
(cid:48)(cid:59)(cid:118)(cid:124)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:319)(cid:311)(cid:2)(cid:114)(cid:134)(cid:2478)(cid:109)(cid:93)(cid:2)(cid:114)(cid:59)(cid:117)(cid:118)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2)(cid:93)(cid:111)(cid:45)(cid:1140)(cid:118)(cid:2)(cid:118)(cid:59)(cid:49)(cid:111)(cid:109)(cid:55)(cid:314)

We emphasize speed in doing our work because speed  

(cid:111)(cid:61)(cid:2)(cid:59)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:55)(cid:59)(cid:124)(cid:59)(cid:117)(cid:108)(cid:98)(cid:109)(cid:59)(cid:118)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:137)(cid:98)(cid:109)(cid:109)(cid:59)(cid:117)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:1140)(cid:111)(cid:118)(cid:59)(cid:117)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)
consumer products industry. By obsessively focusing on the 

(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:117)(cid:98)(cid:59)(cid:109)(cid:49)(cid:59)(cid:311)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:59)(cid:108)(cid:114)(cid:1140)(cid:111)(cid:139)(cid:59)(cid:59)(cid:118)(cid:2)(cid:55)(cid:98)(cid:118)(cid:49)(cid:111)(cid:136)(cid:59)(cid:117)(cid:2)(cid:98)(cid:109)(cid:118)(cid:98)(cid:93)(cid:95)(cid:124)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)
lead to new products which sustain brands that consumers 

(cid:1140)(cid:111)(cid:136)(cid:59)(cid:314)(cid:2)(cid:27)(cid:134)(cid:117)(cid:2)(cid:59)(cid:108)(cid:114)(cid:1140)(cid:111)(cid:139)(cid:59)(cid:59)(cid:118)(cid:317)(cid:2)(cid:137)(cid:98)(cid:1140)(cid:1140)(cid:98)(cid:109)(cid:93)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:114)(cid:98)(cid:124)(cid:49)(cid:95)(cid:2)(cid:98)(cid:109)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:95)(cid:59)(cid:1140)(cid:114)(cid:2)(cid:111)(cid:109)(cid:59)(cid:2)
(cid:45)(cid:109)(cid:111)(cid:124)(cid:95)(cid:59)(cid:117)(cid:2)(cid:108)(cid:45)(cid:104)(cid:59)(cid:118)(cid:2)(cid:124)(cid:59)(cid:45)(cid:108)(cid:137)(cid:111)(cid:117)(cid:104)(cid:2)(cid:45)(cid:2)(cid:95)(cid:45)(cid:1140)(cid:1140)(cid:108)(cid:45)(cid:117)(cid:104)(cid:2)(cid:111)(cid:61)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:317)(cid:118)(cid:2)
(cid:49)(cid:134)(cid:1140)(cid:124)(cid:134)(cid:117)(cid:59)(cid:314)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:59)(cid:117)(cid:118)(cid:2)(cid:95)(cid:45)(cid:136)(cid:59)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:117)(cid:98)(cid:59)(cid:109)(cid:49)(cid:59)(cid:311)(cid:2)(cid:93)(cid:111)(cid:111)(cid:55)(cid:2)(cid:98)(cid:109)(cid:118)(cid:2462)(cid:109)(cid:49)(cid:124)(cid:118)(cid:311)(cid:2)
(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:2)(cid:140)(cid:59)(cid:45)(cid:1140)(cid:2)(cid:124)(cid:111)(cid:2)(cid:318)(cid:93)(cid:59)(cid:124)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:61)(cid:45)(cid:49)(cid:124)(cid:118)(cid:319)(cid:2)(cid:124)(cid:111)(cid:2)(cid:108)(cid:45)(cid:104)(cid:59)(cid:2)(cid:55)(cid:45)(cid:124)(cid:45)(cid:330)(cid:55)(cid:117)(cid:98)(cid:136)(cid:59)(cid:109)(cid:2)(cid:55)(cid:59)(cid:49)(cid:98)(cid:118)(cid:98)(cid:111)(cid:109)(cid:118)(cid:314)(cid:2)
(cid:27)(cid:134)(cid:117)(cid:2)(cid:59)(cid:108)(cid:114)(cid:1140)(cid:111)(cid:139)(cid:59)(cid:59)(cid:118)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:48)(cid:45)(cid:49)(cid:104)(cid:48)(cid:111)(cid:109)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:93)(cid:117)(cid:59)(cid:45)(cid:124)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:314)(cid:2) 
(cid:3)(cid:124)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:118)(cid:124)(cid:117)(cid:98)(cid:136)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:137)(cid:111)(cid:117)(cid:104)(cid:2)(cid:55)(cid:98)(cid:1140)(cid:98)(cid:93)(cid:59)(cid:109)(cid:124)(cid:1140)(cid:139)(cid:2)(cid:124)(cid:111)(cid:2)(cid:49)(cid:117)(cid:59)(cid:45)(cid:124)(cid:59)(cid:2) 
a culture of belonging. We strive for our workplace to be  

(cid:45)(cid:2)(cid:114)(cid:1140)(cid:45)(cid:49)(cid:59)(cid:2)(cid:137)(cid:95)(cid:59)(cid:117)(cid:59)(cid:2)(cid:114)(cid:59)(cid:111)(cid:114)(cid:1140)(cid:59)(cid:2)(cid:108)(cid:45)(cid:130)(cid:59)(cid:117)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:59)(cid:89)(cid:59)(cid:49)(cid:124)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:55)(cid:98)(cid:136)(cid:59)(cid:117)(cid:118)(cid:59)(cid:2)
(cid:49)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:48)(cid:45)(cid:118)(cid:59)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:137)(cid:59)(cid:2)(cid:118)(cid:59)(cid:117)(cid:136)(cid:59)(cid:314)(cid:2)(cid:36)(cid:95)(cid:117)(cid:111)(cid:134)(cid:93)(cid:95)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:9)(cid:98)(cid:136)(cid:59)(cid:117)(cid:118)(cid:98)(cid:124)(cid:139)(cid:311)(cid:2)(cid:11)(cid:116)(cid:134)(cid:98)(cid:124)(cid:139)(cid:2)
(cid:351)(cid:2)(cid:17)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:3)(cid:55)(cid:136)(cid:98)(cid:118)(cid:111)(cid:117)(cid:139)(cid:2)(cid:7)(cid:111)(cid:134)(cid:109)(cid:49)(cid:98)(cid:1140)(cid:311)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:108)(cid:45)(cid:55)(cid:59)(cid:2)(cid:49)(cid:1140)(cid:59)(cid:45)(cid:117)(cid:2)
(cid:111)(cid:134)(cid:117)(cid:2)(cid:118)(cid:134)(cid:114)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:117)(cid:45)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:59)(cid:116)(cid:134)(cid:45)(cid:1140)(cid:98)(cid:124)(cid:139)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:98)(cid:108)(cid:114)(cid:111)(cid:117)(cid:124)(cid:45)(cid:109)(cid:49)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:55)(cid:98)(cid:136)(cid:59)(cid:117)(cid:118)(cid:98)(cid:124)(cid:139)(cid:2)
(cid:48)(cid:111)(cid:124)(cid:95)(cid:2)(cid:98)(cid:109)(cid:118)(cid:98)(cid:55)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:111)(cid:134)(cid:124)(cid:118)(cid:98)(cid:55)(cid:59)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:137)(cid:45)(cid:1140)(cid:1140)(cid:118)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2) 
(cid:30)(cid:95)(cid:98)(cid:1140)(cid:45)(cid:109)(cid:124)(cid:95)(cid:117)(cid:111)(cid:114)(cid:98)(cid:49)(cid:2)(cid:13)(cid:111)(cid:134)(cid:109)(cid:55)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:61)(cid:111)(cid:49)(cid:134)(cid:118)(cid:59)(cid:118)(cid:2)(cid:111)(cid:109)(cid:2)(cid:95)(cid:59)(cid:1140)(cid:114)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:49)(cid:117)(cid:59)(cid:45)(cid:124)(cid:59)(cid:2) 
(cid:59)(cid:116)(cid:134)(cid:98)(cid:124)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:118)(cid:98)(cid:136)(cid:59)(cid:2)(cid:111)(cid:114)(cid:114)(cid:111)(cid:117)(cid:124)(cid:134)(cid:109)(cid:98)(cid:2462)(cid:59)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:55)(cid:136)(cid:45)(cid:109)(cid:49)(cid:98)(cid:109)(cid:93)(cid:2) 
(cid:59)(cid:109)(cid:136)(cid:98)(cid:117)(cid:111)(cid:109)(cid:108)(cid:59)(cid:109)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:117)(cid:136)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:124)(cid:137)(cid:111)(cid:2)(cid:49)(cid:45)(cid:134)(cid:118)(cid:59)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:98)(cid:108)(cid:114)(cid:111)(cid:117)(cid:124)(cid:45)(cid:109)(cid:124)(cid:2) 
(cid:124)(cid:111)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:314)(cid:2)(cid:3)(cid:124)(cid:2)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:311)(cid:2)(cid:137)(cid:59)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:61)(cid:111)(cid:49)(cid:134)(cid:118)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:2)
(cid:49)(cid:117)(cid:59)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:45)(cid:109)(cid:2)(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:118)(cid:98)(cid:136)(cid:59)(cid:311)(cid:2)(cid:118)(cid:124)(cid:117)(cid:111)(cid:109)(cid:93)(cid:59)(cid:117)(cid:311)(cid:2)(cid:108)(cid:111)(cid:117)(cid:59)(cid:2)(cid:117)(cid:59)(cid:118)(cid:98)(cid:1140)(cid:98)(cid:59)(cid:109)(cid:124)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2) 
(cid:137)(cid:95)(cid:98)(cid:1140)(cid:59)(cid:2)(cid:49)(cid:111)(cid:109)(cid:124)(cid:117)(cid:98)(cid:48)(cid:134)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:45)(cid:2)(cid:48)(cid:59)(cid:130)(cid:59)(cid:117)(cid:311)(cid:2)(cid:108)(cid:111)(cid:117)(cid:59)(cid:2)(cid:118)(cid:134)(cid:118)(cid:124)(cid:45)(cid:98)(cid:109)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:2)(cid:137)(cid:111)(cid:117)(cid:1140)(cid:55)(cid:314)(cid:2)

(cid:342)(cid:2)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:111)(cid:134)(cid:124)(cid:1140)(cid:111)(cid:111)(cid:104)(cid:2)(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:1140)(cid:59)(cid:130)(cid:59)(cid:117)(cid:2)(cid:98)(cid:118)(cid:2)(cid:111)(cid:109)(cid:1140)(cid:139)(cid:2)(cid:45)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:13)(cid:59)(cid:48)(cid:117)(cid:134)(cid:45)(cid:117)(cid:139)(cid:2)(cid:401)(cid:311)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)(cid:311)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:55)(cid:45)(cid:124)(cid:59)(cid:2)(cid:98)(cid:124)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:93)(cid:98)(cid:136)(cid:59)(cid:109)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:95)(cid:45)(cid:118)(cid:2)(cid:109)(cid:111)(cid:124)(cid:2)(cid:48)(cid:59)(cid:59)(cid:109)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:118)(cid:2)(cid:109)(cid:111)(cid:124)(cid:2)(cid:48)(cid:59)(cid:98)(cid:109)(cid:93)(cid:2)(cid:134)(cid:114)(cid:55)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:45)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:2462)(cid:108)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:2)(cid:1140)(cid:59)(cid:130)(cid:59)(cid:117)(cid:314)

  A N N U A L   R E P O R T   202 3   |  5

NON-GAAP MEASURES

ADJUSTED OPERATING INCOME AND MARGIN

(cid:36)(cid:95)(cid:59)(cid:2)(cid:61)(cid:111)(cid:1140)(cid:1140)(cid:111)(cid:137)(cid:98)(cid:109)(cid:93)(cid:2)(cid:55)(cid:98)(cid:118)(cid:49)(cid:134)(cid:118)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:45)(cid:55)(cid:55)(cid:117)(cid:59)(cid:118)(cid:118)(cid:59)(cid:118)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:109)(cid:111)(cid:109)(cid:330)(cid:14)(cid:3)(cid:3)(cid:30)(cid:2) 

(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:114)(cid:117)(cid:111)(cid:136)(cid:98)(cid:55)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:117)(cid:59)(cid:93)(cid:45)(cid:117)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)

(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:118)(cid:2)(cid:134)(cid:118)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:117)(cid:59)(cid:49)(cid:111)(cid:109)(cid:49)(cid:98)(cid:1140)(cid:98)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2)

(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:98)(cid:109)(cid:49)(cid:111)(cid:108)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:311)(cid:2)(cid:98)(cid:124)(cid:59)(cid:108)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:401)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2) 

(cid:124)(cid:95)(cid:59)(cid:118)(cid:59)(cid:2)(cid:109)(cid:111)(cid:109)(cid:330)(cid:14)(cid:3)(cid:3)(cid:30)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:108)(cid:111)(cid:118)(cid:124)(cid:2)(cid:55)(cid:98)(cid:117)(cid:59)(cid:49)(cid:124)(cid:1140)(cid:139)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:117)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:2)

(cid:124)(cid:95)(cid:59)(cid:2)(cid:59)(cid:45)(cid:117)(cid:109)(cid:111)(cid:134)(cid:124)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:13)(cid:21)(cid:3)(cid:41)(cid:21)(cid:11)(cid:34)(cid:34)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2) 

(cid:14)(cid:3)(cid:3)(cid:30)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:118)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:118)(cid:59)(cid:2)(cid:109)(cid:111)(cid:109)(cid:330)(cid:14)(cid:3)(cid:3)(cid:30)(cid:2)(cid:67)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:118)(cid:2)(cid:118)(cid:95)(cid:111)(cid:134)(cid:1140)(cid:55)(cid:2)

(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:2)(cid:49)(cid:95)(cid:45)(cid:117)(cid:93)(cid:59)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:98)(cid:118)(cid:118)(cid:134)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:2)

(cid:109)(cid:111)(cid:124)(cid:2)(cid:48)(cid:59)(cid:2)(cid:49)(cid:111)(cid:109)(cid:118)(cid:98)(cid:55)(cid:59)(cid:117)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:98)(cid:118)(cid:111)(cid:1140)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:111)(cid:117)(cid:2)(cid:45)(cid:118)(cid:2)(cid:45)(cid:2)(cid:118)(cid:134)(cid:48)(cid:118)(cid:2462)(cid:124)(cid:134)(cid:124)(cid:59)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2) 

(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:2)(cid:45)(cid:2)(cid:49)(cid:95)(cid:45)(cid:117)(cid:93)(cid:59)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)

(cid:124)(cid:95)(cid:59)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:117)(cid:45)(cid:48)(cid:1140)(cid:59)(cid:2)(cid:14)(cid:3)(cid:3)(cid:30)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:118)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:61)(cid:111)(cid:1140)(cid:1140)(cid:111)(cid:137)(cid:98)(cid:109)(cid:93)(cid:2)(cid:109)(cid:111)(cid:109)(cid:330)(cid:14)(cid:3)(cid:3)(cid:30)(cid:2)

(cid:98)(cid:118)(cid:118)(cid:134)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:48)(cid:59)(cid:1140)(cid:98)(cid:59)(cid:136)(cid:59)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)

measures may not be the same as similar measures provided 

(cid:124)(cid:95)(cid:59)(cid:118)(cid:59)(cid:2)(cid:98)(cid:124)(cid:59)(cid:108)(cid:118)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:98)(cid:109)(cid:49)(cid:111)(cid:108)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:108)(cid:45)(cid:117)(cid:93)(cid:98)(cid:109)(cid:2)(cid:114)(cid:117)(cid:111)(cid:136)(cid:98)(cid:55)(cid:59)(cid:118)(cid:2) 

(cid:48)(cid:139)(cid:2)(cid:111)(cid:124)(cid:95)(cid:59)(cid:117)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:98)(cid:59)(cid:118)(cid:2)(cid:55)(cid:134)(cid:59)(cid:2)(cid:124)(cid:111)(cid:2)(cid:55)(cid:98)(cid:64)(cid:59)(cid:117)(cid:59)(cid:109)(cid:49)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:108)(cid:59)(cid:124)(cid:95)(cid:111)(cid:55)(cid:118)(cid:2)(cid:111)(cid:61)(cid:2) 

(cid:45)(cid:2)(cid:134)(cid:118)(cid:59)(cid:61)(cid:134)(cid:1140)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:111)(cid:109)(cid:93)(cid:111)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2) 

(cid:49)(cid:45)(cid:1140)(cid:49)(cid:134)(cid:1140)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:98)(cid:124)(cid:59)(cid:108)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:59)(cid:136)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:48)(cid:59)(cid:98)(cid:109)(cid:93)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:55)(cid:314)(cid:2)

(cid:114)(cid:59)(cid:117)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:109)(cid:49)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:2)(cid:108)(cid:111)(cid:117)(cid:59)(cid:2)(cid:59)(cid:64)(cid:59)(cid:49)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:49)(cid:111)(cid:108)(cid:114)(cid:45)(cid:117)(cid:98)(cid:118)(cid:111)(cid:109)(cid:2)(cid:124)(cid:111)(cid:2)(cid:114)(cid:117)(cid:98)(cid:111)(cid:117)(cid:2) 

(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:55)(cid:118)(cid:2)(cid:48)(cid:139)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:118)(cid:98)(cid:93)(cid:109)(cid:98)(cid:67)(cid:49)(cid:45)(cid:109)(cid:124)(cid:2)(cid:111)(cid:109)(cid:59)(cid:330)(cid:2462)(cid:108)(cid:59)(cid:2)(cid:59)(cid:136)(cid:59)(cid:109)(cid:124)(cid:118)(cid:314)(cid:2)

ORGANIC SALES GROWTH

(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:114)(cid:117)(cid:111)(cid:136)(cid:98)(cid:55)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:117)(cid:59)(cid:93)(cid:45)(cid:117)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2) 

ADJUSTED EPS

(cid:111)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:311)(cid:2)(cid:109)(cid:45)(cid:108)(cid:59)(cid:1140)(cid:139)(cid:2)(cid:109)(cid:59)(cid:124)(cid:2)(cid:118)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2) 

(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:59)(cid:45)(cid:117)(cid:109)(cid:98)(cid:109)(cid:93)(cid:118)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2) 

(cid:124)(cid:95)(cid:59)(cid:2)(cid:59)(cid:64)(cid:59)(cid:49)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:61)(cid:111)(cid:117)(cid:59)(cid:98)(cid:93)(cid:109)(cid:2)(cid:59)(cid:138)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:2)(cid:117)(cid:45)(cid:124)(cid:59)(cid:2) 

(cid:336)(cid:11)(cid:30)(cid:34)(cid:337)(cid:2)(cid:49)(cid:45)(cid:1140)(cid:49)(cid:134)(cid:1140)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:45)(cid:49)(cid:49)(cid:111)(cid:117)(cid:55)(cid:45)(cid:109)(cid:49)(cid:59)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:14)(cid:3)(cid:3)(cid:30)(cid:311)(cid:2)(cid:45)(cid:118)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2) 

(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:118)(cid:314)(cid:2)(cid:24)(cid:45)(cid:109)(cid:45)(cid:93)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:48)(cid:59)(cid:1140)(cid:98)(cid:59)(cid:136)(cid:59)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:124)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:111)(cid:61)(cid:2)

(cid:124)(cid:111)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:2)(cid:118)(cid:98)(cid:93)(cid:109)(cid:98)(cid:67)(cid:49)(cid:45)(cid:109)(cid:124)(cid:2)(cid:111)(cid:109)(cid:59)(cid:330)(cid:2462)(cid:108)(cid:59)(cid:2)(cid:98)(cid:124)(cid:59)(cid:108)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:109)(cid:111)(cid:124)(cid:2)(cid:98)(cid:109)(cid:55)(cid:98)(cid:49)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2) 

organic sales growth is useful to investors because it enables 

(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:55)(cid:330)(cid:124)(cid:111)(cid:330)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:55)(cid:2)(cid:114)(cid:59)(cid:117)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:109)(cid:49)(cid:59)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2) 

them to assess, on a consistent basis, sales trends related  

believe that this metric provides investors a useful  

to products that were marketed by the Company during  

(cid:114)(cid:59)(cid:117)(cid:118)(cid:114)(cid:59)(cid:49)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:134)(cid:109)(cid:55)(cid:59)(cid:117)(cid:1140)(cid:139)(cid:98)(cid:109)(cid:93)(cid:2)(cid:48)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:124)(cid:117)(cid:59)(cid:109)(cid:55)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:117)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:124)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)

(cid:124)(cid:95)(cid:59)(cid:2)(cid:59)(cid:109)(cid:2462)(cid:117)(cid:59)(cid:124)(cid:139)(cid:2)(cid:111)(cid:61)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:59)(cid:136)(cid:45)(cid:109)(cid:124)(cid:2)(cid:114)(cid:59)(cid:117)(cid:98)(cid:111)(cid:55)(cid:118)(cid:311)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:98)(cid:108)(cid:114)(cid:45)(cid:49)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2) 

(cid:114)(cid:117)(cid:111)(cid:136)(cid:98)(cid:55)(cid:59)(cid:118)(cid:2)(cid:134)(cid:118)(cid:59)(cid:61)(cid:134)(cid:1140)(cid:2)(cid:118)(cid:134)(cid:114)(cid:114)(cid:1140)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:98)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:117)(cid:59)(cid:93)(cid:45)(cid:117)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2) 

(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:61)(cid:111)(cid:117)(cid:59)(cid:98)(cid:93)(cid:109)(cid:2)(cid:59)(cid:138)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:2)(cid:117)(cid:45)(cid:124)(cid:59)(cid:2)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2) 

(cid:139)(cid:59)(cid:45)(cid:117)(cid:330)(cid:111)(cid:136)(cid:59)(cid:117)(cid:330)(cid:139)(cid:59)(cid:45)(cid:117)(cid:2)(cid:59)(cid:45)(cid:117)(cid:109)(cid:98)(cid:109)(cid:93)(cid:118)(cid:2)(cid:114)(cid:59)(cid:117)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:93)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:314)(cid:2)(cid:33)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:59)(cid:55)(cid:2) 

(cid:111)(cid:134)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:49)(cid:111)(cid:109)(cid:124)(cid:117)(cid:111)(cid:1140)(cid:2)(cid:111)(cid:61)(cid:311)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:55)(cid:111)(cid:2)(cid:109)(cid:111)(cid:124)(cid:2)(cid:117)(cid:59)(cid:89)(cid:59)(cid:49)(cid:124)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:114)(cid:59)(cid:117)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:109)(cid:49)(cid:59)(cid:2) 

(cid:401)(cid:399)(cid:401)(cid:400)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:362)(cid:402)(cid:314)(cid:402)(cid:401)(cid:314)(cid:2)(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:401)(cid:399)(cid:401)(cid:400)(cid:2)(cid:11)(cid:30)(cid:34)(cid:2)(cid:137)(cid:45)(cid:118)(cid:2)(cid:362)(cid:402)(cid:314)(cid:399)(cid:401)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)

of, the Company and management. 

(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:118)(cid:2)(cid:98)(cid:124)(cid:59)(cid:108)(cid:118)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:59)(cid:45)(cid:117)(cid:109)(cid:330)(cid:111)(cid:134)(cid:124)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2) 

ADJUSTED SG&A

(cid:124)(cid:95)(cid:59)(cid:2)(cid:13)(cid:21)(cid:3)(cid:41)(cid:21)(cid:11)(cid:34)(cid:34)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:336)(cid:362)(cid:399)(cid:314)(cid:402)(cid:399)(cid:337)(cid:314)(cid:2)(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:401)(cid:399)(cid:401)(cid:401)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:118)(cid:2) 

(cid:45)(cid:2)(cid:13)(cid:21)(cid:3)(cid:41)(cid:21)(cid:11)(cid:34)(cid:34)(cid:2)(cid:98)(cid:108)(cid:114)(cid:45)(cid:98)(cid:117)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:49)(cid:95)(cid:45)(cid:117)(cid:93)(cid:59)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:2)(cid:49)(cid:95)(cid:45)(cid:117)(cid:93)(cid:59)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2) 

(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:114)(cid:117)(cid:59)(cid:118)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:98)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:117)(cid:59)(cid:93)(cid:45)(cid:117)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2) 

(cid:117)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:98)(cid:118)(cid:118)(cid:134)(cid:59)(cid:55)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:314)(cid:2)(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)

(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:118)(cid:59)(cid:1140)(cid:1140)(cid:98)(cid:109)(cid:93)(cid:311)(cid:2)(cid:93)(cid:59)(cid:109)(cid:59)(cid:117)(cid:45)(cid:1140)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:45)(cid:55)(cid:108)(cid:98)(cid:109)(cid:98)(cid:118)(cid:124)(cid:117)(cid:45)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:336)(cid:34)(cid:14)(cid:351)(cid:3)(cid:337)(cid:2) 

(cid:401)(cid:399)(cid:401)(cid:402)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:59)(cid:118)(cid:2)(cid:45)(cid:2)(cid:49)(cid:95)(cid:45)(cid:117)(cid:93)(cid:59)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:124)(cid:59)(cid:55)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:98)(cid:118)(cid:118)(cid:134)(cid:59)(cid:55)(cid:2) 

(cid:59)(cid:138)(cid:114)(cid:59)(cid:109)(cid:118)(cid:59)(cid:118)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:98)(cid:124)(cid:59)(cid:108)(cid:118)(cid:2)(cid:98)(cid:109)(cid:2)(cid:401)(cid:399)(cid:401)(cid:402)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2) 

(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:314)

(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:98)(cid:118)(cid:118)(cid:134)(cid:59)(cid:2)(cid:98)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:15)(cid:11)(cid:33)(cid:27)(cid:2)(cid:45)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:2462)(cid:111)(cid:109)(cid:314)(cid:2)(cid:41)(cid:59)(cid:2)(cid:48)(cid:59)(cid:1140)(cid:98)(cid:59)(cid:136)(cid:59)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2) 

(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:108)(cid:59)(cid:124)(cid:117)(cid:98)(cid:49)(cid:2)(cid:59)(cid:109)(cid:95)(cid:45)(cid:109)(cid:49)(cid:59)(cid:118)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:111)(cid:117)(cid:118)(cid:317)(cid:2)(cid:134)(cid:109)(cid:55)(cid:59)(cid:117)(cid:118)(cid:124)(cid:45)(cid:109)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2) 

FREE CASH FLOW

(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:330)(cid:111)(cid:136)(cid:59)(cid:117)(cid:330)(cid:139)(cid:59)(cid:45)(cid:117)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:109)(cid:118)(cid:59)(cid:118)(cid:2)(cid:48)(cid:139)(cid:2)(cid:59)(cid:138)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:49)(cid:59)(cid:117)(cid:124)(cid:45)(cid:98)(cid:109)(cid:2)

(cid:13)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)(cid:98)(cid:118)(cid:2)(cid:55)(cid:59)(cid:67)(cid:109)(cid:59)(cid:55)(cid:2)(cid:45)(cid:118)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:111)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:45)(cid:49)(cid:2462)(cid:136)(cid:98)(cid:2462)(cid:59)(cid:118)(cid:2) 

(cid:118)(cid:98)(cid:93)(cid:109)(cid:98)(cid:67)(cid:49)(cid:45)(cid:109)(cid:124)(cid:2)(cid:111)(cid:109)(cid:59)(cid:330)(cid:2462)(cid:108)(cid:59)(cid:2)(cid:98)(cid:124)(cid:59)(cid:108)(cid:118)(cid:314)(cid:2)

6  |  CHURCH & DWIGHT CO., INC.

(cid:1140)(cid:59)(cid:118)(cid:118)(cid:2)(cid:49)(cid:45)(cid:114)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:109)(cid:55)(cid:98)(cid:124)(cid:134)(cid:117)(cid:59)(cid:118)(cid:314)(cid:2)(cid:24)(cid:45)(cid:109)(cid:45)(cid:93)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:136)(cid:98)(cid:59)(cid:137)(cid:118)(cid:2)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2) 

(cid:89)(cid:111)(cid:137)(cid:2)(cid:45)(cid:118)(cid:2)(cid:45)(cid:109)(cid:2)(cid:98)(cid:108)(cid:114)(cid:111)(cid:117)(cid:124)(cid:45)(cid:109)(cid:124)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:2)(cid:48)(cid:59)(cid:49)(cid:45)(cid:134)(cid:118)(cid:59)(cid:2)(cid:98)(cid:124)(cid:2)(cid:98)(cid:118)(cid:2)(cid:111)(cid:109)(cid:59)(cid:2)(cid:61)(cid:45)(cid:49)(cid:124)(cid:111)(cid:117)(cid:2)(cid:98)(cid:109)(cid:2) 

determining the amount of cash available for dividends  

(cid:45)(cid:109)(cid:55)(cid:2)(cid:55)(cid:98)(cid:118)(cid:49)(cid:117)(cid:59)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:117)(cid:139)(cid:2)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:314)

FREE CASH FLOW AS PERCENTAGE OF NET INCOME

(cid:13)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)(cid:45)(cid:118)(cid:2)(cid:114)(cid:59)(cid:117)(cid:49)(cid:59)(cid:109)(cid:124)(cid:45)(cid:93)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:109)(cid:59)(cid:124)(cid:2)(cid:98)(cid:109)(cid:49)(cid:111)(cid:108)(cid:59)(cid:2)(cid:98)(cid:118)(cid:2)(cid:55)(cid:59)(cid:67)(cid:109)(cid:59)(cid:55)(cid:2) 

(cid:45)(cid:118)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:2)(cid:111)(cid:61)(cid:2)(cid:61)(cid:117)(cid:59)(cid:59)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)(cid:124)(cid:111)(cid:2)(cid:45)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:109)(cid:59)(cid:124)(cid:2)(cid:98)(cid:109)(cid:49)(cid:111)(cid:108)(cid:59)(cid:314)(cid:2)

(cid:24)(cid:45)(cid:109)(cid:45)(cid:93)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:136)(cid:98)(cid:59)(cid:137)(cid:118)(cid:2)(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:45)(cid:118)(cid:2)(cid:45)(cid:2)(cid:108)(cid:59)(cid:45)(cid:118)(cid:134)(cid:117)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:95)(cid:111)(cid:137)(cid:2)(cid:59)(cid:64)(cid:59)(cid:49)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)

(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:108)(cid:45)(cid:109)(cid:45)(cid:93)(cid:59)(cid:118)(cid:2)(cid:98)(cid:124)(cid:118)(cid:2)(cid:49)(cid:45)(cid:118)(cid:95)(cid:2)(cid:89)(cid:111)(cid:137)(cid:2)(cid:117)(cid:59)(cid:1140)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:137)(cid:111)(cid:117)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)(cid:49)(cid:45)(cid:114)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)

(cid:45)(cid:109)(cid:55)(cid:2)(cid:49)(cid:45)(cid:114)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:59)(cid:138)(cid:114)(cid:59)(cid:109)(cid:55)(cid:98)(cid:124)(cid:134)(cid:117)(cid:59)(cid:118)(cid:314)

2023 ORGANIC SALES RECONCILIATION

TWELVE MONTHS ENDED 12/31/2023

Total  
Company

Worldwide
Consumer

Consumer
Domestic

Consumer
International

Specialty
Products

(cid:33)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:59)(cid:55)(cid:2)(cid:34)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:14)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95) 
(cid:21)(cid:59)(cid:118)(cid:118)(cid:313)
     (cid:3)(cid:49)(cid:116)(cid:134)(cid:98)(cid:118)(cid:98)(cid:124)(cid:98)(cid:111)(cid:109)(cid:118)(cid:2)
(cid:3)(cid:55)(cid:55)(cid:313)
    (cid:13)(cid:42)(cid:2)(cid:326)(cid:2)(cid:27)(cid:124)(cid:95)(cid:59)(cid:117)(cid:2)
(cid:27)(cid:117)(cid:93)(cid:45)(cid:109)(cid:98)(cid:49)(cid:2)(cid:34)(cid:45)(cid:1140)(cid:59)(cid:118)(cid:2)(cid:14)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)

(cid:406)(cid:314)(cid:401)(cid:2)(cid:1143)(cid:2)

(cid:400)(cid:399)(cid:314)(cid:402)(cid:2)(cid:1143)(cid:2)

(cid:400)(cid:399)(cid:314)(cid:405)(cid:2)(cid:1143)(cid:2)

(cid:1142)(cid:314)(cid:406)(cid:2)(cid:1143)(cid:2)

(cid:330)(cid:405)(cid:314)(cid:406)(cid:2)(cid:1143)

(cid:402)(cid:314)(cid:406)(cid:2)(cid:1143)(cid:2)

(cid:403)(cid:314)(cid:400)(cid:2)(cid:1143)(cid:2)

(cid:404)(cid:314)(cid:399)(cid:2)(cid:1143)(cid:2)

(cid:399)(cid:314)(cid:402)(cid:2)(cid:1143)(cid:2)

(cid:399)(cid:314)(cid:399)(cid:2)(cid:1143)

(cid:399)(cid:314)(cid:399)(cid:2)(cid:1143)(cid:2)
(cid:404)(cid:314)(cid:402)(cid:2)(cid:1143)(cid:2)

(cid:399)(cid:314)(cid:399)(cid:2)(cid:1143)(cid:2)
(cid:1141)(cid:314)(cid:401)(cid:2)(cid:1143)(cid:2)

(cid:399)(cid:314)(cid:399)(cid:2)(cid:1143)(cid:2)
(cid:404)(cid:314)(cid:405)(cid:2)(cid:1143)(cid:2)

(cid:330)(cid:399)(cid:314)(cid:400)(cid:2)(cid:1143)(cid:2)
(cid:1142)(cid:314)(cid:404)(cid:2)(cid:1143)(cid:2)

(cid:399)(cid:314)(cid:399)(cid:2)(cid:1143)
(cid:330)(cid:405)(cid:314)(cid:406)(cid:2)(cid:1143)

2023 FREE CASH FLOW AS A PERCENTAGE OF NET INCOME 

(Dollars in Millions)

(cid:7)(cid:45)(cid:118)(cid:95)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:27)(cid:114)(cid:59)(cid:117)(cid:45)(cid:124)(cid:98)(cid:111)(cid:109)(cid:118)(cid:2)
(cid:7)(cid:45)(cid:114)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:11)(cid:138)(cid:114)(cid:59)(cid:109)(cid:55)(cid:98)(cid:124)(cid:134)(cid:117)(cid:59)(cid:118)(cid:2)
Free Cash Flow(cid:2)
(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:25)(cid:59)(cid:124)(cid:2)(cid:17)(cid:109)(cid:49)(cid:111)(cid:108)(cid:59)(cid:2)
Percentage(cid:2)

(cid:2)(cid:2)(cid:2)

(cid:2)(cid:2)(cid:2)

(cid:2)(cid:2)(cid:2)

(cid:2)(cid:2)(cid:2)

(cid:2)

(cid:2)(cid:2)

(cid:2)(cid:2)

(cid:2)(cid:2)

(cid:2)(cid:2)

(cid:2)(cid:2)

(cid:2)

(cid:2)

(cid:2)

(cid:2)

(cid:2)

(cid:2) (cid:362)(cid:400)(cid:311)(cid:399)(cid:402)(cid:399)(cid:314)(cid:1141)(cid:2) (cid:2)(cid:2)

(cid:2) (cid:362)(cid:2) (cid:336)(cid:401)(cid:401)(cid:402)(cid:314)(cid:404)(cid:2)(cid:337)

(cid:2) (cid:362)(cid:2) (cid:2)(cid:2)(cid:1142)(cid:399)(cid:405)(cid:314)(cid:400)(cid:2) (cid:2)(cid:2)

(cid:2) (cid:362)(cid:2) (cid:2)(cid:405)(cid:1142)(cid:403)(cid:314)(cid:405)(cid:2) (cid:2)

(cid:2) (cid:2)

(cid:400)(cid:399)(cid:402)(cid:2)(cid:1143) 

ADJUSTED DILUTED EARNINGS PER SHARE RECONCILIATION 

(cid:9)(cid:98)(cid:1140)(cid:134)(cid:124)(cid:59)(cid:55)(cid:2)(cid:11)(cid:45)(cid:117)(cid:109)(cid:98)(cid:109)(cid:93)(cid:118)(cid:2)(cid:30)(cid:59)(cid:117)(cid:2)(cid:34)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:331)(cid:2)(cid:33)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:59)(cid:55) 
Flawless Impairment 

(cid:15)(cid:59)(cid:117)(cid:111)(cid:2)(cid:33)(cid:59)(cid:118)(cid:124)(cid:117)(cid:98)(cid:49)(cid:124)(cid:59)(cid:55)(cid:2)(cid:34)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)
(cid:9)(cid:98)(cid:1140)(cid:134)(cid:124)(cid:59)(cid:55)(cid:2)(cid:11)(cid:45)(cid:117)(cid:109)(cid:98)(cid:109)(cid:93)(cid:118)(cid:2)(cid:30)(cid:59)(cid:117)(cid:2)(cid:34)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:331)(cid:2)  
(cid:3)(cid:55)(cid:102)(cid:134)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:336)(cid:109)(cid:111)(cid:109)(cid:330)(cid:14)(cid:3)(cid:3)(cid:30)(cid:337)(cid:2) 

2023

2022 % CHANGE

(cid:2)(cid:362)(cid:2) (cid:402)(cid:314)(cid:399)(cid:404)(cid:2)(cid:2)

(cid:2)(cid:362)(cid:2) (cid:332)(cid:2)(cid:2)

(cid:362)(cid:2)(cid:400)(cid:314)(cid:1141)(cid:1142)(cid:2)(cid:2)

(cid:362)(cid:2)(cid:400)(cid:314)(cid:401)(cid:1141)(cid:2)(cid:2)

(cid:2)(cid:362)(cid:2) (cid:399)(cid:314)(cid:400)(cid:401)(cid:2)(cid:2)(cid:2)(cid:2)

(cid:362)(cid:2)(cid:399)(cid:314)(cid:399)(cid:402)(cid:2)(cid:2)

(cid:1142)(cid:400)(cid:314)(cid:404)(cid:2)(cid:1143)

(cid:332)(cid:2)

(cid:332)(cid:2)

(cid:2)(cid:362)(cid:2) (cid:402)(cid:314)(cid:400)(cid:405)(cid:2)(cid:2)

(cid:362)(cid:2)(cid:401)(cid:314)(cid:406)(cid:405)(cid:2)(cid:2)

(cid:1141)(cid:314)(cid:405)(cid:2)(cid:1143) 

  A N N U A L   R E P O R T   202 3   |  7

 
                
  
  
    
 
 
 
  
 
               
 
  
      
 
 
SURABHI POKHRIYAL
Senior Vice President,  

(cid:14)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:9)(cid:98)(cid:93)(cid:98)(cid:124)(cid:45)(cid:1140)(cid:2)(cid:14)(cid:117)(cid:111)(cid:137)(cid:124)(cid:95)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

MICHAEL G. READ
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2) 
(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:2)(cid:7)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:17)(cid:109)(cid:124)(cid:59)(cid:117)(cid:109)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:1140)(cid:2) 
& Specialty Products Division 

RICK SPANN
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2) 
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:34)(cid:134)(cid:114)(cid:114)(cid:1140)(cid:139)(cid:2)(cid:7)(cid:95)(cid:45)(cid:98)(cid:109)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

DIRECTORS

BRADLEN S. CASHAW
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:27)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117) 
(cid:3)(cid:93)(cid:117)(cid:111)(cid:114)(cid:134)(cid:117) 
Director since 2021

MATTHEW T. FARRELL 
Chairman, President and  
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2) 
Church & Dwight Co., Inc. 
Director since 2016

BRADLEY C. IRWIN
(cid:33)(cid:59)(cid:2462)(cid:117)(cid:59)(cid:55)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2) 
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2) 
Welch Foods Inc. 
Director since 2006

PENRY W. PRICE 
(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:2)(cid:24)(cid:45)(cid:117)(cid:104)(cid:59)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:34)(cid:111)(cid:1140)(cid:134)(cid:2462)(cid:111)(cid:109)(cid:118) 
(cid:21)(cid:98)(cid:109)(cid:104)(cid:59)(cid:55)(cid:17)(cid:109)(cid:2)(cid:7)(cid:111)(cid:117)(cid:114)(cid:111)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109) 
Director since 2011

SUSAN G. SAIDEMAN

(cid:13)(cid:111)(cid:134)(cid:109)(cid:55)(cid:59)(cid:117)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2)
(cid:30)(cid:111)(cid:117)(cid:124)(cid:45)(cid:93)(cid:59)(cid:2)(cid:6)(cid:45)(cid:139)(cid:2)(cid:21)(cid:98)(cid:108)(cid:98)(cid:124)(cid:59)(cid:55)(cid:2)(cid:21)(cid:21)(cid:7)(cid:2) 
and former Vice President 
(cid:3)(cid:108)(cid:45)(cid:140)(cid:111)(cid:109)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314) 
Director since 2020

RAVICHANDRA K. SALIGRAM
(cid:21)(cid:59)(cid:45)(cid:55)(cid:2)(cid:9)(cid:98)(cid:117)(cid:59)(cid:49)(cid:124)(cid:111)(cid:117)(cid:311)(cid:2)(cid:33)(cid:59)(cid:2462)(cid:117)(cid:59)(cid:55)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2) 
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2) 
(cid:25)(cid:59)(cid:137)(cid:59)(cid:1140)(cid:1140)(cid:2)(cid:6)(cid:117)(cid:45)(cid:109)(cid:55)(cid:118) 
Director since 2006

ROBERT K. SHEARER
(cid:33)(cid:59)(cid:2462)(cid:117)(cid:59)(cid:55)(cid:2)(cid:34)(cid:59)(cid:109)(cid:98)(cid:111)(cid:117)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:2) 
(cid:45)(cid:109)(cid:55)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:13)(cid:98)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2) 
(cid:40)(cid:13)(cid:2)(cid:7)(cid:111)(cid:117)(cid:114)(cid:111)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109) 
Director since 2008

JANET S. VERGIS 
(cid:13)(cid:111)(cid:117)(cid:108)(cid:59)(cid:117)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:3)(cid:55)(cid:136)(cid:98)(cid:118)(cid:111)(cid:117)(cid:2) 
(cid:30)(cid:117)(cid:98)(cid:136)(cid:45)(cid:124)(cid:59)(cid:2)(cid:11)(cid:116)(cid:134)(cid:98)(cid:124)(cid:139)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:13)(cid:111)(cid:117)(cid:108)(cid:59)(cid:117)(cid:2)(cid:7)(cid:11)(cid:27)(cid:2) 
(cid:27)(cid:117)(cid:45)(cid:30)(cid:95)(cid:45)(cid:117)(cid:108)(cid:45)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314) 
Director since 2014

ART WINKLEBLACK
(cid:33)(cid:59)(cid:2462)(cid:117)(cid:59)(cid:55)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:2) 
(cid:45)(cid:109)(cid:55)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:13)(cid:98)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117) 
(cid:15)(cid:314)(cid:19)(cid:314)(cid:2)(cid:15)(cid:59)(cid:98)(cid:109)(cid:140)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139) 
Director since 2008

LAURIE J. YOLER 
Partner  
Playground Global  
Director since 2018

EMERITUS  
DIRECTOR

DWIGHT C. MINTON
(cid:7)(cid:95)(cid:45)(cid:98)(cid:117)(cid:108)(cid:45)(cid:109)(cid:2)(cid:11)(cid:108)(cid:59)(cid:117)(cid:98)(cid:124)(cid:134)(cid:118) 
Church & Dwight Co., Inc.

PRINCIPAL  
ACCOUNTING  
OFFICER

JOSEPH J. LONGO
Vice President, Controller  

(cid:45)(cid:109)(cid:55)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:3)(cid:49)(cid:49)(cid:111)(cid:134)(cid:109)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

OFFICERS AND  
SIGNIFICANT  
EMPLOYEES

BARRY A. BRUNO 
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2) 
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:24)(cid:45)(cid:117)(cid:104)(cid:59)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2) 
(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:332)(cid:7)(cid:111)(cid:109)(cid:118)(cid:134)(cid:108)(cid:59)(cid:117)(cid:2)(cid:9)(cid:111)(cid:108)(cid:59)(cid:118)(cid:2462)(cid:49)

BRIAN BUCHERT
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311) 
(cid:34)(cid:124)(cid:117)(cid:45)(cid:124)(cid:59)(cid:93)(cid:139)(cid:311)(cid:2)(cid:24)(cid:351)(cid:3)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2) 
Business Partnerships

PATRICK D. DE MAYNADIER, ESQ.
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2) 
General Counsel and Secretary

RICHARD A. DIERKER 
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2) 
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:13)(cid:98)(cid:109)(cid:45)(cid:109)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2) 
(cid:15)(cid:59)(cid:45)(cid:55)(cid:2)(cid:111)(cid:61)(cid:2)(cid:6)(cid:134)(cid:118)(cid:98)(cid:109)(cid:59)(cid:118)(cid:118)(cid:2)(cid:27)(cid:114)(cid:59)(cid:117)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)

MATTHEW T. FARRELL 
Chairman, President and  

(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

KEVIN GOKEY
Senior Vice President,  

(cid:14)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:17)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

RENE M. HEMSEY 
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2) 
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:15)(cid:134)(cid:108)(cid:45)(cid:109)(cid:2)(cid:33)(cid:59)(cid:118)(cid:111)(cid:134)(cid:117)(cid:49)(cid:59)(cid:118)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

CARLEN HOOKER 
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2) 
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:7)(cid:111)(cid:108)(cid:108)(cid:59)(cid:117)(cid:49)(cid:98)(cid:45)(cid:1140)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)

CARLOS G. LINARES
(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:40)(cid:98)(cid:49)(cid:59)(cid:2)(cid:30)(cid:117)(cid:59)(cid:118)(cid:98)(cid:55)(cid:59)(cid:109)(cid:124)(cid:311)(cid:2) 
(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:36)(cid:59)(cid:49)(cid:95)(cid:109)(cid:111)(cid:1140)(cid:111)(cid:93)(cid:139)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2) 
(cid:14)(cid:1140)(cid:111)(cid:48)(cid:45)(cid:1140)(cid:2)(cid:33)(cid:59)(cid:118)(cid:59)(cid:45)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:59)(cid:136)(cid:59)(cid:1140)(cid:111)(cid:114)(cid:108)(cid:59)(cid:109)(cid:124)

8  |  CHURCH & DWIGHT CO., INC.

 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(MARK ONE)
È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

For the fiscal year ended December 31, 2023
OR

SECURITIES EXCHANGE ACT OF 1934
For the transition period from

to
Commission file number 1-10585

CHURCH & DWIGHT CO., INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

13-4996950
(I.R.S. Employer
Identification No.)

500 Charles Ewing Boulevard, Ewing, NJ 08628
(Address of principal executive offices)
Registrant’s telephone number, including area code: (609) 806-1200

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Common Stock, $1 par value

Trading
Symbol(s)

CHD

Name of each exchange
on which registered

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes È No ‘
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ‘ No È
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes È No ‘

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to

Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit such files). Yes È No ‘

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer È Accelerated filer ‘ Non-accelerated filer ‘ Smaller reporting company ‘ Emerging growth company ‘
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ‘

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its
internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting
firm that prepared or issued its audit report. È

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant

included in the filing reflect the correction of an error to previously issued financial statements. ‘

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based

compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ‘

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ‘ No È
The aggregate market value of the voting and non-voting common equity held by non-affiliates as of June 30, 2023 (the last business day of
the registrant’s most recently completed second fiscal quarter) was approximately $24.0 billion. For purposes of making this calculation only, the
registrant excluded the shares of common stock (the “Common Stock”) of Church & Dwight Co., Inc. (the “Company”) held by directors,
executive officers and beneficial owners of more than ten percent of the common stock. The aggregate market value is based on the closing price of
such stock on the New York Stock Exchange on June 30, 2023.

As of February 12, 2024, there were 243,776,939 shares of Common Stock outstanding.

Documents Incorporated by Reference

Certain provisions of the registrant’s definitive proxy statement to be filed not later than April 30, 2023 are incorporated by reference in Items

10 through 14 of Part III of this Annual Report on Form 10-K (this “Annual Report”).

CAUTIONARY NOTE ON FORWARD-LOOKING INFORMATION

This Annual Report contains forward-looking statements, including, among others, statements relating to net

sales and earnings growth; gross margin changes; trade and marketing spending; marketing expense as a percentage
of net sales; sufficiency of cash flows from operations; earnings per share; the impact of new accounting
pronouncements; cost savings programs; recessionary conditions; interest rates; inflation; consumer demand and
spending; the effects of competition; the effect of product mix; volume growth, including the effects of new product
launches into new and existing categories; the decline of condom usage; the Company’s hedge programs; the
impact of foreign exchange, and commodity price fluctuations; impairments and other charges; the Company’s
investments in joint ventures; the impact of acquisitions and divestitures; capital expenditures; the Company’s
effective tax rate; the impact of tax audits; tax changes; the effect of the credit environment on the Company’s
liquidity and capital resources; the Company’s fixed rate debt; compliance with covenants under the Company’s
debt instruments; the Company’s commercial paper program; the Company’s current and anticipated future
borrowing capacity to meet capital expenditure program costs; the Company’s share repurchase programs; payment
of dividends; environmental and regulatory matters; the availability and adequacy of raw materials, including trona
reserves and the conversion of such reserves; and the customers and consumer acceptance of certain ingredients in
our products. Other forward-looking statements in this report are generally identified by the use of such terms as
“may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to
make” or other comparable terms. These statements represent the intentions, plans, expectations and beliefs of the
Company, and are based on assumptions that the Company believes are reasonable but may prove to be incorrect. In
addition, these statements are subject to risks, uncertainties and other factors, many of which are outside the
Company’s control and could cause actual results to differ materially from such forward-looking statements.
Factors that could cause such differences include a decline in market growth, retailer distribution and consumer
demand (as a result of, among other things, political, economic and marketplace conditions and events), including
those relating to the outbreak of contagious diseases; the impact of new legislation such as the U.S. CARES Act, the
EU Medical Device Regulation, new cosmetic and device regulations in Mexico, and the U.S. Modernization of
Cosmetic Regulation Act; the impact on the global economy of the Russia/Ukraine war or increased conflict in the
Middle East, including the impact of export controls and other economic sanctions; potential recessionary
conditions or economic uncertainty; the impact of continued shifts in consumer behavior, including accelerating
shifts to on-line shopping; unanticipated increases in raw material and energy prices, including as a result of the
Russia/Ukraine war or conflict in the Middle East; delays and increased costs in manufacturing and distribution;
increases in transportation costs; labor shortages; the impact of price increases for our products; the impact of
inflationary conditions; the impact of supply chain and labor disruptions; the impact of severe weather on raw
material and transportation costs; adverse developments affecting the financial condition of major customers and
suppliers; competition; changes in marketing and promotional spending; growth or declines in various product
categories and the impact of customer actions in response to changes in consumer demand and the economy,
including increasing shelf space or on-line share of private label and retailer-branded products or other changes in
the retail environment; consumer and competitor reaction to, and customer acceptance of, new product introductions
and features; the Company’s ability to maintain product quality and characteristics at a level acceptable to our
customers and consumers; disruptions in the banking system and financial markets; the Company’s borrowing
capacity and ability to finance its operations and potential acquisitions; higher interest rates; foreign currency
exchange rate fluctuations; transition to, and shifting economic policies in the United States; potential changes in
export/import and trade laws, regulations and policies of the United States and other countries, including any
increased trade restrictions; increased or changing regulation regarding the Company’s products and its suppliers in
the United States and other countries where it or its suppliers operate; market volatility; issues relating to the
Company’s information technology and controls; the impact of natural disasters, including those related to climate
change, on the Company and its customers and suppliers, including third party information technology service
providers; integrations of acquisitions or divestiture of assets; the outcome of contingencies, including litigation,
pending regulatory proceedings and environmental matters; and changes in the regulatory environment in the
countries where we do business.

For a description of additional factors that could cause actual results to differ materially from the forward-

looking statements, please see Item 1A, “Risk Factors” in this Annual Report.

The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required by the United States federal securities laws. You
are advised, however, to consult any further disclosures the Company makes on related subjects in its filings with
the United States Securities and Exchange Commission (the “Commission”).

Unless otherwise specified or the context otherwise requires, all references in this Annual Report on Form

10-K to “Church & Dwight,” “we,” “us,” “our” and “Company” refer to Church & Dwight Co., Inc. and its
consolidated subsidiaries.

TABLE OF CONTENTS

PART I

Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Cybersecurity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Mine Safety Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART II

Market for the Registrant’s Common Equity, Related Stockholder Matters, and Issuer

Purchases of Equity Securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

RESERVED . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . .

Item

1.

1A.

1B.

1C.

2.

3.

4.

5.

6.

7.

7A.

Quantitative and Qualitative Disclosures about Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . .

8.

9.

9A.

9B.

9C.

10.

11.

12.

13.

14.

15.

16.

Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure . . . .

Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections . . . . . . . . . . . . . . . . . . . . . .

PART III

Directors, Executive Officers and Corporate Governance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . . . . . . . .

Principal Accounting Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART IV

Exhibits, Financial Statement Schedule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

99

Form 10-K Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

103

Page

1

14

33

33

34

35

35

36

38

39

54

55

97

97

97

97

98

98

98

98

98

PART I

ITEM 1. BUSINESS

OVERVIEW OF BUSINESS

We were founded in 1846 and incorporated in Delaware in 1925. We develop, manufacture and market a
broad range of consumer household and personal care products and specialty products focused on animal and
food production, chemicals and cleaners. Our well-recognized brands include ARM & HAMMER® baking soda,
cat litter, laundry detergent, carpet deodorizer and other baking soda-based products; OXICLEAN® stain
removers, cleaning solutions, laundry detergents and bleach alternatives; VITAFUSION® and L’IL CRITTERS®
gummy dietary supplements for adults and children, respectively; BATISTE® dry shampoo; WATERPIK® water
flossers and showerheads; THERABREATH® oral care products; HERO® acne treatment products; TROJAN
condoms, lubricants and vibrators; SPINBRUSH battery-operated toothbrushes; FIRST RESPONSE home
pregnancy and ovulation test kits; NAIR depilatories; ORAJEL oral analgesic; XTRA laundry detergent; and
ZICAM cold shortening and relief products. Seven of those brands are designated as “power brands” because
they compete in large categories, and we believe they have the potential for significant global expansion. Those
seven brands are ARM & HAMMER®; OXICLEAN®; VITAFUSION® and L’IL CRITTERS®; BATISTE®;
WATERPIK®; THERABREATH®; and HERO® and represent approximately 70% of our net sales and profits.

We sell our consumer products under a variety of brands through a broad distribution platform that includes

supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and
other discount stores, pet and other specialty stores and websites and other e-commerce channels, all of which
sell our products to consumers. We sell our specialty products to industrial customers, livestock producers and
through distributors.

Our Sustainability Strategy and Environmental, Social and Governance (“ESG”) Pillars

Sustainability is how we refer to our Environmental, Social & Governance (“ESG”) efforts to deliver
growth and profitability while making a meaningful and positive impact. We believe Sustainability is critical to
the health of the communities in which we operate, contributes to a better world and benefits our business both
financially and operationally. Each year we publish a Sustainability Report that discloses our business and
corporate responsibility commitments and details our ESG performance metrics and targets and other
components of our ESG efforts. Our 2022 Sustainability Report is available on our web site at https://
churchdwight.com/pdf/Sustainability/2022-Sustainability-Report.pdf, and our 2023 Sustainability Report will be
available in April 2024 (the “2023 Sustainability Report” and together with the 2022 Sustainability Report, the
“Sustainability Reports”). References to our Sustainability Reports are for informational purposes only and
neither the Sustainability Reports nor the other information on our website is incorporated by reference into this
Annual Report on Form 10-K.

Our global Sustainability strategy is derived from our heritage and organizational values. The following six

pillars are the core focus of our Environmental and Social efforts. Each is supported through our Governance
practices, which are intended to maintain a system of rules and practices that determine how we operate and align
the interests of our stakeholders in support of ethical business practices and financial success.

• Our Brands: Delight consumers with our brands and contribute towards a more sustainable world

• Products: Provide safe and effective products for consumers and the environment

• Packaging: Utilize consumer friendly and environmentally responsible packaging

• Employees and Communities: Embrace the principles of diversity, equity and inclusion (“DEI”),

good corporate citizenship and social responsibility within the communities we can impact

1

• Environment & Climate Change: Minimize environmental impact of our global operations, with a

focus on increased renewable energy usage, reduced water consumption, greenhouse gas emissions and
solid waste to landfills

• Responsible Sourcing: Improve our suppliers’ environmental, labor, health & safety and ethical

practices

Environmental. Our operations are subject to federal, state, local and foreign laws, rules and regulations relating
to environmental concerns, including air emissions, wastewater discharges, solid and hazardous waste
management activities, and the safety of our employees. We endeavor to take actions necessary to comply with
such regulations. These steps include periodic environmental and health and safety audits of our facilities. The
audits, conducted by independent firms with expertise in environmental, health and safety compliance, include
site visits at each location, as well as a review of documentary information, to determine compliance with such
federal, state, local and foreign laws, rules and regulations. However, our environmental priorities extend well
beyond our compliance efforts, and include our focus on providing effective products that are safe for our
consumers, the animals they care for and the environment, utilizing consumer friendly and environmentally
responsible packaging, reducing greenhouse gas emission, reducing water usage, recycling solid waste and
improving our suppliers’ environmental practices.

Social. Our Social focus areas are driven by our goals of delighting consumers with our brands through our
contributions towards a more sustainable world, improving our suppliers’ labor, health & safety, environmental
and ethical practices, and supporting our employees and communities – all to create a stronger, more resilient
company while contributing to a better world. In their everyday work, employees embody our commitments to
integrity, quality, and innovation, and in doing so, directly contribute to our long-standing character and
reputation. Employee safety and wellness remain two of our highest priorities. We have company-wide policies
designed to ensure the safety of each team member and compliance with OSHA and local standards. We embrace
the diversity of our employees and believe that a diverse and inclusive workforce fosters innovation and
promotes an environment that includes unique perspectives, talents and experiences. We strive to cultivate a
culture and processes that support and enhance our ability to recruit, develop and retain diverse talent at every
level. As part of our enhanced diversity and inclusion initiatives and our commitment to transparency and
accountability, we publish workplace demographics of our employees in our Sustainability Reports. We also
encourage our employees to become involved in their communities through our Employee Giving Fund and The
Church & Dwight Philanthropic Foundation (the “Foundation”) which is focused on helping to create DEI
opportunities and advancing environmental preservation. The Foundation is administered by our employees. See
pages 12 to 13 in Item 1 of this Annual Report under “Employees and Human Capital” for a discussion of our
human capital management.

Governance. Our governance focus includes the processes, rules, resources and systems in support of our
operational, Sustainability and ESG efforts, as were described in our 2023 Proxy Statement and will be described
in our Proxy Statement for our upcoming Annual Meeting of Stockholders under the caption “Sustainability
Strategy and ESG Pillars” and in our 2023 Sustainability Report. Our Corporate Issues Council (the “Council”),
comprised of senior executives representing all our key functional areas, guides the integration of Sustainability
with substantially all parts of our business and drives continuous improvement in our Sustainability approach and
performance. The Council takes the lead in defining and implementing our Sustainability strategies across our six
ESG pillars. We have also adopted a Political Contributions Policy, which is posted in the Investor Relations
section of our website. Our Board of Directors, acting principally through its Governance, Nominating &
Corporate Responsibility Committee, oversees our Sustainability efforts, including our climate change policies
and programs, with that Committee and the Compensation & Human Capital and Audit Committees each
focusing on specified areas of Sustainability, including compliance and ethics, human capital and DEI. Our
Independent Lead Director is responsible for ensuring that stockholder requests, recommendations and proposals
are evaluated by the Governance, Nominating & Corporate Responsibility Committee, additional committees
within the Board as appropriate, and then by the Board of Directors, if needed.

2

As described in our Sustainability Reports, our continued progress in key areas of ESG has earned

recognition from various third parties.

We use the standards and guidelines of the Global Reporting Initiative, Sustainability Accounting Standards

Board industry specific standards and the Task Force on Climate-related Financial Disclosures to inform our
Sustainability disclosures included in this Annual Report, our Proxy Statement and our Sustainability Reports.
The “materiality” thresholds in those standards and guidelines may differ from the concept of “materiality” for
purposes of the federal securities laws and disclosures required by the Commission’s rules in this Annual Report.
Moreover, the inclusion of Sustainability disclosures in this Annual Report and in our other filings with the
Commission does not necessarily imply that we consider them to be material for purposes of the federal
securities laws or the Commission’s rules and regulations governing such disclosure.

FINANCIAL INFORMATION ABOUT SEGMENTS AND PRINCIPAL PRODUCTS

As discussed in more detail below, we operate in three principal segments: Consumer Domestic, Consumer

International, and our Specialty Products Division (“SPD”). Refer to Note 17 to the consolidated financial
statements included in this Annual Report and the discussion in “Item 7: Management’s Discussion and Analysis
of Financial Condition and Results of Operations” for information concerning the results of each of our
segments.

All domestic brand “rankings” contained in this Annual Report are based on dollar share rankings from
Information Resources, Inc. (“IRI”) Total US – Multi Outlet (“MULO”) for the period ending December 24,
2023. Foreign brand “rankings” are derived from several sources.

Consumer Domestic

Our founders first marketed sodium bicarbonate, otherwise known as baking soda, in 1846 for use in home

baking. Today, this product has a wide variety of uses in the home, including as a refrigerator and freezer
deodorizer, scratch-free cleaner and deodorizer for kitchen surfaces and cooking appliances, bath additive,
dentifrice, cat litter deodorizer and swimming pool pH stabilizer. We specialize in baking soda-based products,
as well as other products which use the same raw materials or technology and which are sold across multiple
consumer and professional use categories. Our Consumer Domestic segment includes each of our seven power
brands, as well as other well-known brands and household and personal care products. We divide the Consumer
Domestic segment into household and personal care product groups.

Household Products

In 2023, household products constituted approximately 54% of our Consumer Domestic sales and

approximately 42% of our consolidated net sales.

ARM & HAMMER Baking Soda remains the number one leading brand of baking soda in terms of
consumer recognition of the brand name and reputation for quality and value. The cleaning and deodorizing
properties of baking soda have led to the development of numerous baking soda-based household products. For
example, we market ARM & HAMMER FRIDGE FRESH®, a refrigerator deodorizer equipped with a baking
soda filter to help keep food tasting fresher, and ARM & HAMMER Carpet Deodorizer. Our other primary
household products include laundry detergents marketed under the ARM & HAMMER, OXICLEAN and XTRA
brands, fabric softener sheets marketed under the ARM & HAMMER brand, cat litter under our ARM &
HAMMER brand, and household cleaning products under the CLEAN SHOWER®, ORANGE GLO®, and
OXICLEAN brands. Our laundry detergents constitute our largest consumer business, measured by net sales.

3

Personal Care Products

In 2023, personal care products constituted approximately 46% of our Consumer Domestic sales and

approximately 36% of our consolidated net sales.

Our personal care business was founded on the unique strengths of our ARM & HAMMER trademark and

baking soda technology. We have expanded our personal care business through the acquisition of antiperspirants,
oral care products, including mouthwash, depilatories, reproductive health products, oral analgesics, nasal saline
moisturizers, cold shortening and relief, acne treatment, and dietary supplements under a variety of other leading
brand names.

ARM & HAMMER Baking Soda, when used as a dentifrice, helps whiten and polish teeth, removes plaque

and leaves the mouth feeling fresh and clean. These properties led to the development of a complete line of
sodium bicarbonate-based dentifrice products that are marketed and sold nationally primarily under the ARM &
HAMMER® brand name. Our other personal care products include antiperspirants and deodorants under the
ARRID® and ARM & HAMMER® brands, battery-operated toothbrushes under the SPINBRUSH® brand,
condoms under the TROJAN® brand (the number one condom brand in the U.S.), water flossers and
showerheads under the WATERPIK® brand (the number one water flosser brand in the U.S.), home pregnancy
test kits under the FIRST RESPONSE® brand (the number two pregnancy test kit brand in the U.S.), hair-
removal products under the NAIR® brand (the number one depilatory in the U.S.), oral analgesics and oral care
products under the ORAJEL® brand (the number one oral care pain relief in the U.S.), children’s gummy dietary
supplements under the L’IL CRITTERS® brand and adult gummy dietary supplements under the VITAFUSION®
brand (the number two gummy supplement brand in the U.S.), cold shortening and relief products under the
ZICAM® brand (the number one cold shortening brand in the U.S. ), a growing number of hair products under
the BATISTE® brand (the number one dry shampoo brand in the U.S.), VIVISCAL® (the number one leading
supplement for thinning hair in the U.S), TOPPIK® hair fiber brands (the number one leading brand of hair fiber
cosmetics for thinning hair in the U.S.), oral care products under the THERABREATH® brand (the number one
alcohol free mouthwash in the U.S.), nasal saline moisturizers and solutions under the SIMPLY SALINE® brand,
and the HERO® acne treatment products brands (the number one acne patch in the U.S.).

Consumer International

Our Consumer International segment markets a variety of personal care, household and over-the-counter
products in international subsidiary markets, including Australia, Canada, France, Germany, Mexico and the
United Kingdom. We also export to over 130 markets around the world, including China and Japan, through our
global markets group (the “Global Markets Group” or “GMG”) using a broad network of third-party distributors.

Total Consumer International net sales represented approximately 17% of our consolidated net sales in
2023. Net sales of the subsidiary businesses originating in Europe, Canada, Australia and Mexico accounted for
36%, 25%, 8% and 9%, respectively, of our 2023 international net sales in this segment. No other country in
which we operate accounts for more than 20% of our total international net sales and no product line accounts for
more than 20% of our total international net sales.

Some of our U.S. power brands such as ARM & HAMMER, BATISTE, OXICLEAN, VITAFUSION and

L’IL CRITTERS, and WATERPIK are distributed in many of our international markets. In addition, we also
export unique brands such as STERIMAR®, and FEMFRESH® out of the United Kingdom as well as our
FINISHING TOUCH FLAWLESS brand, to many countries around the world.

We also market the CURASH® line of babycare products in Australia, and GRAVOL® anti-nauseant and
RUB-A535 topical analgesic in Canada and other international markets. We also sell WATERPIK water flossers
and showerheads in Australia, Canada, Germany, France, the United Kingdom, Mexico and in other international
markets.

4

Specialty Products Division

Our SPD segment focuses on sales to businesses and participates in three product areas: Animal and Food

Production, Specialty Chemicals and Specialty Cleaners, and accounted for approximately 5% of our
consolidated net sales in 2023.

Animal and Food Production Products

Since the ARM & HAMMER Animal and Food Production business began in 1972, with its launch of

ARM & HAMMER baking soda as a feed additive to help dairy cows produce more milk, we have built a
leading portfolio of nutritional supplements designed to help improve the health and productivity of dairy cows.
In addition, we market a line of high-quality protein and amino acid products, including BIO-CHLOR® and
FERMENTEN®, which are designed to help reduce health issues associated with calving, as well as provide
needed protein to ensure proper growth and milk production.

Over the last several years, we have expanded our product offerings to include unique prebiotics and
probiotics. CELMANAX® Refined Functional Carbohydrate is a yeast-based prebiotic that helps ensure a well-
functioning gastrointestinal track in dairy cows, beef cattle, poultry and other livestock. CERTILLUS® is a
family of probiotics products used in the poultry, dairy, beef and swine industries. Passport Food Safety
Solutions, Inc. is focused on providing pre- and post-harvest food safety solutions for beef, poultry, and swine
primarily for the application to carcasses to reduce food borne pathogens.

Specialty Chemicals

Our specialty chemicals business primarily encompasses the manufacture, marketing and sale of sodium
bicarbonate in a range of grades and granulations for use in industrial markets. In industrial markets, sodium
bicarbonate is used by other manufacturing companies as a leavening agent for commercial baked goods, as an
antacid in pharmaceuticals, as a carbon dioxide release agent in fire extinguishers, as an alkaline agent in
swimming pool chemicals, and as a buffer in kidney dialysis.

We and Occidental Chemical Corporation are equal partners in a joint venture, Armand Products Company,

which manufactures and markets potassium carbonate and potassium bicarbonate for sale in domestic and
international markets. The potassium-based products are used in a wide variety of applications, including
agricultural products, specialty glass and ceramics, and potassium silicates. Armand also manufactures a
potassium carbonate-based animal feed additive for sale by us in the dairy industry, described above under
“Animal and Food Production Products.” Armand’s results are included in our Corporate segment.

Specialty Cleaners

We also provide a line of cleaning and deodorizing products for use in commercial and industrial

applications such as office buildings, hotels, restaurants and other facilities.

We and Safety-Kleen Systems, Inc. (“Safety-Kleen”) are equal partners in a joint venture, ARMAKLEEN®,

which has built a specialty cleaning products business based on our technology and Safety-Kleen’s sales and
distribution organization. In North America, this joint venture distributes our proprietary product line of aqueous
cleaners along with our ARMEX® blast media line, which is designed for the removal of a wide variety of
surface coatings. These results are included in our Corporate segment.

COMPETITION

We compete in the household and personal care consumer product categories, which are highly innovative

categories, characterized by a continuous flow of new products and line extensions, and require significant
advertising and promotion. We compete in these categories primarily on the basis of product innovation and

5

performance, brand recognition, price, value and other consumer benefits. Consumer products, particularly laundry
and dietary supplements, are subject to significant price competition. As a result, we, from time to time, may need to
reduce the prices for some of our products to respond to competitive and customer pressures and to maintain market
share. Product introductions typically involve heavy marketing and trade spending in the year of launch, and we
usually are not able to determine whether the new products and line extensions will be successful until a period of
time has elapsed following the introduction of the new products or the extension of the product line.

Because of the competitive retail environment, we face pricing pressure from our retail customers and

customers selling through other channels, particularly high-volume retail customers including, internet-based
retailers, who have increasingly sought to obtain pricing concessions or better trade terms that could reduce our
margins. Furthermore, if we are unable to maintain price or trade terms acceptable to our customers, they could
increase product purchases from competitors and reduce purchases from us, which would harm our sales and
profitability.

Our competitors in the Consumer Domestic and Consumer International segments include, among others,
Procter & Gamble Company (“P&G”), The Clorox Company, Colgate-Palmolive Company, S.C. Johnson & Son,
Inc., Nestle Purina PetCare Company and Nestle Health Science, Haleon plc, Henkel, Reckitt Benckiser Group
plc, Kenvue Inc., Pfizer Inc., Bayer AG, NBTY, Inc., Koninklijke Philips N.V., Unilever PLC, Sanofi,
Pharmavite LLC and Edgewell Personal Care. Many of these companies have greater financial resources than we
do and have the capacity to outspend us in their attempts to gain market share. In addition, the growing number
of sales channels and business models, such as niche brands, internet-only brands and retailer co-developed and
owned brands, have increased competition in certain product categories, particularly within personal care,
specialty hair and skin care and dietary supplements, from less well capitalized competitors.

Competition within our animal and food production and our specialty chemicals product lines is intense. The
specialty chemicals business operates in a competitive environment influenced by capacity utilization, customers’
leverage and the impact of raw material and energy costs. Product introductions typically involve introductory
educational costs in the year of launch, and we usually are not able to determine whether new products and line
extensions will be successful until a period of time has elapsed following the introduction of new products or the
extension of the product lines. Our key competitors with respect to our SPD segment are Cargill Incorporated,
Lallemand Inc., Solvay Chemicals, Inc., Genesis Alkali and Natural Soda, Inc. For additional discussion of the
competitive environment in which we conduct our business, see Item 1A, “Risk Factors.”

DISTRIBUTION OF OUR PRODUCTS

Our Consumer Domestic and Consumer International segments products are marketed primarily through a

broad distribution platform that includes supermarkets, mass merchandisers, wholesale clubs, drugstores,
convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and
other e-commerce channels, all of which sell our products to consumers. The Consumer Domestic Segment
employs a sales force based regionally throughout the U.S. and utilizes the services of independent brokers, who
represent our products in the food, mass, pet, dollar, club, and numerous other classes of trade. Our Consumer
International segment conducts business through subsidiaries and global export markets. Our subsidiaries employ
local sales and marketing teams that manage the retailer and trade relationships while export sales and marketing
professionals also manage an extensive distributor network in our global export markets. Our products are stored
in our plants and third-party owned warehouses and are either delivered by independent trucking companies or
picked up by customers at our facilities.

SPD markets sodium bicarbonate and other chemicals to industrial and agricultural customers primarily
throughout the U.S. and Canada. Distribution is accomplished through a dedicated sales force supplemented by
manufacturers’ representatives and independent distributors. Our products in this segment are stored in our plants
and public warehouses and are either delivered by independent trucking companies or picked up by customers at
our facilities.

6

SEASONALITY

Our business is generally not seasonal, although the Consumer Domestic and Consumer International
segments are affected by sales of SPINBRUSH battery-operated toothbrushes and WATERPIK water flossers
(which typically are higher during the fall, in advance of the holiday season), sales of NAIR depilatories and
waxes (which typically are higher in the spring and summer months), sales of VITAFUSION and L’IL
CRITTERS dietary supplements and ZICAM cold shortening and relief products (which typically are slightly
higher in the fourth quarter of each year, in advance of the cold and flu season and renewed commitments to
health). In SPD, several of our Animal and Food Production products experience higher demand in warmer
weather months creating higher seasonal demand in the second and third quarters of the year.

RAW MATERIALS AND SOURCES OF SUPPLY

We manufacture sodium bicarbonate for our consumer and specialty products businesses at our plants
located at Green River, Wyoming and Old Fort, Ohio. The primary source of soda ash, a basic raw material used
in the production of sodium bicarbonate, is the mineral trona, which is found in abundance in southwestern
Wyoming near our Green River plant. We have adequate trona reserves under mineral leases to support our
sodium bicarbonate requirements for the foreseeable future.

We are a party to a partnership agreement with Tata Chemicals (Soda Ash) Partners, which mines and
processes trona reserves in Wyoming. We fulfill a substantial amount of our soda ash requirements through the
partnership and related supply and services agreements, enabling us to achieve some of the economies of an
integrated business capable of producing sodium bicarbonate and related products from the basic raw material.
We also have an agreement for the supply of soda ash from another company. The partnership agreement and
other supply agreements between Tata Chemicals (Soda Ash) Partners and us are terminable upon two years
notice by either of us. We believe that sufficient alternative sources of soda ash supply are available.

We believe that ample sources of raw materials are available for all our other major products and we have
increased qualified dual sources of materials to approximately 60% of our total spend on direct materials as part
of our resilient supply focus. Alternative sources of supply are available in case of the disruption or termination
of the supply agreements.

The cost of raw materials, including surfactants, diesel fuel and oil-based raw and packaging materials used
primarily in our consumer businesses, were lower in 2023 relative to 2022. Increases in the prices of certain raw
materials could materially impact our costs and financial results if we are unable to pass such costs along in the
form of price increases to our customers.

We utilize the services of third party contract manufacturers around the world for certain products.

PATENTS AND TRADEMARKS

Our trademarks appear in upper case letters throughout this Annual Report. The majority of our trademarks

are registered with either the U.S. Patent and Trademark Office or with the trademark offices of many foreign
countries. The ARM & HAMMER trademark has been used by us since 1867 and is a valuable asset and
important to the successful operation of our business. Our products are sold under many other valuable
trademarks held by us, including TROJAN, NAIR, ORAJEL, WATERPIK, FIRST RESPONSE, XTRA,
OXICLEAN, SPINBRUSH, BATISTE, SIMPLY SALINE, VITAFUSION, L’IL CRITTERS, ZICAM,
THERABREATH and HERO. Our portfolio of trademarks represents substantial value in the businesses using
the trademarks.

U.S. patents are currently granted for a term of 20 years from the date the patent application is filed.
Although we actively seek and maintain a number of patents, no single patent is considered significant to the
business as a whole.

7

CUSTOMERS AND ORDER BACKLOG

In the years ended December 31, 2023, 2022 and 2021, net sales to our largest customer, Walmart Inc. and

its affiliates (“Walmart”), were 23%, 24% and 24% respectively, of our consolidated net sales. No other
customer accounted for 10% or more of our consolidated net sales in the three-year period. The time between
receipt of orders and shipment is generally short, and as a result, backlog is not significant.

GOVERNMENT REGULATION

General

All of our products are subject to regulation by one or more U.S. agencies, including the U.S. Food and

Drug Administration (“FDA”), the Environmental Protection Agency (“EPA”), the Federal Trade Commission
(“FTC”), the Consumer Product Safety Commission (“CPSC”), the Federal Communications Commission
(“FCC”), as well as foreign agencies such as the European Commission, Health Canada, the Australia
Therapeutic Goods Administration, the Mexico Federal Commission for Protection Against Health Risks
(COFEPRIS), the UK Medicines and Healthcare Products Regulatory Agency, the Chinese National Medical
Products Administration and others.

FDA regulations govern a variety of matters relating to our products, such as product development,
manufacturing, premarket clearance or approval, labeling, distribution and post-market surveillance including
complaint vigilance. The regulations adopted and standards imposed by the FDA and similar foreign agencies
evolve over time and can require us to make changes in our manufacturing processes and quality systems to
remain in compliance. These agencies periodically inspect manufacturing and other facilities. To maintain
certification of our quality system and certain of the technical files of our products, we must monitor and adapt to
changes to applicable standards. These changes may impose burdensome new requirements that require
significant investment or rework. If we fail to comply with applicable regulations and standards, we may be
subject to sanctions, including fines and penalties, the recall of products and cessation of manufacturing and/or
distribution.

In addition, we sell products that are subject to regulation under the Federal Insecticide, Fungicide and
Rodenticide Act and the Toxic Substances Control Act, which are administered by the EPA. Similar laws exist in
other markets and may apply to our products.

We are also subject to regulation by the FTC and its counterparts in other jurisdictions in connection with
the content and truthfulness of our labeling, advertising, promotion, trade practices and other matters. The FTC
and foreign agencies have instituted numerous enforcement actions against companies for failure to adequately
substantiate claims made in advertising or for the use of otherwise false or misleading advertising claims and
practices. These enforcement actions have resulted in consent decrees and the payment of civil penalties and/or
restitution by the companies involved. Such actions can result in substantial financial penalties and significantly
restrict the marketing of our products.

The CPSC and consumer protection agencies around the world have jurisdiction over consumer products,
regulate their safety and have authority over recalls. The CPSC administers the Poison Prevention Packaging Act
and has issued regulations requiring special child resistant packaging for certain products, including
pharmaceuticals, dietary supplements, and dietary substances, containing certain ingredients (e.g., iron). The
CPSC and similar foreign agencies also develop and enforce mandatory product safety standards to address
trending safety concerns, such as the use of button cell batteries or the presence of toxic chemicals in consumer
products.

The FCC regulates interstate and international communications by radio, television, wire, satellite, and cable

in all 50 states, the District of Columbia and U.S. territories. An independent U.S. government agency overseen
by Congress, the Commission is the federal agency responsible for implementing and enforcing America’s

8

communications law and regulations. The FCC administers the Communications Act of 1934, specifically in
Title 47, Section 301. This section grants the FCC the power to regulate and oversee the use of the
electromagnetic spectrum, including electrical products that generate energy or radiofrequency. Our electrical
products, such as WaterPik flossers, Flawless hair removers, Spinbrush powered toothbrushes and Trojan
vibrators, are also subject to the Radiation Control provisions of the federal FDCA. This law, administered by the
FDA, governs products that emit radiation, including medical devices as well as radiation-emitting electronic
products.

Our relationship with certain union employees is regulated by various agencies of the countries, states,

provinces and other localities in which we sell our products.

Medical Device Clearance and Approval

To be commercially distributed in the United States, a medical device must, unless exempt, receive

clearance or approval from the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (“FDCA”). For lower
risk class II devices, we must generally submit a premarket notification requesting clearance for commercial
distribution known as a “510(k)” clearance. Our condoms, lubricants, STERIMAR nasal congestion relief, home
pregnancy test kits and WATERPIK professional dental products are regulated as class II devices. Some other
low risk devices, including SPINBRUSH and other battery powered toothbrushes, therapeutic shower massagers,
nasal congestion relief and wound wash, wrist supports, WATERPIK water flossers and HERO pimple patches
are in class I or are unclassified and are generally exempted from the 510(k) requirements. To obtain 510(k)
clearance, a device must be determined to be substantially equivalent in intended use and in safety and
effectiveness to a benchmark device, or “predicate” that is already legally in commercial distribution. Any
modification to a 510(k) cleared device that could significantly affect its safety or effectiveness, or that would
constitute a change in its intended use, generally requires a new 510(k) clearance. We may determine that a new
510(k) clearance is not required, but if the FDA disagrees, it may retroactively require a 510(k) clearance and
may require us to cease marketing or recall the modified device until 510(k) clearance is obtained.

In many countries outside the United States, to distribute a medical device lawfully, we must demonstrate
conformity to local or regional standards for quality, safety and performance. For class II medical devices, we
must obtain either government approval or certification from an accredited and approved Notified Body (“NB”)
that also performs periodic planned and surprise audits of our files and our quality system. These audits are
shared in some cases, specifically among regulators in the U.S., Canada, Australia, Brazil, and Japan.
Modification to a certified device generally requires government or NB review and approval prior to
implementation of the change. Additionally, all safety incidents reported to a Health Authority must also be
reported to the NB.

OTC/Pharmaceutical and Cosmetic Requirements

We market over-the-counter (“OTC”) pharmaceutical products, such as topical acne products, anticavity
toothpaste, anticavity rinse, antiperspirant, hemorrhoid relief, skin protectant, antinauseant, oral analgesic and
sunscreen drug products, that are subject to FDA and foreign regulation. Under the U.S. OTC monograph system,
OTC pharmaceutical products that meet established conditions are generally recognized as safe and effective and
do not require the submission and approval of a new drug application. The FDA OTC monographs include well-
known ingredients and specify requirements for permitted indications, required warnings and precautions,
allowable combinations of ingredients and dosage levels. Pharmaceutical products marketed under the OTC
monograph system must conform to specific quality, formula and labeling requirements. Following the passage
of the CARES Act, FDA is updating and working to finalize current monographs, including those that affect our
oral care products and HERO sunscreens. With these new regulations, OTC products will now need to be “state
of the art” and will have significant focus on GMPs, especially manufacturing, final formulation testing, stability
testing, and safety incident reporting. Products not in the monograph system can be deemed to be unapproved
new drugs and can be forced from the market. This is particularly the case for homeopathic drug products like

9

certain ZICAM products. Both the FDA and the FTC have taken the position that homeopathic products are
unapproved new drugs. Regulatory action against these products is deemed unlikely unless the products present
an unreasonable safety risk. ZICAM homeopathic products are not currently perceived to pose such risk.

All facilities where OTC pharmaceutical products are manufactured, tested, packaged, stored or distributed

must comply with cGMP regulations and/or regulations promulgated by competent authorities in the countries
where the facilities are located. All of our pharmaceutical products are manufactured, tested, packaged, stored
and distributed according to cGMP regulations. The FDA performs periodic audits to ensure that our facilities
remain in compliance with all appropriate regulations. The failure of a facility to be in compliance may lead to a
breach of representations made to customers or to regulatory action against us related to the products made in
that facility, such as seizure, injunction or recall. Serious product quality concerns could also result in
governmental actions against us that, among other things, could result in the suspension of production or
distribution of our products, product seizures, loss of certain licenses or other governmental penalties, and could
have a material adverse effect on our financial condition or operating results. We are required to report serious
adverse events associated with the use of our OTC pharmaceutical products marketed in the U.S and other
countries where such products are sold.

We cannot predict whether new legislation regulating our activities will be enacted or what effect any

legislation would have on our business.

Medical Device, OTC/Pharmaceutical and Cosmetic Pre- and Postmarket Regulation

Before and after a medical device, OTC/pharmaceutical, and/or cosmetic is commercialized, numerous

regulatory requirements apply, including:

•

•

•

•

•

international quality system regulations, including those of the FDA and other regulatory authorities,
impose current Good Manufacturing Practice (“cGMP”) requirements governing the methods used in,
and the facilities and controls used for, the design, manufacture, packaging, servicing, labeling, storage,
installation, and distribution of all finished medical devices and OTC pharmaceuticals intended for
human use;

global standards and regulations affecting product design and development, including requirements to
keep existing products current to the “state of the art,” and doing an ongoing assessment of the risk
acceptability, adopting risk control measures where appropriate, and re-assessing the clinical benefit;

labeling regulations, including a prohibition on product promotion for unapproved or “off label” uses;

the medical device and drug reporting regulation requiring a manufacturer to report to the regulatory
authorities if its drug or device may have caused or contributed to a death or serious injury or
malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to
recur and ongoing post-market surveillance of the product and like-products to continuously evaluate
the benefit/risk over the life of the product; and

regulations on corrections and removals which require a manufacturer to report recalls and field actions
to the regulatory authorities if initiated to reduce a risk to health posed by the device or to remedy a
violation of the applicable laws.

Food Products

We market baking soda and animal feed products, such as rumen fermentation enhancers and Dietary
Cation-Anion Difference (“DCAD”) balancers that are also subject to FDA and foreign regulation. The Food
Safety Modernization Act (“FSMA”) regulates food and animal feed products and mandates preventive controls,
including hazard analysis, risk controls, supplier qualifications and controls and increased record keeping. FSMA
grants the FDA the authority to require mandatory recalls for products under certain conditions. The FDA is

10

currently in the process of establishing rules and guidance to implement the provisions of FSMA. The potential
impact of these rules and applicable guidance will be determined as they are published, and compliance plans
will be effected as necessary.

Dietary Supplements

The processing, formulation, safety, manufacturing, packaging, labeling, advertising, distribution,

importing, selling, and storing our dietary supplements are subject to regulation by one or more federal agencies,
including the FDA, the FTC, the CPSC, the EPA, and by various agencies of the states and localities in which our
products are sold. The FDCA governs the composition, safety, labeling, manufacturing and marketing of dietary
supplements. Additionally, dietary supplements sold outside the U.S. may be regulated as drugs.

It is unlawful to market as a dietary supplement any article that is approved as a new drug or is authorized

for investigation as a new drug for which substantial clinical investigations have been instituted and made public,
unless that article was first marketed as a dietary supplement or food. The FDA has authority to effectively void
that restriction through the issuance of a regulation finding the article lawful. The FDA has issued Warning
Letters to companies selling supplements with unapproved new dietary ingredients, unsafe food additives, and/or
drug claims.

Dietary ingredients that were not marketed in the U.S. before October 15, 1994 must be the subject of a new

dietary ingredient notification submitted to the FDA at least 75 days before the initial marketing, unless the
ingredient has been present in the food supply as an article used for food without being chemically altered. The
notification must provide evidence of a history of use or other evidence establishing that use of the dietary
ingredient is reasonably expected to be safe. The FDA may determine that notification does not provide an
adequate basis to conclude that a new ingredient is reasonably expected to be safe, which could effectively
prevent the marketing of the ingredient. In May 2022, the FDA issued draft guidance on enforcement policy with
regard to premarket notification of new dietary ingredients. Although the draft guidance was issued for public
comment and does not have the force of law, it is a strong indication of the FDA’s current thinking on the FDA’s
approach to enforcement. The FDA has signaled its intent to enforce the applicable statutes and regulations by
requiring submission of a pre-market safety notification for “new” dietary ingredients.

A company that uses a statement of nutritional support in labeling must possess information substantiating
that the statement is truthful and not misleading. If the FDA determines that a particular statement of nutritional
support is an unacceptable drug claim or an unauthorized version of a health claim, or if the FDA determines that
a particular claim is not adequately supported by existing scientific evidence or is otherwise false or misleading,
the claim could not be used and any product bearing the claim could be subject to regulatory action.

The FDA’s cGMP regulations govern the manufacturing, packaging, labeling and holding operations of

dietary supplement manufacturers. As with OTC products, the FDA performs periodic audits to ensure that our
dietary supplement facilities remain in compliance with all appropriate regulations. The failure of a facility to be
in compliance may lead to a breach of representation made to consumers or to regulatory action against us related
to the products made in that facility, seizure, injunction or recall. There is considerable uncertainty with respect
to the FDA’s interpretation and implementation of the cGMP regulations. The failure of a manufacturing facility
to comply with the cGMP regulations may render products manufactured in that facility adulterated and subjects
those products and the manufacturer to a variety of potential FDA enforcement actions. The manufacturer,
packer, or distributor of a dietary supplement marketed in the U.S. whose name appears on the label of the
supplement is required to report serious adverse events associated with the use of that supplement to the FDA.

Additional legislation may be introduced which, if passed, would impose substantial new regulatory

requirements on dietary supplements. The effect of additional domestic or international governmental legislation,
regulations, or administrative orders, if and when promulgated, cannot be determined. New legislation or
regulations may require the reformulation of certain products to meet new standards and require the recall or
discontinuance of certain products not capable of reformulation.

11

HUMAN CAPITAL

Overview

Much of our success comes from our culture. Our people share a collective energy and ambition towards

making a difference supporting the greater good, by providing affordable, quality products for everyday life, as
reflected in our ESG and sustainability commitments, and by giving back to their communities. Our culture
generates a collective passion, strength and determination to make an outsized impact, every day.

Safety and Wellness

Employee safety and wellness--in both plants and offices—remain two of our highest priorities. We develop

and administer company-wide policies to ensure the safety of each team member and compliance with OSHA
standards.

Our Employees

As of December 31, 2023, we had approximately 5,550 global employees, an increase of approximately 300

compared to December 31, 2022. Approximately 86% of our workforce is located in the Americas, 10% in
Europe, Middle East, and Africa, and 4% in the Asia-Pacific region. About 51% of our employees are salaried
and about 49% are paid hourly wages. During fiscal 2023, our overall turnover rate was approximately 18%. Our
revenue per employee in fiscal 2023 was approximately $1.05 million.

Diversity, Equity and Inclusion

We embrace the diversity of our employees and, our DEI efforts aspire to help us achieve a more diverse
and an inclusive workforce and optimize our long-term performance. We also strive to cultivate a culture and
processes that support and enhance our ability to recruit, develop and retain diverse talent at every level.

As a company we remain committed to fair treatment, access, opportunity, and advancement, while at the
same time striving to identify and eliminate barriers that have prevented the full participation of underrepresented
groups.

In 2020, we established a Diversity, Equity & Inclusion Council (“DE&I Council”) that provides strategic
direction, guidance and advocacy for our DEI initiatives. Led by our Chief Executive Officer and our Director,
Talent Management & Diversity, Equity & Inclusion, the DE&I Council includes diverse employees at every
level around the world. Our Board of Directors, acting principally through its Compensation & Human Capital
Committee, oversees our DEI efforts.

In 2023 we launched several Employee Resource Groups (“ERGs”). These Company-supported,
employee-run groups contribute to our goal of building and maintaining a diverse and inclusive workplace at
Church & Dwight. We started the program with ERGs for military veterans (V.A.L.O.R.), Black employees
(B.O.L.D.) and women (W.A.V.E.). ERGs are intended to create safe, inclusive environments where all global
employees feel connected, valued, and inspired to build customer value and contribute to our Company’s
success.

We are committed to transparency and accountability that will drive continuous progress. As part of our
enhanced diversity and inclusion initiatives and our commitment to transparency and accountability, we publish
workplace demographics of our employees in our Sustainability Reports.

12

Hiring, Development and Retention

Our talent strategy is focused on attracting the best talent and recognizing and rewarding performance, while

continually developing, engaging and retaining our talented employees.

We invest resources in professional development and growth as a means of improving employee
performance and improving retention. This includes management training aimed at continuous learning,
professional training and development opportunities, targeted leadership development courses for new and
existing leaders of different levels of seniority, tuition reimbursement, on-boarding efforts, job specific programs
for our employees, cultural reinforcement and more.

Compensation and Benefits

Attracting and retaining talent is a priority at Church & Dwight. We offer competitive pay and a range of benefits

that support the well-being of our increasingly diverse workforce. This includes offering competitive salaries and
wages, as well as benefits such as health insurance, retirement and profit-sharing plans, and paid time off.

Employees are eligible for health insurance, prescription drug benefits, dental, vision, hospital indemnity,

accident, critical illness, and disability insurance, life insurance, health savings accounts, flexible spending
accounts, reproductive rights coverage, participation in savings plans, and identity theft insurance, in each case
subject to the terms and conditions of the applicable plans and programs.

Communities

We encourage our employees to become involved in their communities, and in 2023, our Employee Giving
Fund supported our communities by providing $1.3 million to 221 deserving community organizations through
annual grants, disaster relief, and other monetary support. Employees purchased back-to-school supplies online
to support disadvantaged youth, donated clothes and non-perishable items for clothing and food drives and
provided supplies for a summer camp and holiday dinner for families in need. The Foundation was established in
2020 with the focus on helping to create equitable and inclusive opportunities and advancing environmental
preservation. The Foundation is administered by our employees. In 2023, seven organizations were chosen and
received grants totaling $875,000. In the DEI space, the following organizations received grants: Junior
Achievement, The Trevor Project, and Virginia State University. In the Sustainability space, the following
organizations received grants: The Recycling Partnership, the Ocean Conservancy, Northeast Wilderness Trust,
and The Xerces Society for Invertebrate Conservation.

PUBLIC INFORMATION

We maintain a website at www.churchdwight.com and on the “Investors-Financial Information-SEC Filings”
page of our website we make available free of charge our Annual Reports on Form 10-K, our Quarterly Reports on
Form 10-Q, and our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after
we electronically file these materials with, or furnish them to, the Securities and Exchange Commission (the
“Commission”). Also available on the “Investors-Corporate Governance” page on our website are our Corporate
Governance Guidelines, charters for the Audit, Compensation, & Human Capital and Governance, Nominating &
Corporate Responsibility Committees of our Board of Directors (the “Board”), our Code of Conduct and our Proxy
Statement. We also publish a Sustainability Report that summarizes our business and corporate responsibility
commitments and accomplishments including those related to our environmental, social, and governance
performance. For more information regarding our sustainability strategy and ESG pillars please see the
“Responsibility” page on our website and the discussion under the capital “Our Sustainability Strategy and
Environmental, Social and Governance (“ESG”) Pillars” included above. Each of the foregoing is also available in
print free of charge and may be obtained upon written request to: Church & Dwight Co., Inc., 500 Charles Ewing
Boulevard, Ewing, New Jersey 08628, attention: Secretary. The information presented on our website is not a part
of this Annual Report and the reference to our website is intended to be an inactive textual reference only.

13

ITEM 1A. RISK FACTORS

The following risks and uncertainties, as well as other factors described elsewhere in this Annual Report or
in our other filings with the Commission, could, individually and collectively, have a material adverse impact on
our business, reputation, financial results, financial condition and/or the trading price of our Common Stock:

Business and Operational Risks

• We face intense competition in our markets.

We face intense competition from consumer products companies, both in the U.S. and in international
markets. Most of our products compete with other widely-advertised promoted and merchandised brands within
each product category and from retailers, including supermarkets, mass merchandisers, wholesale clubs,
drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores and
websites and other e-commerce channels, which are increasingly offering private label and retailer-branded
brands and generic non-branded products in certain categories, which typically are sold at lower prices. In China,
in particular we face strong competition from local manufacturers offering both generic and branded products.
The use of evolving technology to develop more complex pricing models by retailers has led and may continue to
lead to pricing pressures in some categories. In addition, during times of economic uncertainty, consumers may
purchase more “private label” or other lower price brands, especially at a time of rising inflation. These
developments have increased competition in certain product categories in particular, including dietary
supplements, diagnostic kits and oral analgesics. In addition to competition across all our product categories,
there continues to be significant product competition in the gummy dietary supplement category, which has
grown from about 10 competitors a decade ago to more than 60 of significance in recent years. Shifting consumer
behavior, including continuing shifts to online shopping, have also increased competition in e-commerce in many
of our categories, from our larger legacy competitors and newer digitally native brands which have increasingly
moved into consumer products and staples.

Many of our competitors are large companies, including, among others, P&G, The Clorox Company,

Colgate-Palmolive Company, S.C. Johnson & Son, Inc., Nestle Purina PetCare Company and Nestle Health
Science, Haleon plc, Henkel, Reckitt Benckiser Group plc, Kenvue Inc., Pfizer Inc., Bayer AG, NBTY, Inc.,
Koninklijke Philips N.V., Unilever PLC, Sanofi, Pharmavite LLC, and Edgewell Personal Care. Many of these
companies have greater financial resources than we do, and these competitors, as well as new market entrants,
may therefore, have the capacity to outspend us on advertising and promotional activities and introduce
competing products or adopt new technologies, such as artificial intelligence and machine learning, more
quickly, successfully and effectively, and respond more effectively to changing business and economic
conditions than we can.

Our products generally compete on the basis of performance, brand recognition, price, value or other
benefits to consumers. Significant price competition may require us to reduce the prices for some of our products
to price levels that do not offset manufacturing cost increases, to respond to competitive and customer pressures
and to maintain market share. Increases to our prices, as a result of inflationary pressures or otherwise, could
cause declining sales of products whose prices we have increased. In response to ongoing inflationary pressures
and other factors, we have recently raised prices on many of our products across our global portfolio of brands
over the past few years. Ongoing periods of high inflation could lead to additional price increases on these or our
other products. Advertising, promotion, merchandising and packaging also have a significant impact on retail
customer decisions regarding the brands and product lines they sell and on consumer purchasing decisions. A
newly introduced consumer product (whether improved or newly developed) usually encounters intense
competition requiring substantial expenditures for advertising, sales promotion and trade merchandising. If a
product gains consumer acceptance, it normally requires continued advertising, promotional support and product
improvements to maintain its relative market position. If our advertising, marketing and promotional programs,
including the use of digital and social media to reach consumers, are not effective, our sales growth may decline.

14

• A continued change in the retail environment and changing consumer preferences could cause our

sales to decline.

Despite increasing shifts to e-commerce, sales of our products remain highest in the traditional mass

merchandiser, food and drug retail stores, and our products are also sold in club stores and dollar stores channels.
However, alternative retail channels, including direct to consumer, e-commerce retailers, hard discounters,
subscription services and buying clubs, have become more prevalent and the volume of consumer products that
are sold through such alternative retail channels is continuing to increase, which may affect customer and
consumer preferences, including any pricing pressures for consumer goods as retailers face added costs to build
or further expand their e-commerce capacity. In addition, a growing number of alternative sales channels and
business models, such as niche brands, native online brands, private label and store brands, direct-to-consumer
brands and channels and discounter channels, have emerged in the markets we serve. In particular, the growing
presence of, and increasing sales through, e-commerce retailers have affected, and may continue to affect,
consumer behavior or preferences (as consumers increasingly shop online and via mobile and social applications)
and market dynamics, including any pricing pressures for consumer goods as retailers face added costs to build
their e-commerce capacity. Further, consumer preferences continue to evolve due to a number of factors,
including fragmentation of the consumer market and changes in consumer demographics, including the aging of
the general population and the emergence of Millennials and Generation Z who have different spending,
consumption and purchasing habits; evolving consumer concerns or perceptions regarding ESG practices of
manufacturers, including, packaging materials, such as plastic packaging, and their environmental impact;
greenhouse gas emissions; waste disposal practices; a growing demand for natural or organic products and
ingredients; changing consumer sentiment toward non-local products or sources among different demographic
groups; evolving consumer concerns or perceptions regarding the effects of ingredients or substances present in
certain consumer products; reduced brand loyalty; and concerns regarding human capital practices, including
DEI.

We and many of our competitors have increased our online sales as a result of shifting consumer behavior,

benefiting from scale, brand recognition, and other factors. However, as consumers continue to shift their
behavior, retailers may incur higher e-commerce operating costs and will seek to recover those costs by passing
them onto customers and manufacturers. Additionally, we cannot predict the extent to which our increased
e-commerce demand will continue or the impact on our profits as retailers seek to recover higher e-commerce
related operating costs. Any significant changes in consumer preferences or behavior could materially and
negatively impact demand for our products and, in turn, our net sales and results of operations. Consumer
preferences are also influenced by the perception of our brand images or those of our products, the success of
advertising and marketing campaigns, our ability to engage with consumers in the manner they prefer, including
through the use of digital media or assets, and the perception of our advertising content, use of social media and
extent of engagement in political and social issues. If we are not successful in continuing to adapt to changing
consumer preferences and market dynamics or expanding sales through e-commerce retailers or alternative retail
channels, our business, financial condition and results of operations may be negatively impacted.

• Volatility and increases in the price of raw and packaging materials or energy costs could erode our

profit margins.

The principal raw materials and packaging used by us and certain of our suppliers and contract
manufacturers include surfactants (cleaning agents), paper products and resin-based molded components.
Volatility, and increases in the costs of raw materials without offsetting price increases, disruptions in production
or transportation, or increases in the costs of energy, labor, shipping and other necessary services, or other
inflationary pressures, including market conditions, inflation, banking failures, supplier capacity restraints,
geopolitical developments (including the ongoing conflicts in Ukraine and the Middle East), the impact and
results of the presidential election in the U.S., federal government spending disputes and government shutdowns,
port congestions or delays, transport capacity restraints, or other disruptions, could significantly affect our profit
margins if we are unable to pass along any higher costs in the form of price increases or otherwise achieve cost

15

efficiencies, such as in manufacturing and distribution. Significant inflation of material, component and
co-packer input costs impacted our gross margin in 2022, and while we expect general inflationary pressures to
cool in 2024, we may still be affected by increased costs impacting our supplies, transportation or manufacturing
processes. While we have increased prices on a majority of our products in recent years, there is no assurance
that we will be able to fully offset any input costs increases, through cost reduction programs or price increases
of our products or enter locked-in price arrangements or hedge agreements, especially given the competitive
environment. Sustained, those price increases may lead to declines in volume as competitors may reduce their
prices or customers may decide not to pay higher prices or to purchase lower priced alternatives, which could
lead to sales declines and loss of market share. While we seek to project tradeoffs between price increases and
volume, our projections may not accurately predict the volume impact of price increases. In addition, volatility in
certain commodity markets could significantly affect our production cost.

From time to time, we use hedge agreements to mitigate the volatility of commodities and diesel fuel prices.

The hedge agreements are designed to add stability to product costs, enabling us to make pricing decisions and
lessen the economic impact of abrupt changes in prices over the term of the contract. However, in periods of
declining fuel or other commodity prices, the hedge agreements can have the effect of locking us in at above-
market prices.

• Loss of any of our principal customers could significantly decrease our sales and profitability.

A limited number of customers account for a large percentage of our net sales and/or net sales of specific
product lines. Walmart is our largest customer, accounting for approximately 23% of net sales in 2023, 24% of
net sales in 2022, and 24% of net sales in 2021. Our top four customers accounted for approximately 44% and
42% of net sales in 2023 and 2022 respectively, and our top three customers accounted for approximately 37% of
net sales in 2021. We expect that a significant portion of our net sales will continue to be derived from a small
number of customers and that these percentages may increase if the growth of mass merchandisers continues. As
a result, changes in the strategies of Walmart or any of our other largest customers, including a reduction in the
number of brands they carry or of shelf space they dedicate to private label products, could materially harm our
net sales and profitability. Changes in consumer behavior, including continued shifting to online shopping
instead of physical retail shopping, could also impact our sales to our largest customers. Some of our retail
customers have experienced and may experience in the future declining financial performance, which could
affect their ability to pay amounts due to us on a timely basis or at all. If these impacts are prolonged, they can
further increase the difficulty of planning for operations. Moreover, the use of evolving technology by our
customers to develop more complex pricing models may lead to category pricing pressures. We could also lose a
significant customer due to customer service levels or real or perceived product quality or appearance issues. As
our business is based primarily upon individual sales orders rather than long-term contracts and most customer
agreements include customer termination rights after short notice, many of our customers could reduce their
purchasing levels or cease buying products from us at any time and for any reason.

• Decreases in demand for our products would decrease our sales and profitability.

Factors that can affect demand include competitors’ products, advertising and pricing actions, inflationary
pressures, rates of unemployment, consumer confidence, health care costs, including increased costs as a result of
changes in federal regulations, significant shifts in government policies, the deterioration of economic or trade
relations between countries or regions, commodity costs, fuel and other energy costs and other economic factors
affecting consumer spending behavior, including gasoline and home heating oil pricing, reduced unemployment
benefits in periods of high unemployment, restrictions on travel and access to public spaces, and changes in tax
policies, other effects of governmental shutdowns or a lapse of appropriations or fear of exposure to or actual
impacts of a widespread disease outbreak. In particular, we derive a substantial percentage of our revenues from
sales of laundry detergent, and the continued customer demand for these products are critical to our future
success. Some products have seen decreasing demand in recent years, including condoms, as a result of
demographic and other changes. We believe that inflation and recessionary concerns are continuing to drive a

16

decline in consumer spending for our most discretionary brands, Waterpik and Flawless, as consumers reduce
spending in these categories and shift to lower cost alternatives. Most notably, a growing number of water flosser
consumers are continuing to switch to competitors’ value-branded products. Moreover, in our vitamin business,
we are experiencing residual impacts from previous vitamin-specific supply chain challenges that resulted in
increased shelf space and/ or display for certain of our competitors. In addition, our Specialty Products business
has been negatively impacted by the return of foreign competition in the United States dairy market.

An increasing number of our products are more discretionary in nature and, therefore are more likely to be

affected by consumer decisions to control spending.

• We rely on the policies of our key retailer customers.

Larger and increasingly consolidated retailers have increasing influence, and have sought to obtain lower
pricing, special packaging inventory practices, logistics or other changes to the customer-supplier relationship as
a result of this influence. To the extent we provide concessions or better trade terms to those customers, our
profit margins are reduced. Further, if we are unable to effectively respond to the demands of our customers,
these customers could reduce their purchases of our products and increase their purchases of products from
competitors. Reductions in inventory by our customers, including as a result of consolidation in the retail
industry, or these customers managing their working capital requirements, could result in reduced orders for our
products and adversely affect our results of operations and cash flows for financial periods affected by such
reductions.

Protracted unfavorable market conditions have caused many of our customers to more critically analyze the
number of brands they sell, and reduce or discontinue certain of our product lines, particularly those products that
were not number one or two in their category.

In addition, private label and retail-branded products sold by retail trade chains are typically sold at lower

prices than branded products. As consumers look for opportunities to decrease discretionary spending, our
customers have discontinued or reduced distribution of some of our products to encourage those consumers to
purchase the customers’ less expensive and, in some cases, more profitable private label and retail-branded
products (primarily in the dietary supplements, diagnostic kits and oral analgesics categories).

• We have pursued and may continue to pursue strategic acquisitions and divestitures.

We may continue to pursue and consummate additional acquisitions, divestitures or substantial investments
in complementary businesses or products in the future. However, we may not be able to identify and successfully
negotiate suitable strategic acquisition at attractive valuations, obtain financing for future acquisitions on
satisfactory terms or otherwise complete future acquisitions. Potential acquisitions may be significantly larger
than the ones completed in the past and may require us to increase our levels of debt, potentially resulting in us
being assigned a lower credit rating. Recent increases in interest rates may make it more difficult to borrow at
attractive rates. In recent periods, competition from other consumer products companies that are seeking similar
opportunities has been particularly strong, and valuations for potential acquisition assets have been high, which
has placed pressure on our ability to identify, structure and execute transactions. In addition, acquisitions and
investments entail various risks, including the difficulty of entering new markets, product categories, or business
models, the challenges of integrating the operations and personnel of the acquired businesses or products, the
potential disruption of our ongoing business and the ongoing business of the acquired company, the need to
review and, if necessary, upgrade processes and systems of the acquired company to conform to our own
processes and systems and applicable legal and regulatory requirements, managing an increasingly broad and
complex range of businesses and products, and, generally, our potential inability to obtain the desired financial
and strategic benefits from the acquisition or investment. Any of these risks may divert management and other
resources, require us to incur unanticipated costs or delay the anticipated positive impact on our business and

17

results of the acquisition. The risks associated with assimilation are increased to the extent we acquire businesses
that have stand-alone operations or businesses that are in new categories that cannot easily be integrated or
operations or sources of supply outside of the U.S. and Canada, for which products are manufactured locally by
third parties.

Acquired companies or operations or newly-created ventures may not be profitable or may not achieve sales

levels and profitability that justify the investments made. In addition, future acquisitions or investments could
result in substantial cash expenditures, the potentially dilutive issuances of new equity by us or the incurrence of
additional debt or business acquisition liabilities, or the assumption of contingent liabilities, such as those
relating to advertising claims, environmental issues and litigation.

• Market category declines and changes to our product and geographic mix may impact the

achievement of our sales growth targets, planned pricing and financial results.

A significant percentage of our revenues come from mature markets that are subject to high levels of
competition. During 2023, approximately 83% of our sales were generated in U.S. markets. U.S. markets for
consumer products are considered mature and commonly characterized by high household penetration,
particularly with respect to our most significant product categories, such as laundry detergents, deodorizers,
household cleaning products, toothpastes, dietary supplements, antiperspirants and deodorants. Our ability to
quickly innovate to adapt our products (including product packaging and sustainability profiles) to meet changing
consumer demands is essential, especially in light of e-commerce significantly reducing the barriers for even
small competitors to quickly introduce new brands and products directly to consumers. Even if we are successful
in increasing sales within our product categories, a continuing or accelerating decline in the overall markets for
our products could have a negative impact on our financial results. We have implemented price increases and
may implement additional price increases in the future, which may slow sales growth or create volume declines
in the short term as customers and consumers adjust to these price increases. In addition, our Specialty Products
business has been negatively impacted by the entrance of new foreign competition in the United States dairy
market. We expect that low-priced imports will continue to enter the market. Our Specialty Products Division
declined in 2023, largely due to declining sales of our MEGALAC dairy supplement within our Animal Nutrition
business. We will be exiting this part of the Animal Nutrition business during the first quarter of 2024.

Adverse economic conditions continue to impact a portion of our businesses. We believe that inflation and
recessionary concerns are continuing to drive a decline in consumer spending for our most discretionary brands,
Waterpik and Flawless, as consumers reduce spending in these categories and shift to lower cost alternatives.
Most notably, a growing number of water flosser consumers are continuing to switch to competitors’ value-
branded products. Moreover, in our vitamin business, we are experiencing residual impacts from previous
vitamin-specific supply chain challenges that resulted in increased shelf space and/ or display for certain of our
competitors. Overall, we have continued to experience increased online sales. Potential recessionary economic
conditions may impact consumer demand for certain of our products and put downward pressure on product
prices.

• New products and product line extensions may not gain widespread customer acceptance, may be

otherwise discontinued, or cause sales of existing products to decline.

Our future performance and growth depend on our ability to successfully identify, develop and introduce
new products, product line extensions, products in adjacent categories to our current products, and anticipate
changes in consumer preferences. In addition, some of our products have shorter product life spans and depend
heavily on our ability to continuously and timely introduce innovative new products to the marketplace. The
successful development and introduction of new products involves substantial research, development, marketing
and promotional expenditures, which we may be unable to recover if the new products do not gain widespread
market acceptance. New product development and marketing efforts, including efforts to enter markets or
product categories in which we have limited or no prior experience, have inherent risks. These risks include

18

product development or launch delays, competitor actions, regulatory approval hurdles and the failure of new
products and line extensions to achieve anticipated levels of market acceptance. In addition, sales generated by
new products could result in an associated decline in sales of existing products.

Each year, we introduce new products across the majority of our brands, including launches into new “white

space” categories. However, there is no assurance that our new products will continue to have widespread
acceptance. Success in launching new products is also dependent on our ability to deliver effective and efficient
marketing in an evolving media landscape (including digital), which is subject to dynamic and increasingly
restrictive privacy requirements. If product introductions are not successful, costs associated with these efforts
may not be fully recouped and our net earnings or margins could be adversely affected. From time to time, we
have discontinued certain products and product lines, which resulted in returns from customers, asset write-offs
and shutdown costs. We may suffer similar adverse consequences in the future to the extent we discontinue
products that do not meet retailer or consumer expectations or no longer satisfy consumer demand.

• We are subject to cost overruns and delays, regulatory requirements, and miscalculations in capacity
needs with respect to our expansion projects and our manufacturing facilities, as well as disruptions
to our manufacturing facilities and those of our contract manufacturers and other suppliers.

From time to time, we initiate planned and unplanned expansion projects with respect to our facilities and
those of our contract manufacturers and other suppliers which are subject to risks of, and we have from time to
time experienced, delay or cost overruns resulting from numerous factors, including the following: shortages of
equipment, materials or skilled labor; work stoppages; unscheduled delays in the delivery of ordered materials
and equipment; unanticipated cost increases; difficulties in obtaining necessary permits or in meeting permit
conditions; difficulties in meeting regulatory or quality requirements or obtaining regulatory approvals;
availability of suppliers to certify equipment for existing and enhanced regulations; design and engineering
problems; failure or delay of third party service providers; and civil unrest, labor disputes, natural disasters and
pandemics. If we were to experience delays or cost overruns in the future it could result in product allocation and
retailer frustration, the loss of a significant customer or customers and the material decrease of the sales of one or
more of our products. In addition, we could miscalculate our anticipated capacity needs in any of our categories,
such as our laundry detergent, cat litter and dietary supplement categories, including as a result of meeting the
anticipated demand of our customers, or expansion into new product lines or into new markets.

Additionally, the supply of our products depends on the uninterrupted efficient operation of our
manufacturing facilities and those of our contract manufacturers and other suppliers and our ability to meet
customer service levels. The manufacturing of certain of our products is concentrated in one or more of our
plants, contract manufacturers or other suppliers, with limited alternate qualified facilities available. Many of our
manufacturing processes and those of our contract manufacturers and other suppliers are complex and present
difficult technical challenges to obtain the manufacturing yields necessary to operate profitably and may require
complex and specialized equipment which can be expensive to repair or replace with required lead times of up to
a year.

Any event that disrupts or otherwise negatively impacts manufacturing facilities, manufacturing systems or

equipment, or contract manufacturers or other suppliers could result in the delivery of inferior products or our
ability to meet customer requirements or service levels.

• We rely on a number of contract manufacturers and suppliers, including sole source contract

manufacturers and suppliers for certain products, and supply chain issues may result in product
shortages or disruptions to the Company’s business.

We rely on a number of contract manufacturers and suppliers for certain of our commodities and raw
materials, including sole source suppliers for certain of our raw materials, packaging, product components,
finished products and other necessary supplies. New suppliers must be qualified pursuant to our standards and

19

may also have to be qualified under governmental and industry standards and any other standards of our
customers, which can require additional investment and time. We could experience material disruptions in
production and other supply chain issues, largely because of shortages in supplier labor which continues to
impact the availability of many raw and packaging materials, which continues to result in out-of-stock
conditions. In addition, continued out-of-stock supplies or products due to supply chain issues may cause our
customers to switch to competitors’ products that are more available. Moreover, our relationships with customers
could be adversely affected if new or existing suppliers are unable to meet any standards set by us, government
or industry regulations, or our customers, if we are unable to contract with suppliers at the quantity, quality and
price levels needed for our business, if any of our key suppliers becomes insolvent, ceases or significantly
reduces its operations or experiences financial distress, or if any environmental, economic or other outside
factors impact its operations. We may be unable to qualify any needed new contract manufacturers or suppliers
or maintain supplier arrangements and relationships based on a variety of factors; we may be unable to contract
with suppliers at the quantity, quality and price levels needed for our business; certain of our suppliers may not
meet the standards of our customers or licensors; or certain of our key contract manufacturers or suppliers may
become insolvent or experience other financial distress or face closure or suspension of operations. If any of
these events occurs and we have failed to identify and qualify an alternative vendor, then we may be unable to
meet our contractual obligations and customer expectations, which could damage our reputation and result in lost
customers and sales, or the incurrence of fines or higher than expected expenses. Further, in recent years, we
have experienced continuing strain on our supply chain network and its ability to meet demands, including from
disruptions from the COVID-19 pandemic, ongoing conflicts in Ukraine and the Middle East, and other factors.
In addition, our supply chain is dependent on materials, components and other products from Asia and other
geographies that may be subject to disruptions in the supply chain, resulting in shortages that would affect our
revenue and operating margins.

• Reduced availability of transportation or disruptions in our transportation network could adversely

affect us.

We distribute our products and receive raw materials and packaging components primarily by truck, rail and

ship and through various ports of entry. Reduced availability of trucking, rail or shipping capacity due to labor
shortages, adverse weather conditions, natural disasters, including climatic events (including any potential effect
of climate change), allocation of assets to other industries or geographies or otherwise, work stoppages, closure
of operations due to government restrictions or sick employees or other impacts of pandemics, strikes or
shutdowns of ports of entry or such transportation sources, could lead to inflationary cost pressures, cause us to
incur unanticipated expenses and impair our ability to distribute our products or receive our raw materials or
packaging components in a timely manner, which could disrupt our operations, strain our customer relationships
and competitive position.

• Damage to the reputation of one or more of our leading brands could adversely affect us.

Our financial success is directly dependent on the reputation and success of our brands, particularly our
power brands. Seven of those brands are designated as “power brands” because they compete in large categories,
and we believe they have the potential for significant global expansion. Those seven brands are ARM &
HAMMER®; OXICLEAN®; VITAFUSION® and L’IL CRITTERS®; BATISTE®; WATERPIK®;
THERABREATH®; and HERO® and represent approximately 70% of our net sales and profits. The effectiveness
of these brands could suffer if our marketing plans or product initiatives do not have the desired impact on a
brand’s image or its ability to attract consumers. Our brands could suffer damage to their reputations due to real
or perceived, sustainability, quality or safety issues, including as a result of, among other things, significant
product recalls, product-related litigation, defects or impurities in our products, product misuse, changing
consumer perceptions of certain ingredients or environmental impacts (including packaging, energy and water
use and waste management), or allegations of product tampering. In addition, as our sales on various e-commerce
platforms grow, we may be unable to prevent sales of counterfeit, pirated, or stolen goods, unlawful or unethical
sales, unauthorized resellers online, or sales in violation of our policies.

20

Additionally, claims made in our marketing campaigns may become subject to litigation alleging false

advertising and could cause us to alter our marketing plans and may affect sales or result in the imposition of
significant damages against us.

Widespread use of social media and networking sites by consumers has greatly increased the accessibility
and speed of dissemination of negative information. Negative online consumer reviews or inaccurate posting or
comments about us or our brands in the media or on any social networking website, whether accurate or
inaccurate, or the disclosure of non-public sensitive information through social media, could generate adverse
publicity that could damage the reputation of our brands. In addition, given the association of our individual
products with us, an issue with one of our products could negatively affect the reputation of our other products,
or us as a whole.

• We are subject to risks related to our expansion and international operations that could adversely

affect our results of operations.

Our ability to continue to grow our sales and profits is dependent on expanding in the locations in which we

already do business and entering into new geographic locations, both of which require significant resources and
investments which would affect our risk profile. Further, our international operations subject us to risks
customarily associated with foreign operations, including:

• Changing macroeconomic conditions in our markets, including as a result of inflation, interest rates,

volatile commodity prices and increases in the cost of raw and packaging materials, labor, energy and
logistics, which could impact our manufacturing operations and that of our third-party partners;

•

•

currency fluctuations;

the Russia/Ukraine war and ongoing and new conflicts in the Middle East;

• widespread health emergencies, such as COVID-19 or other pandemics or epidemics;

•

•

•

•

•

•

•

•

•

•

•

•

import and export license and taxation requirements and restrictions;

trade restrictions, including local investment or exchange control regulations;

changes in tariffs and taxes;

the effect of foreign income taxes, value-added taxes and withholding taxes, including the inability to
recover amounts owed to us by foreign governments, and the determination of the U.S. Internal
Revenue Service (the “I.R.S.”) regarding the applicability of certain regulations, including those
promulgated under the Foreign Account Tax Compliance Act, to our international transactions;

the possibility of expropriation, confiscatory taxation or price controls;

restrictions on or the costs related to repatriating foreign profits back to the U.S.;

political or economic instability, and civil unrest;

potential disruption from wars and military conflicts, including the war in Ukraine, terrorism or other
types of violence;

disruptions in the global transportation network, such as work stoppages, strikes or shutdowns of ports
of entry or such other transportation sources, or other labor unrest;

extreme weather events resulting in power loss, damage to infrastructure and reduced economic
development in vulnerable areas;

compliance with laws and regulations concerning ethical business practices, including without
limitation, the U.S. Foreign Corrupt Practices Act and United Kingdom Bribery Act;

difficulty in enforcing contractual and intellectual property rights;

21

•

•

regulatory and quality system requirements for certain products; and

difficulties in staffing and managing international operations.

Major developments in trade relations, including the imposition of new or increased tariffs or sanctions by

the U.S. and/or other countries, and any emerging nationalist trends in specific countries could alter the trade
environment and consumer purchasing. All the foregoing risks could have a significant impact on our ability to
commercialize our products on a competitive basis in international markets.

In addition, in all foreign jurisdictions in which we operate, we are subject to laws and regulations that
govern foreign investment, foreign trade and currency exchange transactions. The recent imposition of tariffs on
products imported from certain countries in recent years has introduced greater uncertainty with respect to trade
policies and government regulations affecting trade between the U.S. and other countries. The sanctions
introduced in response to the Ukraine conflict have further exacerbated these issues. Major developments in trade
relations, including the imposition of new or increased tariffs by the U.S. and/or other countries, and any
emerging nationalist trends in specific countries could alter the trade environment and consumer purchasing
behavior which, in turn, could have a material effect on our balance sheet and results of operations. All the
foregoing risks could have a significant impact on our ability to commercialize our products on a competitive
basis in international markets and may have a material adverse effect on our results of operations and cash flows
or financial position.

• Failure to effectively utilize or successfully assert intellectual property rights, and the loss or

expiration of such rights, could materially adversely affect our competitiveness. Infringement by us of
third-party intellectual property rights could result in costly litigation and/or the modification or
discontinuance of our products.

We rely on trademark, trade secret, patent and copyright laws to protect our intellectual property rights. The
market for our products depends to a significant extent upon the value associated with our trademarks and brand
names. We own the material trademarks and brand names used in connection with the marketing and distribution
of our major products both in the U.S. and in other countries. While we hold several valuable patents on our
products, they may not serve as an effective barrier to entry for new competitors. Although most of our material
intellectual property is registered in the U.S. and in certain foreign countries in which we operate, we cannot be
sure that our intellectual property rights will be sufficient or effectively utilized or, if necessary, successfully
asserted. There is a risk that we will not be able to obtain and perfect our own intellectual property rights, or,
where appropriate, license from others intellectual property rights necessary to support our ability to
manufacture, import, export, market and/or sell certain products in certain countries or globally or launch new
product. We cannot be sure that these rights, if obtained, will not be invalidated, circumvented or challenged in
the future, and we could incur significant costs in connection with legal actions relating to such rights. In
addition, even if such rights are obtained in the U.S., the laws of some of the other countries in which our
products are or may be manufactured or sold do not protect intellectual property rights to the same extent as the
laws of the U.S. If other parties infringe our intellectual property rights, they may dilute the value of our brands
in the marketplace, which could diminish the value that consumers associate with our brands and harm our sales.
Our failure to perfect, successfully assert or license intellectual property rights could make us less competitive
and could have a material adverse effect on our business, including our ability to manufacture, import, export,
market and/or sell certain products within certain countries or globally, our operating results and our financial
condition.

In addition, if our products are found to infringe intellectual property rights of others, the owners of those

rights could bring legal actions against us claiming substantial damages for past infringement and seeking to
enjoin manufacturing, importing, exporting, marketing and/or sale of the affected products in certain countries or
globally. If these legal actions are successful, in addition to any potential liability for damages from past
infringement, we could be required to obtain a license in order to continue to manufacture, import, export, market

22

and/or sell the affected products, in certain countries or globally potentially adding significant costs. We might
not prevail in any action brought against us or we may be unsuccessful in securing any license for continued use
and therefore have to discontinue the manufacture, importing, exporting, marketing and/or sale of a product in
certain countries or globally.

•

Impairment of our goodwill and other long-lived intangible and tangible assets may result in a
reduction in net income.

We have a material amount of goodwill, trademarks and other intangible assets, as well as other long-lived

tangible assets, which are periodically evaluated for impairment in accordance with current accounting standards.
Declines in our profitability and/or estimated cash flows related to specific intangible assets, as well as potential
changes in market valuations for similar assets and market discount rates, has resulted in impairment charges
from time to time, and may result in future impairment charges. In the fourth quarter of 2022, we determined that
a review of our ability to recover the carrying value of the global FINISHING TOUCH FLAWLESS intangible
assets was necessary based on the discontinuance of certain products at a major retailer. This loss of distribution
along with an expected continued decline in discretionary consumption and higher interest rates resulted in an
impairment charge as discussed in more detail in “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in this Annual Report on Form 10-K.

Regulatory and Litigation Risks

• We may be subject to product liability claims, withdrawals or recalls or other legal proceedings and

from time to time we are involved in litigation, arbitration or regulatory matters where the outcome is
uncertain and which could entail significant expense.

From time to time, we are subject to product liability or other product-related claims. We may be required to

pay for losses or injuries actually or purportedly caused by our products, including losses or injuries caused by
raw materials or other components provided by third party suppliers that are included in our products. Claims
could be based on allegations that, among other things, our products contain contaminants, are improperly tested,
labeled or designed, or provide inadequate instructions regarding their use or inadequate warnings of potential
dangers related to their use. Whether or not successful, product liability claims could result in negative publicity
that could harm our sales and operating results and the reputation of our brands. In addition, if one of our
products is found to be defective or non-compliant with applicable rules or regulations, we could be required to
withdraw or recall it, which could result in adverse publicity and significant expenses. Although we maintain
product liability and product recall insurance coverage, potential product liability or other product-related
damages claims and/or withdrawal and recall costs may exceed the amount of insurance coverage or may be
excluded under the terms of the policy.

• Litigation, arbitration or regulatory matters where the outcome is uncertain could entail significant

expense.

From time to time, we are the subject of, or party to, various pending or threatened legal actions (including

class actions), government investigations and proceedings, including, without limitation, those relating to,
commercial transactions, product liability, consumer, employment, antitrust, environmental, health, safety and
compliance-related matters. Such proceedings are subject to many uncertainties and the outcome of certain
pending or threatened legal actions, investigations and proceedings may not be reasonably predictable and any
related damages, injunctions and/or settlements may not be estimable.

• Environmental matters create potential liability risks.

We must comply with various environmental laws and regulations in the jurisdictions in which we operate,

including those relating to the handling and disposal of solid and hazardous wastes and the remediation of
contamination associated with the use and disposal of hazardous substances. A release of such substances due to

23

accident or an intentional act could result in substantial liability to governmental authorities or to third parties.
We have incurred, and will continue to incur, capital and operating expenditures and other costs in complying
with environmental laws and regulations.

•

Increasing focus and sensitivity by governmental, non-governmental organizations, customers,
consumers and investors to ESG issues, including those related to DEI, climate change, plastic usage
and ingredients, could result in increased operating or manufacturing costs and compliance
challenges, which could adversely affect our business.

As climate change and other ESG issues become more prominent, so has scrutiny by federal, state and local

governments, non-governmental organizations and our customers, consumers and investors. This will likely
result in new or increased regulatory requirements such as the SEC’s disclosure proposal on climate change and
various state-level Extended Producer Responsibility programs, California’s recently enacted climate reporting
legislation, and customer and consumer standards. In addition, our stakeholders are increasingly demanding
transparency regarding our DEI efforts as well as our efforts to mitigate our impacts on climate change, and to
eliminate chemicals of concern and otherwise reduce or mitigate adverse effects on the environment. For
example, some of our major customers have requested we respond to various questionnaires, including the CDP
Climate Change, Water and Forests Questionnaires, and use our responses and CDP scores to evaluate us.
Compliance with these requirements, standards and disclosure requests may be challenging and could cause
disruptions in the manufacture of our products and/or result in increases in operating costs, and additional legal,
compliance and regulatory risks and costs. We may also be required to contribute funds to support recycling and
other waste management infrastructure, and/or incur costs associated with making necessary changes to our
operations and controlling, assessing and reporting on certain ESG metrics. These disruptions and additional
costs could make our products more costly and less competitive than other products, which would adversely
affect our business.

• Any failure to achieve our ESG goals or to effectively respond to new or current legal, regulatory or

stakeholder ESG requirements could adversely affect our business and reputation.

While we strive to minimize adverse impacts of our global operations, our ability to achieve any stated ESG
goal, target, or objective is subject to numerous factors and conditions, many of which are outside of our control.
We could lose revenue if our consumers change brands, major retailers delist our products or our retail customers
move business from us because we have not effectively responded to regulatory requirements, complied with
their ESG requirements or met their expectations related to our sustainability efforts, including with respect to
DEI, climate change, plastic usage, or ingredients. In addition, our actual or perceived failure to achieve or make
sufficient progress towards our stated ESG goals or comply with ESG related regulations could result in
litigation, regulatory scrutiny or adverse publicity, which could damage our reputation, reduce consumer demand
and devalue our brand equity. Further, ESG-conscious investors may choose not to invest in our securities if we
do not comply with their expectations, and investment managers may not include our securities in
ESG-designated funds.

• Current and future laws and regulations in the countries in which we and our suppliers operate could

expose us to increased costs and other adverse consequences.

The development, manufacturing, processing, formulation (including stability), packaging, labeling,
marketing, distribution and sale of our products are subject to regulation by federal agencies, including the U.S.
FDA, the FTC, the EPA and the CPSC and foreign regulators and agencies. In addition, our and our suppliers’
operations are subject to the oversight of the Occupational Safety and Health Administration and the National
Labor Relations Board. Our activities are also regulated by various agencies of the states, localities and foreign
countries in which our products and their constituent materials and components are manufactured and sold.

24

In particular, the FDA and foreign counterparts regulate the formulation, safety, development,

manufacturing, packaging, labeling and distribution of condoms, home pregnancy and ovulation test kits, vaginal
lubricants, electric and battery powered medical devices, wound dressings, over-the-counter medicines and
dietary supplements, including vitamins, minerals, and homeopathic products. The FDA or a similar foreign
agency also exercises oversight over cosmetic products such as depilatories, hair care and skin care products. In
addition, under a memorandum of understanding between the FDA and the FTC, the FTC has jurisdiction over
the promotion and advertising of these products, and the FTC regulates the promotion and advertising of our
other products as well. As part of its regulatory authority, the FDA may periodically conduct inspections of the
physical facilities, machinery, processes and procedures that we and our suppliers use to manufacture regulated
products and may identify compliance issues that would require us and our suppliers to make certain changes in
our manufacturing facilities and processes. The failure of a facility to be in compliance may lead to regulatory
action against the products made in that facility, including seizure, injunction or recall, as well as to possible
action against the owner of the facility/manufacturer. We may be required to make additional expenditures to
address these issues or possibly stop selling certain products until the compliance issue has been remediated.

Likewise, any future determination by the FDA, the EPA or a similar foreign agency, or by us in reviewing

our compliance with applicable rules and regulations, that our products or quality systems do not comply with
applicable regulations could result in future compliance activities, including product withdrawals or recalls,
import detentions, injunctions preventing the shipment of products, or other enforcement actions. For example,
the FDA may determine that a particular claim that we use to support the marketing of a product is not
substantiated, may not accept the evidence of safety for a new product that we may wish to market, may
challenge the safety or effectiveness of existing products based on, among other things, changes in formulations,
inadequate stability or “shelf-life,” consumer complaints, or improper labeling, may take action against our
homeopathic products, such as our Zicam cold shortening products, on the basis that they are unapproved drugs,
and may determine that our dietary supplement business manufacturing, packaging, labeling and holding
operations do not comply with cGMPs. Similarly, we may identify these or other issues in internal compliance
reviews of our operations and the operations and products of vendors and acquired companies. These other issues
may include the identification of contaminants or non-compliant levels of particular ingredients. Any of the
foregoing could subject us to adverse publicity, force us to incur unanticipated costs and have a material adverse
effect on our business, financial condition, results of operations and cash flows. Additionally, delays in the
acceptance, review and approval of products by the FDA or the EPA, or other required governmental approvals,
may result from government shutdowns due to the failure by Congress to enact regular appropriations.

We are subject to regulations regarding the transportation, storage or use of certain chemicals to protect the
environment, as well as the Commission’s rules with respect to “conflict minerals.” Recent trade policies, tariffs
and government regulations affecting trade between the U.S. and other countries, as well as sanctions by the U.S.
and the European Union in response to the Russia/Ukraine war, have introduced greater uncertainty and
volatility. In addition, renewed significant governmental actions pertaining to pandemics or other health
emergencies, including lockdowns, quarantines or other restrictions on the ability of our employees to travel or
perform necessary business functions or our ability to develop, manufacture, distribute, market or sell our
products, or the ability of our suppliers, customers or third-party partners to effectively run their operations, may
negatively impact our ability to manufacture, distribute, market and sell our products. We are not able to predict
the nature of these changes or of such future laws, regulations, repeals or interpretations or to predict the effect
additional or shifting governmental regulation, when and if it occurs, would have on our business in the future.
Such developments could require reformulation of certain products to meet new standards, recalls or
discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased
documentation of the properties of certain products, additional or different labeling, additional scientific
substantiation, expanded adverse event reporting or other new requirements.

There is also an increased risk of fraud or corruption in certain foreign jurisdictions and related difficulties
in maintaining effective internal controls. Additionally, we could be subject to future inquiries or investigations
by governmental and other regulatory bodies, which may be delayed or disrupted due to any government

25

furlough. We could also be adversely affected by violations, or allegations of violations, of the Foreign Corrupt
Practices Act and similar international anti-bribery laws. The Foreign Corrupt Practices Act and similar
international anti-bribery laws generally prohibit companies and their intermediaries from making improper
payments to government officials or other third parties for the purpose of obtaining or retaining business.

• We are subject to increasingly stringent privacy and security regulation.

We collect, use and store personal data of our employees, customers and other third parties in the ordinary

course of business, and we are required to comply with increasingly complex and changing data privacy and
security laws and regulations, that apply to the collection, storage, use, transmission and protection of personal
information and other consumer and employee data, including particularly the transfer of personal data between
or among countries. High-profile security breaches of the information systems of a number of government
agencies and U.S. companies may result in increased regulations and new security laws. The current
administration and Congress in the United States may seek to pass more stringent regulations in these areas, or
more aggressively enforce existing regulations.

Numerous local, municipal, state, federal and international law and regulations address privacy and security

including the California Online Privacy Protection Act, the Personal information Protection and Electronic
Documents Act, the Controlling the Assault of Non-Solicited Pornography and Marketing (CAN-SPAM) Act, the
Telephone Consumer Protection Act of 1991, the Health Insurance Portability and Accountability Act of 1996
(HIPAA), Section 5© of the Federal Trade Commission Act, and, the California Consumer Privacy Act (CCPA).
These privacy and security laws and regulations change frequently, and new legislation continues to be
introduced such as the California Privacy Rights Act (“CPRA”), which was effective on January 1, 2022 and
modifies the CCPA significantly, as well as the Virginia Consumer Data Protection Act, the Colorado Privacy
Act, Utah Consumer Privacy Act and Connecticut Data Privacy Act which became effective in 2023. In
particular, the CCPA requires new disclosures to California consumers, gives California consumers new rights
with respect to their data, and permits California consumers to opt-out of certain sales of personal information.
The CCPA provides for fines of up to $7,500 per violation. Our website ecommerce and customer relations
businesses that store, process or transmit payment cardholder data are subject to be Payment Card Industry (PCI)
compliance requirements as mandated by the credit card companies (Visa, Mastercard, and American Express)
and the Payment Card Institute Data Security Standard (PCI-DSS).

In Europe, the European Union (“EU”) has adopted strict data privacy regulations. Following the passage of

the EU’s General Data Protection Regulation ((EU) 2016/679) (“GDPR”) and the Regulation on Privacy and
Electronic Communications (the “ePrivacy Regulation”), data privacy and security compliance in the EU are
increasingly complex and challenging. The GDPR in particular has broad extraterritorial effect and imposes a
strict data protection compliance regime with significant penalties for non-compliance (up to 4% of worldwide
annual turnover or €20 million, whichever is higher). It is also important to note that many countries are
following the EU in producing a broad omnibus law in relation to privacy protection. In general, the GDPR and
ePrivacy Regulation, CCPA, and other local privacy laws, could also require adaptation of our technologies or
practices, increased costs and changes to operations to satisfy local privacy requirements and standards.

We may also face audits or investigations by one or more domestic or foreign government agencies relating

to our compliance with these regulations. An adverse outcome under any such investigation or audit could
subject us to fines, penalties or orders to cease, delay or modify collection, use or transfers of personal data. We
could also face rights requests, complaints, claims, or litigation from those persons whose data we collect, use
and store as well as government investigations and fines. Any of these events or other circumstances related to
our collection, use and transfer of personal data could also lead to negative media attention, damage to our
reputation in the market or otherwise adversely affect our business.

26

• Changes in tax laws and regulations or in our operations may impact our effective tax rate and may

adversely affect our business, financial condition and operating results.

Our future effective tax rate could be affected by changes in or the interpretation tax laws and regulations,

changes in the mix of earnings in countries with differing statutory tax rates, or changes in the valuation of
deferred tax assets and liabilities. In addition, we evaluate our deferred income tax assets and record a valuation
allowance if it is “more likely than not” that all or a portion of the deferred tax asset will not be realized. If the
actual amount of our future taxable income is less than the amount we are currently projecting with respect to
specific tax jurisdictions, or if there is a change in the time period within which the deferred tax asset becomes
deductible, we could be required to record a valuation allowance against our deferred tax assets. The recording of
a valuation allowance would result in an increase in our effective tax rate and would have an adverse effect on
our operating results. In addition, changes in statutory tax rates may change our deferred tax assets or liability
balances, which would also impact our effective tax rate.

On October 4, 2021, members of the Organization for Economic Co-operation and Development (“OECD”)

agreed to a global minimum tax rate of 15%. On December 20, 2021, OECD published its model rules on the
agreed minimum tax known as the Global Anti-Base Erosion (“GloBE”) rules. The GloBE Rules consist of an
interlocking and coordinated system of rules which are designed to be implemented into the domestic law of each
jurisdiction and operate together to ensure large multinational enterprise groups are subject to a minimum
effective tax rate of 15% on any excess profits arising in each jurisdiction where they operate. On December 15,
2022, the European Council approved its directive to implement Pillar Two of the GloBE rules regarding a 15%
global minimum tax rate. Japan and South Korea have enacted domestic Pillar Two legislation, and many other
countries, including the UK, Switzerland, Ireland and Germany, have released draft legislation or publicly
announced their plans to introduce legislation based on the OECD Model Rules. Many aspects of Pillar Two will
be effective for tax years beginning in January 2024, with certain remaining impacts to be effective in 2025.
Based on current legislation and available guidance, we have evaluated the impact of Pillar Two and determined
there is no impact to the company. As Pillar Two legislation evolves and countries enact new legislation, we will
continue to evaluate Pillar Two and Pillar Two may increase our future effective tax rate.

• Resolutions of tax disputes may adversely affect our earnings and cash flow.

Significant judgment is required in determining our effective tax rate and in evaluating our tax positions.
We provide for uncertain tax positions with respect to tax positions that do not meet the recognition thresholds or
measurement standards mandated by applicable accounting guidance. Fluctuations in federal, state, local and
foreign taxes or changes to uncertain tax positions, including related interest and penalties, may impact our
effective tax rate and our financial results. We are regularly under audit by tax authorities, and although we
believe our tax estimates are reasonable, the final outcome of tax audits and related litigation could be materially
different than that reflected in our historical income tax provisions and accruals. In addition, when particular tax
matters arise, a number of years may elapse before such matters are audited and finally resolved. Favorable
resolution of such matters could be recognized as a reduction to our effective tax rate in the year of resolution.
Unfavorable resolution of any tax matter could increase the effective tax rate. Any resolution of a tax issue may
require the use of cash in the year of resolution.

• Our amended and restated bylaws include an exclusive forum provision.

Our amended and restated bylaws include an “exclusive forum” provision, which may limit the ability of
our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or
our directors or officers, which may discourage such lawsuits against us and our directors and officers. If a court
outside of Delaware were to find this exclusive forum provision inapplicable to, or unenforceable in respect of,
one or more of the specified types of actions or proceedings described above, we could incur additional costs
associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial
condition or results of operations or cash flows.

27

Financial Risks

• We have substantial indebtedness and we may incur substantially more debt in the future.

As of December 31, 2023, we had approximately $2.406.0 million of total consolidated indebtedness, net of

debt issuance costs. This amount of indebtedness could have important consequences, including:

• making it more difficult for us to satisfy our obligations;

•

•

•

•

•

limiting our ability to fund potential acquisitions;

requiring us to dedicate a portion of our cash flow from operations to payments on our indebtedness,
which would reduce the availability of cash flow to fund capital expenditures and other general
corporate purposes;

limiting our flexibility in reacting to general adverse economic conditions or changes in our business
and the industry in which we operate;

limiting our ability to repurchase our Common Stock; and

placing us at a competitive disadvantage compared to our competitors that have less debt.

Additionally, our term and revolving facilities are subject to certain financial and other customary

covenants. In the event of a breach of those covenants, our lenders under each credit facility may be entitled to
accelerate the related debt (and any lenders in respect of any other debt to which a cross-default provision applies
may be entitled to accelerate such other debt), and we could be required to seek amendments or waivers under
the debt instruments or to refinance the debt. We may incur substantial additional indebtedness in the future to
fund acquisitions, to repurchase shares or to fund other activities for general business purposes. If additional new
debt is added to the current debt levels, the related risks that we now face could intensify. A substantial increase
in our indebtedness could also have a negative impact on our credit ratings. In this regard, a deterioration in our
credit ratings could adversely affect the interest rate available to us in future financings, as well as our liquidity,
competitive position and access to capital markets. The U.S. Federal Reserve has raised interest rates consistently
since March of 2022, and while it has signaled that it expects to hold rates steady or decrease rates in the future,
additional increases or the failure to reduce rates could impact the interest rates available to us for borrowings in
the future. Any decision regarding future borrowings will be based on the facts and circumstances existing at the
time, including market conditions and impact to our credit ratings.

Each of our term and revolving credit facilities use Secured Overnight Financing Rate (“SOFR”) based rates

following the phase out of LIBOR. Given the inherent differences between LIBOR and SOFR or any other
alternative benchmark rate that may be established, there are additional uncertainties regarding a transition from
LIBOR, including but not limited to the impact this transition may have on the cost of our variable rate debt and
certain derivative financial instruments. Since the initial publication of SOFR in 2018, changes in SOFR have, on
occasion, been more volatile than changes in other benchmark or market rates, such as United States dollar
LIBOR.

• Our business is exposed to domestic and foreign currency fluctuations.

We are exposed to foreign currency exchange rate risk (both transaction and translation) with respect to our

sales, profits, assets and liabilities denominated in currencies other than the U.S. Dollar. Outside of the U.S.,
sales and costs are denominated in a variety of currencies, including the Canadian Dollar, Euro, Pound, Mexican
Peso, Australian Dollar and Chinese Yuan, among others. A weakening of the currencies in which sales are
generated relative to the currencies in which costs are denominated would decrease operating profits and cash
flow. Changes in currency exchange rates may also affect the relative prices at which we purchase materials and
services in foreign markets. Although we, from time to time, enter into forward exchange contracts to reduce the
impact of foreign exchange rate fluctuations related to anticipated but not yet committed sales or purchases

28

denominated in the U.S. Dollar, Canadian Dollar, Pound, Euro, Mexican Peso, Australian Dollar and Chinese
Yuan, foreign currency fluctuations could have a material adverse effect on our business, financial condition and
results of operations.

• The estimates and assumptions on which our financial projections are based may prove to be

inaccurate, which may cause our actual results to materially differ from such projections, which may
adversely affect expectations regarding our future profitability and cash flows, which may impact our
stock price.

Our financial projections, including, among other things, any sales or earnings guidance or outlook we may

provide from time to time, are dependent on certain estimates and assumptions related to, among other things,
category growth, development and launch of innovative new products, market share projections, product pricing
and sale, volume and product mix, foreign exchange rates and volatility, tax rates, commodity prices,
distribution, cost savings, accruals for estimated liabilities, including litigation reserves, measurement of benefit
obligations for pension and other postretirement benefit plans, and our ability, among other things, to generate
sufficient cash flow to reinvest in our existing business, fund internal growth, repurchase our stock, make
acquisitions, pay dividends and meet our debt obligations. Our financial projections are based, among other
things, on historical experience, various other estimates and assumptions that we believe to be reasonable under
the circumstances and at the time they are made, and our actual results may differ materially from our financial
projections. Any material variation between our financial projections and our actual results may adversely affect
expectations regarding our future profitability and cash flow, which may impact our stock price.

General Risks

• Our operating results have been, and could be in the future, adversely affected by natural disasters,
public health crises, political crises, or other catastrophic events, or unfavorable worldwide, regional
and local economic and financial market conditions.

Our operations, as well as the operations of our third-party manufacturers, suppliers and customers, may be

subject to disruption from a variety of causes, including a protracted economic downturn or recessionary
conditions, material shortages, inflation, financial difficulties, work stoppages, cyberattacks, and other
disruptions in information technology systems, demonstrations, political instability or uncertainty in the U.S. or
abroad, rising geopolitical tensions and hostilities (for example in the Middle East or between China and
Taiwan), disease outbreaks or pandemics (for example, an outbreak of a virus such as COVID-19), acts of war,
terrorism, fire, earthquakes, flooding or other natural disasters, disruptions in logistics, fuel and energy costs (for
example, the price of gasoline), loss or impairment of key manufacturing sites, supplier capacity constraints, raw
material and product quality or safety issues, industrial accidents or other occupational health and safety issues. If
a major disruption were to occur, it could result in harm to people or the natural environment, delays in
shipments of products to customers or suspension of operations.

Other financial uncertainties in our major markets and unstable geopolitical conditions in certain markets,

including civil unrest and governmental changes, could undermine global consumer confidence and reduce
consumers’ purchasing power, thereby reducing demand for our products. Restrictions on our ability to transfer
earnings or capital across borders, price controls, limitations on profits, retaliatory tariffs, import authorization
requirements and other restrictions on business activities which have been or may be imposed or expanded as a
result of political and economic instability, deterioration of economic relations between countries or otherwise,
could impact our profitability. In addition, U.S. trade sanctions against countries designated by the U.S.
government as state sponsors of terrorism and/or financial institutions accepting transactions for commerce
within such countries could increase significantly, which could make it impossible for us to continue to make
sales to customers in such countries. The imposition of retaliatory sanctions against U.S. multinational
corporations by countries that are or may become subject to U.S. trade sanctions, or the delisting of our branded
products by retailers in various countries in reaction to U.S. trade sanctions or other governmental action or

29

policy, could also negatively affect our business. Ongoing political uncertainty in many countries, including the
ongoing political transition in Hong Kong, and the exit of the United Kingdom from the European Union have
created additional economic uncertainty and volatility in the financial markets. In February 2022, Russia invaded
Ukraine, and in October 2023 hostilities increased between Israel and Hamas in the Gaza Strip, and we have
experienced, and expect to continue to experience, the indirect impacts of the conflict in Ukraine, including
increases in the cost of raw and packaging materials and commodities (including the price of oil), supply chain
and logistics challenges and foreign currency volatility, and it is not possible to predict the broader or longer-
term consequences of this conflict or the sanctions imposed to date. Increasing natural disasters in connection
with climate change could also be a direct threat to our third-party vendors, service providers or other
stakeholders, including disruptions of supply chains or information technology or other necessary services for
our Company.

• We rely significantly on information technology. Any inadequacy, interruption, theft or loss of data,
malicious attack, integration failure, failure to maintain the security, confidentiality or privacy of
sensitive data residing on our systems or other security failure of that technology could harm our
ability to effectively operate our business and damage the reputation of our brands.

We rely extensively on information technology systems, some of which are managed by third-party service

providers, to conduct our business. These systems include, but are not limited to, programs and processes relating
to internal communications and communications with other parties, ordering and managing materials from
suppliers, converting materials to finished products, shipping product to customers, billing customers and
receiving and applying payment, processing transactions, summarizing and reporting results of operations,
complying with regulatory, legal or tax requirements, collecting and storing customer, consumer, employee,
investor, and other stakeholder information and personal data, and other processes necessary to manage our
business. We sell certain of our products directly to consumers online and through websites, mobile apps and
connected devices, and we offer promotions, rebates, customer loyalty and other programs through which it may
receive personal information, and we or our vendors could experience cyber-attacks, privacy breaches, data
breaches or other incidents that may result in unauthorized access, disclosure and misuse of consumer, customer,
employee, vendor or Company information.

Increased information technology security threats and more sophisticated computer crime, including
ransomware, denial of service and phishing attacks and advanced persistent threats, pose a potential risk to the
security of our information technology systems, networks, and services, and those of our customers and other
business partners, as well as the confidentiality, availability, and integrity of our data, and the data of our
customers and other business partners. The rapid evolution and increased adoption of artificial intelligence
technologies may intensify our cybersecurity risks. As a result, our information technology systems, networks or
service providers could be damaged or cease to function properly or we could suffer a loss or disclosure of
business, personal or stakeholder information, due to any number of causes, including catastrophic events, power
outages and security breaches. Although we have business continuity plans in place and have implemented a
breach response plan to address cybersecurity incidents, if these plans do not provide effective alternative
processes on a timely basis, we may suffer interruptions in our ability to manage or conduct our operations which
may adversely affect our business. In addition, if our service providers, suppliers or customers experience a
breach or unauthorized disclosure or system failure, their businesses could be disrupted or otherwise negatively
affected, which may result in a disruption in our supply chain or reduced customer orders or other business
operations. Moreover, any costs related to a breach may exceed the amount of insurance coverage or be excluded
under the terms of our cybersecurity policy. As cyberattacks increase in frequency and magnitude, we may be
unable to obtain cybersecurity insurance in amounts and on terms we view as appropriate for our operations.

Our information technology systems and, our third-party providers’ systems, have been, and will likely
continue to be, subject to advanced computer viruses or other malicious codes, ransomware, unauthorized access
attempts, denial of service attacks, phishing, social engineering, hacking and other cyberattacks. These risks also
may be present to the extent any of our partners, distributors, joint venture partners or suppliers using separate

30

information systems, not integrated with our information systems, suffers a cybersecurity incident and could
result in increased costs related to their inability to timely deliver on their commitments to us and/or our
involvement in investigations or notifications conducted by these third parties. These risks may also be present to
the extent a business we have acquired that does not use our information systems, experiences a system
shutdown, service disruption, or cybersecurity incident. Due to the conflict in Ukraine and the Israel-Hamas war,
there is a possibility that the escalation of tensions could result in cyberattacks that could either directly or
indirectly affect our operations. Such attacks may originate from nation states or attempts by outside parties,
hackers, criminal organizations or other threat actors. In addition, insider actors-malicious or otherwise-could
cause technical disruptions and/or confidential data leakage. To date, we have seen no material impact on our
business or operations from these attacks; however, we cannot guarantee that our security efforts will prevent
attacks and resulting breaches or breakdowns of our, or our third-party service providers’ databases or systems.
In recent months, several of our peer or similarly situated companies have experienced cybersecurity incidents.
In addition, although we have policies and procedures in place governing cybersecurity risk, the secure storage of
personal information collected by us or our third-party service providers, data breaches due to human error or
intentional or unintentional conduct may occur in the future, especially as we have shifted to more employees
and other workers working remotely and having access to our technology infrastructure remotely.

We continuously perform enterprise-wide upgrades to our systems and will continue to monitor and upgrade

systems as appropriate, legacy systems may be vulnerable to increased risk. Additionally, if a new system does
not function properly, it could affect our ability to order supplies, process and deliver customer orders and
process and receive payments for our products. This could adversely impact our results of operations and cash
flows. Upgraded or new technology may not function as designed and any such upgrades may not go as planned.
Moreover, because the techniques, tools and tactics used in cyberattacks frequently change and may be difficult
to detect for periods of time, we may face difficulties in anticipating and implementing adequate preventative
measures or fully mitigating harms after such an attack. As such, we may need to expend additional resources
and incur additional costs in the future to continue to protect against or address problems caused by any business
interruptions or data security breaches. Cyber threats are becoming more sophisticated, are constantly evolving
and are being made by groups and individuals with a wide range of expertise and motives, and this increases the
difficulty of detecting and successfully defending against them. We have incurred, and will continue to incur,
expenses to comply with privacy and data protection standards and protocols imposed by law, regulation,
industry standards and contractual obligations. Increased regulation of data collection, use, and retention
practices, including self-regulation and industry standards, changes in existing laws and regulations, including
reporting requirements, enactment of new laws and regulations, increased enforcement activity, and changes in
interpretation of laws, could increase our cost of compliance and operation, limit our ability to grow our business
or otherwise harm our business.

• We may not be able to attract, retain and develop key personnel.

The labor market in the United States is very competitive. Our future performance depends in significant

part upon the continued service of our executive officers and other key personnel, including at our plants.
Competition for qualified plant personnel remain intense. The loss of the services of one or more executive
officers or other key employees could have a material adverse effect on our business, prospects, financial
condition and results of operations. This effect could be exacerbated if any officers or other keyleft as a group or
at the same time. Our success also depends, in part, on our continuing ability to attract, retain and develop highly
qualified personnel and diverse workforce. Competition for such talent remains, and there can be no assurance
that we can retain our key employees or attract, assimilate and retain other highly qualified personnel in the
future, and the U.S. labor market has experienced wage inflation, sustained labor shortages, and a shift towards
remote work. Factors that may affect our ability to attract and retain sufficient numbers of key employees include
employee morale, our reputation, competition from other employers and the availability of qualified personnel in
a tightening labor market. We experienced an increase in labor turnover in 2021 (20.6%) and 2022 (21.5%) but
saw this ease in 2023 (17.6%). We may continue to experience increased personnel turnover in the future
compared to 2023, either as a result of our business operations or other broad-based economic or cultural factors.

31

In addition, labor costs in the U.S. are rising. Labor cost is one of the primary components in the cost of

operating our business. If we face labor shortages and increased labor costs as a result of increased competition
for employees, higher employee turnover rates, increases in employee benefits costs, or labor union organizing
efforts, our operating expenses could increase and our growth and results of operations could be adversely
impacted. Labor shortages, higher employee turnover rates and labor union organizing efforts could also lead to
disruptions in our business. We may be unable to increase prices of our products in order to pass future increased
labor costs onto our customers, in which case our margins would be negatively affected. Additionally, if we
increase product prices to cover increased labor costs, the higher prices could adversely affect sales volumes.

• Our continued growth and expansion, reliance on third-party service providers and implementation
of new accounting standards could adversely affect our internal control over financial reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial

reporting. Internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting for external purposes in accordance with generally accepted
accounting principles in the U.S. Because of its inherent limitations, internal control over financial reporting
cannot provide absolute assurance that a misstatement of our financial statements would be prevented or
detected. Our continuing growth and expansion in domestic and globally dispersed markets, such as our
acquisition of the ZICAM, THERABREATH, HERO and other businesses, may place significant additional
pressure on our system of internal control over financial reporting and require us to update our internal control
over financial reporting to integrate such acquisitions. Moreover, we engage the services of third parties to assist
with business operations and financial reporting processes, which injects additional monitoring obligations and
risk into the system of internal control, including as a result of cyberattacks. When we are required to comply
with new or revised accounting standards, we must make any appropriate changes to our internal control over
financial reporting to fully implement the standards, which may require significant effort and judgment. Any
failure to maintain an effective system of internal control over financial reporting could limit our ability to report
our results of operations accurately and on a timely basis, or to detect and prevent fraud and could expose us to
regulatory enforcement action and stockholder claims.

• The COVID-19 pandemic and related impacts has had, and could continue to have, an adverse effect

on our business, financial condition, results of operations and cash flows.

The COVID-19 pandemic has affected and could continue to negatively affect our business by causing or

contributing to, among other things:

•

•

Significant disruptions in business operations and in the ability of significant third-party vendors,
manufacturing and other business or commercial partners, including customers, to meet their
obligations to us;

Significant decrease or volatility in sales of or demand for our primary products due to the transition
from a pandemic to endemic state;

• Worldwide, regional and local adverse economic and financial market conditions, all of which could

impact our manufacturing operations or that of our third-party partners;

• Adverse impacts on the supply chain, including manufacturing by us or our third-party partners, due to

raw material, packaging or other supply shortages, labor shortages or reduced availability of
commercial transport and port operational disruptions; and

•

Sustained labor shortages or increased turnover rates.

Although the World Health Organization and the federal government have declared an end to COVID-19 as
a global and national health emergency, respectively, risks related to COVID-19 have adversely affected and may
continue to adversely affect our business, results of operations, cash flows and financial condition.

32

• Our business could be negatively impacted as a result of stockholder activism, an unsolicited takeover

proposal or a proxy contest or short sellers.

In recent years, proxy contests, unsolicited takeovers and other forms of stockholder activism have been
directed against numerous companies in our industry, including us. If such a campaign or proposal were to be
made against us, we would likely incur significant costs. Stockholder activists may also seek to involve
themselves in the governance, strategic direction and operations of our business, or in our ESG and sustainability
management and disclosure, through stockholder proposals or otherwise disrupting our business and diverting the
attention of our management and employees, and any perceived uncertainties as to our future direction resulting
from such a situation could result in the loss of potential business opportunities, the perception that we need a
change in the direction of our business, or the perception that we are unstable or lack continuity, which may be
exploited by our competitors, cause concern to our current or potential customers, and may make it more difficult
for us to attract and retain qualified personnel and business partners. Actions of activist stockholders may cause
significant fluctuations in our stock price based on temporary or speculative market perceptions or other factors
that do not necessarily reflect the underlying fundamentals and prospects of our business. We may also be the
target of short sellers who engage in negative publicity campaigns that may use selective information that may be
presented out of context or that may misrepresent facts and circumstances.

ITEM 1B. UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 1C. CYBERSECURITY

Cybersecurity Risk Management and Strategy

We collect, use and store personal information of our employees, consumers and other third parties in the

ordinary course of business. In addition, we sell certain products directly to consumers online and through
websites, mobile apps and connected devices, and we offer promotions, rebates, loyalty and other programs
through which our data systems may receive personal information. We recognize the importance of data privacy
and security and are committed to safeguarding and protecting our information and any other information
entrusted to us. We have developed and implemented a cybersecurity risk management program intended to
protect the confidentiality, integrity, and availability of our critical systems and information which is integrated
with our overall risk management program. Our cybersecurity risk management program includes a cybersecurity
incident response plan to respond to security breaches and cyberattacks. Our cybersecurity incident response plan
is part of our overall Information Security Program, which is led by the Company’s Vice President, Global Chief
Information Security Officer (“CISO”) and overseen by the Company’s Senior Vice President, Global Chief
Information Officer, and is designed to protect and preserve the confidentiality, integrity and continued
availability of all information owned by, or in the care of, the Company, and the Company’s ability to operate.
Our cybersecurity incident response plan includes controls and procedures for timely and accurate reporting of
any material cybersecurity incident. We design and assess our program based on the National Institute of
Standards and Technology (NIST) Cybersecurity Framework (CSF).

Our cybersecurity risk management program includes:

•

•

•

risk assessments designed to help identify material cybersecurity risks to our critical systems,
information, products, services, and our global enterprise IT environment;

a security team responsible for managing our (1) cybersecurity risk assessment processes, (2) security
controls, and (3) response to security breaches and cyberattacks;

the use of external service providers, where appropriate, to assess, perform tabletop exercises or
otherwise assist with aspects of our security controls and designed to anticipate cyberattacks and
respond to breaches, including an annual maturity assessment of our program by an external third-
party;

33

•

•

•

•

cybersecurity awareness training of our employees and contractors, incident response personnel, and
senior management to help them better understand the issues and risks relative to cybersecurity, as well
as data privacy (for our employees);

Periodically throughout the year, our IT department performs phishing and other exercises to both test
our systems and reinforce training of our personnel;

a cybersecurity incident response plan managed by our CISO that includes procedures for responding
to cybersecurity incidents and is designed to protect and preserve the confidentiality, integrity and
continued availability of all information possessed by the Company; and

a third-party risk management process for service providers, suppliers, and vendors.

We have not identified risks from known cybersecurity threats, including as a result of any prior

cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including
our operations, business strategy, results of operations, or cash flows.

Cybersecurity Governance

Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit

Committee oversight of cybersecurity and other information technology risks. The Audit Committee oversees
management’s implementation of our cybersecurity risk management program, including reviewing risk
assessments from management with respect to our information technology systems and procedures, and
overseeing our cybersecurity risk management processes.

The Audit Committee, which is tasked with oversight of certain risk issues, including cybersecurity,
receives reports from the Senior Vice President, Global Chief Information Officer and the Vice President, Chief
Information Security Officer each quarter. At least annually, the Board of Directors and the Audit Committee
also receive updates about the results of exercises and response readiness assessments led by outside advisors
who provide a third-party independent assessment of our technical program and our internal response
preparedness. The Audit Committee regularly briefs the full Board of Directors on these matters, and the full
Board also receives periodic briefings regarding our Information Security Program and cyber threats, including
threats faced by our peers, in order to enhance our directors’ literacy on cyber issues. In addition, management
will update the Audit Committee, as necessary, regarding cybersecurity incidents, that we may experience.

Our management team, including our Chief Information Officer, is responsible for assessing and managing
our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity
risk management program and oversees both our internal cybersecurity personnel and our retained external
cybersecurity consultants. Our management team’s cybersecurity risk management is led by our CISO, who has
significant experience across digital innovation and technology-enabled growth, information security,
infrastructure, operations and compliance.

Our management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and
incidents through various means, which include briefings from internal security personnel; threat intelligence and
other information obtained from governmental, public or private sources, including external consultants engaged
by us; and alerts and reports produced by security tools deployed in the IT environment.

ITEM 2. PROPERTIES

We lease a corporate office building in Ewing, New Jersey for our global corporate headquarters. The lease
expires in 2033 and includes two 10-year extension terms at our option. In addition, we own an office building in
Fort Collins, Colorado and an office building in Princeton, New Jersey that is occupied by our research and
development department.

34

We own or lease manufacturing facilities, warehouses and other offices in 16 different U.S. states and 11
different countries outside of the U.S. Many of our domestic and international sites manufacture and distribute
products for multiple segments of our business. We believe that our operating and administrative facilities are
adequate and suitable for the conduct of our business. We also believe that our production facilities are suitable
for current manufacturing requirements for our consumer and specialty products businesses.

ITEM 3. LEGAL PROCEEDINGS

We, in the ordinary course of our business are the subject of, or party to, various pending or threatened legal

actions, government investigations and proceedings from time to time, including, without limitation, those
relating to commercial transactions, product liability, purported consumer class actions, employment matters,
antitrust, environmental, health, safety and other compliance related matters. Such proceedings are subject to
many uncertainties and the outcome of certain pending or threatened legal actions may not be reasonably
predictable and any related damages may not be estimable. Certain legal actions could result in an adverse
outcome for us, and any such adverse outcome could have a material adverse effect on our business, financial
condition, results of operations, and cash flows. There are no relevant matters to disclose under this Item for this
period.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

35

PART II

ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER

MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our shares of common stock are traded on the New York Stock Exchange with the stock ticker symbol

“CHD”.

Approximate number of record holders of our Common Stock as of December 31, 2023: 1,600.

The following graph compares the yearly change in the cumulative total stockholder return on our Common

Stock for the past five fiscal years with the cumulative total return of the S&P 500 Index and the S&P 500
Household Products Index described more fully below. The returns are indexed to a value of $100 at
December 31, 2018. Dividend reinvestment has been assumed.

Comparison of Cumulative Five-Year Total Return among Company, S&P 500 Index and the S&P 500
Household Products Index(1)

(1) S&P 500 Household Products Index consists of the Church & Dwight Co., Inc., Clorox Company, Colgate-

Palmolive Company, Kimberly-Clark Corporation and P&G.

COMPARISON OF CUMULATIVE FIVE-YEAR TOTAL RETURN

Five-Year
Average
Annual
Return

Church & Dwight Co., Inc.
S&P 500 Index
S&P 500 Household Products Index

8.8%
15.7%
10.6%

Dollars

250.00

200.00

150.00

100.00

50.00

0.00

2018

2019

2020

2021

2022

2023

Company / Index

2018

2019

2020

2021

2022

2023

Church & Dwight Co., Inc. . . . . . . . . . . . . . . . . . . . . . .
S&P 500 Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
S&P 500 Household Products Index . . . . . . . . . . . . . . .

100.00
100.00
100.00

108.36
131.48
131.49

135.96
155.66
152.22

161.63
200.30
175.42

128.63
163.99
165.04

152.70
207.05
165.25

Share Repurchase Authorization

On October 28, 2021, the Board authorized a new share repurchase program, under which the Company

may repurchase up to $1,000.0 in shares of Common Stock (the “2021 Share Repurchase Program”). The 2021
Share Repurchase Program does not have an expiration and replaced the 2017 Share Repurchase Program. All
remaining dollars authorized for repurchase under the 2017 Share Repurchase Plan have been cancelled. The
2021 Share Repurchase Program did not modify the Company’s evergreen share repurchase program, authorized

36

by the Board on January 29, 2014, under which the Company may repurchase, from time to time, Common Stock
to reduce or eliminate dilution associated with issuances of Common Stock under its incentive plans.

In November 2023, the Company executed an agreement to purchase 3.3 million shares for $300.1,
inclusive of fees, of which $229.3 was purchased under the evergreen share repurchase program and $70.8 was
purchased under the 2021 Share Repurchase Program.

As a result of the Company’s stock repurchases, there remains $658.9 of share repurchase availability under

the 2021 Share Repurchase Program as of December 31, 2023.

Period

Total Number of
Shares Purchased(1)

Average Price Paid per
Share

Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs

Approximate Dollar
Value of Shares that
May Yet Be Purchased
Under All Programs

10/1/2023 to 10/31/2023 . . . . .
11/1/2023 to 11/30/2023 . . . . .
12/1/2023 to 12/31/2023 . . . . .

346
3,144,242
126,245

Total . . . . . . . . . . . . . . . . .

3,270,833

$90.11
91.62
94.92

$91.75

346
3,144,242
126,245

3,270,833

$729,727,297
$658,905,959
$658,905,959

(1)

Includes shares of Common Stock withheld by us to satisfy tax withholding obligations in connection with
the vesting of restricted stock.

37

ITEM 6. RESERVED

38

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in

conjunction with our consolidated financial statements.

OVERVIEW

Our Business

We develop, manufacture and market a broad range of consumer household, personal care and specialty
products. Our well-recognized brands include ARM & HAMMER® baking soda, cat litter, laundry detergent,
carpet deodorizer and other baking soda-based products; OXICLEAN® stain removers, cleaning solutions,
laundry detergents and bleach alternatives; VITAFUSION® and L’IL CRITTERS® gummy dietary supplements
for adults and children, respectively; BATISTE® dry shampoo; WATERPIK® water flossers and showerheads;
THERABREATH® oral care products; HERO® acne treatment products; TROJAN condoms, lubricants and
vibrators; SPINBRUSH battery-operated toothbrushes; FIRST RESPONSE home pregnancy and ovulation test
kits; NAIR depilatories; ORAJEL oral analgesic; XTRA laundry detergent; and ZICAM cold shortening and
relief products. Seven of those brands are designated as “power brands” because they compete in large
categories, and we believe they have the potential for significant global expansion. Those seven brands are
ARM & HAMMER®; OXICLEAN®; VITAFUSION® and L’IL CRITTERS®; BATISTE®; WATERPIK®;
THERABREATH®; and HERO® and represent approximately 70% of our net sales and profits.

We sell our consumer products under a variety of brands through a broad distribution platform that includes
supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar, pet and
other specialty stores and websites and other e-commerce channels, all of which sell the products to consumers.
We sell our specialty products to industrial customers, livestock producers and through distributors.

We operate our business in three segments: Consumer Domestic, Consumer International and the Specialty
Products Division (“SPD”). The segments are based on differences in the nature of products and organizational
and ownership structures. In 2023, the Consumer Domestic, Consumer International and SPD segments
represented approximately 78%, 17% and 5%, respectively, of our consolidated net sales.

Supply Chain, Inflation, Consumer Demand and Competition

We continue to monitor the impact of both inflation and recessionary indicators including the effect of
corresponding government actions, such as raising interest rates to counteract inflation, that may negatively
impact consumer spending, especially for our discretionary brands, and how these factors will potentially
influence future cash flows for the short and long term.

We believe that inflation and recessionary concerns are continuing to drive a decline in consumer spending
for our most discretionary brands, Waterpik and Flawless, as consumers reduce spending in these categories and
shift to lower cost alternatives. Most notably, a growing number of water flosser consumers have switched to
more value-branded products. To address these demand shifts, we are taking steps to better manage production
schedules and inventory levels for those products along with increasing promotional activities and marketing
spend, as well as continuing efforts to develop lower cost water flosser alternatives.

Our vitamin business continues to experience a softening of growth from record high levels during the
COVID-19 pandemic and has seen a significant ramp up in competition coming from new gummy vitamin
category entrants which have increased from about six competitors a decade ago to more than 60 of significance

39

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

today. In addition, residual impacts from previous vitamin-specific supply chain challenges resulted in increased
shelf space and/ or display for certain of our competitors. We are improving our product offerings, redesigning
packaging, launching new advertising and increasing global promotional and marketing efforts to solidify the
business and, ultimately, regain lost market share.

Net sales in our Specialty Products Division declined in 2023, largely due to declining sales of our

MEGALAC dairy supplement within our Animal Nutrition business. During the first quarter of 2024, we will be
exiting this part of the Animal Nutrition business as a result of the return of foreign competition in the United
States dairy market.

Looking forward, the impact that these challenges will continue to have on our operational and financial

performance will depend in part on future developments, including inflationary impacts, interest rates,
recessionary concerns, as well as retail customers’ acceptance of all or a portion of any price increases.
Additionally, we may be impacted by our ability to recruit and retain a workforce and engage third-parties to
manufacture and distribute our products, as well as any future government actions affecting employers and
employees, consumers and the economy in general. While we expect that many of these effects will be transitory
and that our value-focused portfolio positions us well in challenging economic environments, it is impossible to
predict their impact.

2023 Financial Highlights

Key 2023 financial results include:

•

2023 net sales grew 9.2% over 2022, with gains in Consumer Domestic and Consumer International,
partially offset by lower sales in SPD. The gains are primarily due to favorable pricing/product mix,
favorable volumes, and the benefit of recent acquisitions in Consumer Domestic and Consumer
International, partially offset by unfavorable volumes and pricing/product mix in SPD.

• Gross margin increased 220 basis points to 44.1% in 2023 from 41.9% in 2022, primarily due to
favorable price/volume/mix, the impact of productivity programs, lower transportation costs, and
business acquisition benefits, partially offset by higher manufacturing costs including labor and higher
commodities.

• Operating margin increased 690 basis points to 18.0% in 2023 from 11.1% in 2022. The 2022

operating margin included a non-cash charge of $411.0 or 760 basis points related to the Flawless
intangible asset impairment. Excluding the impairment charge, operating margin decreased 70 basis
points as an increase in gross margins was offset by higher marketing expenses and selling general and
administrative costs.

• We reported diluted net earnings per share in 2023 of $3.05, an increase of approximately 81.5% from
2022 diluted net earnings per share of $1.68 which included the non-cash Flawless intangible asset
impairment charge of $1.26 per share.

• Cash provided by operations was $1,030.6 in 2023, a $145.4 increase from the prior year due to an
improvement in working capital and an increase in cash earnings (net income adjusted for non-cash
items) including the impact of recent acquisitions.

• We returned $566.6 in 2023 to our stockholders through cash dividends paid and share repurchases.

Strategic Goals, Challenges and Initiatives

Our ability to generate sales depends on consumer demand for our products and retail customers’ decisions

to carry our products, which are, in part, affected by general economic conditions in our markets. While a vast
majority of our products are consumer staples and less vulnerable to decreases in discretionary spending than

40

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

other products, certain of our products, are more likely to be affected by consumer decisions to control spending.
Some retail customers have responded to economic conditions by increasing their private label offerings
(primarily in the dietary supplements, diagnostic kits and oral analgesics categories), launching their own brands,
and consolidating the product selections they offer to the top few leading brands in each category. In addition, an
increasing portion of our product categories are being sold by club stores, dollar stores, mass merchandisers and
internet-based retailers. These factors have placed downward pressure on our sales and gross margins.

We intend to continue to aggressively pursue several key strategic initiatives: maintain competitive
marketing and trade spending, tightly control our cost structure, expand our online market share, continue to
develop and launch new and differentiated products, and pursue strategic acquisitions. We also intend to continue
to grow our product sales globally and maintain an offering of premium and value brand products to appeal to a
wide range of consumers.

We derive a substantial percentage of our revenues from sales of liquid laundry detergent. As a result, any

delays or reduction of sales of these products, in the event that our product category diversification efforts
discussed below are not successful, could have a material adverse effect on our business, financial condition,
operating results and cash flows. We continue to evaluate and vigorously address these pressures through, among
other things, new product introductions and increased marketing and trade spending. However, there is no
assurance the category will not decline in the future and that we will be able to offset any such decline.

We are continuously focused on strengthening our key brands through the launch of innovative new

products, which span various product categories, including premium and value household products supported by
increased marketing and trade spending. There can be no assurance that these measures will be successful.

Our global product portfolio consists of both premium (63% of total worldwide consumer revenue in 2023)
and value (37% of total worldwide consumer revenue in 2023) brands, which we believe enables us to succeed in
a range of economic environments. We intend to continue to develop a portfolio of appealing new products to
build loyalty among cost-conscious consumers.

Over the past two decades, we have diversified from an almost exclusively U.S. business to a global
company with approximately 17% of sales derived from countries outside of the United States in 2023. We have
subsidiary operations in seven countries (Canada, Mexico, U.K., France, Germany, China and Australia). We
also export products to over 130 other countries through our Global Markets Group using a broad network of
third-party distributors. In 2023, we benefited from our expanded global footprint and expect to continue to focus
on selectively expanding our global business. If we are unable to expand our business internationally at the rate
that we expect, we may not realize our anticipated growth targets.

Although we believe ongoing international expansion represents a significant opportunity to grow our

business, our increasing activity in global markets exposes us to additional complexity and uncertainty. Sales
generated outside of the U.S. are exposed to foreign currency exchange rate fluctuations as well as political
uncertainty which could impact future operating results. Moreover, the current domestic and international
political environment, including existing and potential changes to U.S. policies related to global trade and tariffs,
have resulted in uncertainty regarding the global economy. The impact of U.S. tariffs on certain products was a
component of increased cost of sale during the year ended December 31, 2023. The implementation of more
restrictive trade policies, such as higher tariffs or new barriers to entry, in countries in which we manufacture or
sell large quantities of products could negatively impact our business, cash flows, results of operations and
financial condition.

41

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

We also continue to focus on controlling our costs. Historically, we have been able to mitigate the effects of

cost increases primarily by implementing cost reduction programs and, to a lesser extent, by passing along cost
increases to customers. We have also entered into set pricing and pre-buying arrangements with certain suppliers
and hedge agreements for diesel fuel and other commodities. Additionally, our focus on tight cost controls has
enabled us to effectively navigate challenging economic conditions.

The identification and integration of strategic acquisitions are an important component of our overall

strategy and product category diversification. Acquisitions have added significantly to our sales, profits and
product category diversification over the last decade. This is evidenced by our 2015 acquisition of certain assets
of Varied Industries Corporation (the “Vi-cor Acquisition”), the 2016 acquisitions of Spencer Forrest, Inc., the
maker of TOPPIK (the “Toppik Acquisition”), and the ANUSOL and RECTINOL businesses from Johnson &
Johnson (the “Anusol Acquisition”), the 2017 acquisitions of the VIVISCAL brand from Lifes2Good Holdings
Limited (the “Viviscal Acquisition”), and the WATERPIK brand from Pik Holdings, Inc. (the “Waterpik
Acquisition”), the 2020 acquisition of the ZICAM brand from Consumer Health Holdco LLC, the 2021
acquisition of the THERABREATH brand from Dr. Harold Katz, LLC and HK-IP International, Inc, and the
2022 acquisition of the HERO brand which includes the MIGHTY PATCH acne treatment products. The failure
to effectively identify or integrate any acquisition or achieve expected synergies may cause us to incur material
asset write-downs. We actively seek acquisitions that fit our guidelines, and our strong financial position
provides us with flexibility to take advantage of acquisition opportunities. In addition, our ability to quickly
integrate acquisitions and leverage existing infrastructure has enabled us to establish a strong track record in
making accretive acquisitions. Since 2001, we have acquired six of our seven “power brands.”

We believe we are well positioned to meet the ongoing challenges described above due to our strong

financial condition, experience operating in challenging environments and continued focus on key strategic
initiatives. Our focus is to maintain competitive marketing and trade spending, manage our cost structure,
continue to develop and launch new and differentiated products, while pursuing strategic acquisitions. This focus,
together with the strength of our portfolio of premium and value brands, has enabled us to succeed in a range of
economic environments. Moreover, the generation of a significant amount of cash from operations provides us
with the financial flexibility to pursue acquisitions, drive new product development, make capital expenditures to
support organic growth and gross margin improvements, return cash to stockholders through dividends and share
buy backs, and reduce outstanding debt. These factors position us to continue to increase stockholder value over
the long-term.

For information regarding risks and uncertainties that could materially adversely affect our business, results

of operations and financial condition and cash flows, see “Risk Factors” in Item 1A of this Annual Report.

Recent Developments

Dividend Increase

On January 31, 2024, the Board declared a 4% increase in the regular quarterly dividend from $0.2725 to
$0.28375 per share (equivalent to an annual dividend of $1.135 per share) payable to stockholders of record as of
February 15, 2024. The increase raises the annualized dividend payout from $267.0 to approximately $276.0 on
an annualized basis.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our Consolidated Financial Statements have been prepared in accordance with accounting principles
generally accepted in the U.S. (GAAP). The preparation of these financial statements requires management to
make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and

42

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

related disclosure of contingent assets and liabilities. By their nature, these judgments are subject to uncertainty.
They are based on our historical experience, our observation of trends in industry, information provided by our
customers and information available from other outside sources, as appropriate. Our significant accounting
policies and estimates are described below.

Revenue Recognition and Promotional and Sales Return Reserves

Virtually all of our revenue represents sales of finished goods inventory and is recognized when received or

picked up by our customers. The reserves for consumer and trade promotion liabilities and sales returns are
established based on our best estimate of the amounts necessary to settle future and existing claims on products
sold as of the balance sheet date. Promotional reserves are provided for sales incentives, such as coupons to
consumers, and sales incentives provided to customers (such as slotting, cooperative advertising, incentive
discounts based on volume of sales and other arrangements made directly with customers). All such costs are
netted against sales. Slotting costs are recorded when the product is delivered to the customer. Cooperative
advertising costs are recorded when the customer places the advertisement for our products. Discounts relating to
price reduction arrangements and coupons are recorded when the related sale takes place. Costs associated with
end-aisle or other in-store displays are recorded when product that is subject to the promotion is sold. We rely on
historical experience and forecasted data to determine the required reserves. For example, we use historical
experience to project coupon redemption rates to determine reserve requirements. Based on the total face value
of Consumer Domestic coupons redeemed over the past several years, if the actual rate of redemptions were to
deviate by 0.1% from the rate for which reserves are accrued in the financial statements, a difference of
approximately $0.7 in the reserve required for coupons would result. With regard to other promotional reserves
and sales returns, we use experience-based estimates, customer and sales organization inputs and historical trend
analysis in arriving at the reserves required. If our estimates for promotional activities and sales returns reserves
were to change by 10% the impact to promotional spending and sales return accruals would be approximately
$16.0. While management believes that its promotional and sales returns reserves are reasonable and that
appropriate judgments have been made, estimated amounts could differ materially from actual future obligations.

Impairment of goodwill, trade names and other intangible assets

The Company has intangible assets of substantial value on its consolidated balance sheet. Intangible assets

relate to intangible assets with a useful life, indefinite-lived trade names and goodwill. The Company determines
whether an intangible asset (other than goodwill) has a useful life based on multiple factors, including how long
the Company intends to generate cash flows from the asset.

Intangible assets with a useful life are assessed for impairment when there are business triggering events.

Carrying values of goodwill and indefinite-lived trade names are reviewed at least annually for possible
impairment.

Our impairment analysis is based on a discounted cash flow approach that requires significant judgment
with respect to unit volume, revenue and expense growth rates, and the selection of an appropriate discount rate
and royalty rate. Management uses estimates based on expected trends in making these assumptions. With
respect to goodwill, impairment occurs when the carrying value of the reporting unit exceeds the discounted
present value of cash flows for that reporting unit. For trade names and other intangible assets, an impairment
charge is recorded for the difference between the carrying value and the net present value of estimated future
cash flows, which represents the estimated fair value of the asset. Fair value for indefinite-lived intangible assets
is estimated based on a “relief from royalty” or “excess earnings” discounted cash flow method, which contains
numerous variables that are subject to change as business conditions change, and therefore could impact fair
values in the future. Judgment is required in assessing whether assets may have become impaired between annual

43

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

valuations. Indicators such as unexpected adverse economic factors, unanticipated technological change,
distribution losses, or competitive activities and acts by governments and courts may indicate that an asset has
become impaired.

The result of our annual goodwill impairment test determined that the estimated fair value substantially

exceeded the carrying values of all reporting units. We determined that the fair value of all indefinite-lived
intangible assets for each of the years in the three-year period ended December 31, 2023 exceeded their
respective carrying values based upon the forecasted cash flows and profitability.

Recently, our global TROJAN business has benefited from the successful introduction of new products,
such as TROJAN BARESKIN RAW, which has contributed to expanded distribution resulting in sales growth in
2023 and an improvement in the expected sales growth outlook for this business. While the Company cannot
predict future changes in economic or competitive factors that may adversely impact the underlying cash flows
used to estimate fair value of the trade name, it believes that the improved growth and profitability outlook for
this business has reduced the near-term risk of impairment of the TROJAN trade name. The carrying value of the
TROJAN trade name is $176.4 and fair value represented 162% of the carrying value as of October 1, 2023.

Our global WATERPIK business has continued to experience a significant decline in customer demand for
many of its products, primarily due to lower consumer spending for discretionary products resulting in part from
inflation and a growing number of water flosser consumers switching to more value-branded products.
Waterpik’s profitability has also been impacted by tariffs imposed on its products imported into the United States
that were manufactured in China. As a result, the WATERPIK business has experienced declining sales and
profits resulting in a reduction in expected future cash flows which have eroded a substantial portion of the
excess between the fair and carrying value of the trade name. This indefinite-lived intangible asset may be
susceptible to impairment and a continued decline in fair value could trigger a future impairment charge of the
WATERPIK trade name. While management can and has implemented strategies to address the risk, significant
changes in operating plans or adverse changes in the future could reduce the underlying cash flows used to
estimate fair values and could result in a decline in fair value that could trigger future impairment charges of
these assets. The carrying value of the WATERPIK trade name is $644.7 and fair value represented 109% of the
carrying value as of October 1, 2023.

The vitamin category continues to experience a softening of growth from record high levels during the
COVID-19 pandemic and significant product competition coming from new category entrants. The category has
grown from about 6 competitors a decade ago to more than 60 of significance in recent years. In addition,
residual impacts from previous vitamin-specific supply chain challenges have resulted in reduced shelf space for
VITAFUSION and LIL CRITTERS at certain retailers and consumers switching to competitor’s brands. These
factors, along with higher interest rates, have resulted in a reduction in expected future cash flows which have
eroded a substantial portion of the excess between the fair and carrying value of the trade name. This indefinite-
lived intangible asset may be susceptible to impairment and a continued decline in fair value could trigger a
future impairment charge of the VITAFUSION and LIL’ CRITTERS trade name. While management has
implemented strategies to address the risk, significant changes in operating plans or adverse changes in the future
could reduce the underlying cash flows used to estimate fair value. The carrying value of the VITAFUSION and
LIL’ CRITTERS trade name is $281.3 and fair value represented 154% of the carrying value as of October 1,
2023.

In the fourth quarter of 2022, we determined that a review of our ability to recover the carrying values of the
global FINISHING TOUCH FLAWLESS intangible assets was necessary based on the discontinuance of certain
products at a major retailer. The FINISHING TOUCH FLAWLESS assets consist of the definite-lived trade
name, customer relationships and technology assets recorded at acquisition. We evaluated our ability to recover

44

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

the carrying values of the intangible assets by comparing the carrying amount to the future undiscounted cash
flows and determined that the cash flows would not be sufficient to recover the carrying value of the assets. After
determining the estimated fair value of the assets, which included a reduction in cash flows due to the loss of
distribution mentioned above along with an expected continued decline in discretionary consumption and higher
interest rates, a non-cash impairment charge of $411.0 was recorded in the fourth quarter of 2022. The remaining
net book value of the trade name as of December 31, 2023 is $30.9 and will be amortized over a remaining useful
life of two years. We have implemented strategies to address the decline in profitability. However, if
unsuccessful, a further decline could trigger a future impairment charge.

It is possible that our conclusions regarding impairment or recoverability of goodwill or other intangible
assets could change in future periods if, for example, (i) the businesses or brands do not perform as projected,
(ii) overall economic conditions in future years vary from current assumptions (including changes in discount
rates), (iii) business conditions or strategies change from current assumptions, (iv) investors require higher rates
of return on equity investments in the marketplace or (v) enterprise values of comparable publicly traded
companies, or actual sales transactions of comparable companies, were to decline, resulting in lower multiples of
revenues and EBITDA. A future impairment charge for goodwill or intangible assets could have a material effect
on our consolidated financial position or results of operations.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are
recognized to reflect the future tax consequences attributable to the differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit
carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which the differences are expected to be recovered or settled. Management
provides a valuation allowance against deferred tax assets for amounts which are not considered “more likely
than not” to be realized. We record liabilities for potential assessments in various tax jurisdictions under U.S.
GAAP guidelines. The liabilities relate to tax return positions that, although supportable by us, may be
challenged by the tax authorities and do not meet the minimum recognition threshold required under applicable
accounting guidance for the related tax benefit to be recognized on the income statement. We adjust this liability
as a result of changes in tax legislation, interpretations of laws by courts, guidance and rulings issued by tax
authorities, changes in estimates and the expiration of the statute of limitations. Many of the judgments involved
in adjusting the liability involve assumptions and estimates that are highly uncertain and subject to change. In
this regard, settlement of any issue, or an adverse determination in litigation, with a taxing authority could
require the use of cash and result in an increase in our annual effective tax rate. Conversely, favorable resolution
of an issue with a taxing authority would be recognized as a reduction to our annual effective tax rate.

New Accounting Pronouncements

Refer to Note 1 to the Consolidated Financial Statements included in this Annual Report for recently
adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of
December 31, 2023.

RESULTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021

The discussion of results of operations at the consolidated level presented below is followed by a more
detailed discussion of results of operations by segment. This section of this Form 10-K generally discusses 2023
and 2022 results and year-to-year comparisons between 2023 and 2022. Discussions of 2021 items and
year-to-year comparisons between 2022 and 2021 that are not included in this Form 10-K can be found in

45

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of
our Annual Report on Form 10-K for the year ended December 31, 2022. The segment discussion also addresses
certain product line information. Our operating segments are consistent with our reportable segments.

Consolidated results

2023 compared to 2022

Net Sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross Profit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross Margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Marketing Expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Percent of Net Sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, General & Administrative Expenses . . . . . . . . . . . .
Percent of Net Sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income from Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating Margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income per share—Diluted . . . . . . . . . . . . . . . . . . . . . . . .

Net Sales

Twelve Months
Ended

December 31,
2023

$5,867.9
$2,588.5

Change vs.
Prior Year

9.2%
15.0%

Twelve Months
Ended

December 31,
2022

$5,375.6
$2,250.0

44.1% 220 basis points

41.9%

$ 641.3

19.8%

$ 535.2

10.9% 90 basis points

10.0%

$ 889.8

-20.3%

$1,117.0

15.2% -560 basis points

$1,057.4

76.9%

18.0% 690 basis points
3.05

81.5%

$

20.8%

$ 597.8

11.1%
1.68

$

Net sales for the year ended December 31, 2023 were $5,867.9, an increase of $492.3, or 9.2% compared to

2022 net sales. The components of the net sales increase are as follows:

Net Sales—Consolidated

Product volumes sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pricing/Product mix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquired product lines (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net Sales increase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,
2023

0.9%
4.4%
3.9%

9.2%

(1) On October 13, 2022, the Company acquired all of the issued and outstanding shares of capital stock of

Hero Cosmetics, Inc. (“Hero”), the developer of the HERO® brand which includes the MIGHTY PATCH®
acne treatment products (the “Hero Acquisition”).

The volume change reflects increased volumes in the Consumer Domestic and Consumer International

Segments partially offset by volume declines in SPD. Price/mix was favorable in the Consumer Domestic and
Consumer International Segments partially offset by slightly unfavorable price/mix in the SPD segment.

Gross Profit

Our gross profit for 2023 was $2,588.5, a $338.5 increase compared to 2022. Gross margin was 44.1% in

2023 compared to 41.9% in 2022, a 220 basis points (“bps”) increase. The increase is due to favorable price/
volume/mix of 220 bps, the impact of productivity programs of 150 bps, lower transportation costs of 100 bps,
and benefits from the Hero Acquisition of 90 bps, partially offset by higher manufacturing costs including labor
and higher commodities of 340 bps.

46

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

Operating Costs

Marketing expenses for 2023 were $641.3, an increase of $106.1 compared to 2022. Marketing expenses as

a percentage of net sales increased 90 bps to 10.9% in 2023 as compared to 2022 due to 180 bps on higher
expense from increased marketing spend as our ability to meet customer demand improved, offset by 90 bps of
leverage on higher net sales.

SG&A expenses for 2023 were $889.8, a decrease of $227.2 or 20.3% compared to 2022. SG&A as a
percentage of net sales decreased 560 bps to 15.2% in 2023 compared to 20.8% in 2022 due to 390 bps on lower
expenses and 170 bps of leverage associated with higher sales. The lower expenses of 390 bps were primarily
due to the non-cash Flawless intangible asset impairment charges of $411.0 or 760 bps in 2022, partially offset
by higher expenses associated with the Hero Acquisition of $78.7, investment spending for future growth and
higher incentive compensation costs which reflects improved business performance.

Other Income and Expenses

Other income increased $9.4 in 2023 as compared to 2022 primarily due to higher investment income.

Interest expense in 2023 was $110.9, an increase of $21.3 primarily due to higher average interest rates on

outstanding debt.

Taxation

The 2023 effective income tax rate was 21.9% compared to 20.9% in 2022. The increase in the rate is due to

the tax rate benefit of the FLAWLESS impairment charge recorded in 2022.

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which contains

provisions effective January 1, 2023, including a 15% corporate minimum tax and a 1% excise tax on stock
buybacks. The new law did not have a material impact on our consolidated financial position, results of
operations or cash flows during the year ended December 31, 2023.

Segment results for 2023, 2022 and 2021

We operate three reportable segments: Consumer Domestic, Consumer International and SPD. These
segments are determined based on differences in the nature of products and organizational and ownership
structures. We also have a Corporate segment.

Segment

Products

Consumer Domestic

Household and personal care products

Consumer International

Primarily personal care products

SPD

Specialty chemical products

The Corporate segment income consists of equity in earnings of affiliates. As of December 31, 2023, we

held 50% ownership interests in each of Armand and ArmaKleen, respectively. Our equity in earnings of
Armand and ArmaKleen, totaling $8.7, $12.3 and $9.4 for the three years ended December 31, 2023, 2022 and
2021, respectively, are included in the Corporate segment.

Some of the subsidiaries that are included in the Consumer International segment manufacture and sell

personal care products to the Consumer Domestic segment. These sales are eliminated from the Consumer
International segment results set forth below.

47

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

Segment net sales and income before income taxes for each of the three years ended December 31, 2023,

2022 and 2021 were as follows:

Consumer
Domestic

Consumer
International

SPD

Corporate(3)

Total

Net Sales (1)
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Income before Income Taxes (2)
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022(4)
2021(5)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$4,571.2
4,131.0
3,941.9

$ 842.7
427.3
861.4

$975.7
896.1
912.2

$ 94.8
38.8
127.3

$321.0
348.5
336.0

$ 21.2
44.9
33.6

$ 0.0
0.0
0.0

$ 8.7
12.3
9.4

$5,867.9
5,375.6
5,190.1

$ 967.4
523.3
1,031.7

(1)

(2)

Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table,
were $17.0, $15.1 and $10.8 for the years ended December 31, 2023, 2022 and 2021, respectively.
In determining income before income taxes, interest expense, investment earnings and certain aspects of
other income and expense were allocated among segments based upon each segment’s relative income from
operations.

(3) Corporate segment consists of equity in earnings of affiliates from Armand and ArmaKleen in 2023, 2022

and 2021.

(4) 2022 results include the FLAWLESS non-cash intangible asset impairment charges of $411.0 in SG&A

expenses, of which $349.3 was recorded in the Consumer Domestic segment and $61.7 was recorded in the
Consumer International segment.

(5) 2021 results include a $98.0 reduction in SG&A expenses to reduce the Flawless business acquisition

liability, of which $83.2 was recorded to Consumer Domestic and $14.8 was recorded to Consumer
International.

Product line revenues for external customers for the years ended December 31, 2023, 2022 and 2021 were

as follows:

Household Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Personal Care Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$2,484.1
2,087.1

$2,272.0
1,859.0

$2,103.0
1,838.9

Total Consumer Domestic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total Consumer International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total SPD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4,571.2
975.7
321.0

4,131.0
896.1
348.5

3,941.9
912.2
336.0

Total Consolidated Net Sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$5,867.9

$5,375.6

$5,190.1

2023

2022

2021

Household Products include deodorizing, cleaning and laundry products. Personal Care Products include

condoms, pregnancy kits, oral care products, skin care products, hair care products and gummy dietary
supplements.

48

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

Consumer Domestic

2023 compared to 2022

Consumer Domestic net sales in 2023 were $4,571.2, an increase of $440.2 or 10.7% compared to net sales

of $4,131.0 in 2022. The components of the net sales change are the following:

Net Sales—Consumer Domestic

December 31,
2023

Product volumes sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pricing/Product mix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquired product lines (1)

1.0%
4.7%
5.0%

Net Sales increase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

10.7%

(1)

Includes the Hero Acquisition since October 13, 2022 (the date of the acquisition).

The increase in net sales for 2023 reflects the impact of the Hero Acquisition, and the impact of higher sales

of THERABREATH® mouth wash, ARM & HAMMER® cat litter, ARM & HAMMER® liquid detergent, and
ARM & HAMMER® baking soda, partially offset by declines in FINISHING TOUCH FLAWLESS® hair
removal products, VITAFUSION® and L’IL CRITTERS® gummy dietary supplements, and WATERPIK® water
flossers.

Consumer Domestic income before income taxes for 2023 was $842.7, a $415.4 increase as compared to
2022. The 2022 results include the FINISHING TOUCH FLAWLESS intangible asset impairment charge of
$349.3 in SG&A expenses. Excluding the impairment charge, income before income taxes increased $66.1 due to
favorable price/mix of $193.0, the gross margin benefit of higher sales volumes related to the Hero Acquisition
of $138.1, lower manufacturing and distribution expenses of $12.0, partially offset by higher SG&A expenses of
$165.2 from higher expenses associated with the Hero Acquisition and higher incentive compensation costs,
higher marketing expenses of $96.5, and higher interest and other expenses of $15.3.

Consumer International

2023 compared to 2022

Consumer International net sales in 2023 were $975.7, an increase of $79.6 or 8.9% as compared to 2022.

The components of the net sales change are the following:

Net Sales—Consumer International

Product volumes sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pricing/Product mix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign exchange rate fluctuations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquired product lines (1)

Net Sales increase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,
2023

3.4%
5.1%
0.1%
0.3%

8.9%

(1)

Includes the Hero Acquisition since October 13, 2022 (the date of the acquisition).

Excluding the impact of foreign exchange rates and acquired product lines, the increase in net sales for the

year ended December 31, 2023, is driven by STERIMAR® nasal congestion relief, THERABREATH® mouth
wash, BATISTE® dry shampoo, OXICLEAN® stain removers and WATERPIK in the Global Markets Group;
BATISTE® dry shampoo, OXICLEAN® stain removers, THERABREATH® mouth wash, and GRAVOL® anti-

49

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

nauseant in Canada; STERIMAR® nasal congestion relief and BATISTE® dry shampoo in Europe and
STERIMAR® nasal congestion relief, ARM & HAMMER® dental care, ARM & HAMMER® baking soda, and
ARM & HAMMER® liquid detergent in Mexico.

Consumer International income before income taxes was $94.8 in 2023, an increase of $56.0 compared to
2022. The increase is due to favorable price/mix of $53.4, lower SG&A expenses of $33.3 (including the 2022
FLAWLESS intangible asset impairment charge of $61.7, partially offset by higher incentive compensation
costs), the gross margin benefit of higher sales volumes of $12.1, and favorable foreign exchange rates of $3.1,
partially offset by higher manufacturing and commodity costs of $33.5, higher marketing expenses of $10.2, and
higher interest and other expenses of $2.1.

Specialty Products

2023 compared to 2022

SPD net sales were $321.0 for 2023, a decrease of $27.5, or 7.9% compared to 2022. The components of the

net sales change are the following:

Net Sales—SPD

Product volumes sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pricing/Product mix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net Sales decrease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,
2023

(7.2%)
(0.7%)

(7.9%)

Net sales decreased in the year ended December 31, 2023 primarily due to competitive imports within our

domestic dairy business.

SPD income before income taxes was $21.2 in 2023, a decrease of $23.7 compared to 2022. The decrease in

income before income taxes for 2023 is due to higher SG&A costs of $16.4 (including the Passport intangible
asset impairment charge of $3.5 and higher incentive compensation costs), the gross margin impact of lower
sales volumes of $7.2, unfavorable manufacturing costs of $3.4, and unfavorable price/mix of $2.5, partially
offset by lower interest and other expenses of $5.4, and lower marketing expenses of $0.5.

Corporate

Corporate includes administrative costs of the production, planning and logistics functions which are
elements of Cost of Sales in our Consolidated Statements of Income but are allocated to the operating segments
in SG&A expenses to determine operating segment income before income taxes. Such amounts were $60.4,
$34.3 and $47.1 for 2023, 2022 and 2021, respectively. The increase in 2023 compared to 2022 is primarily due
to higher incentive compensation costs.

Also included in corporate are the equity in earnings of affiliates from Armand and ArmaKleen, totaling

$8.7, $12.3 and $9.4 for the three years ended December 31, 2023, 2022 and 2021, respectively.

Liquidity and Capital Resources

On June 16, 2022, we entered into a credit agreement (the “Credit Agreement”) that provides for our
$1,500.0 unsecured revolving credit facility (the “Revolving Credit Facility”) that matures on June 16, 2027,
unless extended. The Credit Agreement replaced our prior $1,000.0 unsecured revolving credit facility that would

50

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

have matured on March 29, 2024 that was entered into on March 29, 2018. We have the ability to increase our
borrowing up to an additional $750.0, subject to lender commitments and certain conditions as described in the
Credit Agreement. Borrowings under the Credit Agreement are available for general corporate purposes and are
used to support our $1,500.0 commercial paper program.

As of December 31, 2023, we had $344.5 in cash and cash equivalents, and approximately $1,495.0

available through the Revolving Credit Facility and our commercial paper program. To preserve our liquidity, we
invest cash primarily in government money market funds, prime money market funds, short-term commercial
paper and short-term bank deposits.

On October 31, 2022, we issued $500.0 aggregate principal amount of 5.60% Senior Notes due 2032 (the
“2032 Notes”). The proceeds from the sale of the 2032 Notes were used to repay commercial paper debt incurred
to finance the Hero Acquisition, and related fees and expenses. The 2032 Notes will mature on November 15,
2032, unless earlier retired or redeemed pursuant to the terms of the supplemental indenture governing the terms
of the 2032 Notes.

On June 2, 2022, we issued $500.0 aggregate principal amount of 5.00% Senior Notes due 2052 (the “2052

Notes”). In July 2022 a portion of the proceeds from the sale of the 2052 Notes were used to repay all of our
outstanding $300.0 2.45% Senior Notes due August 1, 2022. The 2052 Notes will mature on June 15, 2052,
unless earlier retired or redeemed pursuant to the terms of the supplemental indenture governing the terms of the
2052 Notes.

In October 2022, we repaid all of the outstanding $400.0 2.875% Senior notes due October 1, 2022 with a

portion of the proceeds from the 2052 Notes and cash on hand.

On December 22, 2021, we entered into a $400.0 unsecured term loan facility (as amended on June 16,
2022, the “Term Loan Facility”) with various banks. The loan under the Term Loan Facility (the “Term Loan”)
was fully drawn at closing. Unless repaid early, the Term Loan is due on December 22, 2024. The interest rate is
the Secured Overnight Financing Rate (“SOFR”) plus a spread and an applicable margin based on the
Company’s credit rating, which can range from 60 basis points to 125 bps. The proceeds of the Term Loan were
used to partially fund the TheraBreath Acquisition, with the remaining proceeds used for the repayment of
commercial paper. In 2023, we repaid $200.0 of the Term Loan with cash on hand and commercial paper
borrowings. In January 2024, we repaid an additional $100.0 of the Term Loan with cash on hand.

Additionally, we financed the TheraBreath Acquisition with a portion of the proceeds from an underwritten

public offering of $400.0 aggregate principal amount of 2.3% Senior Notes due 2031 (the “2031 Notes”)
completed on December 10, 2021. The 2031 Notes will mature on December 15, 2031, unless earlier retired or
redeemed pursuant to the terms of the supplemental indenture governing the terms of the 2031 Notes.

We financed the Waterpik Acquisition with a portion of the proceeds from an underwritten public offering

of $1,425.0 aggregate principal amount of Senior Notes completed on July 25, 2017, consisting of $300.0
aggregate principal amount of Floating Rate Senior Notes that were due in 2019 and have been fully repaid,
$300.0 aggregate principal amount of 2.45% Senior Notes that were due in 2022 and have been fully repaid,
$425.0 aggregate principal amount of 3.15% Senior Notes due 2027 and $400.0 aggregate principal amount of
3.95% Senior Notes due 2047.

In 2015, we initiated a Supply Chain Finance program (“SCF Program”). Under the SCF Program,
qualifying suppliers may elect to sell their receivables from us for early payment. Participating suppliers
negotiate their receivables sales arrangements directly with a third party. We are not party to those agreements

51

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

and do not have an economic interest in the supplier’s decision to sell their receivables. The SCF Program may
allow suppliers more favorable terms than they could secure on their own. The terms of our payment obligations
are not impacted by a supplier’s participation in the SCF Program. Our payment terms with suppliers are
consistent between suppliers that elect to participate in the SCF Program and those that do not participate. As a
result, the program does not have an impact to our average days outstanding.

All amounts outstanding to suppliers participating in the SCF Program are recorded within Accounts
Payable in our Consolidated Balance Sheets, and the associated payments are included in operating activities
within our Consolidated Statements of Cash Flows.

The current economic environment presents risks that could have adverse consequences for our liquidity.
See the discussion of this and other risks under “Risk Factors” in Item 1A of this Annual Report. We continue to
manage all aspects of our business including, but not limited to, monitoring the financial health of our customers,
suppliers and other third-party relationships, implementing gross margin enhancement strategies and developing
new opportunities for growth. We do not anticipate that current economic conditions will adversely affect our
ability to comply with the financial covenant in the Credit Agreement because we currently are, and anticipate
that we will continue to be, in compliance with the maximum leverage ratio requirement under the Credit
Agreement.

On October 28, 2021, the Board authorized a new share repurchase program, under which we may

repurchase up to $1,000.0 in shares of Common Stock (the “2021 Share Repurchase Program”). The 2021 Share
Repurchase Program does not have an expiration and replaced the 2017 Share Repurchase Program. All
remaining dollars authorized for repurchase under the 2017 Share Repurchase Plan have been cancelled. The
2021 Share Repurchase Program did not modify our evergreen share repurchase program, authorized by the
Board on January 29, 2014, under which we may repurchase, from time to time, Common Stock to reduce or
eliminate dilution associated with issuances of Common Stock under its incentive plans.

In November 2023, we executed an agreement to purchase 3.3 million shares for $300.1, inclusive of fees,
of which $229.3 was purchased under the evergreen share repurchase program and $70.8 was purchased under
the 2021 Share Repurchase Program.

As a result of our stock repurchases, there remains $658.9 of share repurchase availability under the 2021

Share Repurchase Program as of December 31, 2023.

On January 31, 2024, the Board declared a 4% increase in the regular quarterly dividend from $0.2725 to

$0.28375 per share, equivalent to an annual dividend of $1.135 per share payable to stockholders of record as of
February 15, 2024. The increase raises the annual dividend payout from $267.0 to approximately $276.0 on an
annualized basis.

We anticipate that our cash from operations, together with our current borrowing capacity, will be sufficient

to fund our share repurchase programs to the extent implemented by management, pay debt and interest as it
comes due, pay dividends at the latest approved rate, and meet our capital expenditure program costs, which are
expected to be approximately $180.0 in 2024 primarily for manufacturing capacity investments in laundry, litter
and vitamins to support expected future sales growth. Cash, together with our current borrowing capacity, may be
used for acquisitions that would complement our existing product lines or geographic markets.

52

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

Cash Flow Analysis

Year Ended

December 31,
2023

December 31,
2022

December 31,
2021

Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . .
Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash used in financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,030.6
$ (234.3)
$ (725.6)

$ 885.2
$(728.6)
$(120.9)

$ 993.8
$(682.0)
$(252.1)

2023 compared to 2022

Net Cash Provided by Operating Activities – Our primary source of liquidity is our cash flow provided by

operating activities, which is dependent on the level of net income and changes in working capital. Our net cash
provided by operating activities in 2023 increased by $145.4 to $1,030.6 as compared to $885.2 in 2022 due to an
improvement in working capital and an increase in cash earnings (net income adjusted for non-cash items)
including the impact of recent acquisitions. The improvement in working capital is primarily related to lower
investment in inventory in the U.S. as fill rates have improved, lower investment in inventory related to our
discretionary brands and higher incentive compensation accruals. We measure working capital effectiveness
based on our cash conversion cycle. The following table presents our cash conversion cycle information for the
quarters ended December 31, 2023 and 2022:

As of

December 31,
2023

December 31,
2022

Change

Days of sales outstanding in accounts receivable (“DSO”)
. . . . . . . . . . . . . .
Days of inventory outstanding (“DIO”) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Days of accounts payable outstanding (“DPO”) . . . . . . . . . . . . . . . . . . . . . . .

Cash conversion cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

29
70
72

27

28
69
78

19

1
1
6

8

Our cash conversion cycle (defined as the sum of DSO plus DIO less DPO) at December 31, 2023, which is
calculated using a two period average method, increased 8 days from the prior year primarily due to a reduction
in DPO of 6 days. The reduction in 2023 DPO compared to 2022 is partially driven by our recent acquisitions.
We continue to focus on reducing our working capital requirements.

Net Cash Used in Investing Activities – Net cash used in investing activities during 2023 was $234.3,
primarily reflecting property, plant and equipment additions of $223.5. Net cash used in investing activities
during 2022 was $728.6, primarily reflecting $546.8 for the Hero Acquisition and $178.8 for property, plant and
equipment additions.

Net Cash Used in Financing Activities – Net cash used in financing activities during the twelve months of
2023 was $725.6, reflecting $300.1 of treasury stock purchases, $266.5 of cash dividend payments and $270.6 of
net debt repayments, partially offset by $111.7 of proceeds from stock option exercises. Net cash used in
financing activities during the twelve months of 2022 was $120.9, reflecting $255.0 of cash dividend payments
and $12.0 of financing costs, partially offset by $119.9 of net debt borrowings, and $26.2 of proceeds from stock
option exercises.

53

CHURCH & DWIGHT CO., INC AND SUBSIDIARIES
(Dollars in millions, except share and per share data)

OTHER ITEMS

Market risk

Concentration of Risk

A group of four customers accounted for approximately 44% and 42% of consolidated net sales in 2023 and

2022, respectively. A group of three customers accounted for approximately 37% of consolidated net sales in
2021, of which a single customer (Walmart Inc. and its affiliates) accounted for approximately 23%, 24% and
24% in 2023, 2022 and 2021, respectively.

Interest Rate Risk

We had outstanding total debt at December 31, 2023, of $2,406.0, net of debt issuance costs, of which

approximately 92% has a fixed weighted average interest rate of 4.1% and the remaining 8% was constituted
primarily of the term loan due 2024 with a current rate of approximately 6.2%. From time to time the Company
will enter into interest rate lock agreements to hedge the risk of changes in the interest payments attributable to
changes in the interest rate associated with anticipated issuances of debt.

Other Market Risks

We are also subject to market risks relating to our diesel and other commodity costs, fluctuations in foreign

currency exchange rates, and changes in the market price of the Common Stock. Refer to Note 3 to the
Consolidated Financial Statements included in this Annual Report for a discussion of these market risks and the
derivatives used to manage the risks associated with changing diesel fuel and other commodity prices, foreign
exchange rates and the price of our Common Stock.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This information appears under the heading “Market Risk” in the “Management’s Discussion and Analysis”

section. Refer to page 54 of this Annual Report.

54

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Management of Church & Dwight Co., Inc. (the “Company”) is responsible for establishing and maintaining

adequate internal control over financial reporting. Internal control over financial reporting is a process designed
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A company’s
internal control over financial reporting includes those policies and procedures that pertain to the maintenance of
records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the
company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and
directors of the company; and provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the
financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.

Management evaluated the Company’s internal control over financial reporting as of December 31, 2023. In
making this assessment, management used the framework established in Internal Control-Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). As a result
of this assessment and based on the criteria in the COSO framework, management has concluded that as of
December 31, 2023, the Company’s internal control over financial reporting was effective.

The Company’s independent registered public accounting firm, Deloitte & Touche LLP, has audited the

Company’s internal control over financial reporting. Their opinions on the effectiveness of the Company’s
internal control over financial reporting and on the Company’s consolidated financial statements and financial
statement schedule appear on pages 56 and 59 of this Annual Report on Form 10-K.

/s/ Matthew T. Farrell

Matthew T. Farrell
President and Chief Executive Officer

/s/

Richard A. Dierker
Richard A. Dierker
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

February 15, 2024

55

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of
Church & Dwight Co., Inc.
Ewing, New Jersey

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Church & Dwight Co., Inc. and subsidiaries
(the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of income,
comprehensive income, stockholders’ equity, and cash flows, for each of the three years in the period ended
December 31, 2023, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to
as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its
cash flows for each of the three years in the period ended December 31, 2023, in conformity with the accounting
principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2023,
based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of
Sponsoring Organizations of the Treadway Commission and our report dated February 15, 2024, expressed an
unqualified opinion on the Company’s internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express
an opinion on the Company’s financial statements based on our audits. We are a public accounting firm
registered with the PCAOB and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial
statements that was communicated or required to be communicated to the audit committee and that (1) relates to
accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. The communication of critical audit matters does not alter in any way our
opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter
below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it
relates.

56

Trade Names and Other Intangibles, Net – Waterpik and Vitamins – Refer to Notes 1 and 7 to the
Consolidated Financial Statements

Critical Audit Matter Description

The Company owns trade names that are considered to have indefinite lives. These trade names are required to be
measured periodically for impairment.

The Company’s global Waterpik business has continued to experience a decline in customer demand for many of
its products, primarily due to value-branded competitive products and lower consumer spending on discretionary
products resulting in part from inflation. As a result, the Waterpik business has experienced declining sales and
profits resulting in a reduction in expected future cash flows, eroding a substantial portion of the excess between
the fair and carrying value of the trade name. The carrying value of the WATERPIK trade name is $644.7 million
and the fair value represented 109% of the carrying value as of October 1, 2023.

The vitamin category continues to experience a softening of growth from higher levels during the COVID-19
pandemic and competition from new category entrants. In addition, residual impacts from previous vitamin-
specific supply chain challenges have resulted in reduced shelf space for VITAFUSION and LIL’ CRITTERS at
certain retailers and consumers switching to competitor’s brands. These factors, along with higher interest rates,
have resulted in a reduction in the expected future cash flows which have eroded a substantial portion of the
excess between the fair and carrying value of the trade name. The carrying value of the VITAFUSION and LIL’
CRITTERS trade name is $281.3 million and the fair value represented 154% of the carrying value as of
October 1, 2023.

Management estimates the fair value of these trade names on a periodic basis based on an “excess earnings”
discounted cash flow method. The determination of fair value requires management to make significant estimates
and assumptions related to future performance, such as revenue growth rates, as well as the selection of
appropriate valuation assumptions, such as discount rates. Changes in these assumptions could have a significant
impact on the fair value of the trade names, leading to an impairment.

Given the significant judgments made by management to estimate the trade names’ fair value, performing audit
procedures to evaluate the reasonableness of management’s estimates and assumptions related to the revenue
growth rates and the selection of the discount rates involved a high degree of auditor judgment and an increased
extent of effort, including the need to involve our fair value specialists.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the determination of revenue growth rates and the selection of discount rates for
the trade names included the following, among others:

• We tested the effectiveness of controls over the account balance, including those over the revenue

growth rates and the selection of the discount rates.

• We evaluated management’s ability to accurately forecast revenue growth by comparing actual

performance to management’s historical forecasts.

• We evaluated the reasonableness of management’s forecasted revenue growth by comparing the

forecasts to:

– Historical performance.

–

Internal communications to management and the Board of Directors.

– Forecasted information included in analyst and industry reports for the Company and certain of its

peer companies.

57

• With the assistance of our fair value specialists, we evaluated the reasonableness of the discount rates

by:

– Testing the source information underlying the determination of the discount rates and the

mathematical accuracy of the calculation.

– Developing a range of independent estimates and comparing those to the discount rates selected

by management.

/s/ DELOITTE & TOUCHE LLP

Morristown, NJ
February 15, 2024

We have served as the Company’s auditor since 1968.

58

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of
Church & Dwight Co., Inc.
Ewing, New Jersey

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of Church & Dwight Co., Inc. and subsidiaries (the
“Company”) as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our
opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of
December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by
COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2023,
of the Company and our report dated February 15, 2024, expressed an unqualified opinion on those consolidated
financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and
for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying
Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion
on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm
registered with the PCAOB and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit included obtaining an understanding of internal
control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the
design and operating effectiveness of internal control based on the assessed risk, and performing such other
procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable
basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. A company’s internal control over financial reporting
includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company are being made
only in accordance with authorizations of management and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the
company’s assets that could have a material effect on the financial statements.

59

Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.

/s/ DELOITTE & TOUCHE LLP

Morristown, NJ

February 15, 2024

60

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share data)

Year Ended December 31,

2023

2022

2021

Net Sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$5,867.9
3,279.4

$5,375.6
3,125.6

$5,190.1
2,926.6

Gross Profit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Marketing expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Income from Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity in earnings of affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other income (expense), net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Income before Income Taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,588.5
641.3
889.8

1,057.4
8.7
12.2
(110.9)

967.4
211.8

2,250.0
535.2
1,117.0

597.8
12.3
2.8
(89.6)

523.3
109.4

2,263.5
577.7
606.7

1,079.1
9.4
(2.3)
(54.5)

1,031.7
204.2

Net Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 755.6

$ 413.9

$ 827.5

Weighted average shares outstanding—Basic . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted average shares outstanding—Diluted . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income per share—Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income per share—Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash dividends per share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

244.9
247.6
3.09
3.05
1.09

$
$
$

242.9
246.3
1.70
1.68
1.05

$
$
$

244.9
249.6
3.38
3.32
1.01

$
$
$

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)

Net Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other comprehensive income, net of tax:

Foreign exchange translation adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Defined benefit plan gain (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income (loss) from derivative agreements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2023

2022

2021

$755.6

$413.9

$827.5

8.6
2.9
(9.4)

2.1

(16.2)
2.3
52.8

38.9

(3.8)
(0.6)
13.8

9.4

Comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$757.7

$452.8

$836.9

See Notes to Consolidated Financial Statements.

61

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(In millions, except share and per share data)

Assets
Current Assets
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable, less allowances of $7.3 and $3.5 . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Current Assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Property, Plant and Equipment, Net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity Investment in Affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Trade Names and Other Intangibles, Net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other Assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31, December 31,

2023

2022

$

344.5
526.9
613.3
45.0

1,529.7

927.7
12.0
3,302.3
2,431.5
366.0

$

270.3
422.0
646.6
57.0

1,395.9

761.1
12.7
3,431.6
2,426.8
317.5

Total Assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 8,569.2

$ 8,345.6

Liabilities and Stockholders’ Equity
Current Liabilities
Short-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current portion of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued expenses and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Current Liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Long-term Debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred Income Taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred and Other Long-term Liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Business Acquisition Liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, $1.00 par value, Authorized 2,500,000 shares; none issued . . . . . . . .
Common Stock, $1.00 par value, Authorized 600,000,000 shares; 293,709,982 shares
issued as of December 31, 2023 and 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additional paid-in capital
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Retained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Common stock in treasury, at cost: 50,557,219 shares as of December 31, 2023 and

$

3.9
199.9
630.6
580.4
7.2

1,422.0

2,202.2
743.1
313.7
32.8

4,713.8

$

74.0
0.0
666.7
436.1
7.0

1,183.8

2,599.5
757.0
273.4
42.0

4,855.7

0.0

0.0

293.7
454.8
6,012.3
(27.2)

293.7
366.2
5,524.6
(29.3)

49,814,106 shares as of December 31, 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(2,878.2)

(2,665.3)

Total Stockholders’ Equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,855.4

3,489.9

Total Liabilities and Stockholders’ Equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 8,569.2

$ 8,345.6

See Notes to Consolidated Financial Statements.

62

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOW
(In millions)

Cash Flow From Operating Activities
Net Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Change in fair value of business acquisition liabilities . . . . . . . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Flawless impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity in net earnings of affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Distributions from unconsolidated affiliates . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Asset impairment charge and other asset write-offs . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Change in assets and liabilities:

Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable and accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other operating assets and liabilities, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2023

2022

2021

$ 755.6

$ 413.9

$ 827.5

72.8
152.4
0.0
(13.8)
0.0
(8.7)
9.5
63.6
8.9
(0.4)

(97.4)
38.5
10.4
55.2
(1.8)
(14.2)

67.0
152.0
0.0
(117.7)
411.0
(12.3)
8.7
32.3
2.4
(3.2)

(5.3)
(92.8)
2.5
39.9
14.4
(27.6)

68.4
150.7
(98.0)
20.3
0.0
(9.4)
9.4
23.7
14.9
3.6

2.4
(29.1)
(6.1)
47.5
(16.0)
(16.0)

Net Cash Provided By Operating Activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,030.6

885.2

993.8

Cash Flow From Investing Activities
Additions to property, plant and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(223.5)
0.0
(10.8)

(178.8)
(546.8)
(3.0)

(118.8)
(556.0)
(7.2)

Net Cash Used In Investing Activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(234.3)

(728.6)

(682.0)

Cash Flow From Financing Activities
Long-term debt borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term debt (repayments) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Short-term debt (repayments), net of borrowings . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from stock options exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payment of cash dividends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchase of treasury stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred financing and other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

0.0
(200.0)
(70.6)
111.7
(266.5)
(300.1)
(0.1)

998.8
(700.0)
(178.9)
26.2
(255.0)
0.0
(12.0)

799.2
(300.0)
(98.5)
98.7
(247.5)
(500.0)
(4.0)

Net Cash Used In Financing Activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(725.6)

(120.9)

(252.1)

Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . . . . . . . .

Net Change In Cash and Cash Equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash and Cash Equivalents at Beginning of Period . . . . . . . . . . . . . . . . . . . . . .

3.5

74.2
270.3

(6.0)

(2.2)

29.7
240.6

57.5
183.1

Cash and Cash Equivalents at End of Period . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 344.5

$ 270.3

$ 240.6

63

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOW—(Continued)
(In millions)

Cash paid during the year for:

Interest (net of amounts capitalized) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$111.9

$ 86.0

$ 51.8

Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$228.2

$213.1

$202.8

Supplemental disclosure of non-cash investing activities:

Property, plant and equipment expenditures included in Accounts Payable . . . . .

$ 30.7

$ 13.7

$ 10.7

Year Ended December 31,

2023

2022

2021

See Notes to Consolidated Financial Statements.

64

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Years Ended December 31, 2023, 2022 and 2021
(In millions)

Number of Shares

Amounts

Common
Stock

Treasury
Stock

Common
Stock

Additional
Paid-In
Capital

292.8
0.0

(47.4)
0.0

$292.8
0.0

$274.4
0.0

Accumulated
Other
Comprehensive
Income (Loss)

$(77.6)
0.0

Treasury
Stock

$(2,255.2)
0.0

Retained
Earnings

$4,786.0
827.5

Total
Church &
Dwight Co.,
Inc.
Stockholders’
Equity

$3,020.4
827.5

0.0
0.0
0.0

0.0

292.8
0.0

0.0
0.0
0.0

0.9

293.7
0.0

0.0
0.0
0.0

0.0

0.0
0.0
(5.7)

2.8

(50.3)
0.0

0.0
0.0
(0.2)

0.7

(49.8)
0.0

0.0
0.0
(3.3)

2.5

0.0
0.0
0.0

0.0

$292.8
0.0

0.0
0.0
0.0

0.9

$293.7
0.0

0.0
0.0
0.0

0.0

0.0
0.0
10.0

0.0
(247.5)
0.0

25.9

$310.3
0.0

0.0
0.0
20.0

35.9

$366.2
0.0

0.0
0.0
0.0

0.0

$5,366.0
413.9

0.0
(255.0)
0.0

(0.3)

$5,524.6
755.6

0.0
(266.5)
0.0

88.6

(1.4)

9.4
0.0
0.0

0.0

0.0
0.0
(510.0)

9.4
(247.5)
(500.0)

97.5

123.4

$(68.2)
0.0

$(2,667.7)
0.0

$3,233.2
413.9

38.9
0.0
0.0

0.0
0.0
(20.0)

38.9
(255.0)
0.0

0.0

$(29.3)
0.0

22.4

58.9

$(2,665.3)
0.0

$3,489.9
755.6

2.1
0.0
0.0

0.0

0.0
0.0
(300.1)

2.1
(266.5)
(300.1)

87.2

174.4

December 31, 2020 . . . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . .
Other comprehensive income

(loss) . . . . . . . . . . . . . . . . . . . . . .
Cash dividends . . . . . . . . . . . . . . . .
Stock purchases . . . . . . . . . . . . . . . .
Stock based compensation expense

and stock option plan
transactions . . . . . . . . . . . . . . . . .

December 31, 2021 . . . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . .
Other comprehensive income

(loss) . . . . . . . . . . . . . . . . . . . . . .
Cash dividends . . . . . . . . . . . . . . . .
Stock purchases . . . . . . . . . . . . . . . .
Stock based compensation expense

and stock option plan
transactions . . . . . . . . . . . . . . . . .

December 31, 2022 . . . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . .
Other comprehensive income

(loss) . . . . . . . . . . . . . . . . . . . . . .
Cash dividends . . . . . . . . . . . . . . . .
Stock purchases . . . . . . . . . . . . . . . .
Stock based compensation expense

and stock option plan
transactions . . . . . . . . . . . . . . . . .

December 31, 2023 . . . . . . . . . . . .

293.7

(50.6)

$293.7

$454.8

$6,012.3

$(27.2)

$(2,878.2)

$3,855.4

See Notes to Consolidated Financial Statements.

65

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except share and per share data)

1.

Significant Accounting Policies

Business

The Company, founded in 1846, develops, manufactures and markets a broad range of household, personal

care and specialty products focused on animal productivity, chemicals and cleaners. The Company sells its
consumer products under a variety of brands through a broad distribution platform that includes supermarkets,
mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar, pet and other specialty
stores and websites and other e-commerce channels, all of which sell the products to consumers. The Company
also sells specialty products to industrial customers, livestock producers and through distributors.

Basis of Presentation

The accompanying Consolidated Financial Statements are presented in accordance with accounting

principles generally accepted in the U.S. (“GAAP”) and include the accounts of the Company and its
majority-owned subsidiaries. For equity investments in which the Company does not control or have the ability
to exert significant influence over the investee, which generally is when the Company has less than a 20%
ownership interest, the investments are accounted for under the cost method. In circumstances where the
Company has greater than a 20% ownership interest and has the ability to exercise significant influence over, but
does not control, the investee, the investment is accounted for under the equity method. As a result, the Company
accounts for its 50% interest in its Armand Products Company (“Armand”) joint venture and its 50% interest in
The ArmaKleen Company (“ArmaKleen”) joint venture under the equity method. Armand and ArmaKleen are
specialty chemical businesses. The Company’s equity in earnings of Armand and ArmaKleen are included in the
Corporate segment, as described in Note 16.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent gains and
losses at the date of the financial statements and reported amounts of revenue and expenses during the reporting
period. Management makes estimates regarding inventory valuation, promotional and sales returns reserves, the
carrying amount of goodwill and other intangible assets, the realization of deferred tax assets, tax reserves,
business acquisition liabilities, liabilities related to other postretirement benefit obligations and other matters that
affect the reported amounts and other disclosures in the financial statements. These estimates are based on
judgment and available information. Actual results could differ materially from those estimates, and it is possible
that changes in such estimates could occur in the near term.

Revenue Recognition

Revenue is recognized when control of a promised good is transferred to a customer in an amount that
reflects the consideration that the Company expects to be entitled to in exchange for that good. This usually
occurs when finished goods are delivered to the Company’s customers or when finished goods are picked up by a
customer or a customer’s carrier.

a. Nature of Goods and Services

The Company primarily ships finished goods to its customers and operates in three segments: Consumer

Domestic, Consumer International and Specialty Products Division (“SPD”). The segments are based on

66

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

differences in the nature of products and organizational and ownership structures. The Consumer Domestic and
Consumer International segments market a variety of personal care and household products and over-the-counter
products, including but not limited to baking soda, cat litter, laundry detergent, condoms, stain removers, hair
removal, gummy dietary supplements, dry shampoo, oral care, cold remedy, acne treatment, water flossers and
showerheads. The SPD segment focuses on sales to businesses and participates in three product areas: Animal
and Food Production, Specialty Chemicals and Specialty Cleaners. The Company’s products are distinct and
separately identifiable on customer contracts or invoices, with each product sale representing a separate
performance obligation.

The Company sells consumer products under a variety of brands through a broad distribution platform that

includes supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar,
pet and other specialty stores and websites and other e-commerce channels, all of which sell its products to
consumers. The Company sells its specialty products to industrial customers, livestock producers and through
distributors.

Refer to Note 17 for disaggregated revenue information with respect to each of the Company’s segments.

b. When Performance Obligations are Satisfied

For performance obligations related to the shipping and invoicing of products, control transfers at the point
in time upon which finished goods are delivered to the Company’s customers or when finished goods are picked
up by a customer or a customer’s carrier. Once a product has been delivered or picked up by the customer, the
customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset. The
Company considers control to have transferred upon delivery or customer receipt because the Company has an
enforceable right to payment at that time, the customer has legal title to the asset, the Company has transferred
physical possession of the asset, and the customer has significant risk and rewards of ownership of the asset.

c. Variable Consideration

The Company conducts extensive promotional activities, primarily through the use of off-list discounts,
slotting, coupons, cooperative advertising, periodic price reduction arrangements, and end-aisle and other in-store
displays. The costs of such activities are netted against sales and are recorded when the related sale takes place.
The reserves for sales returns and consumer and trade promotion liabilities are established based on the
Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of
the balance sheet date. The Company uses historical trend experience and coupon redemption inputs in arriving
at coupon reserve requirements, and uses forecasted appropriations, customer and sales organization inputs, and
historical trend analysis in determining the reserves for other promotional activities and sales returns.

d. Practical Expedients

The Company expenses incremental direct costs of obtaining a contract (broker commissions) when the

related sale takes place. These costs are recorded in SG&A expenses in the accompanying consolidated
statements of income.

The Company accounts for shipping and handling costs as fulfillment activities which are therefore

recognized upon shipment of the goods.

67

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

The Company has applied the portfolio approach to all open contracts as they have similar characteristics
and can reasonably expect that the effects on the financial statements of applying this guidance to the portfolio of
contracts would not differ materially from applying this guidance to the individual contracts within the portfolio.

The Company excludes from its revenue any amounts collected from customers for sales (and similar) taxes.

Sales of Accounts Receivable

The Company entered into a factoring agreement with a financial institution to sell certain customer

receivables at discounted rates in 2015. Transactions under this agreement are accounted for as sales of accounts
receivable and are removed from the Consolidated Balance Sheet at the time of the sales transaction. The level of
customers associated with the Company’s factoring program and the sales performance by those customers has
driven the amount factored each year. The total amount factored in each year was $144.2, $211.2, and $181.2
during the years ended December 31, 2023, 2022 and 2021, respectively.

Cost of Sales, Marketing and Selling, General and Administrative Expenses

Cost of sales include costs related to the manufacture and distribution of the Company’s products, including
raw material, inbound freight, import duties and tariffs, direct labor (including employee compensation benefits)
and indirect plant costs such as plant supervision, receiving, inspection, maintenance labor and materials,
depreciation, taxes and insurance, purchasing, production planning, operations management, logistics, freight to
customers, warehousing costs, internal transfer freight costs and plant impairment charges.

Marketing expenses include costs for advertising (excluding the costs of cooperative advertising programs,

which are reflected in net sales), costs for coupon insertion (mainly the cost of printing and distribution),
consumer promotion costs (such as on-shelf advertisements and floor ads), public relations, package design
expense and market research costs.

Selling, general and administrative (“SG&A”) expenses include, among others, costs related to functions

such as sales, corporate management, research and development, marketing administration, information
technology and legal. Such costs include salary compensation related costs (such as benefits, incentive
compensation and profit sharing), stock option costs, depreciation, travel and entertainment related expenses,
professional and other consulting fees and amortization of intangible assets.

Foreign Currency Translation

Unrealized gains and losses related to currency translation are recorded in Accumulated Other

Comprehensive Income (Loss). Gains and losses on foreign currency transactions are recorded in the
Consolidated Statements of Income.

Cash Equivalents

Cash equivalents consist of highly liquid short-term investments and term bank deposits, which mature

within three months of their original maturity date.

Inventories

Inventories are valued at the lower of cost or market (net realizable value, which reflects any costs to sell or
dispose). The Company identifies any slow moving, obsolete or excess inventory to determine whether an adjustment
is required to establish a new carrying value. The determination of whether inventory items are slow moving, obsolete

68

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

or in excess of needs requires estimates and assumptions about the future demand for the Company’s products,
technological changes, and new product introductions. Estimates as to the future demand used in the valuation of
inventory involve judgments regarding the ongoing success of the Company’s products. The Company evaluates its
inventory levels and expected usage on a periodic basis and records adjustments as required. Adjustments to reflect
inventory at net realizable value were $52.5 at December 31, 2023, and $46.0 at December 31, 2022.

Property, Plant and Equipment

Property, Plant and Equipment (“PP&E”) are stated at cost. Depreciation is recorded using the straight-line

method over the estimated useful lives of the respective assets. Estimated useful lives for building and
improvements, machinery and equipment, and office equipment range from 9-40, 3-20 and 3-10 years, respectively.
Routine repairs and maintenance are expensed when incurred. Leasehold improvements are depreciated over a
period no longer than the respective lease term, except where a lease renewal has been determined to be reasonably
assured and failure to renew the lease results in a significant penalty to the Company.

PP&E is reviewed annually and whenever events or changes in circumstances indicate that possible
impairment exists. The Company’s impairment review is based on an undiscounted cash flow analysis at the
lowest level at which cash flows of the long-lived assets are largely independent of other groups of Company
assets and liabilities. The analysis requires management judgment with respect to changes in technology, the
continued success of product lines, and future volume, revenue and expense growth rates. The Company
conducts annual reviews to identify idle and underutilized equipment, and reviews business plans for possible
impairment. An indication of impairment occurs when the carrying value of the asset exceeds the future
undiscounted cash flows. When an impairment is indicated, the estimated future cash flows are then discounted
to determine the estimated fair value of the asset and an impairment charge is recorded for the difference between
the carrying value and the net present value of estimated future cash flows.

Software

The Company capitalizes certain costs of developing computer software. Amortization is recorded using the

straight-line method over the estimated useful life of the software, which is estimated to be no longer than 10 years.

Fair Value of Financial Instruments

Certain financial instruments are required to be recorded at fair value. The estimated fair values of such
financial instruments (including investment securities and other derivatives) have been determined using market
information and generally accepted valuation methodologies. Changes in assumptions or estimation methods could
affect the fair value estimates. Other financial instruments, including cash equivalents and short-term debt, are
recorded at cost, which approximates fair value. Additional information regarding the Company’s risk management
activities, including derivative instruments and hedging activities, are separately disclosed. See Notes 2 and 3.

Goodwill and Other Intangible Assets

The Company has intangible assets of substantial value on its consolidated balance sheet. Intangible assets

are generally related to intangible assets with a useful life, indefinite-lived trade names and goodwill. The
Company determines whether an intangible asset (other than goodwill) has a useful life based on multiple
factors, including how long the Company intends to generate cash flows from the asset.

Carrying values of goodwill and indefinite-lived trade names are reviewed periodically for possible
impairment. The Company’s impairment analysis is based on a discounted cash flow approach that requires

69

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

significant judgment with respect to unit volume, revenue and expense growth rates, and the selection of an
appropriate discount rate and royalty rate. Management uses estimates based on expected trends in making these
assumptions. With respect to goodwill, impairment occurs when the carrying value of the reporting unit exceeds
the discounted present value of cash flows for that reporting unit. For trade names and other intangible assets, an
impairment charge is recorded for the difference between the carrying value and the net present value of
estimated future cash flows, which represents the estimated fair value of the asset. Judgment is required in
assessing whether assets may have become impaired between annual valuations. Indicators such as unexpected
adverse economic factors, unanticipated technological change, distribution losses, or competitive activities and
acts by governments and courts may indicate that an asset has become impaired. Intangible assets with finite
lives are amortized over their estimated useful lives, which range from 3-20 years, using the straight-line method,
and reviewed for impairment when changes in market circumstances occur.

Research and Development

The Company incurred research and development expenses in the amount of $122.4, $110.0 and $105.2 in

2023, 2022 and 2021, respectively. These expenses are included in SG&A expenses and are expensed as incurred.

Earnings Per Share (“EPS”)

Basic EPS is calculated based on income available to holders of the Company’s common stock (“Common

Stock”) and the weighted-average number of shares outstanding during the reported period. Diluted EPS includes
dilution from potential Common Stock issuable pursuant to the exercise of outstanding stock options. The
following table sets forth a reconciliation of the weighted-average number of shares of Common Stock
outstanding to the weighted-average number of shares outstanding on a diluted basis:

Weighted average common shares outstanding— basic . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dilutive effect of stock options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

244.9
2.7

242.9
3.4

244.9
4.7

Weighted average common shares outstanding—diluted . . . . . . . . . . . . . . . . . . . . . . . . . .

247.6

246.3

249.6

Antidilutive stock options outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2.6

3.0

1.6

2023

2022

2021

Employee and Director Stock Based Compensation

The fair value of stock-based compensation is determined at the grant date and the related expense is
generally recognized over the required employee service period in which the share-based compensation vests.
For employees and Directors that meet retirement eligibility requirements, the expense related to stock-based
compensation is recognized on the date of grant as there is no service period required to vest in the awards. The
following table presents the pre-tax expense associated with the fair value of stock awards included in SG&A
expenses and in cost of sales:

Cost of sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 3.4
61.5

$ 2.5
30.1

$ 3.3
22.3

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$64.9

$32.6

$25.6

For the Year Ended
December 31,

2023

2022

2021

70

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are
recognized to reflect the future tax consequences attributable to the differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit
carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which the differences are expected to be recovered or settled. Management
provides a valuation allowance against deferred tax assets for amounts which are not considered “more likely
than not” to be realized. The Company records liabilities for potential assessments in various tax jurisdictions in
accordance with GAAP. The liabilities relate to tax return positions that, although supportable by the Company,
may be challenged by the tax authorities and do not meet the minimum recognition threshold required under
applicable accounting guidance for the related tax benefit to be recognized in the income statement. The
Company adjusts this liability as a result of changes in tax legislation, interpretations of laws by courts, rulings
by tax authorities, changes in estimates and the expiration of the statute of limitations. Many of the judgments
involved in adjusting the liability involve assumptions and estimates that are highly uncertain and subject to
change. In this regard, settlement of any issue with, or an adverse determination in litigation against, a taxing
authority could require the use of cash and result in an increase in the Company’s annual effective tax rate.
Conversely, favorable resolution of an issue with a taxing authority would be recognized as a reduction to the
Company’s annual effective tax rate.

Recently Adopted Accounting Pronouncements

In September 2022, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards

Update (“ASU”) 2022-04, Liabilities-Supplier Finance Programs (Topic 405-50): Disclosure of Supplier Finance
Program Obligations, intended to add certain qualitative and quantitative disclosure requirements for a buyer in a
supplier finance program. The amendments require a buyer that uses supplier finance programs to make annual
disclosures about the program’s key terms, the balance sheet presentation of related amounts, the confirmed
amount outstanding at the end of the period, and associated rollforward information. Only the amount
outstanding at the end of the period must be disclosed in interim periods. The amendments are effective for all
entities for fiscal years beginning after December 15, 2022 on a retrospective basis, including interim periods
within those fiscal years, except for the requirement to disclose rollforward information, which is effective
prospectively for fiscal years beginning after December 15, 2023. The Company has adopted the standard which
resulted in additional disclosures. Refer to Note 9.

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to
Reportable Segment Disclosures intended to improve reportable segment disclosure requirements, primarily
through enhanced disclosures about significant expenses. The amendments will require public entities to disclose
significant segment expenses that are regularly provided to the chief operating decision maker and included
within segment profit and loss. The standard is effective for fiscal years beginning after December 15, 2023, and
interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and will be
applied retrospectively to all prior periods presented in the financial statements. The Company is currently
evaluating the impact of adoption on our consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income

Tax Disclosure which includes amendments that further expand income tax disclosures, by requiring the

71

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

disaggregation of information in the rate reconciliation table, and income taxes paid by jurisdiction. The
amendments are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and
are to be applied either prospectively or retrospectively. The Company is currently evaluating the impact of
adoption on the Company’s related disclosures.

There have been no other accounting pronouncements issued but not yet adopted by the Company which are

expected to have a material impact on the Company’s consolidated financial position, results of operations or
cash flows.

2. Fair Value Measurements

Fair Value Hierarchy

Accounting guidance on fair value measurements and disclosures establishes a hierarchy that prioritizes the

inputs used to measure fair value (generally, assumptions that market participants would use in pricing an asset
or liability) based on the quality and reliability of the information provided by the inputs, as follows:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Fair Values of Other Financial Instruments

The following table presents the carrying amounts and estimated fair values of the Company’s other

financial instruments at December 31, 2023 and 2022:

December 31, 2023

December 31, 2022

Input
Level

Carrying
Amount

Fair
Value

Carrying
Amount

Fair
Value

Financial Assets:

Cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1

$217.7

$217.7

$153.9

$153.9

Financial Liabilities:

Short-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 2
Term loan due December 22, 2024 . . . . . . . . . . . . . . . . . . . Level 2
3.15% Senior notes due August 1, 2027 . . . . . . . . . . . . . . . Level 2
2.3% Senior notes due December 15, 2031 . . . . . . . . . . . . . Level 2
5.6% Senior notes due November 15, 2032 . . . . . . . . . . . . Level 2
3.95% Senior notes due August 1, 2047 . . . . . . . . . . . . . . . Level 2
5.0% Senior notes due June 15, 2052 . . . . . . . . . . . . . . . . . Level 2

3.9
200.0
424.8
399.3
499.2
397.7
499.8

3.9
200.0
406.9
338.6
535.6
333.7
498.1

74.0
400.0
424.8
399.3
499.1
397.6
499.7

74.0
400.0
397.3
321.3
518.9
316.7
464.7

The Company recognizes transfers between input levels as of the actual date of the event. There were no

transfers between input levels during the twelve months ended December 31, 2023.

72

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

The following methods and assumptions were used to estimate the fair value of each class of financial

instruments reflected in the Consolidated Balance Sheets:

Cash Equivalents: Cash equivalents consist of highly liquid short-term investments and term bank deposits,

which mature within three months. The estimated fair value of the Company’s cash equivalents approximates
their carrying value.

Short-Term Borrowings: The carrying amounts of the Company’s unsecured lines of credit and commercial

paper issuances approximates fair value because of their short maturities and variable interest rates.

Senior Notes: The Company determines the fair value of its senior notes based on their quoted market value

or broker quotes, when possible. In the absence of observable market quotes, the notes are valued using
non-binding market consensus prices that the Company seeks to corroborate with observable market data.

Other: The carrying amounts of Accounts Receivable, and Accounts Payable and Accrued Expenses,

approximated estimated fair values as of December 31, 2023 and 2022.

3. Derivative Instruments and Risk Management

Changes in interest rates, foreign exchange rates, the price of the Common Stock and commodity prices
expose the Company to market risk. The Company manages these risks by the use of derivative instruments, such
as cash flow and fair value hedges, diesel and commodity hedge contracts, equity derivatives and foreign
exchange forward contracts. The Company does not use derivatives for trading or speculative purposes.

The Company formally designates and documents qualifying instruments as hedges of underlying exposures

when it enters into derivative arrangements. Changes in the fair value of derivatives designated as hedges and
qualifying for hedge accounting are recorded in other comprehensive income and reclassified into earnings
during the period in which the hedged exposure affects earnings. The Company reviews the effectiveness of its
hedging instruments on a quarterly basis. If the Company determines that a derivative instrument is no longer
effective in offsetting changes in fair values or cash flows, it recognizes the hedge ineffectiveness in current
period earnings and discontinues hedge accounting with respect to the derivative instrument. Changes in the fair
value of derivatives not designated as hedges or those not qualifying for hedge accounting are recognized in
current period earnings. Upon termination of cash flow hedges, the Company reclassifies gains and losses from
accumulated other comprehensive income based on the timing of the underlying cash flows, unless the
termination results from the failure of the intended transaction to occur in the expected timeframe. Such untimely
transactions require immediate recognition in earnings of gains and losses previously recorded in other
comprehensive income.

During 2023 and 2022, the Company used derivative instruments to mitigate risk, some of which were
designated as hedging instruments. The tables following the discussion of the derivative instruments below
summarize the fair value of the Company’s derivative instruments and the effect of derivative instruments on the
Company’s consolidated Statements of Income and on other comprehensive income.

73

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

Derivatives Designated as Hedging Instruments

Diesel Fuel Hedges

The Company uses independent freight carriers to deliver its products. The carriers charge the Company a

basic rate per mile for diesel fuel. The Company has entered into hedge agreements with counterparties to
mitigate the volatility of diesel fuel prices, and not to speculate in the future price of diesel fuel. Under the hedge
agreements, the Company agreed to pay a fixed price per gallon of diesel fuel determined at the time the
agreements were executed and to receive a floating rate payment that is determined on a monthly basis based on
the average price of the Department of Energy’s Diesel Fuel Index during the applicable month and is designed
to offset any increase or decrease in fuel costs that the Company pays to it common carriers. The agreements
covered approximately 75.0% of the Company’s 2023 diesel fuel requirements. These diesel fuel hedge
agreements qualified for hedge accounting. Therefore, changes in the fair value of such agreements are recorded
under Accumulated Other Comprehensive Income (Loss) on the Consolidated Balance Sheet.

Foreign Currency

The Company is subject to exposure from fluctuations in foreign currency exchange rates, primarily U.S.
Dollar/Euro, U.S. Dollar/ Pound, U.S. Dollar/Canadian Dollar, U.S. Dollar/Mexican Peso, U.S Dollar/Chinese
Yuan and U.S. Dollar/Australian Dollar.

The Company enters into forward exchange contracts to reduce the impact of foreign exchange rate

fluctuations related to anticipated but not yet committed sales or purchases denominated in U.S. Dollar, Canadian
Dollar, Pound, Euro, Mexican Peso, Chinese Yuan, and
Australian Dollar. The Company entered into forward exchange contracts to hedge itself from the risk that, due to
fluctuations in currency exchange rates, it would be adversely affected by net cash outflows. The face value of
the unexpired contracts as of December 31, 2023 totaled $228.9 in U.S. Dollars, of which $228.9 qualifies as
foreign currency cash flow hedges and, therefore, changes in the fair value of the contracts are recorded in
Accumulated Other Comprehensive Income (Loss) and reclassified to earnings when the hedged transaction
affected earnings.

Interest Rate Lock Agreements

From time to time the Company will enter into interest rate lock agreements to hedge the risk of changes in

the interest payments attributable to changes in the interest rates associated with anticipated issuances of debt.
The interest rate lock agreements outstanding at December 31, 2021 were settled in the second quarter of 2022
for a loss of $4.2. The Company entered into additional interest rate lock agreements in the third quarter of 2022
which were settled in the fourth quarter of 2022 for a gain of $21.9. These agreements were used to hedge the
interest rate risk associated with the first ten years of semi-annual interest payments associated with the Senior
Notes due in 2052 and 2032, respectively, and will each be amortized over a ten-year period to interest expense.
There were no interest rate lock agreements outstanding as of December 31, 2023 or 2022. The net gain on the
settlement of these interest rate lock agreements was included in Accumulated Other Comprehensive Income
(“AOCI”).

Commodity Hedges

The Company is subject to exposure due to changes in prices of commodities used in production. To limit

the effects of fluctuations in the future market price paid and related volatility in cash flows, the Company enters

74

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

into commodity forward swap contracts. These hedges are designated as cash flow hedges for accounting
purposes and, therefore, changes in the fair value of the contracts are recorded in AOCI and reclassified to
earnings when the hedged transaction affected earnings. The fair value of these commodity hedge agreements is
reflected in the Consolidated Balance Sheet within Other Current Assets and Accounts Payable and Accrued
Expenses.

Derivatives not Designated as Hedging Instruments

Equity Derivatives

The Company has entered into equity derivative contracts covering its Common Stock in order to minimize
its liability under its Executive Deferred Compensation Plan resulting from changes in the quoted fair values of
its Common Stock to participants who have investments under the Plan in a notional Common Stock fund. The
contracts are settled in cash. Since the equity derivatives contracts do not qualify for hedge accounting, the
Company is required to mark such contracts to market throughout the contract term and record changes in fair
value in the consolidated Statements of Income.

The notional amount of a derivative instrument is the nominal or face amount used to calculate payments

made on that instrument. Notional amounts are presented in the following table:

Notional
Amount

Notional
Amount

December 31,
2023

December 31,
2022

Derivatives designated as hedging instruments

Foreign exchange contracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diesel fuel contracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Commodities contracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

228.9
2.3 gallons
59.0 pounds

$

231.5
5.0 gallons
26.8 pounds

Derivatives not designated as hedging instruments

Foreign exchange contracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$
$

0.0
23.2

$
$

1.6
22.5

Excluding the interest rate lock agreements disclosed above, the fair values and amount of gain (loss)

recognized in income and other comprehensive income associated with the derivative instruments disclosed
above did not have a material impact on the Company’s consolidated financial statements for the periods ended
December 31, 2023, 2022, and 2021.

4.

Inventories

Inventories consist of the following:

Raw materials and supplies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Work in process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Finished goods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,
2023

December 31,
2022

$137.5
40.2
435.6

$613.3

$149.5
46.8
450.3

$646.6

75

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

5.

Property, Plant and Equipment, Net (“PP&E”)

PP&E consists of the following:

December 31,
2023

December 31,
2022

Land . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Buildings and improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Machinery and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Office equipment and other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Construction in progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

28.3
317.8
895.1
122.6
105.2
348.4

$

28.1
299.1
856.5
109.1
96.9
211.5

Gross PP&E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less accumulated depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,817.4
889.7

1,601.2
840.1

Net PP&E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 927.7

$ 761.1

For the Year Ended December 31,

2023

2022

2021

Depreciation expense on PP&E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$72.8

$67.0

$68.4

6. Acquisitions

On October 13, 2022, the Company acquired all of the issued and outstanding shares of capital stock of
Hero Cosmetics, Inc. (“Hero”), the developer of the HERO® brand which includes MIGHTY PATCH® acne
treatment products (the “Hero Acquisition”). The Company paid $546.8, net of cash acquired, at closing, and
deferred an additional cash payment of $8.0 for five years to satisfy certain indemnification obligations, if
necessary. The Company also issued $61.5 of restricted stock which will be recognized as compensation expense
as the vesting requirements for individuals who received the restricted stock, and will continue to be employed
by the Company, are satisfied. The vesting requirements are satisfied at various dates over a three-year period
from the date of the acquisition. Hero’s annual net sales for the year ended December 31, 2022 were
approximately $179.0. The Hero Acquisition was financed with cash on hand and commercial paper borrowings
and is managed in the Consumer Domestic and Consumer International segments. In the first quarter of 2023, the
Company made a net cash payment of $3.5 primarily associated with final working capital adjustments. In the
third quarter of 2023, the Company completed its determination of the acquired tax position of Hero Cosmetics
Inc. resulting in a $1.3 adjustment to increase goodwill.

The fair values of the net assets at acquisition are set forth as follows:

Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property, plant and equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Trade name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable and accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred and Other Long-term Liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Business acquisition liabilities—long-term . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 19.5
25.4
1.2
0.4
400.0
71.9
156.1
(1.1)
(1.4)
(117.2)
(8.0)

Cash purchase price (net of cash acquired) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 546.8

76

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

The trade name and other intangible assets were valued using a discounted cash flow model. The trade name

and other intangible assets recognized from the Hero Acquisition have useful lives which range from 10—20
years. The goodwill is a result of expected synergies from combined operations of the acquired business and the
Company. Pro forma results are not presented because the impact of the acquisition is not material to the
Company’s consolidated financial results. The goodwill and other intangible assets associated with the Hero
Acquisition are not deductible for U.S. tax purposes.

On December 24, 2021, the Company acquired all of the outstanding equity of Dr. Harold Katz, LLC and
HK-IP International, Inc., the owners of the THERABREATH® brand of oral care products (the “TheraBreath
Acquisition”). The Company paid $556.0, net of cash acquired, at closing and deferred an additional cash
payment of $14.0 related to certain indemnity obligations provided by the seller. The additional amount, to the
extent not used in satisfaction of such indemnity obligations, is payable in installments between two and four
years from the closing. THERABREATH’s annual net sales for the year ended December 31, 2021 were
approximately $100.0. The acquisition was financed by the proceeds from a $400.0 three-year term loan and the
Company’s underwritten public offering of $400.0 aggregate principal Senior Notes due on December 15, 2031.
The THERABREATH business is managed in the Consumer Domestic and Consumer International segments. In
2022, the Company made net cash payments of $3.8 primarily associated with final working capital adjustments.

The fair values of the net assets at acquisition are set forth as follows:

Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Trade name (indefinite lived) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable and accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Business acquisition liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 11.3
12.9
487.0
30.1
43.7
(15.0)
(14.0)

Cash purchase price (net of cash acquired) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$556.0

The trade names and other intangible assets were valued using a discounted cash flow model. The trade
name has an indefinite life. The life of the other intangible assets recognized from the TheraBreath Acquisition
have useful lives which range from 10—20 years. The goodwill is a result of expected synergies from combined
operations of the acquired business and the Company. Pro forma results are not presented because the impact of
the acquisition is not material to the Company’s consolidated financial results. The goodwill and other intangible
assets associated with the TheraBreath Acquisition are deductible for U.S. tax purposes.

7. Goodwill and Other Intangibles, Net

The Company has intangible assets of substantial value on its consolidated balance sheet. These intangible
assets are generally related to intangible assets with a useful life, indefinite-lived trade names and goodwill. The
Company determines whether an intangible asset (other than goodwill) has a useful life based on multiple
factors, including how long the Company intends to generate cash flows from the asset. These intangible assets
are more fully explained in the following sections.

77

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

Intangible Assets With a Useful Life

The following table provides information related to the carrying value of amortizable intangible assets:

December 31, 2023

December 31, 2022

Gross
Carrying
Amount(1)

Accumulated
Amortization(1) Impairments

Net

Amortization
Period
(Years)

Gross
Carrying
Amount

Accumulated
Amortization Impairments

Net

Amortizable intangible assets:

Trade names . . . . . . . . . . . $1,385.5
Customer

Relationships . . . . . . . .
Patents/Formulas . . . . . . .

644.9
208.3

$(403.5)

$ 0.0

$ 982.0

3-20

$1,785.8

$(406.2)

$(319.0) $1,060.6

(373.3)
(116.1)

(3.5)
(1.9)

268.1
90.3

15-20
4-20

723.4
251.7

(358.9)
(114.6)

(59.3)
(32.7)

305.2
104.4

Total . . . . . . . . . . . . . . . . . $2,238.7

$(892.9)

$(5.4)

$1,340.4

$2,760.9

$(879.7)

$(411.0) $1,470.2

(1) The gross carrying value of the Flawless intangible assets was reduced by impairment charges and

accumulated amortization as of December 31, 2022.

Intangible amortization expense amounted to $124.3 for 2023, $122.4 for 2022 and $120.3 for 2021,
respectively. The Company estimates that intangible amortization expense will be approximately $123.0 in 2024
and approximately $122.0 to $92.0 annually over the next five years.

In the fourth quarter of 2022, the Company determined that a review of our ability to recover the carrying

values of the global FINISHING TOUCH FLAWLESS intangible assets was necessary based on the
discontinuance of certain products at a major retailer. The FINISHING TOUCH FLAWLESS assets consist of
the definite-lived trade name, customer relationships and technology assets recorded at acquisition. The
Company evaluated our ability to recover the intangible assets by comparing the carrying amount to the future
undiscounted cash flows and determined that the cash flows would not be sufficient to recover the carrying value
of the assets. After determining the estimated fair value of the assets, which included a reduction in cash flows
due to the loss of distribution mentioned above along with an expected continued decline in discretionary
consumption and higher interest rates, a non-cash impairment charge of $411.0 was recorded in the fourth quarter
of 2022. The impairment charge is included in SG&A with $349.3 recorded in the Consumer Domestic segment
and $61.7 recorded in the Consumer International segment. The impairment charge was applied as a full
impairment of the customer relationship and technology assets and a partial impairment of the trade name. The
remaining net book value of the trade name as of December 31, 2023 is $30.9 and will be amortized over a
remaining useful life of two years. The estimated fair value of the intangible assets was determined using the
income approach with Level 3 inputs. The Level 3 inputs include the discount rate of 8.5% applied to
management’s estimates of future cash flows based on projections of revenue, gross margin, marketing expense
and tax rates considering the loss of product distribution and the reduction in customer demand that FINISHING
TOUCH FLAWLESS had been experiencing through December 31, 2022. The Company has implemented
strategies to address the decline in profitability. However, if unsuccessful, a further decline could trigger a future
impairment charge.

The Company’s Passport Food Safety business has experienced sales and profit declines primarily due to
decreased demand driven by the COVID-19 pandemic and pressures from new competitive activities resulting
from the loss of exclusivity on a key product line. In the fourth quarter of 2021, management’s review of the
outlook for the Passport business indicated an assessment of our ability to recover the carrying values of the
long-lived assets associated with the business was necessary. That review determined that the estimated future
cash flows would not be sufficient to recover the carrying value of the assets resulting in an impairment of the

78

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

associated trade name and other intangible assets of $11.3 in the fourth quarter of 2021. The charge was recorded
in SG&A. In the fourth quarter of 2023, management re-evaluated the outlook for this business and recorded an
additional impairment charge of $3.5. The assets have a current net book value of $3.3 and are being amortized
over their remaining weighted average life of 2 years. The Company is implementing strategies to address the
decline in profitability. However, if unsuccessful, a further decline could trigger a future impairment charge.

Indefinite-Lived Intangible Assets

The following table presents the carrying value of indefinite-lived intangible assets:

Trade names . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,961.9

$1,961.4

December 31,
2023

December 31,
2022

The Company’s indefinite-lived intangible impairment review is completed in the fourth quarter of each

year.

Fair value for indefinite-lived intangible assets was estimated based on a “relief from royalty” or “excess
earnings” discounted cash flow method, which contains numerous variables that are subject to change as business
conditions change, and therefore could impact fair values in the future. The key assumptions used in determining
fair value are sales growth, profitability margins, tax rates, discount rates and royalty rates. The Company
determined that the fair value of all indefinite-lived intangible assets for each of the years in the three-year period
ended December 31, 2023 exceeded their respective carrying values based upon the forecasted cash flows and
profitability.

Recently, the Company’s global TROJAN® business has benefited from the successful introduction of new

products, such as TROJAN BARESKIN RAW®, which has contributed to expanded distribution resulting in
sales growth in 2023 and an improvement in the expected sales growth outlook for this business. While the
Company cannot predict future changes in economic or competitive factors that may adversely impact the
underlying cash flows used to estimate fair value of the trade name, it believes that the improved growth and
profitability outlook for this business has reduced the near-term risk of impairment of the TROJAN trade name.
The carrying value of the TROJAN trade name is $176.4 and fair value represented 162% of the carrying value
as of October 1, 2023. The key assumptions used in the projections from the Company’s October 1, 2023
impairment analysis include discount rates of 8.5% in the U.S. and 10.0% internationally, revenue assumptions
including management’s estimates of the success of new product launches, and an average royalty rate of
approximately 10%.

The Company’s global WATERPIK business has continued to experience a significant decline in customer

demand for many of its products, primarily due to lower consumer spending for discretionary products from
inflation and a growing number of water flosser consumers switching to more value-branded products.
Waterpik’s profitability has also been impacted by tariffs imposed on its products imported into the United States
that were manufactured in China. As a result, the WATERPIK business has experienced declining sales and
profits resulting in a reduction in expected future cash flows which have eroded a substantial portion of the
excess between the fair and carrying value of the trade name. This indefinite-lived intangible asset may be
susceptible to impairment and a continued decline in fair value could trigger a future impairment charge of the
WATERPIK trade name. The carrying value of the WATERPIK trade name is $644.7 and fair value represented
109% of the carrying value as of October 1, 2023. The key assumptions used in the projections from the

79

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

Company’s October 1, 2023 impairment analysis include a discount rate of 8.8%, revenue growth rates between
0% and 4.5% and EBITA margins between 19% and 26%. These assumptions are based on current market
conditions, recent trends and management’s expectation of the success of initiatives to lower costs and to develop
lower-cost water flosser alternatives as well as improvement in the supply chain. While management has
implemented strategies to address the risk, significant changes in operating plans or adverse changes in the future
could reduce the underlying cash flows used to estimate fair value.

The vitamin category continues to experience a softening of growth from record high levels during the
COVID-19 pandemic and significant product competition coming from new category entrants. The category has
grown from about 6 competitors a decade ago to more than 60 of significance in recent years. In addition,
residual impacts from previous vitamin-specific supply chain challenges have resulted in reduced shelf space for
VITAFUSION and LIL’ CRITTERS at certain retailers and consumers switching to competitor’s brands. These
factors along with higher interest rates have resulted in a reduction in the expected future cash flows which have
eroded a substantial portion of the excess between the fair and carrying value of the trade name. This indefinite-
lived intangible asset may be susceptible to impairment and a continued decline in fair value could trigger a
future impairment charge of the VITAFUSION and LIL’ CRITTERS trade name. The carrying value of the
VITAFUSION and LIL’ CRITTERS trade name is $281.3 and fair value represented 154% of the carrying value
as of October 1, 2023. The key assumptions used in the projections from the Company’s October 1, 2023
impairment analysis include a discount rate of 8.6%, revenue growth rates between 3% and 5% and EBITA
margins between 12% and 15%. These assumptions are based on current market conditions, recent trends and
management’s expectation of the success of growth initiatives primarily from higher promotional and marketing
spend, new product introductions as well as e-Commerce and international expansion. While management has
implemented strategies to address the risk, significant changes in operating plans or adverse changes in the future
could reduce the underlying cash flows used to estimate fair value.

Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2023 and 2022 are as

follows:

Balance at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
TheraBreath adjustment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hero acquired goodwill

Balance at December 31, 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hero Acquisition adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,899.8
0.5
156.1

$2,056.4
4.7

Balance at December 31, 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$2,061.1

$238.7
(4.3)
0.0

$234.4
0.0

$234.4

Total

$2,274.5
(3.8)
156.1

$2,426.8
4.7

$136.0
0.0
0.0

$136.0
0.0

$136.0

$2,431.5

Consumer
Domestic

Consumer
International

Specialty
Products

The result of the Company’s annual goodwill impairment test, performed in the beginning of the second

quarter of 2023, determined that the estimated fair value substantially exceeded the carrying values of all
reporting units. The determination of fair value contains numerous variables that are subject to change as
business conditions change and therefore could impact fair value in the future.

80

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

8. Leases

The Company leases certain manufacturing facilities, warehouses, office space, railcars and equipment.

Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. All
recorded leases are classified as operating leases and lease expense is recognized on a straight-line basis over the
lease term. For leases beginning in 2019, lease components (base rental costs) are accounted for separately from
the nonlease components (e.g., common-area maintenance costs). For leases that do not provide an implicit rate,
the Company uses its estimated secured incremental borrowing rate based on the information available at
commencement date in determining the present value of lease payments.

A summary of the Company’s lease information is as follows:

Classification

December 31,
2023

December 31,
2022

Assets
Right of use assets . . . . . . . . . . . . . . . . . . . . Other Assets
Liabilities
Current lease liabilities . . . . . . . . . . . . . . . . . Accrued and Other Liabilities
Long-term lease liabilities . . . . . . . . . . . . . . Deferred and Other Long-term Liabilities

Total lease liabilities . . . . . . . . . . . . . . . . . .

Other information
Weighted-average remaining lease term

(years) . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted-average discount rate . . . . . . . . . .

$186.0

$162.6

$ 24.7
174.9

$199.6

$ 21.9
151.9

$173.8

8.1
4.5%

8.9
4.4%

Statement of Income
Lease cost(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$31.7

$31.0

$32.7

Twelve Months
Ended
December 31, 2023

Twelve Months
Ended
December 31, 2022

Twelve Months
Ended
December 31, 2021

Twelve Months
Ended
December 31, 2023

Twelve Months
Ended
December 31, 2022

Other information
Leased assets obtained in exchange for new lease liabilities(2) . . . . . . . . . . . .
Cash paid for amounts included in the measurement of lease liabilities . . . . .

$47.2
$30.9

$27.9
$31.4

(1) Lease expense is included in cost of sales or SG&A expenses based on the nature of the leased item. Short-
term lease expense is excluded from this amount and is not material. The Company also has certain variable
leases which are not material. The noncash component of lease expense for the twelve months ended
December 31, 2023, 2022 and 2021 was $24.3, $24.0 and $25.4, respectively, is included in the amortization
caption in the consolidated statement of cash flows.

(2) Leased assets obtained in exchange for new lease liabilities in 2023 consisted of $40.9 of real estate lease

additions and $6.3 of equipment lease additions, net of modifications. These additions included $36.9 for an
agreement between the Company and a third-party warehouse provider for warehouse space. Leased assets
obtained in exchange for new lease liabilities in 2022 primarily consisted of a contract amendment to one of
the Company’s international locations, which resulted in an increase to the Company’s right of use assets
and corresponding lease liabilities of approximately $8.2 recorded in the third quarter of 2022, and an

81

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

amendment to its contract at one of its leased manufacturing facilities, which resulted in an increase to the
Company’s right of use assets and corresponding lease liabilities of approximately $15.2 recorded in the
second quarter of 2022.

The Company’s minimum annual rentals including reasonably assured renewal options under lease

agreements are as follows:

2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2027 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2028 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2029 and thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Operating
Leases

$ 32.7
35.3
26.9
25.6
23.1
98.5

Total future minimum lease commitments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Imputed interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

242.1
(42.5)

Present value of lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$199.6

9. Accounts Payable, Accrued and Other Liabilities

Accounts payable, accrued and other liabilities consist of the following:

Trade accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued marketing and promotion costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued wages and related benefit costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other accrued current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 630.6
276.7
152.3
151.4

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,211.0

$ 666.7
234.4
66.8
134.9

$1,102.8

December 31,
2023

December 31,
2022

In 2015, the Company initiated a Supply Chain Finance program (“SCF Program”). Under the SCF

Program, qualifying suppliers may elect to sell their receivables from the Company for early payment.
Participating suppliers negotiate their receivables sales arrangements directly with a third party. The Company is
not party to those agreements and do not have an economic interest in the suppliers’ decisions to sell their
receivables and has not been required to pledge any assets as security nor to provide any guarantee to third-party
finance providers or intermediaries. The SCF Program may allow suppliers to obtain more favorable terms than
they could secure on their own. The terms of the Company’s payment obligations are not impacted by a
supplier’s participation in the SCF Program. The Company’s payment terms with suppliers are consistent
between suppliers that elect to participate in the SCF Program and those that do not participate. As a result, the
program does not have an impact to the Company’s average days outstanding.

As of December 31, 2023, the obligations outstanding related to the SCF program amount to $82.0,

recorded within Accounts Payable in the condensed consolidated balance sheets and $387.1 payments included in
operating activities within the Company’s consolidated statements of cash flows.

82

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

10. Short-Term Borrowings and Long-Term Debt

Short-term borrowings and long-term debt consist of the following:

December 31,
2023

December 31,
2022

Short-term borrowings
Commercial paper issuances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Various debt due to international banks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total short-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

0.0
3.9

3.9

$

$

70.6
3.4

74.0

Long-term debt
Term loan due December 22, 2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.15% Senior notes due August 1, 2027 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3% Senior notes due December 15, 2031 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5.6% Senior notes due November 15, 2032 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.95% Senior notes due August 1, 2047 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5.0% Senior notes due June 15, 2052 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Debt issuance costs, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total long-term debt
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Current maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 200.0
425.0
(0.2)
400.0
(0.7)
500.0
(0.8)
400.0
(2.3)
500.0
(0.2)
(18.7)

2,402.1
(199.9)

$ 400.0
425.0
(0.2)
400.0
(0.7)
500.0
(0.9)
400.0
(2.4)
500.0
(0.3)
(21.0)

2,599.5
0.0

Net long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$2,202.2

$2,599.5

Commercial Paper

Under the Company’s commercial paper program, the Company may issue commercial paper notes up to an

aggregate principal amount outstanding at any given time of $1,500.0. The maturities of the notes will vary but
may not exceed 397 days. The interest rates on the notes will vary based on market conditions and the ratings
assigned to the notes by the rating agencies designated in the agreement at the time of issuance. Subject to market
conditions, the Company intends to utilize the commercial paper program as its primary short-term borrowing
facility. If, for any reason, the Company is unable to access the commercial paper market, the Company’s
Revolving Credit Facility would be utilized to meet the Company’s short-term liquidity needs. The Company did
not have any commercial paper outstanding as of December 31, 2023 and had $70.6 of commercial paper
outstanding as of December 31, 2022 with a weighted-average interest rate of approximately 4.0%. As of
December 31, 2023, the Company had approximately $1,495.0 available through the Revolving Credit Facility
and commercial paper program.

December 22, 2024 Term Loan

On December 22, 2021, the Company entered into a $400.0 unsecured term loan facility (as amended on
June 16, 2022, the “Term Loan Facility”) with various banks. The loan under the Term Loan Facility (the “Term
Loan”) was fully drawn at closing. Unless prepaid, the Term Loan is due on December 22, 2024. The interest rate

83

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

is the Secured Overnight Financing Rate (“SOFR”) plus a spread and an applicable margin based on the
Company’s credit rating, which can range from 60 basis points to 125 bps. The proceeds of the Loan were used
to partially fund the TheraBreath Acquisition, with the remaining proceeds used for the repayment of commercial
paper. In 2023, the Company repaid $200.0 of the Term Loan with cash on hand and commercial paper
borrowings. In January 2024, the Company repaid an additional $100.0 of the Term Loan with cash on hand.

The Term Loan Facility also contains customary events of default, including failure to make certain
payments under the Term Loan Facility when due, breach of covenants, materially incorrect representations and
warranties, default on other material indebtedness, events of bankruptcy, material adverse judgments, certain
events relating to pension plans, the failure of any of the loan documents to remain in full force and effect and the
occurrence of any change in control with respect to the Company.

3.15% Senior Notes due August 1, 2027

On July 25, 2017, the Company issued $425.0 aggregate principal amount of 3.15% Senior Notes due 2027
(the “2027 Notes”). The 2027 Notes bear interest at 3.15%. Interest on the 2027 Notes is payable semi-annually,
on each February 1 and August 1. The 2027 Notes will mature on August 1, 2027 unless earlier retired or
redeemed.

2.3% Senior Notes due December 15, 2031

The Company financed the TheraBreath Acquisition with a portion of the proceeds from an underwritten
public offering of $400.0 aggregate principal amount Senior Notes due 2031 (the “2031 Notes”). The 2031 Notes
bear interest at 2.30%. Interest on the 2031 Notes is payable semi-annually, on each June 15 and December 15.
The 2031 Notes will mature on December 15, 2031, unless earlier retired or redeemed.

5.6% Senior Notes due November 15, 2032

On October 31, 2022, the Company issued $500.0 aggregate principal amount of 5.60% Senior Notes due
2032 (the “2032 Notes”). The proceeds from the sale of the 2032 Notes were used to repay commercial paper
borrowings incurred to finance the Company’s acquisition of Hero Cosmetics, Inc. The 2032 Notes will mature
on November 15, 2032, unless earlier retired or redeemed.

3.95% Senior Notes due August 1, 2047

On July 25, 2017, the Company issued $400.0 aggregate principal amount of 3.95% Senior Notes due
August 1, 2047 (the “2047 Notes”) to partially finance the Waterpik Acquisition and repay a portion of the
Company’s outstanding commercial paper borrowings. The 2047 Notes bear interest at 3.95%. Interest on the
2047 Notes is payable semi-annually, on each February 1 and August 1. The 2047 Notes will mature on
August 1, 2047, unless earlier retired or redeemed.

5.0% Senior Notes due June 15, 2052

On June 2, 2022, the Company issued $500.0 aggregate principal amount of 5.00% Senior Notes due 2052

(the “2052 Notes”). In July 2022 a portion of the proceeds from the sale of the Notes were used to repay all of the
Company’s outstanding $300.0 2.45% Senior Notes due August 1, 2022. The remaining proceeds were used to
pay a portion of the Company’s $400.0 outstanding 2.875% Senior Notes due October 1, 2022. The 2052 Notes
will mature on June 15, 2052, unless earlier retired.

84

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

Revolving Credit Facility

On June 16, 2022, the Company entered into a $1,500 Credit Agreement providing for a revolving credit

facility (the “Revolving Credit Facility”). The Revolving Credit Facility matures on June 16, 2027, unless
extended. Prior to the maturity date, the Company may request a one-year extension of the facility (not to exceed
a total of two years beyond the initial maturity date). We have the ability to increase our borrowing up to an
additional $750.0, subject to lender commitments and certain conditions as described in the Credit Agreement.
Borrowings under the Credit Agreement are available for general corporate purposes and are used to support our
$1,500.0 commercial paper program.

The Revolving Credit Facility also contains customary events of default, including failure to make certain

payments under the Term Loan Facility when due beyond the grace period, event of default on other material
indebtedness, breach of covenants, materially incorrect representations and warranties, events of bankruptcy,
material adverse judgments, certain events relating to pension plans, the failure of any of the loan documents to
remain in full force and effect and the occurrence of any change in control with respect to the Company.

11. Income Taxes

The components of income before taxes are as follows:

Domestic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$872.4
95.0

$447.1
76.2

$ 958.6
73.1

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$967.4

$523.3

$1,031.7

2023

2022

2021

The following table summarizes the provision for U.S. federal, state and foreign income taxes:

Current:

U.S. federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$159.1
40.9
25.6

$162.0
44.8
20.3

$130.6
34.1
19.2

2023

2022

2021

Deferred:

U.S. federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

225.6

227.1

183.9

(11.3)
(2.8)
0.3

(78.8)
(38.3)
(0.6)

(13.8)

(117.7)

16.5
4.5
(0.7)

20.3

Total provision . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$211.8

$109.4

$204.2

85

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

Deferred tax assets (liabilities) consist of the following at December 31, 2023 and 2022:

Deferred tax assets:
Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pension, postretirement and postemployment benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventory reserve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sec 174 R&D Capitalization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tax credit carryforwards/other tax attributes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
International operating loss carryforwards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total gross deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Valuation allowances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Deferred tax liabilities:
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Trade names and other intangibles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property, plant and equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest rate swaps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2023

2022

$ 10.1
50.7
4.8
9.0
41.9
2.6
9.0
9.9

$

8.9
46.9
5.0
8.8
22.0
2.8
8.8
7.3

138.0
(9.8)

128.2

110.5
(9.4)

101.1

(285.7)
(496.3)
(81.1)
(4.1)

(272.1)
(504.5)
(74.2)
(4.5)

Total deferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(867.2)

(855.3)

Net deferred tax liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$(739.0) $(754.2)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long term net deferred tax asset
Long term net deferred tax liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4.1
(743.1)

2.8
(757.0)

Net deferred tax liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$(739.0) $(754.2)

The difference between tax expense and the tax that would result from the application of the federal

statutory rate is as follows:

Statutory rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tax that would result from use of the federal statutory rate . . . . . . . . . . . . . . . . . . . . .
State and local income tax, net of federal effect
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Varying tax rates of foreign affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Valuation Allowances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stock Options Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Reserve for Uncertain Tax Position . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2023

2022

2021

21% 21%

21%

$203.1
30.1
6.8
0.0
(21.8)
(0.3)
(6.1)

$109.9
5.2
2.9
(4.1)
(5.2)
(0.9)
1.6

$216.6
30.5
2.6
(8.5)
(29.0)
0.0
(8.0)

Recorded tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$211.8

$109.4

$204.2

Effective tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

21.9% 20.9% 19.8%

At December 31, 2023, certain foreign subsidiaries of the Company had net operating loss carryforwards of

approximately $9.0. The net operating loss carryforwards are not subject to expiration. The Company believes

86

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

that it is more likely than not that the benefit from these net operating loss carryforwards will not be realized. In
recognition of this risk, the Company has provided a valuation allowance of $9.0 and $8.9 at December 31, 2023
and 2022, respectively, on the deferred tax asset relating to these net operating loss carryforwards.

The Company also believes that it is more likely than not that the benefit from certain additional deferred

tax assets of a foreign subsidiary will not be realized. In recognition of this risk, the Company maintains a
valuation allowance of $0.8 and $0.5 at December 31, 2023 and 2022, respectively, on these deferred tax
assets.

As of December 31, 2020 the Company maintained a valuation allowance of $12.6 relating to certain
foreign tax credit carryforwards. During 2021, the Company determined that it was able to utilize approximately
$8.5 in foreign tax credits in 2018, 2019, and 2020, resulting in a reduction in the valuation allowance, and a
corresponding tax benefit. Accordingly, the Company filed amended returns with the Internal Revenue Service
claiming refunds for 2018 and 2019, totaling $6.5, and utilized $2.0 of foreign tax credits in 2020. During 2022,
the Company determined that it was able to utilize the remaining foreign tax credit carryforwards in 2022 and
future years. This resulted in a reduction of the remaining valuation allowance and a corresponding tax benefit of
approximately $4.0. The Company has received the refunds related to 2018 and 2019. The Company does not
have any undistributed earnings of foreign subsidiaries that are considered to be indefinitely reinvested outside of
the U.S.

The Company has recorded liabilities in connection with uncertain tax positions, which, although

supportable by the Company, may be challenged by tax authorities.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

Unrecognized tax benefits at January 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross increases—tax positions in current period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross increases—tax positions in prior period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross decreases—tax positions in prior period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Decreases due to settlements and payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lapse of statute of limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2023

2022

2021

$ 5.8
0.0
0.0
0.0
0.0
(0.7)

$ 4.7
2.4
0.0
(0.1)
0.0
(1.2)

$ 7.3
0.3
0.8
0.0
0.0
(3.7)

Unrecognized tax benefits at December 31 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 5.1

$ 5.8

$ 4.7

Included in the balance of unrecognized tax benefits at December 31, 2023, 2022 and 2021 are $4.2, $4.8

and $4.1, respectively, of tax benefits that, if recognized, would affect the effective tax rate. Also included in the
balance of unrecognized tax benefits at December 31, 2023, 2022 and 2021 are $0.9, $1.0 and $0.6, respectively,
of tax benefits that, if recognized, would result in adjustments to deferred taxes.

The Company is subject to U.S. federal income tax as well as income tax in multiple state and international

jurisdictions. The Company’s U.S. federal income tax returns are closed for tax years through 2019. The
Company is currently under audit by several state taxing authorities for the years 2017 through 2021. It is
reasonably possible that a decrease of approximately $0.5 in the unrecognized tax benefits may occur within the
next twelve months related to the settlement of these audits or the lapse of applicable statutes of limitations.

87

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

The Company’s policy for recording interest associated with income tax examinations is to record interest

as a component of Income before Income Taxes. During the twelve months ended December 31, 2023, 2022, and
2021, the Company recognized interest expense associated with uncertain tax positions of approximately $0.3,
$0.1 and $0.5, respectively. As of December 31, 2023, 2022, and 2021, the Company had accrued interest
expense related to unrecognized tax benefits of $0.9, $0.7 and $0.5, respectively.

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (the “Act”), which

contains provisions effective January 1, 2023, including a 15% corporate minimum tax and a 1% excise tax on
stock buybacks. The law did not have any material impacts on the Company’s consolidated financial position,
results of operations or cash flows during the year ended December 31, 2023.

12. Stock Based Compensation Plans and Other Benefit Plans

In the first quarter of 2023, the Company updated its Long-Term Incentive Program (“LTIP”) to provide

employees with an award of stock options and initial grants of restricted stock units (“RSUs”), and made an
initial grant of performance share units (“PSUs”) to members of the Company’s Executive Leadership Team
(“ELT”). In connection with this update, the awards, which were granted in the second quarter in previous years,
were granted in the first quarter of 2023 and are expected to be granted in the first quarter in subsequent
years. The Company recognizes the grant-date fair value for each of these awards, less estimated forfeitures, as
compensation expense ratably over the vesting period. For employees and Directors that meet retirement
eligibility requirements, the expense related to share-based compensation is recognized on the date of grant as
there is no future service period required to vest in the awards.

Stock Options

The Company has non-qualified options outstanding under the LTIP. Stock options outstanding are issued at

market value on the date of grant, vest on the third anniversary of the date of grant and must be exercised within
10 years of the date of grant.

However, upon a participant’s termination of employment (other than termination for cause, death,

disability or retirement), a participant will generally have 30 days (90 days for grants made after May 13, 2022)
to exercise any vested stock options, subject to specified conditions. If, upon termination of a participant’s
employment (other than a termination for cause), a participant is at least 55 years old, has at least five years of
service, and the sum of the participant’s age and years of service is at least 65, the participant may exercise any
vested stock options granted between 2007 through 2017 within a period of three years from the date of
termination or, if earlier, the date such stock options otherwise would have expired, subject to specified
conditions. Starting with stock options granted in 2018, a terminated employee who meets the above conditions
may exercise any stock options until the date such stock options otherwise would have expired, subject to
specified conditions. Issuances of Common Stock to satisfy employee stock option exercises currently are made
from treasury stock.

88

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

Stock option transactions for the year ended December 31, 2023 were as follows:

Outstanding as of December 31, 2022 . . . . . . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cancelled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Options

11.9
1.0
(2.5)
(0.2)

Outstanding as of December 31, 2023 . . . . . . . . . . . . . . . . . . . . . . . .

10.2

Weighted
Average
Exercise
Price

$62.64
83.64
44.72
81.33

$68.77

Exercisable as of December 31, 2023 . . . . . . . . . . . . . . . . . . . . . . . .

6.4

$59.26

Weighted
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value

5.8

4.3

$265.1

$226.4

The following table summarizes information relating to options outstanding and exercisable as of

December 31, 2023:

Range of Exercise Prices

$30.01 - $40.00
$40.01 - $50.00
$50.01 - $60.00
$60.01 - $70.00
$70.01 - $80.00
$80.01 - $90.00
$90.01 - $100.00

. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .

Options Outstanding

Options Exercisable

Outstanding
as of
12/31/2023

Weighted
Average
Remaining
Contractual Life

Weighted
Average
Exercise
Price

Exercisable
as of
12/31/2023

Weighted
Average
Exercise
Price

0.2
1.3
2.3
0.0
2.5
3.8
0.1

10.2

0.5
2.1
4.0
0.0
6.0
8.3
8.1

5.8

$34.81
$44.25
$51.85
0.0
$
$75.33
$84.35
$94.13

$68.77

0.2
1.3
2.3
0.0
2.5
0.0
0.1

6.4

$34.81
$44.25
$51.85
0.0
$
$75.33
$
0.0
$90.83

$59.26

The table above represents the Company’s estimate of stock options fully vested and expected to vest.

Expected forfeitures are not material and, therefore, are not reflected in the table above.

The following table provides information regarding the intrinsic value of stock options exercised and stock

compensation expense related to stock option awards:

Intrinsic Value of Stock Options Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stock Compensation Expense Related to Stock Option Awards . . . . . . . . . . . . . . . . . .
Issued Stock Options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
Weighted Average Fair Value of Stock Options issued (per share)
Fair Value of Stock Options Issued . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$125.5
$ 26.3
1.0
$24.06
$ 24.9

$ 32.1
$ 25.7
1.6
$21.50
$ 33.6

$157.3
$ 23.3
1.5
$17.32
$ 26.6

2023

2022

2021

89

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

The following table provides a summary of the assumptions used in the valuation of issued stock options:

Risk-free interest rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected life in years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected volatility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dividend yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4.0% 2.9% 1.3%
7.3
7.1
22.4%21.7% 20.7%
1.3% 1.2% 1.2%

7.2

2023

2022

2021

The fair value of stock options is based upon the Black Scholes option pricing model. The Company
determined the stock options’ lives based on historical exercise behavior and their expected volatility and
dividend yield based on the historical changes in stock price and dividend payments. The risk-free interest rate is
based on the yield of an applicable term Treasury instrument.

As of December 31, 2023, there was a fair value of $19.1 related to unamortized stock option compensation
expense, which is expected to be recognized over the next three years. The Company’s Consolidated Statements
of Cash Flow reflect an add back related to stock option awards of $26.3, $25.7 and $23.3 in 2023, 2022 and
2021, respectively, for non-cash compensation expense.

Restricted Stock Units

The Company granted employees 120,080 RSUs with a total fair value of $10.4 at a weighted average grant

date fair value of $86.20 per RSU during the year ended December 31, 2023. The annual RSU grants vest
one-third on each of the first, second and third anniversaries of the grant date, subject to the recipient’s continued
employment with the Company from the grant date through the applicable vesting date, and are settled with
shares of the Company’s Common Stock within 60 days following the applicable vesting date.

Additionally, in connection with the Hero Acquisition (see Note 6), 854,882 shares of restricted stock were
issued in October 2022 with a total fair value of $61.5. The restricted stock will be recognized as compensation
expense as the stock is subject to vesting requirements for individuals who received the restricted stock and will
continue to be employed by the Company. The vesting requirements are satisfied at various dates over a three-
year period from the date of the acquisition. The restricted stock expense associated with the Hero Acquisition
for the twelve months ended December 31, 2023 and 2022 was $29.2 and $6.0, respectively, and is included in
the non-cash compensation expense caption in the consolidated statement of cash flows.

In January 2021, the Company issued cash-settled stock units under the Omnibus Equity Plan to all
employees at the level of vice president and below. These restricted stock units are scheduled to vest and be
settled on the third anniversary of the date of grant, subject to continued employment through such date.

As a result of the issued cash-settled stock units, the Company recorded stock compensation expense of
$1.3, $0.3 and $1.9 in 2023, 2022 and 2021, respectively. The liability was approximately $3.5 and $2.2 as of
December 31, 2023 and 2022, respectively.

Performance Stock Units

In the first quarter of 2023, the Company granted PSUs to members of the ELT including the CEO, with an

aggregate award fair value equal to $2.2. 19,650 PSUs were issued at a weighted average grant date fair value
equal to $110.95 per PSU using a Monte Carlo model. The performance target is based on the Company’s total
shareholder return (“TSR”) relative to a Company selected peer group. The PSUs vest on the later of (i) the third
anniversary of the grant date, and (ii) the date that the Compensation & Human Capital Committee certifies the

90

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

achievement of the applicable performance goals, in each case, subject to the recipient’s continued employment
with the Company from the grant date through the vesting date. The number of shares that may be issued ranges
from 0% to 200% based on relative TSR during the three-year performance period. Vested PSUs will be settled
into shares of the Company’s Common Stock, if at all, within 60 days following the vesting date.

Other Benefit Plans

Deferred Compensation Plans

The Company maintains a non-qualified deferred compensation plan under which certain members of
management are eligible to defer a maximum of 85% of their regular compensation (i.e., salary) and, in general,
up to 85% of their incentive bonus. As of January 1, 2024, the limit was decreased from 85% to a maximum of
70% for both regular compensation and incentive bonus. The amounts deferred under this plan are credited with
earnings or losses based upon changes in values of notional investments selected by the plan participant. The
investment options available include notional investments in various stock, bond and money market funds as well
as the Company’s Common Stock. Each plan participant is fully vested in the amounts the participant defers. The
plan permits the Company to make profit sharing contributions that cannot otherwise be contributed to the
qualified savings and profit-sharing plan due to limitations established by the Internal Revenue Service. These
contributions vest under the same vesting schedule applicable to the qualified plan.

The liability to plan participants for contributions designated for notional investment in Common Stock is
based on the quoted fair value of the Common Stock plus any dividends credited. The Company uses cash-settled
hedging instruments to minimize the cost related to the volatility of Common Stock. At December 31, 2023 and
2022, the amount of the Company’s liability under the deferred compensation plan is included in Current and
Deferred and Other Long-term Liabilities and was $118.2 and $105.8, respectively and the funded balances
recorded in Other Assets amounted to $112.9 and $92.6, respectively. The amounts charged to earnings,
including the effect of the hedges, totaled expense of $3.7, $1.2 and $2.2 in 2023, 2022 and 2021, respectively.

Non-employee members of the Company’s Board are eligible to defer up to 100% of their directors’
compensation into a similar plan; however, the only option for investment is Common Stock. Members of the
Board are fully vested in their account balance. As of December 31, 2023, there were approximately 109,000
shares of Common Stock from shares held as Treasury Stock in a rabbi trust to protect the interest of the
directors’ deferred compensation plan participants in the event of a change of control.

13. Share Repurchases

On November 1, 2017, the Board authorized a share repurchase program, under which the Company may

repurchase up to $500.0 in shares of Common Stock (the “2017 Share Repurchase Program”).

In August 2021, the Company executed an agreement to purchase up to $200.0 of its Common Stock
through October 31, 2021. The Company purchased 1.6 million shares for approximately $130.0 through
October, inclusive of fees, all of which was purchased under the 2017 Share Repurchase Program.

On October 28, 2021, the Board authorized a new share repurchase program, under which the Company

may repurchase up to $1,000.0 in shares of Common Stock (the “2021 Share Repurchase Program”). The 2021
Share Repurchase Program does not have an expiration and replaced the 2017 Share Repurchase Program. All
remaining dollars authorized for repurchase under the 2017 Share Repurchase Plan have been cancelled. The
2021 Share Repurchase Program did not modify the Company’s evergreen share repurchase program, authorized
by the Board on January 29, 2014, under which the Company may repurchase, from time to time, Common Stock
to reduce or eliminate dilution associated with issuances of Common Stock under its incentive plans.

91

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

In December 2021, the Company executed open market purchases of 1.8 million shares for $170.3, inclusive

of fees, of which $100.0 was purchased under the evergreen share repurchase program and $70.3 was purchased
under the 2021 Share Repurchase Program. In December 2021, the Company also entered into an accelerated
share repurchase (“ASR”) contract with a commercial bank to purchase Common Stock. The Company paid
$200.0 to the bank, inclusive of fees, and received an initial delivery of shares equal to $180.0, or 1.8 million
shares. The Company used cash on hand and short-term borrowings to fund the initial purchase price. Upon the
completion of the ASR, which ended in February 2022, the bank delivered an additional 0.2 million shares to the
Company. The final shares delivered to the Company were determined by the average price per share paid by the
bank during the purchase period. All 2.0 million shares were purchased under the 2021 Share Repurchase
Program.

In November 2023, the Company executed an agreement to purchase 3.3 million shares for $300.1,
inclusive of fees, of which $229.3 was purchased under the evergreen share repurchase program and $70.8 was
purchased under the 2021 Share Repurchase Program.

As a result of the Company’s stock repurchases, there remains $658.9 of share repurchase availability under

the 2021 Share Repurchase Program as of December 31, 2023.

14. Accumulated Other Comprehensive Income (Loss)

Comprehensive income is defined as net income and other changes in stockholders’ equity from transactions

and other events from sources other than stockholders.

The components of changes in accumulated other comprehensive income (“AOCI”) are as follows:

Foreign
Currency
Adjustments

Defined
Benefit
Plans

Derivative
Agreements

Accumulated
Other
Comprehensive
Income (Loss)

Balance December 31, 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $(26.4)
(3.8)
Other comprehensive income before reclassifications . . . . . . . . . . .
0.0
Amounts reclassified to consolidated statement of income(a) . . . . . .
0.0
Tax benefit (expense) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . .

(3.8)

Balance December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $(30.2)
(16.2)
Other comprehensive income (loss) before reclassifications . . . . . .
0.0
Amounts reclassified to consolidated statement of income(a) . . . . . .
0.0
Tax benefit (expense) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 0.0
(0.8)
0.0
0.2

(0.6)

$(0.6)
3.1
0.0
(0.8)

$(51.2)
26.7
(8.2)
(4.7)

13.8

$(37.4)
72.6
(2.5)
(17.3)

Other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . .

(16.2)

2.3

52.8

Balance December 31, 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $(46.4)
8.6
Other comprehensive income (loss) before reclassifications . . . . . .
0.0
Amounts reclassified to consolidated statement of income(a) . . . . . .
0.0
Tax benefit (expense) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . .

8.6

$ 1.7
3.9
0.0
(1.0)

2.9

$ 15.4
(4.9)
(7.3)
2.8

(9.4)

$(77.6)
22.1
(8.2)
(4.5)

9.4

$(68.2)
59.5
(2.5)
(18.1)

38.9

$(29.3)
7.6
(7.3)
1.8

2.1

Balance December 31, 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $(37.8)

$ 4.6

$ 6.0

$(27.2)

(a) Amounts reclassified to cost of sales, selling, general and administrative expenses, or interest expense.

92

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

15. Commitments, Contingencies and Guarantees

Commitments

a. The Company has a partnership with a supplier of raw materials that mines and processes sodium-based
mineral deposits. The Company purchases the majority of its sodium-based raw material requirements from the
partnership. The partnership agreement terminates upon two years’ written notice by either partner. Under the
partnership agreement, the Company has an annual commitment to purchase 240,000 tons of sodium-based raw
materials at the prevailing market price. The Company is not engaged in any other material transactions with the
partnership or the partner supplier.

b. As of December 31, 2023, the Company had commitments of approximately $369.6. These commitments

include the purchase of raw materials, packaging supplies and services from its vendors at market prices to
enable the Company to respond quickly to changes in customer orders or requirements, as well as costs
associated with licensing and promotion agreements.

c. As of December 31, 2023, the Company had various guarantees and letters of credit totaling $6.1.

d. In connection with the December 1, 2020 acquisition of the ZICAM® brand (the “Zicam Acquisition”),
the Company deferred an additional cash payment of $20.0 related to certain indemnifications provided by the
seller. The additional amount is payable five years from the closing.

In connection with the December 24, 2021 TheraBreath Acquisition, the Company deferred an additional

cash payment of $14.0 related to certain indemnity obligations provided by the seller. The additional amount, to
the extent not used in satisfaction of such indemnity obligations, is payable in installments between two and four
years from the closing, with the first installment payment of $2.0 paid in January 2024.

In connection with the October 13, 2022 Hero Acquisition, the Company deferred an additional cash
payment of $8.0 to satisfy certain indemnification obligations. The additional amount is payable five years from
the closing.

e. In addition, in conjunction with the Company’s acquisition and divestiture activities, the Company

entered into select guarantees and indemnifications of performance with respect to the fulfillment of the
Company’s commitments under applicable purchase and sale agreements. The arrangements generally indemnify
the buyer or seller for damages associated with breach of contract, inaccuracies in representations and warranties
surviving the closing date and satisfaction of liabilities and commitments retained under the applicable contract.
Representations and warranties that survive the closing date generally survive for periods up to five years or the
expiration of the applicable statutes of limitations. Potential losses under the indemnifications are generally
limited to a portion of the original transaction price, or to other lesser specific dollar amounts for select
provisions. With respect to sale transactions, the Company also routinely enters into non-competition agreements
for varying periods of time. Guarantees and indemnifications with respect to acquisition and divestiture activities,
if triggered, could have a materially adverse impact on the Company’s financial condition, results of operations
and cash flows.

Legal proceedings

f. In addition to the matters described above, from time to time in the ordinary course of its business the
Company is the subject of, or party to, various pending or threatened legal, regulatory or governmental actions or

93

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

other proceedings, including, without limitation, those relating to, intellectual property, commercial transactions,
product liability, purported consumer class actions, employment matters, antitrust, environmental, health, safety
and other compliance related matters. Such proceedings are generally subject to considerable uncertainty and
their outcomes, and any related damages, may not be reasonably predictable or estimable. Any such proceedings
could result in a material adverse outcome negatively impacting the Company’s business, financial condition,
results of operations or cash flows.

16. Related Party Transactions

The following summarizes the balances and transactions between the Company and each of Armand and

ArmaKleen, in which the Company holds a 50% ownership interest:

Armand

Year Ended
December 31,

ArmaKleen

Year Ended
December 31,

2023

2022

2021

2023

2022

2021

Purchases by Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sales by Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Outstanding Accounts Receivable . . . . . . . . . . . . . . . . . . . . . . . . . . .
Outstanding Accounts Payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . .
Administration & Management Oversight Services(1)

$14.9
$ 0.0
$ 1.6
$ 0.8
$ 2.3

$13.7
$ 0.0
$ 0.9
$ 1.0
$ 2.2

$12.9
$ 0.0
$ 1.0
$ 1.2
$ 2.2

$0.0
$1.4
$1.4
$0.0
$2.1

$0.0
$0.9
$1.1
$0.0
$2.0

$0.0
$1.2
$0.9
$0.0
$2.1

(1) Billed by Company and recorded as a reduction of SG&A expenses.

17. Segments

Segment Information

The Company operates three reportable segments: Consumer Domestic, Consumer International and
Specialty Products Division. These segments are determined based on differences in the nature of products and
organizational and ownership structures. The Company also has a Corporate segment.

Segment revenues are derived from the sale of the following products:

Segment

Consumer Domestic
Consumer International
SPD

Products

Household and personal care products
Primarily personal care products
Specialty chemical products

The Corporate segment income consists of equity in earnings of affiliates. As of December 31, 2023, the
Company held 50% ownership interests in each of Armand and ArmaKleen, respectively. The Company’s equity
in earnings of Armand and ArmaKleen, totaling $8.7, $12.3, and $9.4 for the three years ending December 31,
2023, 2022 and 2021, respectively, are included in the Corporate segment.

Certain subsidiaries that are included in the Consumer International segment manufacture and sell personal

care products to the Consumer Domestic segment. These sales are eliminated from the Consumer International
segment results set forth in the table below.

94

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

The following table presents selected financial information relating to the Company’s segments for each of

the three years in the period ended December 31, 2023:

Consumer
Domestic

Consumer
International

SPD

Corporate(1) As Reported

Net sales
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross profit
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Marketing Expenses
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, General and Administrative Expenses
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income from Operations
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity in Earnings of Affiliates
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income Before Income Taxes
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Identifiable Assets
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Capital Expenditures
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation & Amortization
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$4,571.2
4,131.0
3,941.9

$ 975.7
896.1
912.2

2,137.2
1,794.1
1,795.8

509.5
412.9
442.1

698.0
882.1
445.3

929.7
499.1
908.4

0.0
0.0
0.0

842.7
427.3
861.4

407.0
372.4
402.1

127.7
117.7
131.1

175.1
208.5
135.7

104.2
46.2
135.3

0.0
0.0
0.0

94.8
38.8
127.3

7,011.4
6,846.9
6,354.5

1,106.1
1,060.5
1,192.9

190.0
159.1
100.3

182.7
172.1
170.0

20.4
10.0
8.4

27.7
30.1
31.1

$321.0
348.5
336.0

104.7
117.8
112.7

4.1
4.6
4.5

77.1
60.7
72.8

23.5
52.5
35.4

0.0
0.0
0.0

21.2
44.9
33.6

326.8
332.9
332.7

13.1
9.7
10.1

13.6
13.8
15.4

$

0.0
0.0
0.0

(60.4)
(34.3)
(47.1)

0.0
0.0
0.0

(60.4)
(34.3)
(47.1)

0.0
0.0
0.0

8.7
12.3
9.4

8.7
12.3
9.4

124.9
105.3
116.4

0.0
0.0
0.0

1.2
3.0
2.6

$5,867.9
5,375.6
5,190.1

2,588.5
2,250.0
2,263.5

641.3
535.2
577.7

889.8
1,117.0
606.7

1,057.4
597.8
1,079.1

8.7
12.3
9.4

967.4
523.3
1,031.7

8,569.2
8,345.6
7,996.5

223.5
178.8
118.8

225.2
219.0
219.1

(1)

Corporate reflects the following:
(A) The administrative costs of the production planning and logistics functions which are elements of Cost of
Sales in the Company’s Consolidated Statements of Income but are allocated to the operating segments in
Selling, General and Administrative expenses to determine operating segment income before income
taxes. Such amounts were $60.4, $34.3, and $47.1 for 2023, 2022 and 2021, respectively. The increase in
2023 compared to 2022 is primarily due to higher incentive compensation costs.

95

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(In millions, except share and per share data)

(B) Equity in earnings (loss) of affiliates from Armand and ArmaKleen for the year ended December 31,

2023, 2022 and 2021.

(C) Corporate assets include deferred compensation investments and the Company’s investment in

unconsolidated affiliates.

Other than the differences noted in the footnote above, the accounting policies followed by each of the
segments, including intersegment transactions, are substantially consistent with the accounting policies described
in Note 1.

Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table

above, were $17.0, $15.1 and $10.8 for the twelve months ended December 31, 2023, 2022 and 2021,
respectively.

Product line revenues from external customers for each of the three years ended December 31, 2023, 2022

and 2021 were as follows:

Household Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Personal Care Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$2,484.1
2,087.1

$2,272.0
1,859.0

$2,103.0
1,838.9

Total Consumer Domestic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total Consumer International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total SPD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4,571.2
975.7
321.0

4,131.0
896.1
348.5

3,941.9
912.2
336.0

Total Consolidated Net Sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$5,867.9

$5,375.6

$5,190.1

2023

2022

2021

Household Products include laundry, deodorizing, and cleaning products. Personal Care Products include

condoms, pregnancy kits, oral care products, skin care products, hair care products and gummy dietary
supplements.

Geographic Information

Approximately 83%, 83% and 82% of the net sales reported in the accompanying consolidated financial
statements in 2023, 2022 and 2021, respectively, were to customers in the U.S. Approximately 96%, 97% and
96% of long-lived assets were located in the U.S. at December 31, 2023, 2022 and 2021, respectively. Other than
the U.S., no one country accounts for more than 5% of consolidated net sales and 5% of total assets.

Customers

A group of four customers accounted for approximately 44% and 42% of consolidated net sales in 2023 and

2022, respectively. A group of three customers accounted for approximately 37% of consolidated net sales in
2021, of which a single customer (Walmart Inc. and its affiliates) accounted for approximately 23%, 24% and
24% in 2023, 2022 and 2021, respectively.

96

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND

FINANCIAL DISCLOSURE

Not applicable.

ITEM 9A. CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief
Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in
Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at
the end of the period covered by this Annual Report. Based on that evaluation, the Chief Executive Officer and
Chief Financial Officer concluded that the Company’s disclosure controls and procedures as of the end of the
period covered by this Annual Report are effective to provide reasonable assurance that the information required
to be disclosed by the Company in reports filed under the Exchange Act are (i) recorded, processed, summarized
and reported within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and
communicated to the Company’s management, including the Chief Executive Officer and Chief Financial
Officer, as appropriate to allow timely decisions regarding the disclosure.

b) Management’s Report on Internal Control Over Financial Reporting

The Company’s management’s report on internal control over financial reporting is set forth in Item 8 of

this Annual Report and is incorporated by reference herein. The Company’s independent registered public
accounting firm has issued an audit report on the effectiveness of the Company’s internal control over financial
reporting, which is set forth in Item 8 of this Annual Report.

c) Change in Internal Control over Financial Reporting

No change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and
15d-15(f) under the Exchange Act) occurred during the Company’s most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

(c) During the quarter ended December 31, 2023, no director or officer (as defined in Rule 16a-1(f) under
the Exchange Act) of the Company adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule
10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT

INSPECTIONS

Not applicable.

97

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Information required by this item is incorporated by reference to the information under the captions
“Election of Directors,” “Information about the Company’s Executive Officers,” “Corporate Governance and
Other Board Matters – Code of Conduct,” and “Corporate Governance and Other Board Matters– Board of
Directors Meetings and Committees – Audit Committee,” in the Company’s definitive proxy statement, which
will be filed with the Commission not later than 120 days after the close of the fiscal year covered by this Annual
Report.

ITEM 11. EXECUTIVE COMPENSATION

Information required by this item is incorporated by reference to the information under the captions
“Compensation Discussion and Analysis,” “2023 Summary Compensation Table,” “2023 Grants of Plan Based
Awards,” “2023 Outstanding Equity Awards at Fiscal Year-End,” “2023 Option Exercises and Stock Vested,”
“2023 Nonqualified Deferred Compensation,” “Potential Payments Upon Termination or Change in Control” and
“Compensation & Human Capital Committee Report” in the Company’s definitive proxy statement, which will
be filed with the Commission not later than 120 days after the close of the fiscal year covered by this Annual
Report.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

AND RELATED STOCKHOLDER MATTERS

Information required by this item is incorporated by reference to the information under the captions “Equity

Compensation Plan Information as of December 31, 2023” and “Securities Ownership of Certain Beneficial
Owners and Management” in the Company’s definitive proxy statement, which will be filed with the
Commission not later than 120 days after the close of the fiscal year covered by this Annual Report.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR

INDEPENDENCE

Information required by this item is incorporated by reference to the information under the caption
“Corporate Governance and other Board Matters – Board of Directors Independence” in the Company’s
definitive proxy statement, which will be filed with the Commission not later than 120 days after the close of the
fiscal year covered by this Annual Report.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Information required by this item in relation to our principal accountant, Deloitte & Touche LLP (PCAOB

ID No. 34) is incorporated by reference to the information under the caption “Fees Paid to Independent
Registered Public Accounting Firm” in the Company’s definitive proxy statement, which will be filed with the
Commission not later than 120 days after the close of the fiscal year covered by this Annual Report.

98

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

PART IV

(a) 1. Financial Statements and Schedule

The following Consolidated Financial Statements are included in Item 8 of this Form 10-K:

Consolidated Statements of Income for each of the three years in the period ended December 31,

2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Balance Sheets as of December 31, 2023 and 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Cash Flow for each of the three years in the period ended December 31,

2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Consolidated Statements of Stockholders’ Equity for each of the three years in the period ended

December 31, 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Schedule II - Valuation and Qualifying Accounts for each of the three years in the period ended

61
62

63

65
66

December 31, 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

106

(a) 3. Exhibits

Unless otherwise noted, the file number for all the Company’s filings with the Securities and Exchange

Commission referenced below is 1-10585.

(3.1) Amended and Restated Certificate of Incorporation of the Company, incorporated by reference to
Exhibit 3.1 to the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2020.

(3.2) Amendment to the Company’s Amended and Restated Certificate of Incorporation, incorporated
by reference to Exhibit 3.1 to the Company’s current report on Form 8-K filed on April 30, 2021.

(3.3) By-laws of the Company, amended and restated as of April 27, 2023, incorporated by reference to

Exhibit 3.1 to the Company’s current report on Form 8-K filed on April 28, 2023.

(4.1)

(4.2)

(4.3)

(4.4)

(4.5)

Indenture, dated as of December 15, 2010, between Church & Dwight Co., Inc. and The Bank of
New York Mellon Trust Company, N.A., as trustee, relating to the 2.875% Notes due 2022,
incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K filed on
December 15, 2010.

Second Supplemental Indenture, dated as of September 26, 2012, between Church & Dwight Co.,
Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to the 2.875%
Notes due 2022, incorporated by reference to Exhibit 4.2 to the Company’s current report on
Form 8-K filed on September 26, 2012.

Indenture, dated as of December 9, 2014, between Church & Dwight Co., Inc. and Wells Fargo
Bank, National Association, as trustee, incorporated by reference to Exhibit 4.1 to the Company’s
current report on Form 8-K filed on December 9, 2014.

Second Supplemental Indenture, dated as of July 25, 2017, between Church & Dwight Co., Inc.
and Wells Fargo Bank, National Association, as trustee, relating to the Notes, incorporated by
reference to Exhibit 4.2 of the Company’s current report on Form 8-K filed on July 25, 2017.

Indenture, dated as of December 10, 2021, between Church and Dwight Co., Inc. and Deutsche
Bank Trust Company Americas, as trustee, relating to the Notes, incorporated by reference to
Exhibit 4.1 to the Company’s current report on Form 8-K filed on December 10, 2021.

99

(4.6)

(4.7)

(4.8)

(4.9)

(10.1)

(10.2)

(10.3)

(10.4)

(10.5)

(10.6)

First Supplemental Indenture, dated as of December 10, 2021, between Church & Dwight Co.,
Inc. and Deutsche Bank Trust Company Americas, as trustee, relating to the Notes, incorporated
by reference to Exhibit 4.2 to the Company’s current report on Form 8-K filed on December 10,
2021.

Second Supplemental Indenture, dated as of June 2, 2022, between Church & Dwight Co., Inc.
and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to Exhibit 4.2
to the Company’s current report on Form 8-K filed on June 2, 2022.

Third Supplemental Indenture, dated as of November 2, 2022, between Church & Dwight Co.,
Inc. and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to Exhibit
4.2 to the Company’s current report on Form 8-K filed on November 2, 2022.

Description of Registrant’s Securities, incorporated by reference to Exhibit 4.5 to the Company’s
annual report on Form 10-K for the year ended December 31, 2019.

Credit Agreement dated June 16, 2022, among Church & Dwight Co., Inc., the initial lenders
named therein, Bank of America, N.A., as lead administrative agent, swing line lender, and L/C
issuer, Wells Fargo Bank, National Association, as co-administrative agent and syndication agent,
and Truist Bank, as syndication agent incorporated by reference to Exhibit 10.1 of the Company’s
Current Report on Form 8-K filed on June 21, 2022.

Term Credit Agreement dated December 22, 2021, by and among Church & Dwight Co., Inc. the
lenders party thereto, and Bank of America, N.A., as administrative agent, incorporated by
reference to Exhibit 10.2 to the Company’s annual report on Form 10-K for the year ended
December 31, 2022.

First Amendment to Credit Agreement dated June 16, 2022, among Church & Dwight Co., Inc.,
the lenders named therein, and Bank of America, N.A., as administrative agent incorporated by
reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed on June 21, 2022.

Form of Commercial Paper Dealer Agreement, dated February 23, 2017, by and between
Church & Dwight Co., Inc. and Dealer, incorporated by reference to Exhibit 10.2 to the
Company’s annual report on Form 10-K for the year ended December 31, 2016.

Form of Amended and Restated Commercial Paper Dealer Agreement, dated February 23, 2017,
by and between Church & Dwight Co., Inc. and Dealer, incorporated by reference to Exhibit 10.3
to the Company’s annual report on Form 10-K for the year ended December 31, 2016.

Stock Purchase Agreement, dated as of July 17, 2017, among Church & Dwight Co., Inc., PIK
Holdings, Inc., the Representative and the stockholders party thereto, incorporated by reference to
Exhibit 2.1 of the Company’s current report on Form 8-K filed on July 17, 2017.

* (10.7)

* (10.8)

* (10.9)

Church & Dwight Co., Inc. Executive Deferred Compensation Plan, effective as of June 1, 1997,
incorporated by reference to Exhibit 10(f) to the Company’s annual report on Form 10-K for the
year ended December 31, 1997.

Amendment to the Church & Dwight Co., Inc. Executive Deferred Compensation Plan, effective
January 1, 2007, incorporated by reference to Exhibit 10.4.1 to the Company’s annual report on
Form 10-K for the year ended December 31, 2011.

Amendment to the Church & Dwight Co., Inc. Executive Deferred Compensation Plan, effective
February 1, 2012, incorporated by reference to Exhibit 10.4.2 to the Company’s annual report on
Form 10-K for the year ended December 31, 2011.

* (10.10)

Amendment to the Church & Dwight Co., Inc. Executive Deferred Compensation Plan II, dated
July 25, 2023, incorporated by reference to Exhibit 10.3 to the Company’s quarterly report on
Form 10-Q for the quarter ended September 30, 2023.

100

• * (10.11)

Amendment to the Church & Dwight Co., Inc. Executive Deferred Compensation Plan II, dated
January 10, 2024

* (10.12)

* (10.13)

* (10.14)

* (10.15)

* (10.16)

* (10.17)

* (10.18)

* (10.19)

* (10.20)

* (10.21)

* (10.22)

* (10.23)

* (10.24)

* (10.25)

Church & Dwight Co., Inc. Executive Deferred Compensation Plan II, amended and restated as of
January 1, 2012, incorporated by reference to Exhibit 10.5 to the Company’s annual report on
Form 10-K for the year ended December 31, 2011.

Deferred Compensation Plan for Directors effective as of May 1, 2008, incorporated by reference
to Exhibit 10.5 to the Company’s quarterly report on Form 10-Q for the quarter ended March 28,
2008.

Amended and Restated Compensation Plan for Directors, effective January 1, 2015, incorporated
by reference to Exhibit 10.7 to the Company’s annual report on Form 10-K for the year ended
December 31, 2015.

Amended and Restated Compensation Plan for Directors, dated November 1, 2017, incorporated
by reference to Exhibit 10.9.2 to the Company’s annual report on Form 10-K for the year ended
December 31, 2017.

Amended and Restated Compensation Plan for Directors, dated February 1, 2023, incorporated by
reference to Exhibit 10.14 to the Company’s annual report on Form 10-K for the year ended
December 31, 2022.

Amended and Restated Compensation Plan for Directors, dated November 1, 2023, incorporated
by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter
ended September 30, 2023.

The Church & Dwight Co., Inc. Stock Award Plan as amended, incorporated by reference to
Exhibit 10 to the Company’s quarterly report on Form 10-Q for the quarter ended June 29, 2007.

The Stock Option Plan for Directors, effective as of January 1, 1991, incorporated by reference to
Exhibit 10(j) to the Company’s annual report on Form 10-K for the year ended December 31,
2005.

Church & Dwight Co., Inc., Amended and Restated Omnibus Equity Compensation Plan,
incorporated by reference to Exhibit A to the Company’s proxy statement for its 2013 Annual
Meeting of Stockholders, filed on March 21, 2013.

First Amendment to Church & Dwight Co., Inc. Amended and Restated Omnibus Equity
Compensation Plan, incorporated by reference to Exhibit 10.1 to the Company’s quarterly report
on Form 10-Q for the quarter ended September 30, 2019.

Form of Award Agreement for CEO and EVPs Under the Church & Dwight Co., Inc., Amended
and Restated Omnibus Equity Compensation Plan, incorporated by reference to Exhibit 10.2 to
the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2019.

Form of Award Agreement for CEO and EVPs Under the Church & Dwight Co., Inc., Amended
and Restated Omnibus Equity Compensation Plan incorporated by reference to Exhibit 10.13.1 to
the Company’s annual report on Form 10-K for the year ended December 31, 2021.

Form of Award Agreement for Employees Under the Church & Dwight Co., Inc., Amended and
Restated Omnibus Equity Compensation Plan, incorporated by reference to Exhibit 10.12.2 to the
Company’s annual report on Form 10-K for the year ended December 31, 2018.

Form of Award Agreement for Employees Under the Church & Dwight Co., Inc., Amended and
Restated Omnibus Equity Compensation Plan incorporated by reference to Exhibit 10.14.1 to the
Company’s annual report on Form 10-K for the year ended December 31, 2021.

101

* (10.26)

* (10.27)

* (10.28)

* (10.29)

* (10.30)

* (10.31)

* (10.32)

* (10.33)

* (10.34)

* (10.35)

* (10.36)

* (10.37)

* (10.38)

* (10.39)

Form of Award Agreement for Directors Under the Church & Dwight Co., Inc., Amended and
Restated Omnibus Equity Compensation Plan, incorporated by reference to Exhibit 10.12.1 to the
Company’s annual report on Form 10-K for the year ended December 31, 2018.

Church & Dwight Co., Inc. Amended and Restated Omnibus Equity Compensation Plan,
incorporated by reference to Appendix A to the Company’s proxy statement for its 2022 Annual
Meeting of Stockholders, filed on March 18, 2022.

Form of Non-Qualified Stock Option Grant Agreement, incorporated by reference to Exhibit 10.1
to the Company’s current report on Form 8-K filed on June 3, 2022.

Form of Restricted Stock Unit Grant Agreement, incorporated by reference to Exhibit 10.1 to the
Company’s current report on Form 8-K filed on February 6, 2023.

Form of Performance Stock Unit Grant Agreement, incorporated by reference to Exhibit 10.2 to
the Company’s current report on Form 8-K filed on February 6, 2023.

Form of Non-Qualified Stock Option Grant Agreement, for Directors, incorporated by reference
to Exhibit 10.28 to the Company’s annual report on Form 10-K for the year ended December 31,
2022.

Form of Restricted Stock Unit Grant Agreement, for Directors, incorporated by reference to
Exhibit 10.29 to the Company’s annual report on Form 10-K for the year ended December 31,
2022.

Church & Dwight Co., Inc. Third Amended and Restated Annual Incentive Plan, incorporated by
reference to Exhibit 10.1 to the Company’s current report on Form 8-K filed on December 6,
2018.

Church & Dwight Co., Inc. Fourth Amended and Restated Annual Incentive Plan, dated
October 31, 2023, incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on
Form 10-Q for the quarter ended October 31, 2023.

Church & Dwight Co., Inc Employee Stock Purchase Plan, as approved by the Company’s
stockholders on April 27, 2023, incorporated by reference to Appendix A to the Company’s proxy
statement for its 2023 Annual Meeting of Stockholders filed on March 17, 2023.

Employment Agreement, dated October 31, 2011, by and between the Company and Patrick de
Maynadier, incorporated by reference to Exhibit 10.18 to the Company’s annual report on Form
10-K for the year ended December 31, 2011.

Employment Agreement, dated August 23, 2006, by and between the Company and Matthew T.
Farrell, incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q
for the quarter ended September 29, 2006.

Amended and Restated Change in Control and Severance Agreement, entered into by and between
the Company and Matthew T. Farrell, incorporated by reference to Exhibit 10.1 to the Company’s
current report on Form 8-K filed on February 2, 2016.

Form of Amended and Restated Change in Control and Severance Agreement entered into by and
between the Company and each of the senior executive officers (other than Matthew T. Farrell),
incorporated by reference to Exhibit 10.2 to the Company’s current report on Form 8-K filed on
February 2, 2016.

* (10.40)

Employment Agreement, dated September 4, 2021, by and between the Company and Barry
Bruno incorporated by reference to Exhibit 10.21 to the Company’s annual report on Form 10-K
for the year ended December 31, 2021.

102

(10.41)

Lease Agreement (Build to Suit), dated July 20, 2011, between Church & Dwight Co., Inc. and
CD 95 L.L.C., incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on
Form 10-Q for the quarter ended September 30, 2011.

•

•

•

•

•

•

•

(21)

(23)

(31.1)

(31.2)

(32.1)

(32.2)

List of the Company’s subsidiaries.

Consent of Independent Registered Public Accounting Firm.

Certification of the Chief Executive Officer of the Company pursuant to Rule 13a-14(a) under the
Securities Exchange Act.

Certification of the Chief Financial Officer of the Company pursuant to Rule 13a-14(a) under the
Securities Exchange Act.

Certification of the Chief Executive Officer of the Company pursuant to Rule 13a-14(b) under the
Exchange Act and 18 U.S.C. Section 1350.

Certification of the Chief Financial Officer of the Company pursuant to Rule 13a-14(b) under the
Exchange Act and 18 U.S.C. Section 1350.

(97.1)

Policy Relating to Recovery of Erroneously Awarded Compensation

(101.INS)

Inline XBRL Instance Document—the instance document does not appear in the Interactive Data
File because its XBRL tags are embedded within the Inline XBRL document.

(101.SCH) Inline XBRL Taxonomy Extension Schema Document.

(101.CAL) Inline XBRL Taxonomy Extension Calculation Linkbase Document.

(101.DEF) Inline XBRL Taxonomy Extension Definition Linkbase Document.

(101.LAB) Inline XBRL Taxonomy Extension Label Linkbase Document.

(101.PRE) Inline XBRL Taxonomy Extension Presentation Linkbase Document.

(104)

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

•
*

Indicates documents filed herewith.
Constitutes management contract or compensatory plan or arrangement required to be filed as an exhibit to
this Annual Report.

ITEM 16. FORM 10-K SUMMARY

None.

103

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant
has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized, on
February 15, 2024.

CHURCH & DWIGHT CO., INC.

By:

/s/ Matthew T. Farrell

MATTHEW T. FARRELL

PRESIDENT AND CHIEF EXECUTIVE OFFICER

104

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below
by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

/s/ Matthew T. Farrell

Matthew T. Farrell

/s/ Bradlen S. Cashaw

Bradlen S. Cashaw

/s/ Bradley C. Irwin

Bradley C. Irwin

/s/ Penry W. Price

Penry W. Price

/s/

Susan G. Saideman
Susan G. Saideman

/s/ Ravichandra K. Saligram

Ravichandra K. Saligram

/s/ Robert K. Shearer

Robert K. Shearer

/s/

Janet S. Vergis
Janet S. Vergis

/s/ Arthur B. Winkleblack

Arthur B. Winkleblack

/s/ Laurie J. Yoler

Laurie J. Yoler

/s/ Richard A. Dierker

Richard A. Dierker

Chairman, President and Chief
Executive Officer, Director

February 15, 2024

Director

February 15, 2024

Director

February 15, 2024

Director

February 15, 2024

Director

February 15, 2024

Director

February 15, 2024

Director

February 15, 2024

Director

February 15, 2024

Director

February 15, 2024

Director

February 15, 2024

Executive Vice President
and Chief Financial Officer
(Principal Financial Officer)

February 15, 2024

/s/

Joseph J. Longo
Joseph J. Longo

Vice President and Controller
(Principal Accounting Officer)

February 15, 2024

105

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

SCHEDULE II—Valuation and Qualifying Accounts
For each of the three years in the period ended December 31, 2023
(Dollars in millions)

Additions

Deductions

Beginning
Balance

Charged
to

Expenses Acquired

Amounts
Written
Off

Foreign
Exchange

Ending
Balance

Allowance for Doubtful Accounts

2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Allowance for Cash Discounts

2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sales Returns and Allowances

2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Inventory Reserves

2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 3.5
5.5
3.7

$ 6.6
5.9
6.0

$34.8
32.4
24.5

$46.0
36.2
17.8

$

4.0
0.4
0.6

$115.1
106.0
98.4

$128.9
128.5
129.4

$ 40.5
48.1
40.5

$0.0
0.0
1.9

$0.0
0.0
0.0

$0.0
0.0
0.0

$0.0
0.0
0.4

$

(0.2)
(2.4)
(0.7)

$(112.7)
(105.2)
(98.5)

$(128.7)
(126.0)
(121.5)

$ (34.5)
(37.7)
(22.3)

$ 0.0
0.0
0.0

$(0.1)
(0.1)
0.0

$ 0.0
(0.1)
0.0

$ 0.5
(0.6)
(0.2)

$ 7.3
3.5
5.5

$ 8.9
6.6
5.9

$35.0
34.8
32.4

$52.5
46.0
36.2

106

I, Matthew T. Farrell, certify that:

CERTIFICATIONS

EXHIBIT 31.1

1.

I have reviewed this annual report on Form 10-K of Church & Dwight Co., Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of any material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and

procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over
financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on our evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in
the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant’s auditors and the audit committee of
registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a

significant role in the registrant’s internal control over financial reporting.

Date: February 15, 2024

/s/ Matthew T. Farrell

Matthew T. Farrell
President and Chief Executive Officer

I, Richard A. Dierker, certify that:

CERTIFICATIONS

EXHIBIT 31.2

1.

I have reviewed this annual report on Form 10-K of Church & Dwight Co., Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of any material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and

procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over
financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on our evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in
the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant’s auditors and the audit committee of
registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a

significant role in the registrant’s internal control over financial reporting.

Date: February 15, 2024

/s/ Richard A. Dierker

Richard A. Dierker
Executive Vice President and Chief Financial Officer

CERTIFICATION PURSUANT TO
RULE 13a-14(b) UNDER THE SECURITIES EXCHANGE ACT AND
18 U.S.C. SECTION 1350

EXHIBIT 32.1

I, Matthew T. Farrell, President and Chief Executive Officer of Church & Dwight Co., Inc. (the

“Company”), hereby certify that, based on my knowledge:

1. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the

“Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and

2. The information contained in the Report fairly presents, in all material respects, the financial condition

and results of operations of the Company.

By: /s/ Matthew T. Farrell
Matthew T. Farrell
President and Chief Executive Officer

Dated: February 15, 2024

CERTIFICATION PURSUANT TO
RULE 13a-14(b) UNDER THE SECURITIES EXCHANGE ACT AND
18 U.S.C. SECTION 1350

EXHIBIT 32.2

I, Richard A. Dierker, Executive Vice President and Chief Financial Officer of Church & Dwight Co., Inc.

(the “Company”), hereby certify that, based on my knowledge:

1. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the

“Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and

2. The information contained in the Report fairly presents, in all material respects, the financial condition

and results of operations of the Company.

By: /s/ Richard A. Dierker
Richard A. Dierker
Executive Vice President and Chief Financial Officer

Dated: February 15, 2024

(cid:17)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:111)(cid:117)(cid:2)(cid:17)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2) 
Corporate Headquarters

(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:7)(cid:111)(cid:314)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)
(cid:30)(cid:117)(cid:98)(cid:109)(cid:49)(cid:59)(cid:124)(cid:111)(cid:109)(cid:2)(cid:34)(cid:111)(cid:134)(cid:124)(cid:95)(cid:2)(cid:7)(cid:111)(cid:117)(cid:114)(cid:111)(cid:117)(cid:45)(cid:124)(cid:59)(cid:2)(cid:30)(cid:45)(cid:117)(cid:104)
500 Charles Ewing Blvd.,
Ewing, New Jersey 08628
(cid:1141)(cid:399)(cid:406)(cid:314)(cid:1142)(cid:399)(cid:1141)(cid:314)(cid:400)(cid:401)(cid:399)(cid:399)

Corporate Website
www.churchdwight.com

Independent Registered  
(cid:30)(cid:134)(cid:48)(cid:1140)(cid:98)(cid:49)(cid:2)(cid:3)(cid:49)(cid:49)(cid:111)(cid:134)(cid:109)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:13)(cid:98)(cid:117)(cid:108)

(cid:9)(cid:59)(cid:1140)(cid:111)(cid:98)(cid:130)(cid:59)(cid:2)(cid:351)(cid:2)(cid:36)(cid:111)(cid:134)(cid:49)(cid:95)(cid:59)(cid:2)(cid:21)(cid:21)(cid:30)
(cid:400)(cid:400)(cid:399)(cid:2)(cid:24)(cid:111)(cid:117)(cid:117)(cid:98)(cid:118)(cid:2)(cid:34)(cid:124)(cid:117)(cid:59)(cid:59)(cid:124)
(cid:24)(cid:111)(cid:117)(cid:117)(cid:98)(cid:118)(cid:124)(cid:111)(cid:137)(cid:109)(cid:311)(cid:2)(cid:25)(cid:19)(cid:2)(cid:399)(cid:405)(cid:406)(cid:1141)(cid:399)

Transfer Agent and Registrar 
Computershare Inc.

(cid:401)(cid:404)(cid:399)(cid:2)(cid:33)(cid:111)(cid:139)(cid:45)(cid:1140)(cid:1140)(cid:2)(cid:34)(cid:124)(cid:117)(cid:59)(cid:59)(cid:124) 
(cid:7)(cid:45)(cid:109)(cid:124)(cid:111)(cid:109)(cid:311)(cid:2)(cid:24)(cid:3)(cid:2)(cid:399)(cid:401)(cid:399)(cid:401)(cid:400)
(cid:1142)(cid:1141)(cid:1141)(cid:314)(cid:401)(cid:406)(cid:406)(cid:314)(cid:403)(cid:401)(cid:400)(cid:406)

(cid:34)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:21)(cid:98)(cid:118)(cid:2462)(cid:109)(cid:93)

(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:7)(cid:111)(cid:314)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)(cid:2)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:118)(cid:2)
(cid:45)(cid:117)(cid:59)(cid:2)(cid:1140)(cid:98)(cid:118)(cid:124)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:25)(cid:59)(cid:137)(cid:2)(cid:43)(cid:111)(cid:117)(cid:104)(cid:2)(cid:34)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)
(cid:11)(cid:138)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:118)(cid:139)(cid:108)(cid:48)(cid:111)(cid:1140)(cid:2)(cid:98)(cid:118)(cid:2)(cid:7)(cid:15)(cid:9)(cid:314)

10-K Report

(cid:34)(cid:124)(cid:111)(cid:49)(cid:104)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:118)(cid:2)(cid:108)(cid:45)(cid:139)(cid:2)(cid:111)(cid:48)(cid:124)(cid:45)(cid:98)(cid:109)(cid:2)(cid:45)(cid:2)(cid:49)(cid:111)(cid:114)(cid:139)(cid:2)
(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:317)(cid:118)(cid:2)(cid:3)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:33)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)
(cid:111)(cid:109)(cid:2)(cid:13)(cid:111)(cid:117)(cid:108)(cid:2)(cid:400)(cid:399)(cid:330)(cid:20)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:139)(cid:59)(cid:45)(cid:117)(cid:2)(cid:59)(cid:109)(cid:55)(cid:59)(cid:55)(cid:2)
(cid:400)(cid:401)(cid:326)(cid:402)(cid:400)(cid:326)(cid:401)(cid:402)(cid:2)(cid:67)(cid:1140)(cid:59)(cid:55)(cid:2)(cid:137)(cid:98)(cid:124)(cid:95)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:34)(cid:59)(cid:49)(cid:134)(cid:117)(cid:98)(cid:2462)(cid:59)(cid:118)(cid:2)
(cid:45)(cid:109)(cid:55)(cid:2)(cid:11)(cid:138)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:108)(cid:98)(cid:118)(cid:118)(cid:98)(cid:111)(cid:109)(cid:2)(cid:48)(cid:139)(cid:2) 
(cid:137)(cid:117)(cid:98)(cid:2462)(cid:109)(cid:93)(cid:2)(cid:124)(cid:111)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:34)(cid:59)(cid:49)(cid:117)(cid:59)(cid:124)(cid:45)(cid:117)(cid:139)(cid:2)(cid:45)(cid:124)(cid:2) 
Corporate Headquarters.

Stockholder Inquiries

For details, contact: 

(cid:9)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:2)(cid:33)(cid:59)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)(cid:30)(cid:1140)(cid:45)(cid:109)
(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:7)(cid:111)(cid:314)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)
(cid:7)(cid:111)(cid:108)(cid:114)(cid:134)(cid:124)(cid:59)(cid:117)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:36)(cid:117)(cid:134)(cid:118)(cid:124)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:311)(cid:2)(cid:25)(cid:314)(cid:3)(cid:314)
(cid:401)(cid:404)(cid:399)(cid:2)(cid:33)(cid:111)(cid:139)(cid:45)(cid:1140)(cid:1140)(cid:2)(cid:34)(cid:124)(cid:117)(cid:59)(cid:59)(cid:124) 
(cid:7)(cid:45)(cid:109)(cid:124)(cid:111)(cid:109)(cid:311)(cid:2)(cid:24)(cid:3)(cid:2)(cid:399)(cid:401)(cid:399)(cid:401)(cid:400)
(cid:1142)(cid:1141)(cid:1141)(cid:314)(cid:401)(cid:406)(cid:406)(cid:314)(cid:403)(cid:401)(cid:400)(cid:406)

(cid:36)(cid:95)(cid:59)(cid:2)(cid:136)(cid:98)(cid:117)(cid:124)(cid:134)(cid:45)(cid:1138)(cid:2)(cid:45)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1138)(cid:2)(cid:108)(cid:59)(cid:59)(cid:2236)(cid:109)(cid:93)(cid:2)(cid:111)(cid:61)(cid:2) 
stockholders will be held at:

(cid:400)(cid:401)(cid:313)(cid:399)(cid:399)(cid:2)(cid:30)(cid:314)(cid:24)(cid:314)(cid:2)(cid:36)(cid:95)(cid:134)(cid:117)(cid:118)(cid:55)(cid:45)(cid:139)(cid:311)(cid:2)(cid:24)(cid:45)(cid:139)(cid:2)(cid:401)(cid:311)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)

New York Stock  
(cid:11)(cid:138)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:2)(cid:7)(cid:59)(cid:117)(cid:2462)(cid:67)(cid:49)(cid:45)(cid:2462)(cid:111)(cid:109)

(cid:27)(cid:134)(cid:117)(cid:2)(cid:7)(cid:95)(cid:98)(cid:59)(cid:61)(cid:2)(cid:11)(cid:138)(cid:59)(cid:49)(cid:134)(cid:2462)(cid:136)(cid:59)(cid:2)(cid:27)(cid:76)(cid:49)(cid:59)(cid:117)(cid:2) 
has provided the required annual 
(cid:49)(cid:59)(cid:117)(cid:2462)(cid:67)(cid:49)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:124)(cid:111)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:25)(cid:59)(cid:137)(cid:2)(cid:43)(cid:111)(cid:117)(cid:104)(cid:2) 
(cid:34)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:11)(cid:138)(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:314)

(cid:7)(cid:111)(cid:108)(cid:108)(cid:134)(cid:109)(cid:98)(cid:49)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:49)(cid:111)(cid:109)(cid:49)(cid:59)(cid:117)(cid:109)(cid:98)(cid:109)(cid:93)(cid:2)
(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:2)(cid:117)(cid:59)(cid:49)(cid:111)(cid:117)(cid:55)(cid:118)(cid:311)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:124)(cid:117)(cid:45)(cid:109)(cid:118)(cid:61)(cid:59)(cid:117)(cid:311)(cid:2)
changes of ownership, account  
(cid:49)(cid:111)(cid:109)(cid:118)(cid:111)(cid:1140)(cid:98)(cid:55)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:311)(cid:2)(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)
(cid:49)(cid:95)(cid:45)(cid:109)(cid:93)(cid:59)(cid:2)(cid:111)(cid:61)(cid:2)(cid:45)(cid:55)(cid:55)(cid:117)(cid:59)(cid:118)(cid:118)(cid:2)(cid:118)(cid:95)(cid:111)(cid:134)(cid:1140)(cid:55)(cid:2)(cid:48)(cid:59)(cid:2) 
directed to: 

(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:7)(cid:111)(cid:314)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)
(cid:7)(cid:111)(cid:108)(cid:114)(cid:134)(cid:124)(cid:59)(cid:117)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)
(cid:34)(cid:95)(cid:45)(cid:117)(cid:59)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:2)(cid:33)(cid:59)(cid:1140)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:118)
(cid:1142)(cid:1141)(cid:1141)(cid:314)(cid:401)(cid:406)(cid:406)(cid:314)(cid:403)(cid:401)(cid:400)(cid:406)

Stockholder correspondence  
should be mailed to: 

(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:7)(cid:111)(cid:314)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)
(cid:7)(cid:111)(cid:108)(cid:114)(cid:134)(cid:124)(cid:59)(cid:117)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)
(cid:30)(cid:314)(cid:27)(cid:314)(cid:2)(cid:6)(cid:27)(cid:42)(cid:2)(cid:402)(cid:399)(cid:400)(cid:405)(cid:399)
(cid:7)(cid:111)(cid:1140)(cid:1140)(cid:59)(cid:93)(cid:59)(cid:2)(cid:34)(cid:124)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:36)(cid:42)(cid:2)(cid:405)(cid:405)(cid:1142)(cid:403)(cid:401)(cid:330)(cid:402)(cid:400)(cid:405)(cid:399)

Overnight correspondence  
should be sent to: 

(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:7)(cid:111)(cid:314)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)
(cid:7)(cid:111)(cid:108)(cid:114)(cid:134)(cid:124)(cid:59)(cid:117)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)
(cid:401)(cid:400)(cid:400)(cid:2)(cid:32)(cid:134)(cid:45)(cid:1140)(cid:98)(cid:124)(cid:139)(cid:2)(cid:7)(cid:98)(cid:117)(cid:49)(cid:1140)(cid:59)(cid:311)(cid:2)(cid:34)(cid:134)(cid:98)(cid:124)(cid:59)(cid:2)(cid:401)(cid:400)(cid:399)
(cid:7)(cid:111)(cid:1140)(cid:1140)(cid:59)(cid:93)(cid:59)(cid:2)(cid:34)(cid:124)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:36)(cid:42)(cid:2)(cid:405)(cid:405)(cid:1142)(cid:403)(cid:404)
www.computershare.com/investor

Dividend Reinvestment Plan

(cid:7)(cid:111)(cid:108)(cid:114)(cid:134)(cid:124)(cid:59)(cid:117)(cid:118)(cid:95)(cid:45)(cid:117)(cid:59)(cid:2)(cid:36)(cid:117)(cid:134)(cid:118)(cid:124)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:311)(cid:2)(cid:25)(cid:314)(cid:3)(cid:314)(cid:2)
(cid:45)(cid:55)(cid:108)(cid:98)(cid:109)(cid:98)(cid:118)(cid:124)(cid:59)(cid:117)(cid:118)(cid:2)(cid:45)(cid:2)(cid:55)(cid:98)(cid:136)(cid:98)(cid:55)(cid:59)(cid:109)(cid:55)(cid:2)(cid:117)(cid:59)(cid:98)(cid:109)(cid:136)(cid:59)(cid:118)(cid:124)(cid:108)(cid:59)(cid:109)(cid:124)(cid:2)
(cid:45)(cid:109)(cid:55)(cid:2)(cid:118)(cid:124)(cid:111)(cid:49)(cid:104)(cid:2)(cid:114)(cid:134)(cid:117)(cid:49)(cid:95)(cid:45)(cid:118)(cid:59)(cid:2)(cid:114)(cid:1140)(cid:45)(cid:109)(cid:2)(cid:61)(cid:111)(cid:117)(cid:2)(cid:111)(cid:134)(cid:117)(cid:2)
(cid:34)(cid:124)(cid:111)(cid:49)(cid:104)(cid:95)(cid:111)(cid:1140)(cid:55)(cid:59)(cid:117)(cid:118)(cid:314)(cid:2)

(cid:7)(cid:45)(cid:134)(cid:2462)(cid:111)(cid:109)(cid:45)(cid:117)(cid:139)(cid:2)(cid:25)(cid:111)(cid:124)(cid:59)(cid:2)(cid:27)(cid:109)(cid:2)(cid:13)(cid:111)(cid:117)(cid:137)(cid:45)(cid:117)(cid:55)(cid:330)(cid:21)(cid:111)(cid:111)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)(cid:17)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:313)(cid:2)

(cid:36)(cid:95)(cid:98)(cid:118)(cid:2)(cid:3)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:33)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:2)(cid:49)(cid:111)(cid:109)(cid:124)(cid:45)(cid:98)(cid:109)(cid:118)(cid:2)(cid:61)(cid:111)(cid:117)(cid:137)(cid:45)(cid:117)(cid:55)(cid:330)(cid:1140)(cid:111)(cid:111)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)(cid:118)(cid:124)(cid:45)(cid:124)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:137)(cid:95)(cid:98)(cid:49)(cid:95)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:48)(cid:45)(cid:118)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:2)(cid:49)(cid:134)(cid:117)(cid:117)(cid:59)(cid:109)(cid:124)(cid:2)(cid:45)(cid:118)(cid:118)(cid:134)(cid:108)(cid:114)(cid:2462)(cid:111)(cid:109)(cid:118)(cid:2)(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:45)(cid:117)(cid:59)(cid:2)(cid:118)(cid:134)(cid:48)(cid:102)(cid:59)(cid:49)(cid:124)(cid:2)(cid:124)(cid:111)(cid:2)(cid:117)(cid:98)(cid:118)(cid:104)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:134)(cid:109)(cid:49)(cid:59)(cid:117)(cid:124)(cid:45)(cid:98)(cid:109)(cid:2462)(cid:59)(cid:118)(cid:2)

(cid:124)(cid:95)(cid:45)(cid:124)(cid:2)(cid:108)(cid:45)(cid:139)(cid:2)(cid:49)(cid:45)(cid:134)(cid:118)(cid:59)(cid:2)(cid:45)(cid:49)(cid:124)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:117)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:124)(cid:118)(cid:2)(cid:124)(cid:111)(cid:2)(cid:55)(cid:98)(cid:64)(cid:59)(cid:117)(cid:2)(cid:108)(cid:45)(cid:124)(cid:59)(cid:117)(cid:98)(cid:45)(cid:1140)(cid:1140)(cid:139)(cid:2)(cid:61)(cid:117)(cid:111)(cid:108)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:61)(cid:111)(cid:117)(cid:137)(cid:45)(cid:117)(cid:55)(cid:330)(cid:1140)(cid:111)(cid:111)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)(cid:118)(cid:124)(cid:45)(cid:124)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:118)(cid:311)(cid:2)(cid:98)(cid:109)(cid:49)(cid:1140)(cid:134)(cid:55)(cid:98)(cid:109)(cid:93)(cid:2)(cid:124)(cid:95)(cid:59)(cid:2)(cid:117)(cid:98)(cid:118)(cid:104)(cid:118)(cid:2)(cid:45)(cid:109)(cid:55)(cid:2)(cid:134)(cid:109)(cid:49)(cid:59)(cid:117)(cid:124)(cid:45)(cid:98)(cid:109)(cid:2462)(cid:59)(cid:118)(cid:2)(cid:55)(cid:98)(cid:118)(cid:49)(cid:134)(cid:118)(cid:118)(cid:59)(cid:55)(cid:2)(cid:111)(cid:109)(cid:2)

(cid:114)(cid:45)(cid:93)(cid:59)(cid:118)(cid:2)(cid:400)(cid:403)(cid:330)(cid:402)(cid:402)(cid:2)(cid:111)(cid:61)(cid:2)(cid:124)(cid:95)(cid:98)(cid:118)(cid:2)(cid:3)(cid:109)(cid:109)(cid:134)(cid:45)(cid:1140)(cid:2)(cid:33)(cid:59)(cid:114)(cid:111)(cid:117)(cid:124)(cid:314)(cid:2)(cid:36)(cid:95)(cid:59)(cid:2)(cid:7)(cid:111)(cid:108)(cid:114)(cid:45)(cid:109)(cid:139)(cid:2)(cid:134)(cid:109)(cid:55)(cid:59)(cid:117)(cid:124)(cid:45)(cid:104)(cid:59)(cid:118)(cid:2)(cid:109)(cid:111)(cid:2)(cid:111)(cid:48)(cid:1140)(cid:98)(cid:93)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:2)(cid:124)(cid:111)(cid:2)(cid:134)(cid:114)(cid:55)(cid:45)(cid:124)(cid:59)(cid:2)(cid:111)(cid:117)(cid:2)(cid:117)(cid:59)(cid:136)(cid:98)(cid:118)(cid:59)(cid:2)(cid:114)(cid:134)(cid:48)(cid:1140)(cid:98)(cid:49)(cid:1140)(cid:139)(cid:2)(cid:45)(cid:109)(cid:139)(cid:2)(cid:61)(cid:111)(cid:117)(cid:137)(cid:45)(cid:117)(cid:55)(cid:330)(cid:1140)(cid:111)(cid:111)(cid:104)(cid:98)(cid:109)(cid:93)(cid:2)(cid:118)(cid:124)(cid:45)(cid:124)(cid:59)(cid:108)(cid:59)(cid:109)(cid:124)(cid:118)(cid:311)(cid:2)

(cid:137)(cid:95)(cid:59)(cid:124)(cid:95)(cid:59)(cid:117)(cid:2)(cid:45)(cid:118)(cid:2)(cid:45)(cid:2)(cid:117)(cid:59)(cid:118)(cid:134)(cid:1140)(cid:124)(cid:2)(cid:111)(cid:61)(cid:2)(cid:109)(cid:59)(cid:137)(cid:2)(cid:98)(cid:109)(cid:61)(cid:111)(cid:117)(cid:108)(cid:45)(cid:2462)(cid:111)(cid:109)(cid:311)(cid:2)(cid:61)(cid:134)(cid:124)(cid:134)(cid:117)(cid:59)(cid:2)(cid:59)(cid:136)(cid:59)(cid:109)(cid:124)(cid:118)(cid:2)(cid:111)(cid:117)(cid:2)(cid:111)(cid:124)(cid:95)(cid:59)(cid:117)(cid:137)(cid:98)(cid:118)(cid:59)(cid:311)(cid:2)(cid:59)(cid:138)(cid:49)(cid:59)(cid:114)(cid:124)(cid:2)(cid:45)(cid:118)(cid:2)(cid:117)(cid:59)(cid:116)(cid:134)(cid:98)(cid:117)(cid:59)(cid:55)(cid:2)(cid:48)(cid:139)(cid:2)(cid:1140)(cid:45)(cid:137)(cid:314) 

(cid:355)(cid:7)(cid:95)(cid:134)(cid:117)(cid:49)(cid:95)(cid:2)(cid:351)(cid:2)(cid:9)(cid:137)(cid:98)(cid:93)(cid:95)(cid:124)(cid:2)(cid:7)(cid:111)(cid:314)(cid:311)(cid:2)(cid:17)(cid:109)(cid:49)(cid:314)(cid:2)(cid:401)(cid:399)(cid:401)(cid:403)

CHURCH & DWIGHT CO., INC. 
(cid:1157)
Princeton South Corporate Center
500 Charles Ewing Boulevard
Ewing, NJ 08628

www.churchdwight.com